,Article,Date,Symbol,Time,Title,Url
0,"  Gilead Sciences Inc said on Monday that its head of commercial operations for the past decade, Kevin Young, who oversaw tremendous sales growth at the U.S. biotechnology company, will retire next month.Young, who plans to step down on February 4, has held the top commercial post for the world's leading maker of HIV/AIDS medicines since 2004. During his tenure Gilead's annual sales grew from $1.24 billion in 2004 to about $11 billion in 2013.""Over the past nine years, he has greatly expanded and strengthened our commercial organization, preparing the company to introduce products in new therapeutic areas,"" Gilead Chief Executive John Martin said in a statement. The company said it was not ready to announce any succession plans but said Young will continue to work with Gilead as a senior advisor after his retirement.Young, 56, leaves the top commercial post just as Gilead is launching what is widely expected to be its biggest and most important new therapy in years - an all-oral regimen for treating hepatitis C that has garnered analyst forecasts for eventual annual sales of $3 billion to $16 billion. During his tenure, Young oversaw the launch of eight new therapies, including Atripla, the first single tablet regimen for the treatment of HIV, which is the top seller for treating the virus that causes AIDS in the United States and Europe, Gilead said. Before joining Gilead, Young held posts with U.S. biotech Amgen Inc and British drugmaker AstraZeneca.(Reporting by Bill Berkrot; Editing by Cynthia Osterman)",2014-01-06,GILD,"Mon Jan 6, 2014 | 6:31pm EST",Gilead says head of commercial operations to retire,http://www.reuters.com//article/us-gilead-young-idUSBREA0516U20140106?type=companyNews
1,"  Jan 6 Gilead Sciences Inc said on Monday that its head of commercial operations for the past decade, Kevin Young, who oversaw tremendous sales growth at the U.S. biotechnology company, will retire next month.Young, who plans to step down on Feb. 4, has held the top commercial post for the world's leading maker of HIV/AIDS medicines since 2004. During his tenure Gilead's annual sales grew from $1.24 billion in 2004 to about $11 billion in 2013.""Over the past nine years, he has greatly expanded and strengthened our commercial organization, preparing the company to introduce products in new therapeutic areas,"" Gilead Chief Executive John Martin said in a statement. The company said it was not ready to announce any succession plans but said Young will continue to work with Gilead as a senior advisor after his retirement. Young, 56, leaves the top commercial post just as Gilead is launching what is widely expected to be its biggest and most important new therapy in years - an all-oral regimen for treating hepatitis C that has garnered analyst forecasts for eventual annual sales of $3 billion to $16 billion. During his tenure, Young oversaw the launch of eight new therapies, including Atripla, the first single tablet regimen for the treatment of HIV, which is the top seller for treating the virus that causes AIDS in the United States and Europe, Gilead said.Before joining Gilead, Young held posts with U.S. biotech Amgen Inc and British drugmaker AstraZeneca.",2014-01-06,GILD,"Mon Jan 6, 2014 | 6:29pm EST",Gilead says head of commercial operations to retire,http://www.reuters.com//article/gilead-young-idUSL2N0KG1Y520140106?type=companyNews
2,"  LONDON Jan 17 Gilead Sciences Inc's  high-profile new hepatitis C drug Sovaldi has won final European approval, the company said on Friday, paving the way for its launch across the European Union.The green light from the European Commission had been expected following a positive recommendation from the European Medicines Agency in November.  The once-a-day pill, also known as sofosbuvir, is the first approved to treat certain types of hepatitis C infection without the need for interferon, an injected drug that can cause severe flu-like symptoms. ",2014-01-17,GILD,"Fri Jan 17, 2014 | 10:42am EST",Europe approves Gilead's new hepatitis C pill,http://www.reuters.com//article/gilead-europe-idUSL5N0KR2KR20140117?type=companyNews
3,"   By Deena Beasley  Gilead Sciences Inc (GILD.O), which recently began selling a new hepatitis C drug seen reaching multibillion-dollar sales, posted a better-than-expected quarterly profit on Tuesday as sales of its flagship HIV drugs beat Wall Street estimates.Fourth-quarter net income rose 4 percent to $791.4 million from $762.5 million a year earlier. Adjusting for one-time items, the California-based company earned 55 cents a share, which beat the average analyst estimate of 50 cents a share, according to Thomson Reuters I/B/E/S.Revenue rose 20 percent to $3.12 billion, ahead of the average Wall Street forecast of $2.85 billion.Sales of hepatitis C drug Sovaldi, which was approved by U.S. regulators in early December, totaled $139.4 million for the quarter.Gilead declined to estimate 2014 sales of the drug but said demand is strong. ""We've got a well-tolerated, highly effective cure,"" said Kevin Young, head of commercial operations at Gilead. ""This is transformational medicine."" RBC Capital Markets analyst Michael Yee said he expects 2014 Sovaldi sales of $6 billion.""It looks like the prescription trend we've all been watching was spot on for the revenue trajectory, which means that there's going to be off-the-charts numbers this year,"" said Sanford Bernstein analyst Geoffrey Porges. ""And behind all that the HIV business is chugging along nicely.""Hepatitis C affects about 3.2 million Americans, killing more than 15,000 each year, mostly from illnesses such as cirrhosis and liver cancer. The often-undiagnosed virus is transmitted through contaminated blood. While infection rates have dropped since the early 1990s - due in part to the introduction of blood and organ screening - many older adults remain at risk, according to the Centers for Disease Control and Prevention, which has called for baby boomers to be routinely tested for the virus.Gilead excluded sales of Sovaldi and other hepatitis C drugs from its forecast for 2014 product sales, which it projected would increase between 6 percent and 8 percent from 2013 to total between $11.3 billion and $11.5 billion. Analysts have forecast the company's full-year 2014 revenue at $14.66 billion.""It's hard to imagine that they won't exceed $15 billion or $16 billion with Sovaldi,"" Porges said. ""Revenue is going to be up 40 to 50 percent.""Gilead's fourth-quarter sales of HIV drug Atripla rose 2 percent to $933.6 million, while sales of an older product, Truvada, fell 2 percent to $832.7 million. Sales of the company's newest HIV drug, Stribild, rose 409 percent to $203.8 million.Shares of Gilead, which rose 4 percent to close at $82.02 in regular Nasdaq trading, were down 27 cents at $81.75 after hours. Over the past 12 months, the stock has nearly doubled.(Reporting by Deena Beasley in Los Angeles; Additional reporting by Bill Berkrot in New York; Editing by Jonathan Oatis and Lisa Shumaker)",2014-02-04,GILD,"Tue Feb 4, 2014 | 6:26pm EST","Gilead posts higher profit, strong hepatitis C drug sales",http://www.reuters.com//article/us-gilead-results-idUSBREA131OA20140204?type=companyNews
4,"  By Deena BeasleyFeb 4 Gilead Sciences Inc, which recently began selling a new hepatitis C drug seen reaching multibillion-dollar sales, posted a better-than-expected quarterly profit on Tuesday as sales of its flagship HIV drugs beat Wall Street estimates.Fourth-quarter net income rose 4 percent to $791.4 million from $762.5 million a year earlier. Adjusting for one-time items, the California-based company earned 55 cents a share, which beat the average analyst estimate of 50 cents a share, according to Thomson Reuters I/B/E/S.Revenue rose 20 percent to $3.12 billion, ahead of the average Wall Street forecast of $2.85 billion.Sales of hepatitis C drug Sovaldi, which was approved by U.S. regulators in early December, totaled $139.4 million for the quarter. Gilead declined to estimate 2014 sales of the drug but said demand is strong. ""We've got a well-tolerated, highly effective cure,"" said Kevin Young, head of commercial operations at Gilead. ""This is transformational medicine.""RBC Capital Markets analyst Michael Yee said he expects 2014 Sovaldi sales of $6 billion.""It looks like the prescription trend we've all been watching was spot on for the revenue trajectory, which means that there's going to be off-the-charts numbers this year,"" said Sanford Bernstein analyst Geoffrey Porges. ""And behind all that the HIV business is chugging along nicely."" Hepatitis C affects about 3.2 million Americans, killing more than 15,000 each year, mostly from illnesses such as cirrhosis and liver cancer.The often-undiagnosed virus is transmitted through contaminated blood. While infection rates have dropped since the early 1990s - due in part to the introduction of blood and organ screening - many older adults remain at risk, according to the Centers for Disease Control and Prevention, which has called for baby boomers to be routinely tested for the virus.Gilead excluded sales of Sovaldi and other hepatitis C drugs from its forecast for 2014 product sales, which it projected would increase between 6 percent and 8 percent from 2013 to total between $11.3 billion and $11.5 billion. Analysts have forecast the company's full-year 2014 revenue at $14.66 billion.""It's hard to imagine that they won't exceed $15 billion or $16 billion with Sovaldi,"" Porges said. ""Revenue is going to be up 40 to 50 percent.""Gilead's fourth-quarter sales of HIV drug Atripla rose 2 percent to $933.6 million, while sales of an older product, Truvada, fell 2 percent to $832.7 million. Sales of the company's newest HIV drug, Stribild, rose 409 percent to $203.8 million.Shares of Gilead, which rose 4 percent to close at $82.02 in regular Nasdaq trading, were down 27 cents at $81.75 after hours. Over the past 12 months, the stock has nearly doubled.",2014-02-04,GILD,"Tue Feb 4, 2014 | 6:25pm EST","UPDATE 1-Gilead posts higher profit, strong hepatitis C drug sales",http://www.reuters.com//article/gilead-results-idUSL2N0L924220140204?type=companyNews
5,"  Feb 4 Gilead Sciences Inc, which recently began marketing a new drug for hepatitis C expected to be a multibillion-dollar seller, posted a 4 percent rise in quarterly profit on Tuesday as sales of its flagship HIV drugs beat Wall Street estimates.Gilead posted a fourth-quarter net profit of $791.4 million, or 47 cents a share, compared with $762.5 million, or 47 cents a share, a year earlier. Earnings per share were unchanged because the number of shares rose.Fourth-quarter revenue rose 20 percent to $3.12 billion, ahead of Wall Street analysts' average forecast of $2.85 billion, according to Thomson Reuters I/B/E/S. Sales of HIV drug Atripla rose 2 percent to $933.6 million, while sales of an older product, Truvada, fell 2 percent to $832.7 million. Sales of the company's newest HIV drug, Stribild, rose 409 percent to $203.8 million. Sales of hepatitis C drug Sovaldi, which was approved by regulators in early December, totaled $139.4 million for the quarter. Gilead excluded sales of Sovaldi and other hepatitis C drugs from its forecast for 2014 product sales, which it projected would total between $11.3 billion and $11.5 billion.Analysts have forecast the company's full-year 2014 revenue at $14.66 billion.",2014-02-04,GILD,"Tue Feb 4, 2014 | 4:57pm EST",Gilead Q4 profit beats expectations as some HIV drug sales rise,http://www.reuters.com//article/gilead-results-idUSL2N0L51BF20140204?type=companyNews
6,"  Gilead Sciences plans to license its breakthrough hepatitis C drug Sovaldi to a number of Indian generic pharmaceutical manufacturers, allowing for lower-priced sales of the medication in that developing nation, according to the company.Although prices for the drug have not been set, company spokesman Nick Francis said in an emailed statement on Wednesday that Gilead aims to establish ""tiered pricing.""For example, the price discussed for 24 weeks of Sovaldi therapy would run about $2,500 for certain patients at public hospitals, community clinics and non-governmental agencies in India, the Hindu Business Line reported earlier this week.""Providing treatment in resource-limited settings presents complex challenges, and we will work with partners in multiple sectors around the world to ensure our access program reaches as many patients as possible,"" Francis said.Gilead said final details of the program in India will be announced in coming months. The company has a similar program in place for lower-cost versions of its HIV/AIDS drugs.In the United States, where Sovaldi was approved by regulators in December, the drug costs $84,000 for 12 weeks of therapy or $1,000 for a daily pill. The Foster City, California-based company has said the price is fair because the treatment offers a potential cure for the liver-destroying virus without injections of interferon, which can cause severe side effects that compromise patient outcomes.Prices in Europe are also lower than in the United States. The cost for treatment in the United Kingdom is about $57,000 while the price in Germany is around $66,000, the company has said.Analysts have estimated that the drug will eventually generate billions of dollars in annual sales. Sanford Bernstein has forecast sales this year alone of $6.7 billion. But some have questioned whether that is achievable. Many patients including those in the United States, where more than half of hepatitis C patients are estimated to rely on public funding, could have difficulty securing reimbursement for such a high-priced drug.Other companies including Johnson & Johnson, AbbVie and Merck & Co are also working to develop new hepatitis C treatments with some in advanced stages of clinical studies. Gilead, which reported 2013 earnings on Tuesday, declined to include an estimate for hepatitis C sales in its 2014 sales forecast, saying only that Sovaldi sales so far have been strong and broadly based.Sales of Sovaldi in the last three weeks of 2013 totaled more than $139 million.The World Health Organization estimates that about three percent of the world's population has been infected with the hepatitis C virus and that more than 170 million chronic carriers are at risk of developing liver cirrhosis, liver cancer or both.Shares of Gilead fell $3.87, or nearly five percent, to close at $78.15 in Nasdaq trading on Wednesday. Over the past two years, the stock has nearly tripled.(Reporting By Deena Beasley; Editing by Diane Craft)",2014-02-05,GILD,"Wed Feb 5, 2014 | 5:58pm EST",Gilead to license hepatitis C drug to lower-cost manufacturers in India,http://www.reuters.com//article/us-gilead-india-hepatitis-idUSBREA1426F20140205?type=companyNews
7,"  Feb 5 Gilead Sciences plans to license its breakthrough hepatitis C drug Sovaldi to a number of Indian generic pharmaceutical manufacturers, allowing for lower-priced sales of the medication in that developing nation, according to the company.Although prices for the drug have not been set, company spokesman Nick Francis said in an emailed statement on Wednesday that Gilead aims to establish ""tiered pricing.""For example, the price discussed for 24 weeks of Sovaldi therapy would run about $2,500 for certain patients at public hospitals, community clinics and non-governmental agencies in India, the Hindu Business Line reported earlier this week.""Providing treatment in resource-limited settings presents complex challenges, and we will work with partners in multiple sectors around the world to ensure our access program reaches as many patients as possible,"" Francis said.Gilead said final details of the program in India will be announced in coming months. The company has a similar program in place for lower-cost versions of its HIV/AIDS drugs.In the United States, where Sovaldi was approved by regulators in December, the drug costs $84,000 for 12 weeks of therapy or $1,000 for a daily pill. The Foster City, California-based company has said the price is fair because the treatment offers a potential cure for the liver-destroying virus without injections of interferon, which can cause severe side effects that compromise patient outcomes.Prices in Europe are also lower than in the United States. The cost for treatment in the United Kingdom is about $57,000 while the price in Germany is around $66,000, the company has said.Analysts have estimated that the drug will eventually generate billions of dollars in annual sales. Sanford Bernstein has forecast sales this year alone of $6.7 billion. But some have questioned whether that is achievable. Many patients including those in the United States, where more than half of hepatitis C patients are estimated to rely on public funding, could have difficulty securing reimbursement for such a high-priced drug.Other companies including Johnson & Johnson, AbbVie  and Merck & Co are also working to develop new hepatitis C treatments with some in advanced stages of clinical studies. Gilead, which reported 2013 earnings on Tuesday, declined to include an estimate for hepatitis C sales in its 2014 sales forecast, saying only that Sovaldi sales so far have been strong and broadly based.Sales of Sovaldi in the last three weeks of 2013 totaled more than $139 million.The World Health Organization estimates that about three percent of the world's population has been infected with the hepatitis C virus and that more than 170 million chronic carriers are at risk of developing liver cirrhosis, liver cancer or both.Shares of Gilead fell $3.87, or nearly five percent, to close at $78.15 in Nasdaq trading on Wednesday. Over the past two years, the stock has nearly tripled.",2014-02-05,GILD,"Wed Feb 5, 2014 | 5:58pm EST",Gilead to license hepatitis C drug to lower-cost manufacturers in India,http://www.reuters.com//article/gilead-india-hepatitis-idUSL2N0LA1S420140205?type=companyNews
8,"  * ADP jobs report a tick below expectations, Dec. revised lower* Services sector grows at faster clip than forecast* Gilead Sciences shares weigh the most on S&P 500* Twitter slumps in extended-hours trade after results* Dow off 0.03 pct, S&P 500 down 0.20 pct, Nasdaq off 0.50 pctBy Chuck MikolajczakNEW YORK, Feb 5 U.S. stocks slipped on Wednesday as technical support offset the latest batch of mixed data, which failed to lift sentiment after a string of soft economic indicators earlier in the week.In a volatile trading session, the benchmark Standard & Poor's 500 Index hit a session low of 1,737.92, marking its lowest level since Oct. 18, before rebounding to briefly climb into positive territory with a session high of 1,755.79.U.S. data is being closely watched after a weak reading in the factory sector on Monday sent Wall Street into a tailspin and triggered a global equity selloff. Wednesday's data left investors with little clarity about the economic impact from the harsh weather this winter.Growth picked up in the U.S. services sector in January, with steady strength in private-sector hiring, suggesting the winter weather that socked the country over the last several weeks had a limited effect on the economy. ""Clearly, we are getting that support off that 1,740 area, which has held so far this week, at least,"" said Ryan Detrick, senior technical strategist at Schaeffer's Investment Research in Cincinnati.""Today's (data) almost just added to the confusion, or added to the indecision, as to what exactly should we believe - is it weather-related or is it not - and that is the big question that isn't answered yet and won't be answered for a little bit of time.""Investors were also cautious with the U.S. nonfarm payrolls report looming on Friday. Last month's surprisingly low jobs number was discounted by many as an outlier negatively affected by the severe weather.But as other data has also been uninspiring, there is concern that another weak report could be an indication of a greater macroeconomic problem. The Dow Jones industrial average slipped 5.01 points or 0.03 percent, to end at 15,440.23. The S&P 500 dipped 3.56 points or 0.20 percent, to finish at 1,751.64. The Nasdaq Composite fell 19.968 points or 0.50 percent, to close at 4,011.552.After the closing bell, Walt Disney Co. reported a higher quarterly profit. Its stock climbed to $72.99 in extended-hours trading - up 1.7 percent from its close at $71.76.Twitter Inc shares slid 11.1 percent to $58.64 in extended-hours trading after the social media company reported its slowest pace of user growth during the fourth quarter, dashing hopes that it can sustain its torrid pace of expansion.In another substantial move after the close, Green Mountain Coffee Roasters Inc shares surged nearly 40 percent to $112.25 after Coca-Cola Co bought a 10 percent stake in the maker of the Keurig single-cup brewer for $1.25 billion as part of a 10-year partnership agreement. In contrast, shares of SodaStream International Ltd, a manufacturer of home soda-making appliances, dropped 8.9 percent to $32.60 after the bell.The limp data earlier in the week added to concerns about growth in China and the outlook for some emerging market economies. A recent rout in emerging markets' currencies spurred some central banks to act, pressuring bond and stock holdings and luring investors into assets perceived as relatively safe, like the yen, U.S. Treasuries and German government debt. Charles Plosser, the president of the Federal Reserve Bank of Philadelphia and a hawkish policymaker, said the central bank should wind down its bond purchases faster than planned and end the stimulus program before mid-year.Of the 298 companies in the S&P 500 that had reported earnings through Wednesday morning, Thomson Reuters data showed that 69.5 percent have topped Wall Street's expectations, above the 63 percent beat rate since 1994 and the 67 percent rate for the past four quarters.Gilead Sciences Inc fell 4.7 percent to close at $78.15. The stock was the heaviest weight on the S&P 500 a day after the company reported quarterly results.Shares of Cognizant Technology Solutions fell 4.3 percent to $92.85. The IT services provider forecast slower-than-expected revenue growth.Tableau Software shares jumped 12.8 percent to end at $89.61 after the data analysis software maker forecast better-than-expected revenue for this quarter and results handily beat analysts' estimates.CVS Caremark Corp said it would stop selling tobacco products at its 7,600 stores by October, becoming the first U.S. drugstore chain to take cigarettes off the shelf. Its shares declined 1 percent to close at $65.44.Volume was modest, with about 6.61 billion shares traded on U.S. exchanges, slightly below the 6.94 billion average in January, according to data from BATS Global Markets.Declining stocks outnumbered advancing ones on the NYSE by a ratio of about 3 to 2. On the Nasdaq, nine stocks fell for every four that rose.",2014-02-05,GILD,"Wed Feb 5, 2014 | 5:46pm EST","US STOCKS-Wall St ends lower, but able to bounce off support",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LA22Q20140205?type=companyNews
9,"  * ADP jobs report a tick below expectations, Dec. revised lower* Services sector grows at faster clip than forecast* Gilead Sciences shares weigh the most on S&P 500* Dow off 0.03 pct, S&P 500 down 0.20 pct, Nasdaq off 0.50 pctBy Chuck MikolajczakNEW YORK, Feb 5 U.S. stocks dipped on Wednesday as technical support offset the latest batch of mixed data, which failed to lift sentiment after a string of soft economic indicators earlier in the week.In a volatile trading session, the benchmark Standard & Poor's 500 Index hit a session low of 1,737.92, marking its lowest level since Oct. 18, before rebounding to briefly climb into positive territory with a session high of 1,755.79.U.S. data is being closely watched after a weak reading in the factory sector on Monday sent Wall Street into a tailspin and triggered a global equity selloff. Wednesday's data left investors with little clarity about the economic impact from the harsh weather this winter.Growth picked up in the U.S. services sector in January, with steady strength in private-sector hiring, suggesting the winter weather that socked the country over the last several weeks had a limited effect on the economy. ""Clearly, we are getting that support off that 1,740 area, which has held so far this week, at least,"" said Ryan Detrick, senior technical strategist at Schaeffer's Investment Research in Cincinnati.""Today's (data) almost just added to the confusion, or added to the indecision, as to what exactly should we believe - is it weather-related or is it not - and that is the big question that isn't answered yet and won't be answered for a little bit of time.""Investors were also cautious with the U.S. unemployment report looming on Friday. Last month's surprisingly low number was discounted by many as an outlier negatively affected by the severe weather.But as other data has also been uninspiring, there is concern that another weak report could be an indication of a greater macroeconomic problem. The Dow Jones industrial average slipped 5.01 points or 0.03 percent, to end at 15,440.23. The S&P 500 dipped 3.56 points or 0.20 percent, to finish at 1,751.64. The Nasdaq Composite fell 19.968 points or 0.50 percent, to close at 4,011.552.After the closing bell, Walt Disney Co. reported a higher quarterly profit and its stock climbed 1.5 percent to $72.81 in extended-hours trading.The limp data earlier in the week added to concerns about growth in China and the outlook for some emerging market economies. A recent rout in emerging currencies spurred some central banks to act, pressuring bond and stock holdings and luring investors into assets perceived as relatively safe, like the yen and U.S. and German government debt.In the latest comments from the Federal Reserve,  Philadelphia Federal Reserve Bank President Charles Plosser, a hawkish policymaker, said the central bank should wind down its bond purchases faster than planned and end the stimulus program before mid-year. Of the 298 companies in the S&P 500 that have reported earnings, 69.5 percent have topped Wall Street's expectations, according to Thomson Reuters data through Wednesday morning. That performance exceeds the 63 percent beat rate since 1994 and the 67 percent rate for the past four quarters.Gilead Sciences Inc fell 4.7 percent to close at $78.15. The stock was the heaviest weight on the S&P 500 a day after the company reported quarterly results.Shares of Cognizant Technology Solutions fell 4.3 percent to $92.85. The IT services provider forecast slower-than-expected revenue growth.Tableau Software shares jumped 12.8 percent to end at $89.61 after the data analysis software maker forecast better-than-expected revenue for this quarter and results handily beat analysts' estimates.CVS Caremark Corp said it would stop selling tobacco products at its 7,600 stores by October, becoming the first U.S. drugstore chain to take cigarettes off the shelf. Its shares declined 1 percent to close at $65.44.Volume was modest, with about 6.61 billion shares traded on U.S. exchanges, slightly below the 6.94 billion average in January, according to data from BATS Global Markets.Declining stocks outnumbered advancing ones on the NYSE by a ratio of about 3 to 2. On the Nasdaq, nine stocks fell for every four that rose.",2014-02-05,GILD,"Wed Feb 5, 2014 | 4:48pm EST","US STOCKS-Wall St closes lower, but bounces off support",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LA1XW20140205?type=companyNews
10,"  * ADP jobs report a tick below expectations, Dec. revised lower* Services sector grows at faster clip than forecast* Gilead Sciences shares weigh the most on S&P 500* Dow up 0.1 pct, S&P off 0.1 pct, Nasdaq down 0.3 pctBy Chuck MikolajczakNEW YORK, Feb 5 U.S. stocks bounced off a technical support level on Wednesday, after the S&P 500 hit its lowest level since mid-October, although mixed data gave investors few reasons to buy equities.In a volatile trading session, the benchmark S&P index hit a session low of 1,737.92, marking its lowest level since Oct. 18, before rebounding to briefly climb into positive territory. U.S. data is being closely watched after a weak reading in the factory sector on Monday sent Wall Street into a tailspin and triggered a global equity selloff. Wednesday's data left investors with little clarity about the economic impact from the harsh weather this winter.Growth picked up in the dominant U.S. services sector in January, with steady strength in private-sector hiring. The data suggested that the U.S. economy was digging through the winter weather that socked the country over the last several weeks.""Clearly, we are getting that support off that 1,740 area, which has held so far this week, at least,"" said Ryan Detrick, senior technical strategist at Schaeffer's Investment Research in Cincinnati. ""Today's (data) almost just added to the confusion, or added to the indecision, as to what exactly should we believe - is it weather-related or is it not - and that is the big question that isn't answered yet and won't be answered for a little bit of time.""The Dow Jones industrial average rose 13.52 points or 0.09 percent, to 15,458.76. The S&P 500 lost 1.44 points or 0.08 percent, to 1,753.76. The Nasdaq Composite  dropped 11.65 points or 0.29 percent, to 4,019.87.The limp data earlier in the week added to concerns about growth in China and the outlook for some emerging market economies. A recent rout in emerging currencies spurred some central banks to act, pressuring bond and stock holdings and luring investors into assets perceived as relatively safe, like the yen and U.S. and German government debt. According to Thomson Reuters data through Wednesday morning, of the 298 companies in the S&P 500 that have reported earnings, 69.5 percent have topped Wall Street's expectations, above the 63 percent beat rate since 1994 and the 67 percent rate for the past four quarters.Gilead Sciences fell 3.1 percent to $79.49 and was the heaviest weight on the S&P 500 a day after quarterly results.Shares of Cognizant Technology Solutions fell 4.2 percent to $92.95. The IT services provider forecast slower-than-expected revenue growth.Tableau Software shares jumped 13.9 percent to $90.43 after the data analysis software maker forecast better-than-expected revenue for this quarter and results handily beat analysts' estimates.CVS Caremark Corp said it would stop selling tobacco products at its 7,600 stores by October, becoming the first U.S. drugstore chain to take cigarettes off the shelf. Its shares declined 0.6 percent to $65.73.",2014-02-05,GILD,"Wed Feb 5, 2014 | 2:21pm EST","US STOCKS-S&P 500 dips after technical bounce, mixed data",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LA1IB20140205?type=companyNews
11,"  * ADP report a tick below expectations, Dec. revised lower* Services sector grows at faster clip than forecast* Gilead Sciences shares weigh the most on S&P 500* Indexes down: Dow 0.3 pct, S&P 0.6 pct, Nasdaq 1.2 pctBy Rodrigo CamposNEW YORK, Feb 5 U.S. stocks fell on Wednesday after mixed data gave investors few reasons to return to the market in what could be the middle of a long-awaited correction.U.S. data is being closely watched after a weak reading in the factory sector on Monday sent Wall Street into a tailspin and triggered a global equity selloff.At its session low, the S&P 500 was 6 percent below its Jan. 15 record high, and technicians are looking at the 1,730/1,740 area - the mid September high and Monday's low - for support.""We are now at critical support at 1,740 so they are going to try to defend that,"" said Paul Mendelsohn, chief investment strategist at Windham Financial Services in Charlotte, Vermont. ""It will be a buying opportunity when investors feel comfortable this rout we're in is over,"" he said.""I don't think they want to step in front of it just yet until they have a feeling of where the bottom is going to be. We're not there yet.""The Dow Jones industrial average fell 44.44 points or 0.29 percent, to 15,400.8, the S&P 500 lost 11.02 points or 0.63 percent, to 1,744.18 and the Nasdaq Composite  dropped 46.696 points or 1.16 percent, to 3,984.824.Investors are not ready to call the bottom and are paying more for protection against further slides. The CBOE Volatility Index rose 5.5 percent to trade above 20 for a third-straight session. The vast U.S. services sector rebounded in January after two months of slower growth and firms added workers at the fastest clip in more than three years, according to the Institute for Supply Management. Separate data showed the U.S. private sector created 175,000 jobs in January, slightly below estimates, while the December reading was revised lower.The limp data earlier in the week added to concerns about growth in China and the outlook for some emerging market economies. A recent rout in emerging currencies spurred some central banks to act, pressuring bond and stock holdings and luring investors into assets perceived as relatively safe, like the yen and U.S. and German government debt.""There's fear as we move into Friday's (jobs) report that we're going to see a weather impact that is going to distort the number and make if difficult to know if it is covering up something more substantial,"" said Mendelsohn. EARNINGS TRICKLE IN According to Thomson Reuters data through Wednesday morning, of the 298 companies in the S&P 500 that have reported earnings, 69.5 percent have topped Wall Street expectations, above the 63 percent beat rate since 1994 and the 67 percent rate for the past four quarters.Gilead Sciences fell 5.4 percent to $77.60 and was the heaviest weight on the S&P 500 a day after quarterly results.Shares of Cognizant Technology Solutions fell 6.9 percent to $90.36. The IT services provider forecast slower-than-expected revenue growth.Merck shares rose 1.7 percent to $54.43 on enthusiasm for newly announced cancer-drug partnerships with rival U.S. companies, even as the Dow component's sales and profit just missed analysts' estimates.Tableau Software shares jumped 15.9 percent to $92.02 after the data analysis software maker forecast better-than-expected revenue for this quarter and results handily beat analysts' estimates.CVS Caremark Corp said it would stop selling tobacco products at its 7,600 stores by October, becoming the first U.S. drugstore chain to take cigarettes off the shelf. Its shares fell 1.6 percent to $65.06.",2014-02-05,GILD,"Wed Feb 5, 2014 | 11:13am EST",US STOCKS-Data not strong enough to stop the selling on Wall Street,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LA13B20140205?type=companyNews
12,"   By Deena Beasley  Gilead Sciences Inc (GILD.O), which recently began selling a new hepatitis C drug seen generating billions of dollars in sales, posted a better-than-expected quarterly profit on Tuesday as sales of its flagship HIV drugs beat Wall Street estimates.Fourth-quarter net income rose 4 percent to $791.4 million from $762.5 million a year earlier. Adjusting for one-time items, the California-based company earned 55 cents a share, which beat the average analyst estimate of 50 cents a share, according to Thomson Reuters I/B/E/S.Revenue rose 20 percent to $3.12 billion, ahead of the average Wall Street forecast of $2.85 billion.Sales of hepatitis C drug Sovaldi, which was approved by U.S. regulators in early December, totaled $139.4 million for the quarter.Gilead declined to estimate 2014 sales of the drug but said demand is strong and broadly based. ""We've got a well-tolerated, highly effective cure,"" said Kevin Young, head of commercial operations at Gilead. ""This is transformational medicine.""RBC Capital Markets analyst Michael Yee said he expects 2014 Sovaldi sales of $6 billion. In the United States, the drug is priced at $84,000 for a 12-week course of treatment. The U.K. price is about $57,000 - likely the benchmark for European countries overall - while the price in Germany is slightly higher at around $66,000, Young said.""It looks like the prescription trend we've all been watching was spot on for the revenue trajectory, which means that there's going to be off-the-charts numbers this year,"" said Sanford Bernstein analyst Geoffrey Porges. ""And behind all that the HIV business is chugging along nicely.""The World Health Organization estimates that about 3 percent of the world's population has been infected with the hepatitis C virus and that more than 170 million chronic carriers are at risk of developing liver cirrhosis, liver cancer or both. The often-undiagnosed virus is transmitted through contaminated blood. While U.S. infection rates have dropped since the early 1990s - due in part to the introduction of blood and organ screening - many older adults remain at risk, according to the Centers for Disease Control and Prevention, which has called for baby boomers to be routinely tested for the virus.Gilead excluded sales of Sovaldi and other hepatitis C drugs from its forecast for 2014 product sales, which it projected would increase between 6 percent and 8 percent from 2013 to total between $11.3 billion and $11.5 billion.Analysts have forecast the company's full-year 2014 revenue at $14.66 billion. ""It's hard to imagine that they won't exceed $15 billion or $16 billion with Sovaldi,"" Porges said. ""Revenue is going to be up 40 to 50 percent.""The robust early Sovaldi sales provided further evidence that thousands of hepatitis C patients had put off treatment while awaiting newer therapies that did not require the use of injected interferon, which causes miserable flu-like symptoms.For the past two years Vertex Pharmaceuticals Inc's (VRTX.O) Incivek owned 75 percent of the hepatitis C market with annual sales in excess of $1 billion. By the fourth quarter of last year with the approval of Sovaldi, Incivek sales all but evaporated, plunging some 90 percent to just $19.3 million.Gilead's fourth-quarter sales of HIV drug Atripla rose 2 percent to $933.6 million, while sales of an older product, Truvada, fell 2 percent to $832.7 million. Sales of the company's newest HIV drug, Stribild, rose 409 percent to $203.8 million.Shares of Gilead, which rose 4 percent to close at $82.02 in regular Nasdaq trading, were down 27 cents at $81.75 after hours. Over the past 12 months, the stock has nearly doubled.(Reporting by Deena Beasley in Los Angeles; Additional reporting by Bill Berkrot in New York; Editing by Jonathan Oatis and Lisa Shumaker)",2014-02-05,GILD,"Tue Feb 4, 2014 | 7:14pm EST","Gilead posts higher profit, strong hepatitis C drug sales",http://www.reuters.com//article/us-gilead-results-idUSBREA131OA20140205?type=companyNews
13,"  By Deena BeasleyFeb 4 Gilead Sciences Inc, which recently began selling a new hepatitis C drug seen generating billions of dollars in sales, posted a better-than-expected quarterly profit on Tuesday as sales of its flagship HIV drugs beat Wall Street estimates.Fourth-quarter net income rose 4 percent to $791.4 million from $762.5 million a year earlier. Adjusting for one-time items, the California-based company earned 55 cents a share, which beat the average analyst estimate of 50 cents a share, according to Thomson Reuters I/B/E/S.Revenue rose 20 percent to $3.12 billion, ahead of the average Wall Street forecast of $2.85 billion.Sales of hepatitis C drug Sovaldi, which was approved by U.S. regulators in early December, totaled $139.4 million for the quarter.Gilead declined to estimate 2014 sales of the drug but said demand is strong and broadly based. ""We've got a well-tolerated, highly effective cure,"" said Kevin Young, head of commercial operations at Gilead. ""This is transformational medicine."" RBC Capital Markets analyst Michael Yee said he expects 2014 Sovaldi sales of $6 billion.In the United States, the drug is priced at $84,000 for a 12-week course of treatment. The U.K. price is about $57,000 - likely the benchmark for European countries overall - while the price in Germany is slightly higher at around $66,000, Young said.""It looks like the prescription trend we've all been watching was spot on for the revenue trajectory, which means that there's going to be off-the-charts numbers this year,"" said Sanford Bernstein analyst Geoffrey Porges. ""And behind all that the HIV business is chugging along nicely.""The World Health Organization estimates that about 3 percent of the world's population has been infected with the hepatitis C virus and that more than 170 million chronic carriers are at risk of developing liver cirrhosis, liver cancer or both. The often-undiagnosed virus is transmitted through contaminated blood. While U.S. infection rates have dropped since the early 1990s - due in part to the introduction of blood and organ screening - many older adults remain at risk, according to the Centers for Disease Control and Prevention, which has called for baby boomers to be routinely tested for the virus.Gilead excluded sales of Sovaldi and other hepatitis C drugs from its forecast for 2014 product sales, which it projected would increase between 6 percent and 8 percent from 2013 to total between $11.3 billion and $11.5 billion.Analysts have forecast the company's full-year 2014 revenue at $14.66 billion. ""It's hard to imagine that they won't exceed $15 billion or $16 billion with Sovaldi,"" Porges said. ""Revenue is going to be up 40 to 50 percent.""The robust early Sovaldi sales provided further evidence that thousands of hepatitis C patients had put off treatment while awaiting newer therapies that did not require the use of injected interferon, which causes miserable flu-like symptoms.For the past two years Vertex Pharmaceuticals Inc's  Incivek owned 75 percent of the hepatitis C market with annual sales in excess of $1 billion. By the fourth quarter of last year with the approval of Sovaldi, Incivek sales all but evaporated, plunging some 90 percent to just $19.3 million.Gilead's fourth-quarter sales of HIV drug Atripla rose 2 percent to $933.6 million, while sales of an older product, Truvada, fell 2 percent to $832.7 million. Sales of the company's newest HIV drug, Stribild, rose 409 percent to $203.8 million.Shares of Gilead, which rose 4 percent to close at $82.02 in regular Nasdaq trading, were down 27 cents at $81.75 after hours. Over the past 12 months, the stock has nearly doubled.",2014-02-05,GILD,"Tue Feb 4, 2014 | 7:14pm EST","UPDATE 2-Gilead posts higher profit, strong hepatitis C drug sales",http://www.reuters.com//article/gilead-results-idUSL2N0L924220140205?type=companyNews
14,"   By Bill Berkrot | NEW YORK  NEW YORK When Gilead Sciences Inc declined to project 2014 revenue for its high-profile new hepatitis C drug last week, its shares fell nearly 7 percent over the next two days.Wall Street analysts say investors were likely spooked by the omission, concerned it could signal that sales of the new drug, Sovaldi, might not approach sky-high forecasts.On Tuesday, Gilead President and Chief Operating Officer John Milligan again declined to predict sales of the medicine that won U.S. marketing approval in December. But he also did not dismiss analysts' record-shattering forecasts that the treatment could rake in $5 billion to $6 billion in its first year on the market.""It would be unprecedented for a drug to launch at that level, but because of the duration of therapy being short, because of the number of patients who are out there who have the disease, it's not unreasonable math to come to that conclusion,"" Milligan told Reuters on the sidelines at the Bio CEO & Investor conference in New York.""We're in early launch phase, just two months in, so it's dangerous to extrapolate from two months. I can see the number that's out there. I don't know if it's too high or too low based on the dynamics,"" Milligan said. Along with its fourth-quarter results released last week, Gilead reported $139.4 million in Sovaldi sales after less than one month on the market. The drug promises to increase cure rates with a much shorter duration of treatment and far fewer side effects than previous standard regimens.""We've seen great enthusiasm from the doctors, and the question is how long will they continue to bring those patients in, what experience will they have as we get through this year?"" Milligan said.He noted that a rival hepatitis C regimen from AbbVie Inc with an equally impressive cure rate could hit the market this year and affect sales. But AbbVie's treatment involves more drugs and many more pills a day, likely giving Gilead a competitive edge. Gilead this week applied for approval of a combination of Sovaldi and an experimental antiviral drug, ledipasvir, that would be taken as one pill once a day, which could also impact future sales.In late stage clinical trials, the combination provided cure rates well in excess of 90 percent, in some cases with as little as eight weeks of treatment. It would allow patients to avoid use of older hepatitis drugs that can cause troublesome side effects. Current standard treatment regimens take 24 to 48 weeks and include injected interferon that causes miserable flu-like symptoms, leading many patients to discontinue or delay treatment, and ribavirin, which can cause anemia and other unpleasant side effects.It is widely believed that thousands of patients have put off treating the virus in order to wait for new drugs such as Gilead's. By being the first of the expected new wave of oral hepatitis C treatments to market, many analysts believe that Gilead will grab the lion's share of those ""warehoused"" patients.""Remember, patients who started in December haven't gotten through their 12 weeks of therapy yet, so (doctors) haven't seen that full experience of seeing patients cured and they really won't understand that until we get into the mid part of this year,"" Milligan said.""So I encourage people not to get too far ahead of themselves in thinking about that,"" he said of the multibillion-dollar first-year Wall Street sales forecasts. ""I can understand the enthusiasm because you can get to pretty big numbers in a hurry.""(Editing by Matthew Lewis)",2014-02-11,GILD,"Tue Feb 11, 2014 | 6:10pm EST",Gilead COO: Analysts' sky-high hep C drug view 'not unreasonable',http://www.reuters.com//article/us-gilead-hepatitis-idUSBREA1A29120140211?type=companyNews
15,"   By Bill Berkrot | NEW YORK  NEW YORK Feb 11 When Gilead Sciences Inc  declined to project 2014 revenue for its high-profile new hepatitis C drug last week, its shares fell nearly 7 percent over the next two days.Wall Street analysts say investors were likely spooked by the omission, concerned it could signal that sales of the new drug, Sovaldi, might not approach sky-high forecasts.On Tuesday, Gilead President and Chief Operating Officer John Milligan again declined to predict sales of the medicine that won U.S. marketing approval in December. But he also did not dismiss analysts' record-shattering forecasts that the treatment could rake in $5 billion to $6 billion in its first year on the market.""It would be unprecedented for a drug to launch at that level, but because of the duration of therapy being short, because of the number of patients who are out there who have the disease, it's not unreasonable math to come to that conclusion,"" Milligan told Reuters on the sidelines at the Bio CEO & Investor conference in New York.""We're in early launch phase, just two months in, so it's dangerous to extrapolate from two months. I can see the number that's out there. I don't know if it's too high or too low based on the dynamics,"" Milligan said. Along with its fourth-quarter results released last week , Gilead reported $139.4 million in Sovaldi sales after less than one month on the market. The drug promises to increase cure rates with a much shorter duration of treatment and far fewer side effects than previous standard regimens.""We've seen great enthusiasm from the doctors, and the question is how long will they continue to bring those patients in, what experience will they have as we get through this year?"" Milligan said. He noted that a rival hepatitis C regimen from AbbVie Inc  with an equally impressive cure rate could hit the market this year and affect sales. But AbbVie's treatment involves more drugs and many more pills a day, likely giving Gilead a competitive edge.Gilead this week applied for approval of a combination of Sovaldi and an experimental antiviral drug, ledipasvir, that would be taken as one pill once a day, which could also impact future sales.In late stage clinical trials, the combination provided cure rates well in excess of 90 percent, in some cases with as little as eight weeks of treatment. It would allow patients to avoid use of older hepatitis drugs that can cause troublesome side effects. Current standard treatment regimens take 24 to 48 weeks and include injected interferon that causes miserable flu-like symptoms, leading many patients to discontinue or delay treatment, and ribavirin, which can cause anemia and other unpleasant side effects.It is widely believed that thousands of patients have put off treating the virus in order to wait for new drugs such as Gilead's. By being the first of the expected new wave of oral hepatitis C treatments to market, many analysts believe that Gilead will grab the lion's share of those ""warehoused"" patients.""Remember, patients who started in December haven't gotten through their 12 weeks of therapy yet, so (doctors) haven't seen that full experience of seeing patients cured and they really won't understand that until we get into the mid part of this year,"" Milligan said.""So I encourage people not to get too far ahead of themselves in thinking about that,"" he said of the multibillion-dollar first-year Wall Street sales forecasts. ""I can understand the enthusiasm because you can get to pretty big numbers in a hurry.""",2014-02-11,GILD,"Tue Feb 11, 2014 | 6:02pm EST",Gilead COO: Analysts' sky-high hep C drug view 'not unreasonable',http://www.reuters.com//article/gilead-hepatitis-idUSL2N0LG25220140211?type=companyNews
16,"  By Bill BerkrotNEW YORK Feb 11 When Gilead Sciences Inc  declined to project 2014 revenue for its high-profile new hepatitis C drug last week, its shares fell nearly 7 percent over the next two days.Wall Street analysts say investors were likely spooked by the omission, concerned it could signal that sales of the new drug, Sovaldi, might not approach sky-high forecasts.On Tuesday, Gilead President and Chief Operating Officer John Milligan again declined to predict sales of the medicine that won U.S. marketing approval in December. But he also did not dismiss analysts' record-shattering forecasts that the treatment could rake in $5 billion to $6 billion in its first year on the market.""It would be unprecedented for a drug to launch at that level, but because of the duration of therapy being short, because of the number of patients who are out there who have the disease, it's not unreasonable math to come to that conclusion,"" Milligan told Reuters on the sidelines at the Bio CEO & Investor conference in New York. ""We're in early launch phase, just two months in, so it's dangerous to extrapolate from two months. I can see the number that's out there. I don't know if it's too high or too low based on the dynamics,"" Milligan said.Along with its fourth-quarter results released last week , Gilead reported $139.4 million in Sovaldi sales after less than one month on the market. The drug promises to increase cure rates with a much shorter duration of treatment and far fewer side effects than previous standard regimens.""We've seen great enthusiasm from the doctors, and the question is how long will they continue to bring those patients in, what experience will they have as we get through this year?"" Milligan said. He noted that a rival hepatitis C regimen from AbbVie Inc  with an equally impressive cure rate could hit the market this year and affect sales. But AbbVie's treatment involves more drugs and many more pills a day, likely giving Gilead a competitive edge.Gilead this week applied for approval of a combination of Sovaldi and an experimental antiviral drug, ledipasvir, that would be taken as one pill once a day, which could also impact future sales. In late stage clinical trials, the combination provided cure rates well in excess of 90 percent, in some cases with as little as eight weeks of treatment. It would allow patients to avoid use of older hepatitis drugs that can cause troublesome side effects.Current standard treatment regimens take 24 to 48 weeks and include injected interferon that causes miserable flu-like symptoms, leading many patients to discontinue or delay treatment, and ribavirin, which can cause anemia and other unpleasant side effects.It is widely believed that thousands of patients have put off treating the virus in order to wait for new drugs such as Gilead's. By being the first of the expected new wave of oral hepatitis C treatments to market, many analysts believe that Gilead will grab the lion's share of those ""warehoused"" patients.""Remember, patients who started in December haven't gotten through their 12 weeks of therapy yet, so (doctors) haven't seen that full experience of seeing patients cured and they really won't understand that until we get into the mid part of this year,"" Milligan said.""So I encourage people not to get too far ahead of themselves in thinking about that,"" he said of the multibillion-dollar first-year Wall Street sales forecasts. ""I can understand the enthusiasm because you can get to pretty big numbers in a hurry.""",2014-02-12,GILD,"Wed Feb 12, 2014 | 7:00am EST",RPT-Gilead COO: Analysts' sky-high hep C drug view 'not unreasonable',http://www.reuters.com//article/gilead-hepatitis-idUSL2N0LG2CX20140212?type=companyNews
17,"   By Bill Berkrot and Deena Beasley  U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs.The news pushed shares of Gilead down as much as 6 percent on Friday and sparked a sell-off among other leading biotech names on concerns they may have a harder time pricing new medicines. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.Some health insurers, including the government's Medicaid program for the poor, are holding off on authorizing use of Gilead's new hepatitis C drug. While the treatment has been shown to cure many patients, the payors are balking at the prospect of covering the therapy for millions of people at a cost in the billions of dollars.Separately on Friday, Gilead confirmed that it had agreed to supply the new drug in Egypt - which has the world's highest prevalence of the virus due to use of contaminated needles in the 1970s - at around $900 for a 12-week course of therapy, or about 1 percent of the U.S. price.The company has proposed a system of worldwide tiered pricing based on a country's per capita gross national income. Sovaldi's U.K. price is about $57,000, while the price in Germany is around $66,000, Gilead has said.A letter to Gilead from Democrats in the House Energy & Commerce Committee, including ranking member Henry Waxman, asks for information on the company's pricing methodology and its impact on public health.Sovaldi is seen as a breakthrough in the treatment of the serious liver disease. It has been shown to raise cure rates and cut treatment duration with fewer side effects than older medicines, but critics maintain that a price of $1,000 each is too high for an easy-to-make pill needed by millions.Gilead, in an emailed statement, said it has been working with a number of stakeholders, including federal and state officials, and looks forward to meeting with members of Congress to address concerns about Sovaldi.The drug, approved by the Food and Drug Administration late last year, is expected to post record-breaking sales in its first year on the market. ""What is really scaring folks is the volume,"" ISI Group analyst Mark Schoenebaum said on a conference call, referring to the fact that more than 3 million Americans are believed to be infected with the hepatitis C virus. He said sales of Sovaldi will total between $7 billion and $12 billion this year alone.The head of commercial business at health insurer WellPoint Inc said the company is working with regulators and drug manufacturers to bring prices for hepatitis C drugs down to a ""reasonable"" level.""Our concern is that a treatment will not cure patients if they cannot afford it,"" the committee letter, addressed to Gilead Chief Executive John Martin, said. It asked that the company provide a briefing no later than April 3.COMBO DRUG RAISES PRICE FURTHER The letter cited a Reuters report noting that doctors are combining Sovaldi with a newly approved drug from Johnson & Johnson called Olysio, raising the treatment cost to $150,000. ""The costs are likely too high for many patients, both those with public insurance and private insurance,"" the letter said. It added, ""The extraordinarily high cost of your drug raises additional concerns because of the role of the federal government in speeding up its approval.""Sovaldi was approved on an expedited basis by the FDA after being designated as a ""breakthrough therapy.""Answers being sought by committee Democrats include the methodology used by Gilead to establish Sovaldi's price and the public health impact of insurers' and public health programs' decisions not to cover Sovaldi for all patients with hepatitisC.  Sovaldi is the first in a wave of expected new all-oral treatment regimens for the hepatitis C virus that have shown impressively high cure rates, well in excess of 90 percent, in clinical trials.The likely launch over the next two years of drugs similar to Sovaldi, under development at companies like AbbVie, Bristol-Myers Squibb Co and Merck & Co, could trigger cost competition, Schoenebaum said.""We are going to go from a monopoly to seven or eight players,"" he said. ""In my mind that is what will drive pricing down.""These new drugs are meant to replace older treatment regimens that include the injected drug interferon, which causes miserable flu-like symptoms that have led thousands of patients to delay treatment and wait for the newer medicines.The older drugs cure about 75 percent of those treated and take 24 to 48 weeks of treatment. The new drugs have been shown to cure patients in 12 weeks or less.JP Morgan analyst Geoff Meacham noted that there was no such outcry from Congress following the last wave of new hepatitis C treatments that could cost about $100,000, cured fewer patients and came with far worse side effects.""Given the very high cure rates with Sovaldi, Gilead is in position to 'guarantee a cure' to payers, thereby dramatically reducing the downstream economic burden of a liver transplant, risk of liver cancer or cirrhosis,"" Meacham said in a research note.Gilead shares fell $3.46, or 4.6 percent, to close at $72.07 after being down as much as $70.85 earlier in the day. Over the past year the stock has gained 70 percent.(Additional reporting by Michele Gershberg and Deena Beasley; Editing by Michele Gershberg, David Gregorio, Andrew Hay and Bernard Orr)",2014-03-21,GILD,"Fri Mar 21, 2014 | 4:56pm EDT",U.S. lawmakers want Gilead to explain Sovaldi's hefty price,http://www.reuters.com//article/us-gilead-sovaldi-idUSBREA2K18H20140321?type=companyNews
18,"  (Adds company comment, details of Egypt price deal, updates share prices)By Bill Berkrot and Deena BeasleyMarch 21 U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs.The news pushed shares of Gilead down as much as 6 percent on Friday and sparked a sell-off among other leading biotech names on concerns they may have a harder time pricing new medicines. Biogen Idec fell 8 percent, Amgen Inc  dropped 3 percent and Celgene Corp lost 3.7 percent.Some health insurers, including the government's Medicaid program for the poor, are holding off on authorizing use of Gilead's new hepatitis C drug. While the treatment has been shown to cure many patients, the payors are balking at the prospect of covering the therapy for millions of people at a cost in the billions of dollars.Separately on Friday, Gilead confirmed that it had agreed to supply the new drug in Egypt - which has the world's highest prevalence of the virus due to use of contaminated needles in the 1970s - at around $900 for a 12-week course of therapy, or about 1 percent of the U.S. price.The company has proposed a system of worldwide tiered pricing based on a country's per capita gross national income. Sovaldi's U.K. price is about $57,000, while the price in Germany is around $66,000, Gilead has said.A letter to Gilead from Democrats in the House Energy & Commerce Committee, including ranking member Henry Waxman, asks for information on the company's pricing methodology and its impact on public health.Sovaldi is seen as a breakthrough in the treatment of the serious liver disease. It has been shown to raise cure rates and cut treatment duration with fewer side effects than older medicines, but critics maintain that a price of $1,000 each is too high for an easy-to-make pill needed by millions.Gilead, in an emailed statement, said it has been working with a number of stakeholders, including federal and state officials, and looks forward to meeting with members of Congress to address concerns about Sovaldi. The drug, approved by the Food and Drug Administration late last year, is expected to post record-breaking sales in its first year on the market.""What is really scaring folks is the volume,"" ISI Group analyst Mark Schoenebaum said on a conference call, referring to the fact that more than 3 million Americans are believed to be infected with the hepatitis C virus. He said sales of Sovaldi will total between $7 billion and $12 billion this year alone.The head of commercial business at health insurer WellPoint Inc said the company is working with regulators and drug manufacturers to bring prices for hepatitis C drugs down to a ""reasonable"" level.""Our concern is that a treatment will not cure patients if they cannot afford it,"" the committee letter, addressed to Gilead Chief Executive John Martin, said. It asked that the company provide a briefing no later than April 3. COMBO DRUG RAISES PRICE FURTHER The letter cited a Reuters report noting that doctors are combining Sovaldi with a newly approved drug from Johnson & Johnson called Olysio, raising the treatment cost to $150,000.""The costs are likely too high for many patients, both those with public insurance and private insurance,"" the letter said. It added, ""The extraordinarily high cost of your drug raises additional concerns because of the role of the federal government in speeding up its approval.""Sovaldi was approved on an expedited basis by the FDA after being designated as a ""breakthrough therapy."" Answers being sought by committee Democrats include the methodology used by Gilead to establish Sovaldi's price and the public health impact of insurers' and public health programs' decisions not to cover Sovaldi for all patients with hepatitis C.Sovaldi is the first in a wave of expected new all-oral treatment regimens for the hepatitis C virus that have shown impressively high cure rates, well in excess of 90 percent, in clinical trials.The likely launch over the next two years of drugs similar to Sovaldi, under development at companies like AbbVie, Bristol-Myers Squibb Co and Merck & Co, could trigger cost competition, Schoenebaum said.""We are going to go from a monopoly to seven or eight players,"" he said. ""In my mind that is what will drive pricing down.""These new drugs are meant to replace older treatment regimens that include the injected drug interferon, which causes miserable flu-like symptoms that have led thousands of patients to delay treatment and wait for the newer medicines.The older drugs cure about 75 percent of those treated and take 24 to 48 weeks of treatment. The new drugs have been shown to cure patients in 12 weeks or less.JP Morgan analyst Geoff Meacham noted that there was no such outcry from Congress following the last wave of new hepatitis C treatments that could cost about $100,000, cured fewer patients and came with far worse side effects.""Given the very high cure rates with Sovaldi, Gilead is in position to 'guarantee a cure' to payers, thereby dramatically reducing the downstream economic burden of a liver transplant, risk of liver cancer or cirrhosis,"" Meacham said in a research note.Gilead shares fell $3.46, or 4.6 percent, to close at $72.07 after being down as much as $70.85 earlier in the day. Over the past year the stock has gained 70 percent.   (Additional reporting by Michele Gershberg and Deena Beasley; Editing by Michele Gershberg, David Gregorio, Andrew Hay and Bernard Orr)",2014-03-21,GILD,"Fri Mar 21, 2014 | 4:52pm EDT",UPDATE 4-U.S. lawmakers want Gilead to explain Sovaldi's hefty price,http://www.reuters.com//article/gilead-sovaldi-idUSL2N0MI0UP20140321?type=companyNews
19,"   By Maggie Fick and Ben Hirschler | CAIRO/LONDON  CAIRO/LONDON Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price.While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of the $84,000 charged for a course of treatment in the United States.The high price tag in America prompted questions from U.S. lawmakers on Friday, after U.S. health insurers said they were seeking help from state health officials to foot the bill.Gilead said it was ""pleased to have finalized an agreement"" for the introduction of Sovaldi in Egypt, which has the highest prevalence rate of hepatitis C in the world.""We believe Sovaldi could have a major impact on public health in Egypt by significantly increasing the number of people who can be cured of hepatitis C,"" Gregg Alton, head of corporate and medical affairs at Gilead, said in an emailed statement.Egyptian health minister Adel El-Adawi said Cairo had struck a deal with U.S.-based Gilead for the government to buy Sovaldi for $300 for a one-month box, according to a recent report on the state news agency MENA. That would imply a cost of $900 if Sovaldi is used as part of a 12-week drug regimen, although the cost would be higher if it was used for 24 weeks, which is also an option based on different drug combinations.El-Adawi said Gilead's offer would apply to Sovaldi supplies used in government clinics, adding that access programmes would start in the second half of 2014, following completion of registration procedures in Egypt.Sovaldi is in the vanguard of a wave of pills which could cure the liver-destroying disease in millions of people worldwide, or even eradicate it entirely. But that will only happen if the new therapies are affordable enough to allow widespread use. Nowhere is the problem more acute than in Egypt, which has the world's highest prevalence of the virus, following the use of poorly sterilized needles in campaigns dating back to the 1970s to stamp out the parasitic disease schistosomiasis.Like HIV, hepatitis C (HCV) can be spread through blood, often via contaminated needles.The World Health Organization estimates that more than 150 million people worldwide are chronically infected, most of them in developing countries, putting them at risk of cirrhosis and liver cancer. Other companies such as Johnson & Johnson, AbbVie, Bristol-Myers Squibb and Merck & Co are also developing oral treatment regimens for HCV that have shown dramatic results in clinical trials, while reducing the need for debilitating interferon injections.Doctors and industry analysts believe the new drugs will transform HCV treatment - and prove hugely profitable. In the developed world, they are tipped to become major blockbusters, with consensus sales forecasts for Sovaldi alone standing at $9.1 billion in 2017, according to Thomson Reuters Pharma.But the risk of a gulf in access between patients in the rich and poor parts of the world is causing alarm among health campaigners who warn of a potential re-run of the battle over HIV drugs in Africa more than a decade ago.Medecins du Monde, a non-profit group that provides medical care around the world, highlighted Egypt as a country in dire need of the new hepatitis C drugs in a report this week.Gilead has also said it plans to license Sovaldi to a number of Indian generic pharmaceutical manufacturers, which would be able to sell lower-priced copies of the medication.(Additional reporting by Deena Beasley; Editing by James Dalgleish)",2014-03-21,GILD,"Fri Mar 21, 2014 | 4:10pm EDT",Gilead offers Egypt new hepatitis C drug at 99 percent discount,http://www.reuters.com//article/us-hepatitis-egypt-gilead-sciences-idUSBREA2K1VF20140321?type=companyNews
20,"   By Maggie Fick and Ben Hirschler | CAIRO/LONDON, March 21  CAIRO/LONDON, March 21 Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price.While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of the $84,000 charged for a course of treatment in the United States.The high price tag in America prompted questions from U.S. lawmakers on Friday, after U.S. health insurers said they were seeking help from state health officials to foot the bill.Gilead said it was ""pleased to have finalized an agreement"" for the introduction of Sovaldi in Egypt, which has the highest prevalence rate of hepatitis C in the world.""We believe Sovaldi could have a major impact on public health in Egypt by significantly increasing the number of people who can be cured of hepatitis C,"" Gregg Alton, head of corporate and medical affairs at Gilead, said in an emailed statement.Egyptian health minister Adel El-Adawi said Cairo had struck a deal with U.S.-based Gilead for the government to buy Sovaldi for $300 for a one-month box, according to a recent report on the state news agency MENA. That would imply a cost of $900 if Sovaldi is used as part of a 12-week drug regimen, although the cost would be higher if it was used for 24 weeks, which is also an option based on different drug combinations.El-Adawi said Gilead's offer would apply to Sovaldi supplies used in government clinics, adding that access programmes would start in the second half of 2014, following completion of registration procedures in Egypt.Sovaldi is in the vanguard of a wave of pills which could cure the liver-destroying disease in millions of people worldwide, or even eradicate it entirely. But that will only happen if the new therapies are affordable enough to allow widespread use. Nowhere is the problem more acute than in Egypt, which has the world's highest prevalence of the virus, following the use of poorly sterilised needles in campaigns dating back to the 1970s to stamp out the parasitic disease schistosomiasis.Like HIV, hepatitis C (HCV) can be spread through blood, often via contaminated needles.The World Health Organisation estimates that more than 150 million people worldwide are chronically infected, most of them in developing countries, putting them at risk of cirrhosis and liver cancer. Other companies such as Johnson & Johnson, AbbVie , Bristol-Myers Squibb and Merck & Co  are also developing oral treatment regimens for HCV that have shown dramatic results in clinical trials, while reducing the need for debilitating interferon injections.Doctors and industry analysts believe the new drugs will transform HCV treatment - and prove hugely profitable. In the developed world, they are tipped to become major blockbusters, with consensus sales forecasts for Sovaldi alone standing at $9.1 billion in 2017, according to Thomson Reuters Pharma.But the risk of a gulf in access between patients in the rich and poor parts of the world is causing alarm among health campaigners who warn of a potential re-run of the battle over HIV drugs in Africa more than a decade ago.Medecins du Monde, a non-profit group that provides medical care around the world, highlighted Egypt as a country in dire need of the new hepatitis C drugs in a report this week.Gilead has also said it plans to license Sovaldi to a number of Indian generic pharmaceutical manufacturers, which would be able to sell lower-priced copies of the medication.     (Additional reporting by Deena Beasley; Editing by James Dalgleish)",2014-03-21,GILD,"Fri Mar 21, 2014 | 3:56pm EDT",Gilead offers Egypt new hepatitis C drug at 99 pct discount,http://www.reuters.com//article/hepatitis-egypt-gilead-sciences-idUSL2N0MI1ID20140321?type=companyNews
21,"  The head of WellPoint Inc's commercial business said on Friday that the price of new hepatitis c drugs, which are made by Gilead Sciences Inc and Johnson and Johnson, are too high.Ken Goulet, speaking to investors, said the company is working with regulators and drug manufacturers to bring these prices down to a ""reasonable"" level. He said that as of mid-February the company had filled 100 prescriptions for commercial members. On the Medicaid side of the business, WellPoint said that it is working with states on trying to determine how to proceed with either figuring out a managed care cost for the drug or excluding the drug from the managed care plans. (Reporting by Caroline Humer, Editing by Franklin Paul)",2014-03-21,GILD,"Fri Mar 21, 2014 | 12:22pm EDT",WellPoint says new hepatitis c drug prices are too high,http://www.reuters.com//article/us-wellpoint-hepatitisc-idUSBREA2K1DS20140321?type=companyNews
22,"  March 21 The head of WellPoint Inc's  commercial business said on Friday that the price of new hepatitis c drugs, which are made by Gilead Sciences Inc  and Johnson and Johnson, are too high.Ken Goulet, speaking to investors, said the company is working with regulators and drug manufacturers to bring these prices down to a ""reasonable"" level. He said that as of mid-February the company had filled 100 prescriptions for commercial members.  On the Medicaid side of the business, WellPoint said that it is working with states on trying to determine how to proceed with either figuring out a managed care cost for the drug or excluding the drug from the managed care plans.    (Reporting by Caroline Humer, Editing by Franklin Paul)",2014-03-21,GILD,"Fri Mar 21, 2014 | 12:20pm EDT",WellPoint says new hepatitis c drug prices are too high,http://www.reuters.com//article/wellpoint-hepatitisc-idUSL2N0MI10V20140321?type=companyNews
23,"  March 21 U.S. lawmakers have asked for a briefing from Gilead Sciences Inc on the price of new hepatitis C drug Sovaldi.A letter to Gilead from Democrats in the House Energy & Commerce Committee asks for information on Sovaldi discounts to payors and patients. The recently approved medicine, seen as a breakthrough in the treatment of the serious liver disease, costs about $84,000 per patient.  Gilead shares were down 4 percent in morning trading on Nasdaq.   (Reporting by Michele Gershberg and Bill Berkrot; Editing by Jeffrey Benkoe)",2014-03-21,GILD,"Fri Mar 21, 2014 | 10:47am EDT",U.S. lawmakers ask Gilead about Sovaldi pricing,http://www.reuters.com//article/gilead-sovaldi-idUSL2N0MI0SG20140321?type=companyNews
24,"   By Deena Beasley  Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.The medication, Sovaldi, has a list price of $84,000 for a 12-week course of therapy and is seen as a breakthrough in the treatment of the serious liver disease.It has been shown to raise cure rates and cut treatment time with fewer side effects than older medicines, but critics maintain that a price of $1,000 each is too high for an easy-to-make pill needed by millions of Americans.On March 20, Democratic lawmakers led by California Representative Henry Waxman asked Gilead to explain the price tag, and a meeting with the company is scheduled for next week.Health insurers and state Medicaid programs for the poor are pushing for further discounts, fearing a multibillion-dollar pricetag from treating most hepatitis C sufferers with Sovaldi and similar new medicines likely to be approved in coming years.Gilead shares have dropped 9 percent in the last week on concerns over the pushback on drug pricing. The news has also weighed on other biotechnology companies that are banking on their ability to command high prices for new treatments.""It's the volume (of patients) payers are looking at here. It's not the price,"" said Gregg Alton, Gilead's executive vice president, corporate and medical affairs. ""A lot of them are looking for a discount, but I think the real issue here is how many patients they now have in their plans that need hepatitis C treatment."" The Centers for Disease Control and Prevention estimates that about 3.2 million Americans are infected with hepatitis C, a liver-destroying virus transmitted through blood.If each were treated with full-priced Sovaldi, the cost would be $269 billion. Gilead already provides a mandated discount off its list price to U.S. government health plans and insurers at about 23 percent.Alton said the company has deals for ""supplemental discounts"" for government-funded agencies such the Veterans Administration and the Department of Defense, on top of the 23 percent. He would not provide details.He said the VA, which accounts for about 10 to 15 percent of the hepatitis C population in the United States, has been ""proactive"" in recognizing the need to treat the disease, which can lead to liver failure and necessitate liver transplants. He estimated that patients eligible for Medicaid, the government-funded health plan for the poor, account for another 10 to 15 percent of Americans with hepatitis C.Alton singled out health maintenance organization Kaiser Permanente for taking action to secure Sovaldi, also at a discount, for its patients.""We have an arrangement with Kaiser that works very well for both of us,"" the Gilead executive said. ""They recognize that if they make the investment today, they get all the benefit."" He said that is because many Kaiser patients stay for many years with the organization known for quality, integrated care, even into retirement when they qualify for a managed Medicare plan. So Kaiser's upfront investment treating hepatitis C will pay off years later by averting future costs of liver disease. Kaiser officials were not immediately available for comment.But many traditional insurers can't rely on the same kind of stability among their policyholders, who tend to switch health plans more frequently, meaning they cannot be sure of the same savings over time.""One of the challenges we have with some insurers is that the benefits may not come to them,"" the Gilead executive said. ""No matter how we price this product, the benefits and the savings are going to come later.""Alton also sees the concerns over a deluge of patients demanding immediate treatment as unlikely to materialize.""Most of the patients are not diagnosed, and many aren't seeking care currently,"" he said. ""This is going to take some time.""ISI Group analyst Mark Schoenebaum noted on Friday data showing that new prescriptions of Sovaldi had dropped 5 percent in the past week. He estimated that Gilead's 2014 U.S. sales of Sovaldi, which was approved by the Food and Drug Administration late last year, will total as much as $9 billion even if it sees no new prescription growth.(Reporting By Deena Beasley; Editing by Michele Gershberg, Tom Brown and David Gregorio)",2014-03-29,GILD,"Sat Mar 29, 2014 | 12:13pm EDT",Gilead says has discounted hepatitis C drug for some health plans,http://www.reuters.com//article/us-gilead-hepatitis-idUSBREA2S0EZ20140329?type=companyNews
25,"  April 2 A pivotal trial of Gilead Sciences Inc's  hepatitis C drug sofosbuvir, sold under the brand name Sovaldi in the United States, showed that the drug is safe and effective in treating Japanese patients infected with a common form of the virus.Gilead, based in Foster City, California, said on Wednesday it expects to file by mid-year for regulatory approval of the pill in Japan.The trial involved 153 patients infected with genotype 2 hepatitis C, which the most common form of the liver-destroying virus in Japan and China. Gilead said the study met its goal, showing that 98 percent of previously-untreated patients achieved undetectable levels of the virus three months after completing 12 weeks of treatment with a combination of sofosbuvir and ribavirin. For previously-treated patients, the response rate was 95 percent. Side effects seen in the trial included anemia and headache. Wall Street analysts, on average, have forecast Sovaldi sales of $9.1 billion in 2017, according to Thomson Reuters Pharma.   (Reporting by Deena Beasley; Editing by Marguerita Choy)",2014-04-02,GILD,"Wed Apr 2, 2014 | 5:17pm EDT",Gilead says Japanese hepatitis C trial meets goal,http://www.reuters.com//article/gilead-sciences-sovaldi-japan-idUSL1N0MU22L20140402?type=companyNews
26,"   By Ben Hirschler | LONDON  LONDON Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.Clifford Samuel, head of access operations and emerging markets at the U.S. drugmaker, told Reuters he expected to have deals in place shortly with the Indian firms, which would be able to produce the drug in high volumes and at low margins.Gilead is under pressure to address the high cost of its breakthrough pill, which is the first of a new wave of drugs that have been shown to raise cure rates and cut treatment duration without the side effects of current injections.""We're in the midst of discussions right now. We're nailing down the geographical scope, and we should have these licenses in place and ready to go in short order,"" Samuel said on a visit to London for an international liver conference.He said Gilead was looking to strike deals with firms that had proven experience in producing generic versions of its HIV/AIDS drugs, such as the Indian division of Mylan. The Foster City, California-based company has been operating a similar voluntary licensing programme for many years for low-cost HIV drugs, which covers 112 countries.Under the hepatitis C plan, Indian-made generics would be available in most of sub-Saharan Africa, selected Asian countries including India, Pakistan and Myanmar, and some smaller developing nations.Gilead is also working to establish ""tiered pricing"" for Sovaldi in other low- and middle-income countries, Samuel said. The company struck the first such tiered pricing deal last month in Egypt, where it has agreed to supply the government at just over 1 percent of the U.S. price, or $300 for a 28-day bottle against $28,000.For India, the company is currently discussing a price of $2,000 based on 24 weeks of treatment, although no final deal has been reached, Samuel added. Egypt has the world's highest prevalence of the liver-destroying hepatitis C virus, which is spread through blood, making it an obvious first market for more affordable, tiered pricing.""We're targeting key, high-prevalence countries like India, Pakistan and Egypt. We are sitting down with them and looking at differential pricing,"" Samuel said.Gilead's tiered pricing will not apply, however, to some large middle-income countries with significant hepatitis C populations such as Ukraine and China, which are viewed as commercial market opportunities.In the United States, Sovaldi's price tag of $84,000 for a 12-week course of treatment has been described by one health provider as ""outrageous"", while U.S. lawmakers have written to the firm demanding an explanation of the price.(Editing by Jane Baird)",2014-04-08,GILD,"Tue Apr 8, 2014 | 11:42am EDT",Gilead aims to license hepatitis C drug to 3-4 Indian firms,http://www.reuters.com//article/us-hepatitis-gilead-idUSBREA371DI20140408?type=companyNews
27,"  * London congress showcases dramatic treatment advances* WHO guidelines back Gilead, J&J pills but flag up cost* UN agency wants ""concerted effort"" to reduce prices* Hepatitis C pricing a hot issue for biotech investorsBy Ben HirschlerLONDON, April 9 The World Health Organisation wants a ""concerted effort"" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.The forthright comments from the UN agency on Wednesday   add to pressure on drugmakers such as Gilead Sciences - which is already facing protests in the United States over its $1,000-a-day pill - to do more to improve access.In its first-ever treatment guidelines for the disease, issued at a meeting of international liver experts in London, the WHO strongly recommended new drugs from Gilead and Johnson & Johnson - with a big caveat on their cost.Treating the approximately 150 million people in the world living with chronic hepatitis C infection is the new front-line in the battle over access to medicines.As with AIDS 15 years ago, modern drugs are transforming the ability to fight hepatitis C because pills such as Gilead's Sovaldi are far more effective and better-tolerated than older injection regimens, with cure rates well above 90 percent in many cases.""These drugs are fantastic - they are a real breakthrough,"" Markus Peck-Radosavljevic, a professor of medicine in Vienna and secretary-general of the European Association for the Study of the Liver, told Reuters. ""But the prices are too high."" Pharmaceutical companies say they need to charge high prices on new successful drugs to cover the huge cost of development, including of those that fail to make it to the market.A record number of promising results from late-stage clinical trials on a range of new oral medicines will be showcased at the International Liver Congress this week.Hepatitis C virus, or HCV, is spread through blood, often via contaminated needles. It causes cirrhosis and liver cancer. The vast majority of cases are in poorer countries where the complexity, cost and side effects of current treatments have made treatment impractical.The arrival of simple pills, taken for as little as a couple of months, could revolutionise therapy, if the price is right.By giving governments a plan setting out how to test for, treat and prevent HCV, the WHO is laying foundations for tackling the disease, while spurring demand and sending a strong message on price. ""I hope these guidelines will help to promote a reduction in price and thereby an increase in access,"" said Stefan Wiktor, who leads the WHO hepatitis programme.COMPULSORY LICENCES? Drawing a clear parallel with the experience of HIV/AIDS, the WHO believes a ""multi-pronged"" approach is needed. This could include tiered price discounts by branded drugmakers, voluntary licensing and also compulsory licensing.Voluntary licensing involves a patent owner agreeing to license its drug to generic manufacturers, while a compulsory licence is issued by a government without any such agreement - something the pharmaceuticals industry is keen to avoid. After dragging their feet for years over access to AIDS drugs in Africa, pharmaceuticals makers are trying to take the initiative this time. Market leader Gilead recently agreed a 99 percent price discount for Egypt and plans to grant voluntary licences to several Indian generics firms.J&J has also promised to work on access and others entering the area - such as AbbVie, Bristol-Myers Squibb  and Merck & Co - are expected to follow suit.But campaigners want more. The Medecins Sans Frontieres group believes a 12-week course of treatment and diagnosis should cost no more than $500. That compares with the $84,000 and $66,000 charged by Gilead and J&J respectively for their drugs in the United States.There is also a big concern about middle-income countries such as China, India and Russia, which are home to most cases of HCV worldwide but where drug companies are more reluctant to accept rock-bottom prices than in the poorest nations.Charles Gore, president of the patient-led World Hepatitis Alliance, welcomed the WHO guidelines but said international funding along the lines of the Global Fund to Fight AIDS, Tuberculosis and Malaria was now needed.When it comes to profits, drug companies are expecting to make most of their money in the United States, where medicines traditionally fetch a premium.But the scale of the expected demand for new hepatitis C drugs - which industry analysts believe will translate into annual sales of $9.1 billion for Sovaldi alone by 2017, according to Thomson Reuters data - means the industry is under fire.U.S. lawmakers asked Gilead last month to explain the $84,000 price tag on Sovaldi, hitting shares in the firm and raising fears across the biotech sector.""Until we develop a better model, we are still in the situation where investors in pharma want to recompensed on the winners for all the losers - and there have been a lot of losers in hepatitis C over the years,"" said Gore.(Reporting by Ben Hirschler; editing by David Stamp)",2014-04-09,GILD,"Wed Apr 9, 2014 | 7:00am EDT",WHO joins clamour to make new hepatitis C pills affordable,http://www.reuters.com//article/health-hepatitis-idUSL6N0MZ47K20140409?type=companyNews
28,"   By Caroline Valetkevitch | NEW YORK  NEW YORK The Nasdaq suffered its biggest drop in two-and-a-half years on Thursday after another sharp selloff in biotech and momentum names, including Gilead Sciences (GILD.O) and TripAdvisor (TRIP.O), increasing investor anxiety about a broader pullback.The Nasdaq biotechnology index .NBI shed 5.6 percent, its biggest one-day drop since August 2011, adding to recent losses since a large drop in Gilead more than two weeks ago triggered a wider selloff for biotechs and other recent big gainers. That index is now down 18.8 percent since its February 25 record close.The S&P 500 also posted its biggest percentage loss since February 3, while the Nasdaq has dropped 7 percent from its closing high for the year, set on March 5. All stocks in the Nasdaq 100 index .NDX posted a loss, with the exception of CH Robinson Worldwide (CHRW.O), which ended up 1.6 percent at $53.80.The selling also hit the shares of three companies in their first day of public trading after their initial public offerings were priced on Wednesday night. All three IPOs ended lower.""Momentum names have been driving this market higher. A lot of these names have been trading at stratospheric valuations, and on long-term outlooks, that may or may not materialize. The question is, 'At what point do they get too expensive?' Right now, I think they're looking a little expensive,"" said Randy Frederick, managing director of active trading and derivatives for Charles Schwab in Austin, Texas.There's a good chance the selloff in these stocks could continue and the pullback could extend to areas beyond the momentum names, Frederick said.The CBOE Volatility Index or the VIX .VIX, Wall Street's measure of investor anxiety, jumped 15 percent, its biggest daily percentage gain since February 3, to end at 15.89.Alexion Pharma (ALXN.O) was the S&P 500's biggest decliner, off 7.5 percent at $144.19, followed by Gilead Sciences, down 7.3 percent at $65.48, and TripAdvisor, down 7 percent at $81.90. The move was a sharp reversal from the previous day, when shares rallied after minutes from the latest Federal Reserve policymakers' meeting showed members were more keen to keep rates low than previously expected.The Dow Jones industrial average .DJI plummeted 266.96 points or 1.62 percent, to end at 16,170.22. The S&P 500 .SPX lost 39.09 points or 2.09 percent, to close at 1,833.09.The Nasdaq Composite .IXIC dropped 129.794 points or 3.1 percent - its biggest daily percentage loss since November 9, 2011 - to 4,054.106.The S&P 500 closed below its 50-day moving average for the first time since February 10. The stock of bailed-out auto lender Ally Financial Inc (ALLY.N) fell 4.1 percent to close at $23.98 in its market debut.Two biotech companies - Cerulean Pharma Inc (CERU.O) and Adamas Pharmaceuticals Inc (ADMS.O) - also slid in their trading debuts. Cerulean fell 2.1 percent to close at $6.85, while Adamas lost 12.4 percent to end at $14.01.Among Internet-related tech shares, which were among last year's biggest advancers, Facebook Inc (FB.O) fell 5.2 percent to end at $59.16, while Netflix Inc (NFLX.O) sank 5.2 percent to close at $334.73.""You've basically more than erased the bounce of the last two days, so I would imagine any bounce from these levels is probably going to be met with supply because the market is on very tenuous legs right now,"" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. Among other big decliners, shares of Imperva Inc (IMPV.N) plunged 43.7 percent to $28 after the data center security company reported preliminary first-quarter results. Rival FireEye Inc (FEYE.O) lost 11.8 percent to $49.75.On the earnings front, Bed, Bath & Beyond (BBBY.O) shares slumped 6.2 percent to $63.72 after the home-goods retailer reported fourth-quarter sales that fell from a year ago and gave a first-quarter outlook that was below expectations.The day's economic data was encouraging, however, with initial jobless claims dropping sharply last week to the lowest in almost seven years, suggesting job growth may be picking up after a harsh winter.After the bell, shares of Gap (GPS.N) dropped 2.4 percent to $38.33. The slide followed the clothing retailer's report on its March sales and reaffirmation of its 2014 outlook. In contrast, shares of H&R Block (HRB.N) rose 7.7 percent to $30.60 in extended-hours trading after the U.S. tax preparer said it would sell some assets and transfer certain liabilities to BofI Federal Bank.Volume was high, with 7.5 billion shares changing hands on U.S. exchanges, well above the 6.8 billion average so far this month, according to data from BATS Global Markets.Decliners outnumbered advancers on the New York Stock Exchange by a ratio of 3.6 to 1. On the Nasdaq, about 6.6 stocks fell for every one that rose.(Editing by Jan Paschal)",2014-04-10,GILD,"Thu Apr 10, 2014 | 6:51pm EDT","Nasdaq drops 3 percent, worst day since November 2011",http://www.reuters.com//article/us-markets-stocks-idUSBREA360QI20140410?type=companyNews
29,"  * Nasdaq posts biggest daily percentage loss since Nov. 9, 2011* Biotech index has worst day since August 2011* VIX, Wall Street's fear index, jumps 15 percent* Dow down 1.6 pct; S&P 500 off 2.1 pct; Nasdaq off 3.1 pct   (Updates to close)By Caroline ValetkevitchNEW YORK, April 10 The Nasdaq suffered its biggest drop in two-and-a-half years on Thursday after another sharp selloff in biotech and momentum names, including Gilead Sciences and TripAdvisor, increasing investor anxiety about a broader pullback.The Nasdaq biotechnology index shed 5.6 percent, its biggest one-day drop since August 2011, adding to recent losses since a big drop in Gilead more than two weeks ago triggered a wider selloff for biotechs and other recent big gainers. The Nasdaq biotech index has fallen 19.3 percent from its all-time high of 2,872.29 on Feb. 25.The S&P 500 also posted its biggest percentage loss since Feb. 3, while the Nasdaq has dropped 7 percent from its closing high for the year, set on March 5. All stocks in the Nasdaq 100 index posted a loss, with the exception of CH Robinson Worldwide, which ended up 1.6 percent at $53.80. The selling also hit the shares of three companies in their first day of public trading after their initial public offerings were priced on Wednesday night. All three IPOs ended lower.""This is a pretty dramatic selloff, but it's not entirely unexpected,"" said Randy Frederick, managing director of active trading and derivatives for Charles Schwab in Austin, Texas.""Momentum names have been driving this market higher. A lot of these names have been trading at stratospheric valuations, and on long-term outlooks, that may or may not materialize. The question is, 'At what point do they get too expensive?' Right now, I think they're looking a little expensive.""There's a good chance that the selling could spread to areas beyond the momentum names, Frederick said. Alexion Pharma was the S&P 500's biggest decliner, off 7.5 percent at $144.19, followed by Gilead Sciences, down 7.3 percent at $65.48, and TripAdvisor, down 7 percent at $81.90.The move was a sharp reversal from the previous day, when shares rallied after minutes from the latest Federal Reserve policymakers' meeting showed members were more keen to keep rates low than previously expected.The Dow Jones industrial average plummeted 266.96 points or 1.62 percent, to end at 16,170.22. The S&P 500  lost 39.09 points or 2.09 percent, to close at 1,833.09. The Nasdaq Composite dropped 129.794 points or 3.1 percent, to 4,054.106. The S&P 500 closed below its 50-day moving average for the first time since Feb. 10, wile the CBOE Volatility index, Wall Street's measure of investor anxiety, spiked 14.98 percent to end at 15.89, still at historically low levels.The stock of bailed-out auto lender Ally Financial Inc  fell 4.1 percent to close at $23.98 in its market debut.Two biotech companies - Cerulean Pharma Inc and Adamas Pharmaceuticals Inc - also slid in their trading debuts. Cerulean fell 2.1 percent to close at $6.85, while Adamas lost 12.4 percent to end at $14.01.Among Internet-related tech shares, which were among last year's biggest advancers, Facebook Inc fell 5.2 percent to end at $59.16, while Netflix Inc sank 5.2 percent to close at $334.73.""You've basically more than erased the bounce of the last two days, so I would imagine any bounce from these levels is probably going to be met with supply because the market is on very tenuous legs right now,"" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.Volume was high, with 7.5 billion shares changing hands on U.S. exchanges, well above the 6.8 billion average so far this month, according to data from BATS Global Markets.Decliners outnumbered advancers on the New York Stock Exchange by a ratio of 3.6 to 1. On the Nasdaq, about 6.6 stocks fell for every one that rose.   (Editing by Jan Paschal)",2014-04-10,GILD,"Thu Apr 10, 2014 | 4:47pm EDT",US STOCKS-Nasdaq marks worst day since Nov. 2011 as biotechs sink,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0N220F20140410?type=companyNews
30,"   By Susan Heavey | WASHINGTON  WASHINGTON The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.""Their lives, in short, will be transformed,"" Pharmaceutical Research and Manufacturers of America (PhRMA) President John Castellani said at the group's annual meeting in Washington. ""The value to these patients, and to their loved ones and society - you can't put a price tag on it.""Gilead's Sovaldi costs about $84,000 for a 12-week course of treatment, or $1,000 a day.That has drawn fire from health insurers, including state Medicaid programs, as well as U.S. lawmakers who are investigating Sovaldi's hefty price tag. This week, the World Health Organization joined the chorus of those seeking affordability for such drugs.While Gilead has said it is working to offer lower prices in dozens of developing countries, critics say such treatments should cost hundreds of dollars, rather than tens of thousands. Another treatment from Johnson & Johnson that some doctors have been combining with Sovaldi as other new medicines advance toward approval, costs about $66,000.Sovaldi, which was approved by the U.S. Food and Drug Administration late last year, is well on track to post record-breaking sales in its first year on the market.Analysts with Capital Alpha have said 2014 sales of the drug could reach up to $15 billion, a figure that would top peak sales of Pfizer Inc's cholesterol fighter Lipitor, which had been the world's top-selling medicine before its patent protection lapsed. As many as 150 million people worldwide, including about 3.2 million in the United States, have hepatitis C, which is caused by contact with contaminated blood, often through shared needles by drug abusers or, prior to routine blood screening, from blood and organ transplants.Many people can carry the virus for decades before symptoms appear. But if untreated, it can cause serious liver damage and lead to cirrhosis, liver cancer, the need for a liver transplant or death.""For the first time, 150 million people who are chronically infected with hepatitis C can be treated and cured of this terrible disease,"" Castellani said. He said debate over the price of new anti-viral drugs to treat the chronic condition, and the value they bring to patients, has gone ""askew,"" and warned that researching and developing them comes at a high cost to manufacturers.Defenders of the new medicines point out that older current multi-drug regimens cost at least as much, cure about 75 percent of patients, require 24 or 48 weeks of treatment and have miserable side effects that lead many to delay or discontinue treatment.The newer medicines being developed by several companies have demonstrated in clinical trials cure rates well in excess of 90 percent with minimal side effects and will require 12 weeks or fewer of treatment.Those companies, including AbbVie Inc, Merck & Co and Bristol-Myers Squibb Co, are likely to be drawn into the pricing controversy as their new medicines edge closer to approval amid fears that millions of patients will now come forward to seek treatment, causing a massive cost burden to insurers and governments. Merck and Bristol-Myers presented new hepatitis C data on Thursday at a major liver disease meeting in London [ID:nL2N0N12E2] [ID:nL2N0N12BT]. Gilead, AbbVie and others will also present clinical trial data at the meeting.""Policy makers ... need to value innovation and stop implying that it comes cheap,"" Castellani said.Foster City, California-based Gilead, which paid $11 billion to acquire the company that had the rights to Sovaldi, has said it is working with government officials and others to help create a globally tiered pricing structure.That plan includes licensing the drug to three or four Indian generic manufacturers to allow sale of the medicine at lower prices in some 60 developing nations.Separately on Thursday, Indian generic drugmaker Natco Pharma Ltd called on the government to deny Sovaldi a patent in India, a source with knowledge of the matter said, potentially clearing the way to launch a much cheaper version of the drug.(Additional reporting by Bill Berkrot in New York; editing by Matthew Lewis)",2014-04-10,GILD,"Thu Apr 10, 2014 | 1:10pm EDT",U.S. drug industry group defends price of Gilead hepatitis drug,http://www.reuters.com//article/us-hepatitis-gilead-phrma-idUSBREA391I220140410?type=companyNews
31,"  * Gilead drug costs $84,000 for 12-week treatment* Insurers, WHO, congressmen critical of pricing* New drugs feature high cure rates, few side effectsBy Susan HeaveyWASHINGTON, April 10 The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.""Their lives, in short, will be transformed,"" Pharmaceutical Research and Manufacturers of America (PhRMA) President John Castellani said at the group's annual meeting in Washington. ""The value to these patients, and to their loved ones and society - you can't put a price tag on it.""Gilead's Sovaldi costs about $84,000 for a 12-week course of treatment, or $1,000 a day.That has drawn fire from health insurers, including state Medicaid programs, as well as U.S. lawmakers who are investigating Sovaldi's hefty price tag. This week, the World Health Organization joined the chorus of those seeking affordability for such drugs.While Gilead has said it is working to offer lower prices in dozens of developing countries, critics say such treatments should cost hundreds of dollars, rather than tens of thousands. Another treatment from Johnson & Johnson that some doctors have been combining with Sovaldi as other new medicines advance toward approval, costs about $66,000. Sovaldi, which was approved by the U.S. Food and Drug Administration late last year, is well on track to post record-breaking sales in its first year on the market.Analysts with Capital Alpha have said 2014 sales of the drug could reach up to $15 billion, a figure that would top peak sales of Pfizer Inc's cholesterol fighter Lipitor, which had been the world's top-selling medicine before its patent protection lapsed.As many as 150 million people worldwide, including about 3.2 million in the United States, have hepatitis C, which is caused by contact with contaminated blood, often through shared needles by drug abusers or, prior to routine blood screening, from blood and organ transplants.Many people can carry the virus for decades before symptoms appear. But if untreated, it can cause serious liver damage and lead to cirrhosis, liver cancer, the need for a liver transplant or death. ""For the first time, 150 million people who are chronically infected with hepatitis C can be treated and cured of this terrible disease,"" Castellani said.He said debate over the price of new anti-viral drugs to treat the chronic condition, and the value they bring to patients, has gone ""askew,"" and warned that researching and developing them comes at a high cost to manufacturers.Defenders of the new medicines point out that older current multi-drug regimens cost at least as much, cure about 75 percent of patients, require 24 or 48 weeks of treatment and have miserable side effects that lead many to delay or discontinue treatment.The newer medicines being developed by several companies have demonstrated in clinical trials cure rates well in excess of 90 percent with minimal side effects and will require 12 weeks or fewer of treatment. Those companies, including AbbVie Inc, Merck & Co  and Bristol-Myers Squibb Co, are likely to be drawn into the pricing controversy as their new medicines edge  closer to approval amid fears that millions of patients will now come forward to seek treatment, causing a massive cost burden to insurers and governments.Merck and Bristol-Myers presented new hepatitis C data on Thursday at a major liver disease meeting in London  . Gilead, AbbVie and others will also present clinical trial data at the meeting.""Policy makers ... need to value innovation and stop implying that it comes cheap,"" Castellani said.Foster City, California-based Gilead, which paid $11 billion to acquire the company that had the rights to Sovaldi, has said it is working with government officials and others to help create a globally tiered pricing structure.That plan includes licensing the drug to three or four Indian generic manufacturers to allow sale of the medicine at lower prices in some 60 developing nations.Separately on Thursday, Indian generic drugmaker Natco Pharma Ltd called on the government to deny Sovaldi a patent in India, a source with knowledge of the matter said, potentially clearing the way to launch a much cheaper version of the drug.(Additional reporting by Bill Berkrot in New York; editing by Matthew Lewis)",2014-04-10,GILD,"Thu Apr 10, 2014 | 1:04pm EDT",U.S. drug industry group defends price of Gilead hepatitis drug,http://www.reuters.com//article/health-hepatitis-gilead-phrma-idUSL2N0N20YI20140410?type=companyNews
32,"   By Zeba Siddiqui | MUMBAI  MUMBAI India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.If successful, the move could clear the way for the Indian company to launch a cheap generic version of the drug.Gilead, whose medicine has been hailed by doctors as a breakthrough in treating the liver-destroying disease, has come under fire over its product's $1,000 per pill price tag in the United States.India's patent laws allow a third party to dispute the validity of a pending patent application. Natco has filed a so-called ""pre-grant opposition"" with the Controller General of Patents, Designs & Trademarks, said the source, who declined to be named because the information was not public yet.It was not clear when Natco filed the opposition and Reuters could not immediately obtain a copy of the filing.Natco Chief Executive Rajeev Nannapaneni declined to comment. Officials at Gilead and at the patent department in Mumbai were not immediately available for comment. Natco has opposed the patent on the same grounds as New York-based Initiative for Medicines, Access & Knowledge (I-MAK), arguing that Sovaldi is not ""inventive"" enough, the source told Reuters.I-MAK, a group of lawyers and scientists, filed an opposition in November 2013 to the grant of a patent in India on Sovaldi, chemically called sofosbuvir, saying the drug uses ""old science"".Natco's opposition comes amid a growing clamor by healthcare campaigners and doctors to ensure that Sovaldi and other new hepatitis C pills are made affordable in developing countries. In the United States, some healthcare providers have described the $84,000 price tag for a 12-week course of treatment as ""outrageous"".""OLD SCIENCE"" CLAIM The medical charity Mdecins Sans Frontires (MSF) supported I-MAK's opposition and believes a 12-week course of treatment and diagnosis should cost no more than $500, saying a high cost would put the drug out of reach to most of the 90 percent of hepatitis C patients living in low-and middle-income countries. The World Health Organization estimates as many as 12 million people in India, a country of more than 1.2 billion people, have hepatitis C. Other experts put the figure even higher.Egypt, where Gilead has agreed a voluntary deal to cut its drug price by 99 percent, has the world's highest prevalence of the liver-destroying virus.Foster City, California-based Gilead is already in talks to license Sovaldi to three or four Indian generic manufacturers, and launch the drug in India at a price of $2,000 for 24 weeks of treatment, a company executive told Reuters on Tuesday.Indian-made generics of the drug would be available in most of sub-Saharan Africa, selected Asian countries including India, Pakistan and Myanmar, and some smaller developing nations.Sovaldi is the first among a bunch of new hepatitis C drugs that have been shown to raise cure rates and cut treatment duration without the side-effects of current injection-based treatment regimes.(Additional reporting by Ben Hirschler in LONDON; Editing by Tony Munroe and Elaine Hardcastle)",2014-04-10,GILD,"Thu Apr 10, 2014 | 10:53am EDT",Natco seeks to block Gilead's hepatitis C drug patent in India: source,http://www.reuters.com//article/us-natco-pharma-sovaldi-idUSBREA390VK20140410?type=companyNews
33,"  * Indian firm files ""pre-grant opposition"" to Sovaldi patent* Natco filing argues Sovaldi not inventive - source* Sovaldi's high cost under fire in U.S., developing world   (Adds details on Sovaldi and patent opposition grounds)By Zeba SiddiquiMUMBAI, April 10 India's Natco Pharma Ltd  has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.If successful, the move could clear the way for the Indian company to launch a cheap generic version of the drug.Gilead, whose medicine has been hailed by doctors as a breakthrough in treating the liver-destroying disease, has come under fire over its product's $1,000 per pill price tag in the United States.India's patent laws allow a third party to dispute the validity of a pending patent application. Natco has filed a so-called ""pre-grant opposition"" with the Controller General of Patents, Designs & Trademarks, said the source, who declined to be named because the information was not public yet. It was not clear when Natco filed the opposition and Reuters could not immediately obtain a copy of the filing.Natco Chief Executive Rajeev Nannapaneni declined to comment. Officials at Gilead and at the patent department in Mumbai were not immediately available for comment.Natco has opposed the patent on the same grounds as New York-based Initiative for Medicines, Access & Knowledge (I-MAK), arguing that Sovaldi is not ""inventive"" enough, the source told Reuters. I-MAK, a group of lawyers and scientists, filed an opposition in November 2013 to the grant of a patent in India on Sovaldi, chemically called sofosbuvir, saying the drug uses ""old science"".Natco's opposition comes amid a growing clamour by healthcare campaigners and doctors to ensure that Sovaldi and other new hepatitis C pills are made affordable in developing countries.In the United States, some healthcare providers have described the $84,000 price tag for a 12-week course of treatment as ""outrageous"".""OLD SCIENCE"" CLAIM  The medical charity Mdecins Sans Frontires (MSF) supported I-MAK's opposition and believes a 12-week course of treatment and diagnosis should cost no more than $500, saying a high cost would put the drug out of reach to most of the 90 percent of hepatitis C patients living in low-and middle-income countries.The World Health Organisation estimates as many as 12 million people in India, a country of more than 1.2 billion people, have hepatitis C. Other experts put the figure even higher.Egypt, where Gilead has agreed a voluntary deal to cut its drug price by 99 percent, has the world's highest prevalence of the liver-destroying virus.Foster City, California-based Gilead is already in talks to license Sovaldi to three or four Indian generic manufacturers, and launch the drug in India at a price of $2,000 for 24 weeks of treatment, a company executive told Reuters on Tuesday.Indian-made generics of the drug would be available in most of sub-Saharan Africa, selected Asian countries including India, Pakistan and Myanmar, and some smaller developing nations.Sovaldi is the first among a bunch of new hepatitis C drugs that have been shown to raise cure rates and cut treatment duration without the side-effects of current injection-based treatment regimes.      (Additional reporting by Ben Hirschler in LONDON; Editing by Tony Munroe and Elaine Hardcastle)",2014-04-10,GILD,"Thu Apr 10, 2014 | 10:46am EDT",UPDATE 1-Natco seeks to block Gilead's hepatitis C drug patent in India-source,http://www.reuters.com//article/natco-pharma-sovaldi-idUSL3N0N23RU20140410?type=companyNews
34,"  MUMBAI, April 10 India's Natco Pharma Ltd  has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's breakthrough hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.If successful, the move could clear the way for the Indian company to launch a generic version of the drug.Natco has filed a so-called ""pre-grant opposition"" with India's Controller General of Patents, Designs & Trademarks, said the source, who declined to be named because the information was not public yet. Reuters could not immediately obtain a copy of the filing. Natco Chief Executive Rajeev Nannapaneni declined to comment. Officials at the Indian patent department in Mumbai were not immediately available for comment. India's patent laws allow a third party to dispute the validity of a pending patent application. Natco has opposed the patent on the grounds that Sovaldi is not ""inventive"" enough, the source said.Foster City, California,-based Gilead aims to license Sovaldi to three or four Indian generic manufacturers to allow sale of the medicine at lower prices in some 60 developing nations including India.    (Reporting by Zeba Siddiqui in MUMBAI; Editing by Tony Munroe)",2014-04-10,GILD,"Thu Apr 10, 2014 | 8:38am EDT",Natco moves to oppose Gilead hepatitis C drug patent in India-source,http://www.reuters.com//article/natco-pharma-sovaldi-idUSL3N0N23PE20140410?type=companyNews
35,"   By Caroline Humer  Texas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday.The Texas Health and Human Services Commission, which oversees Medicaid, had proposed a policy to allow the drug, Sovaldi, to be used mainly for sicker patients such as those whose hepatitis C had developed into advanced liver disease, according to state documents reviewed by Reuters.As with most state Medicaid programs, an outside committee of pharmacists and doctors in Texas meets quarterly to review new drugs and recommend policies to the program's director. The agency had been planning to begin offering coverage in July if the committee recommended the policy at its Thursday meeting.""The board asked state staff to meet with stakeholders, including gastroenterologists, about the criteria, whether it was too strict, and the prior authorization process,"" Texas Health and Human Services Commission spokeswoman Stephanie Goodman said. In the interim, Medicaid patients in Texas will still not be prescribed the drug.""We're looking at our options and how that will affect our timeline to get the drug covered,"" Goodman said.A Gilead spokeswoman declined to comment.The deliberations in Texas, one of the most populous states and home to a relatively large number of hepatitis C patients, underline the difficulties of state health officials in deciding how to cover the Gilead treatment. It would have been the first major state to craft a policy. Discussions are continuing in California, Colorado and Virginia among others. The Texas move has also tabled a plan that the state had hoped could be in place by July in which it would make supplemental payments to insurers to help offset the high cost of the drug.Texas is among states including California and Florida asked by insurers who manage Medicaid plans to pay for the treatments directly, a move they said was needed because they would otherwise lose money on their contracts.Leerink managed care analyst Ana Gupta said that the Texas per-use payment could be a viable approach to compensating insurers in other states.""It covers the use of the drug while still potentially limiting the utilization only where medically necessary,"" Gupta said. She said the price tag to insurers may be $8 billion for eligible patients in Medicaid and similarly structured plans such as those sold on the Obamacare exchanges. Sovaldi has become the focal point for a global outcry over the price of novel medicines, attracting criticism from the World Health Organization, doctors' groups, state officials and insurance industries. Sovaldi is the first drug to provide a true cure for most patients who take it, but its cost could reach more than $200 billion if widely used in the United States, posing huge risks to state budgets and insurers' financial results.Gilead Sciences received U.S. regulatory approval for the treatment in December. Many patients are prescribed the drug in combination with another new drug, Johnson & Johnson's Olysio, pushing the treatment cost to around $150,000.Gilead shares, which have been hit by questions over Sovaldi's price in recent weeks, rose as much as 4 percent on Friday. The company reported new data on a combination therapy including Sovaldi.CARVING OUT THE DRUG  One of the country's largest insurers, WellPoint Inc, told investors last month that it was in talks with state Medicaid agencies about these high costs.""Our view is pretty simply it either needs to be covered in the rates and covered quickly or you have to take it out of managed care and put it into fee for service and pay for it that way,"" said Richard Zoretic, president of WellPoint's government business division.Some patient advocates prefer the second approach because it could encourage better access to the drug.""There is this basic bar in Medicaid where they do have to cover the drug. The question is who is going to get it and what will the rules around that be,"" said Anne Donnelly, director of healthcare policy at Project Inform based in San Francisco.For instance, Texas' policy on use of the drug this year appears to be stricter than the policy adopted in Oregon. Its pharmacy committee has recommended limiting the use of Sovaldi to patients who have moderate to severe fibrosis of the liver whereas Texas was targeting advanced liver disease.State Medicaid programs, funded by both state and federal government, set the policy for drug use in their fee-for-service programs. Coverage can differ because the vast majority of patients are in plans managed by private insurers that heed the state's recommendations but may also have their own practices.(Reporting by Caroline Humer; Editing by Jonathan Oatis and Grant McCool)",2014-04-11,GILD,"Fri Apr 11, 2014 | 2:49pm EDT",Texas Medicaid holds off on proposed limits for Gilead hepatitis drug,http://www.reuters.com//article/us-usa-healthcare-hepatitisc-idUSBREA3A1BH20140411?type=companyNews
36,"   By Caroline Humer | April 11  April 11 Texas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday.The Texas Health and Human Services Commission, which oversees Medicaid, had proposed a policy to allow the drug, Sovaldi, to be used mainly for sicker patients, such as those whose hepatitis C had developed into advanced liver disease, according to state documents reviewed by Reuters.As with most state Medicaid programs, an outside committee of pharmacists and doctors in Texas meets quarterly to review new drugs and recommend policies to the state's Medicaid director. The agency had been planning to begin offering coverage of the drug in July if the committee recommended the policy at its Thursday meeting.""The board asked state staff to meet with stakeholders, including gastroenterologists, about the criteria, whether it was too strict, and the prior authorization process,"" Texas Health and Human Services Commission spokeswoman Stephanie Goodman said. In the interim, Medicaid patients in Texas will still not be prescribed the drug. ""We're looking at our options and how that will affect our timeline to get the drug covered,"" Goodman said.The deliberations in Texas, one of the most populous states and home to a relatively large number of hepatitis C patients, underline the difficulties of state health officials in deciding how to cover the Gilead treatment. It was expected to be the first major state to make a decision; discussions are continuing in California, Colorado and Virginia among others. Sovaldi has become the focal point for a global outcry over the price of novel medicines, attracting criticism from the World Health Organization, doctors' groups, state officials and insurance industries. The drug is the first to provide a true cure to the disease for most patients who take it, but its cost could reach more than $200 billion if widely used in the United States, posing huge risks to state budgets and insurers' financial results.The Texas move has also tabled a plan that the state had hoped could also be in place by July to make supplemental payments to insurers to help offset the high cost of the drug. Gilead Sciences received U.S. regulatory approval for the treatment in December. Many patients are prescribed the drug in combination with another new drug, Johnson & Johnson's Olysio, pushing the cost of a 12-week treatment to around $150,000.Texas is among states including California and Florida which were asked by insurers who manage Medicaid plans to pay for the treatments directly, a move they said was needed because they would otherwise lose money on their contracts.California is still discussing the issue. Florida said it has no plans to carve out the drug but continues to monitor the drug's use within managed care plans.   (Reporting by Caroline Humer; Editing by Michele Gershberg and Jonathan Oatis)",2014-04-11,GILD,"Fri Apr 11, 2014 | 12:22pm EDT",Texas Medicaid holds off on proposed limits for Gilead hepatitis drug,http://www.reuters.com//article/usa-healthcare-hepatitisc-idUSL2N0N30GV20140411?type=companyNews
37,"   By Deena Beasley and Ben Hirschler | LOS ANGELES/LONDON  LOS ANGELES/LONDON Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.Gilead, under fire from insurers and legislators for the $1,000-a-pill price of its Sovaldi drug, presented pivotal data on Friday at the European Association for the Study of the Liver conference in London, showing a cure rate of 94 percent after eight weeks of treatment with its experimental two-drug pill.Midstage trial results from Merck & Co Inc, also presented at the meeting, showed that 12 weeks of therapy with its two-drug combination cured 98 percent of previously-untreated patients.AbbVie and Bristol-Myers Squibb are also developing new generation all-oral hepatitis C treatments that have demonstrated cure rates in excess of 90 percent.Citi Research sees Gilead as the clear market leader, but in the long term expects that Merck will be the second largest player, followed by AbbVie.""We assume Merck will use aggressive pricing to maximize market share,"" Citi analyst Yaron Werber said in a research note.Wall Street analysts, on average, forecast Sovaldi sales of $9.1 billion in 2017, according to Thomson Reuters Pharma. Doctors at the London meeting said the value proposition of the new direct-acting antiviral drugs should stack up for governments and insurers, given the potential huge costs down the line from the disease, which can lead to liver cirrohosis and liver transplants.""Competition will drive the price down, but probably not far enough,"" said Markus Peck-Radosavljevic, professor of medicine in the Medical University of Vienna and secretary-general of EASL.The current U.S. price for a 12-week course of treatment with Sovaldi is $84,000, and Gilead has said the price in the United Kingdom is about $57,000. ""We spend at least this sort of money for cancer drugs, which only prolong patients' lives by a few weeks, and often with much worse side effects,"" said Dr Mark Thurz, professor of hepatology at Imperial College, London.AVOIDING STRONGER SIDE EFFECTS The World Health Organization estimates that 150 million people worldwide are infected with hepatitis C, which can be spread through blood, often via contaminated needles.Before Sovaldi's launch late last year, patients with hepatitis C had to be treated for at least six months with several drugs, including interferon, an injected medicine that can cause severe flu-like symptoms, and ribavirin, which can cause rash, anemia and other side effects. The combination of Gilead's Sovaldi and ledipasvir, an experimental drug from a class known as NS5A inhibitors, was shown to work better than the same regimen plus ribavirin.The trial, also published in the New England Journal of Medicine, involved 647 previously untreated patients with genotype 1 hepatitis C - the hardest to treat, but the most common type in the United States - who had not developed liver cirrhosis.""The key points useful to clinicians here are the very high rates of sustained virologic response and very good safety profile,"" said Dr Kris Kowdley, director of the liver center at Seattle's Virginia Mason Medical Center and the study's lead author.More patients in the ribavirin group suffered side effects such as fatigue, headache and nausea.The U.S. Food and Drug Administration has granted priority review to Gilead's application for the once-daily combination of Sovaldi, or sofosbuvir, and ledipasvir. The agency is slated to decide on the marketing application by October 10.(Additional reporting by Bill Berkrot; Editing by Michele Gershberg and Ken Wills)",2014-04-11,GILD,"Fri Apr 11, 2014 | 1:04am EDT","Doctors welcome hepatitis C drug rivals, Gilead still leads",http://www.reuters.com//article/us-hepatitis-gilead-sciences-idUSBREA3A0CL20140411?type=companyNews
38,"   By Caroline Humer  UnitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was ""multiple"" times what it had expected.UnitedHealth is the first insurer to quantify its costs to cover patients using Gilead's new Sovaldi treatment, whose $84,000 price tag has spurred a national outcry over the rising costs of specialty medicines.UnitedHealth shares fell nearly 4 percent on Thursday and shares of rivals WellPoint Inc and Aetna Inc fell 3.8 percent and 3.4 percent, respectively, as investors weighed what their potential costs could be as well.The disclosure indicates that industry-wide, insurers spent $1 to $1.5 billion on treatments in the first quarter, Goldman Sachs analyst Matthew Borsch said in a research note.U.S. drug regulators approved Sovaldi in December, the first of a handful of ground-breaking hepatitis C treatments that are expected to be on the market in the next few years.Sovaldi has been shown to cure most patients of the liver-wasting virus with few side effects, but health officials, insurers and Medicaid directors are balking at the cost. The national cost of treating even two-thirds of the estimated 3.2 million people with the virus could reach $200 billion.This has focused scrutiny on U.S. drug prices, which outstrip the rest of the world. Biotechnology shares were already in the midst of a selloff when U.S. lawmakers asked on March 21 for Gilead Sciences to explain the price for the Sovaldi treatment.Since then, shares of Gilead have lost more than 7 percent as investors feared that regulators and insurers would pressure the company to restrain prices. It pulled other biotech stocks down in tandem and the Nasdaq Biotechnology Index has dropped nearly 14 percent since March 20. Some doctors and health officials say the drug's cost must be viewed in comparison to spending on treating liver disease or on liver transplants, which can be more expensive and may not prevent a relapse in hepatitis C.Daniel Schumacher, chief financial officer of the group's UnitedHealthcare division, said the spending on Sovaldi could begin to moderate after the first big wave of patients are treated with the drug.He did not disclose what it had anticipated spending on the hepatitis C drug but said the cost ""is a multiple of what we had expected.""Because Sovaldi is widely viewed as a breakthrough in treating the liver-wasting virus in typically as few as 12 weeks, many doctors had waited for the drug before prescribing treatment to patients. ""What we're seeing is ... higher pent-up demand as there were more patients that were warehoused leading up to the launch,"" Schumacher said.UnitedHealth saw increased spending levels due to Sovaldi in its Medicaid, Medicare and commercial businesses during the first quarter of 2014, he said. A Gilead spokeswoman declined to comment.Schumacher said the company is working with state Medicaid directors, whose agencies could bear much of the cost because they cover a disproportionate share of people with the virus, and expects to be reimbursed at some point.State Medicaid directors are pushing Gilead for discounts, but it so far has refused to give much ground. Medicaid receives at least a mandatory 23 percent discount from pharmaceutical makers, but states can negotiate for more cuts. Some insurers, such as pharmacy benefit manager Express Scripts Holding Co, has said it will use anticipated products from AbbVie Inc and Merck & Co as price leverage with Gilead. ACA COSTS UnitedHealth said its quarterly profit was cut by 35 cents a share due to costs and taxes related to President Barack Obama's healthcare law, more formally known as the Affordable Care Act, and government cuts to private Medicare funding.The hepatitis C cost is one of several new pressures UnitedHealth said it has an eye on this year including commercial premium prices in several markets. In New York, which is also a large market for WellPoint, it said new competitors were underpricing at unsustainable levels.""This is really the first look of anyone operating under the full brunt of ACA-mandated cuts and sequestration and you have to revise your thinking a little bit,"" CRT Capital analyst Sheryl Skolnick said.UnitedHealth, a small player on the Obamacare exchanges created by that reform law in 2014, said that it had a ""bias"" towards expansion in 2015. Insurers must submit new plans and rates to the federal government by the end of June if they want to participate.The company's quarterly results slightly beat analyst expectations. UnitedHealth said net profit was $1.1 billion, or about $1.10 per share, compared with $1.2 billion, or $1.16 per share a year earlier. Analysts had expected first quarter profit of $1.09 per share, according to Thomson Reuters I/B/E/S.UnitedHealth stuck by its previous forecast for 2014 earnings of $5.40 to $5.60 per share and said it sees revenue growth of about 5 percent to $128 billion to $129 billion.(Reporting by Caroline Humer; Editing by Michele Gershberg, Chizu Nomiyiama and Cynthia Osterman)",2014-04-17,GILD,"Thu Apr 17, 2014 | 2:30pm EDT",UnitedHealth: New hepatitis C drug costs far more than forecast,http://www.reuters.com//article/us-unitedheal-grp-results-idUSBREA3G0KN20140417?type=companyNews
39,"  (Adds more details on hepatitis c, analyst comment)By Caroline HumerApril 17 UnitedHealth Group Inc, the largest U.S. health insurer, said it spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc in its first three months on the market, an amount that was ""multiple"" times what it had expected.UnitedHealth is the first insurer to quantify its costs to cover patients using Gilead's new Sovaldi treatment, whose $84,000 price tag has spurred a national outcry over the rising costs of specialty medicines.UnitedHealth shares fell nearly 4 percent on Thursday and shares of rivals WellPoint Inc and Aetna Inc  fell 3.8 percent and 3.4 percent, respectively, as investors weighed what their potential costs could be as well.The disclosure indicates that industry-wide, insurers spent $1 to $1.5 billion on treatments in the first quarter, Goldman Sachs analyst Matthew Borsch said in a research note.U.S. drug regulators approved Sovaldi in December, the first of a handful of ground-breaking hepatitis C treatments that are expected to be on the market in the next few years.Sovaldi has been shown to cure most patients of the liver-wasting virus with few side effects, but health officials, insurers and Medicaid directors are balking at the cost. The national cost of treating even two-thirds of the estimated 3.2 million people with the virus could reach $200 billion.This has focused scrutiny on U.S. drug prices, which outstrip the rest of the world. Biotechnology shares were already in the midst of a selloff when U.S. lawmakers asked on March 21 for Gilead Sciences to explain the price for the Sovaldi treatment. Since then, shares of Gilead have lost more than 7 percent as investors feared that regulators and insurers would pressure the company to restrain prices. It pulled other biotech stocks down in tandem and the Nasdaq Biotechnology Index has dropped nearly 14 percent since March 20.Some doctors and health officials say the drug's cost must be viewed in comparison to spending on treating liver disease or on liver transplants, which can be more expensive and may not prevent a relapse in hepatitis C.Daniel Schumacher, chief financial officer of the group's  UnitedHealthcare division, said the spending on Sovaldi could begin to moderate after the first big wave of patients are treated with the drug.He did not disclose what it had anticipated spending on the hepatitis C drug but said the cost ""is a multiple of what we had expected.""Because Sovaldi is widely viewed as a breakthrough in treating the liver-wasting virus in typically as few as 12 weeks, many doctors had waited for the drug before prescribing treatment to patients. ""What we're seeing is ... higher pent-up demand as there were more patients that were warehoused leading up to the launch,"" Schumacher said.UnitedHealth saw increased spending levels due to Sovaldi in its Medicaid, Medicare and commercial businesses during the first quarter of 2014, he said. A Gilead spokeswoman declined to comment.Schumacher said the company is working with state Medicaid directors, whose agencies could bear much of the cost because they cover a disproportionate share of people with the virus, and expects to be reimbursed at some point.State Medicaid directors are pushing Gilead for discounts, but it so far has refused to give much ground. Medicaid receives at least a mandatory 23 percent discount from pharmaceutical makers, but states can negotiate for more cuts. Some insurers, such as pharmacy benefit manager Express Scripts Holding Co , has said it will use anticipated products from AbbVie Inc and Merck & Co as price leverage with Gilead. ACA COSTS UnitedHealth said its quarterly profit was cut by 35 cents a share due to costs and taxes related to President Barack Obama's healthcare law, more formally known as the Affordable Care Act, and government cuts to private Medicare funding.The hepatitis C cost is one of several new pressures UnitedHealth said it has an eye on this year including commercial premium prices in several markets. In New York, which is also a large market for WellPoint, it said new competitors were underpricing at unsustainable levels.""This is really the first look of anyone operating under the full brunt of ACA-mandated cuts and sequestration and you have to revise your thinking a little bit,"" CRT Capital analyst Sheryl Skolnick said.UnitedHealth, a small player on the Obamacare exchanges created by that reform law in 2014, said that it had a ""bias"" towards expansion in 2015. Insurers must submit new plans and rates to the federal government by the end of June if they want to participate.The company's quarterly results slightly beat analyst expectations. UnitedHealth said net profit was $1.1 billion, or about $1.10 per share, compared with $1.2 billion, or $1.16 per share a year earlier. Analysts had expected first quarter profit of $1.09 per share, according to Thomson Reuters I/B/E/S.UnitedHealth stuck by its previous forecast for 2014 earnings of $5.40 to $5.60 per share and said it sees revenue growth of about 5 percent to $128 billion to $129 billion.   (Reporting by Caroline Humer; Editing by Michele Gershberg,  Chizu Nomiyiama and Cynthia Osterman)",2014-04-17,GILD,"Thu Apr 17, 2014 | 2:28pm EDT",UPDATE 4-UnitedHealth: New hepatitis C drug costs far more than forecast,http://www.reuters.com//article/unitedheal-grp-results-idUSL2N0N90CG20140417?type=companyNews
40,"  LONDON, April 17 Health authorities in England have approved an 18.7 million pound ($31 million) investment to provide Gilead Sciences' controversial new hepatitis C pill Sovaldi for seriously ill patients.Healthcare provider NHS England said the decision would benefit about 500 patients suffering from acute liver failure, many of whom are awaiting a liver transplant.The recommendation means that while Sovaldi has not yet been approved by the National Institute for Health and Clinical Excellence (NICE), the country's cost-effectiveness watchdog, it will be funded for those patients at significant risk of dying. NICE is due to publish its guidance on whether Sovaldi is worth using widely on the state-run National Health Service later this year. Sovaldi is far more effective and better-tolerated than older treatments, but its high cost has provoked criticism from healthcare campaigners and insurers. The current U.S. price for a 12-week course of treatment with Sovaldi is $84,000, or $1,000 for each once-daily pill, but Gilead has said the price in Britain will be about $57,000.  ($1 = 0.5955 British Pounds)   (Reporting by Ben Hirschler; Editing by David Goodman)",2014-04-17,GILD,"Thu Apr 17, 2014 | 11:43am EDT",England agrees funding for Gilead hepatitis C drug,http://www.reuters.com//article/gilead-england-idUSL6N0N943720140417?type=companyNews
41,"   By Deena Beasley  Gilead Sciences Inc (GILD.O), which has ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated record-breaking sales of $2.27 billion, helping the company's quarterly net profit nearly triple.The Foster City, California-based company on Tuesday posted an adjusted profit of $1.48 a share, soundly beating the average Wall Street estimate of 91 cents a share, according to Thomson Reuters I/B/E/S.""It's pretty remarkable that they can generate $2.3 billion in revenue (from hepatitis C drug Sovaldi) in the first 3 months on the market,"" said Sanford Bernstein analyst Geoffrey Porges. ""People's numbers are going to go up dramatically for this year and next for Gilead.""Analysts had expected Sovaldi sales of $1.01 billion, according to Deutsche Bank.The drug's quarterly sales of over $2 billion are the highest ever for a new medicine, said RBC Capital Markets analyst Michael Yee.Shares of Gilead, which rose 1.8 percent to close at $72.86, were up another 2 percent at $74.62 after hours. The shares have more than doubled over the past two years, but have fallen some 15 percent since their high for the year in late February.Gilead's decision to price Sovaldi, which was approved by U.S. regulators in December, at $84,000 for a 12-week course of therapy has rankled lawmakers and insurers, spurring an outcry over the rising costs of specialty medicines. Investor concern over the pricing complaints has pressured shares of Gilead, as well as the wider biotech sector. The Nasdaq Biotechnology Index .NBI has fallen about 5 percent so far this year.But sales of the drug led to a tripling of Gilead's first quarter net income to $2.23 billion from $722 million a year earlier.The company's revenue doubled to $5 billion, beating by a wide margin the $3.98 billion average Wall Street analyst forecast. Gilead continued to exclude sales of Sovaldi and other hepatitis C drugs from its forecast for 2014 product sales, which it still expects to total between $11.3 billion and $11.5 billion.John Milligan, Gilead's chief operating officer, said during a conference call with analysts and investors that the drug has been ""priced appropriately based on its benefit.""Gilead is awaiting U.S. approval for a combination of Sovaldi and experimental drug ledipasvir that would allow more patients to be cured of the virus with a single-pill regimen.The company's pricing for that ""simpler"" regimen will take into account the additional benefit it provides, Milligan said. UnitedHealth Group Inc (UNH.N), the largest U.S. health insurer, said last week that its first quarter costs to cover Sovaldi were much higher than expected, but it anticipated spending would moderate after the first big wave of patients are treated with the drug.Pharmacy plan manager Express Scripts (ESRX.O) suggested its clients should stop using Sovaldi once rival products are on the market. Democratic lawmakers in the House of Representatives, led by California's Henry Waxman, have asked Gilead to explain the pricing on Sovaldi.Before the new drug was available, patients infected with the liver-destroying hepatitis C virus had to be treated for at least six months with several drugs, including interferon, an injected medicine that can cause severe flu-like symptoms, and ribavirin, which can casue rash, anemia and other side effects.Those regimens were shown in clinical trials to cure around 75 percent of patients, compared with Sovaldi's cure rate of more than 90 percent.Around 3.2 million Americans are infected with hepatitis C, according to the Centers for Disease Control and Prevention. The World Health Organization estimates that globally, 150 million people are infected with the virus.(Reporting by Deena Beasley; Editing by Leslie Adler, Chizu Nomiyama and Andrew Hay)",2014-04-22,GILD,"Tue Apr 22, 2014 | 6:43pm EDT","Gilead profit triples, hepatitis C drug sales beat by $1 billion",http://www.reuters.com//article/us-gilead-sciences-idUSBREA3L1ML20140422?type=companyNews
42,"  (Adds company comment, analyst comment, share price)By Deena BeasleyApril 22 Gilead Sciences Inc, which has ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated record-breaking sales of $2.27 billion, helping the company's quarterly net profit nearly triple.The Foster City, California-based company on Tuesday posted an adjusted profit of $1.48 a share, soundly beating the average Wall Street estimate of 91 cents a share, according to Thomson Reuters I/B/E/S.""It's pretty remarkable that they can generate $2.3 billion in revenue (from hepatitis C drug Sovaldi) in the first 3 months on the market,"" said Sanford Bernstein analyst Geoffrey Porges. ""People's numbers are going to go up dramatically for this year and next for Gilead.""Analysts had expected Sovaldi sales of $1.01 billion, according to Deutsche Bank.The drug's quarterly sales of over $2 billion are the highest ever for a new medicine, said RBC Capital Markets analyst Michael Yee.Shares of Gilead, which rose 1.8 percent to close at $72.86, were up another 2 percent at $74.62 after hours. The shares have more than doubled over the past two years, but have fallen some 15 percent since their high for the year in late February. Gilead's decision to price Sovaldi, which was approved by U.S. regulators in December, at $84,000 for a 12-week course of therapy has rankled lawmakers and insurers, spurring an outcry over the rising costs of specialty medicines.Investor concern over the pricing complaints has pressured shares of Gilead, as well as the wider biotech sector. The Nasdaq Biotechnology Index has fallen about 5 percent so far this year.But sales of the drug led to a tripling of Gilead's first quarter net income to $2.23 billion from $722 million a year earlier. The company's revenue doubled to $5 billion, beating by a wide margin the $3.98 billion average Wall Street analyst forecast.Gilead continued to exclude sales of Sovaldi and other hepatitis C drugs from its forecast for 2014 product sales, which it still expects to total between $11.3 billion and $11.5 billion.John Milligan, Gilead's chief operating officer, said during a conference call with analysts and investors that the drug has been ""priced appropriately based on its benefit.""Gilead is awaiting U.S. approval for a combination of Sovaldi and experimental drug ledipasvir that would allow more patients to be cured of the virus with a single-pill regimen. The company's pricing for that ""simpler"" regimen will take into account the additional benefit it provides, Milligan said.UnitedHealth Group Inc, the largest U.S. health insurer, said last week that its first quarter costs to cover Sovaldi were much higher than expected, but it anticipated spending would moderate after the first big wave of patients are treated with the drug.Pharmacy plan manager Express Scripts suggested its clients should stop using Sovaldi once rival products are on the market. Democratic lawmakers in the House of Representatives, led by California's Henry Waxman, have asked Gilead to explain the pricing on Sovaldi.Before the new drug was available, patients infected with the liver-destroying hepatitis C virus had to be treated for at least six months with several drugs, including interferon, an injected medicine that can cause severe flu-like symptoms, and ribavirin, which can casue rash, anemia and other side effects.Those regimens were shown in clinical trials to cure around 75 percent of patients, compared with Sovaldi's cure rate of more than 90 percent.Around 3.2 million Americans are infected with hepatitis C, according to the Centers for Disease Control and Prevention. The World Health Organization estimates that globally, 150 million people are infected with the virus.   (Reporting by Deena Beasley; Editing by Leslie Adler, Chizu Nomiyama and Andrew Hay)",2014-04-22,GILD,"Tue Apr 22, 2014 | 6:39pm EDT","UPDATE 2-Gilead profit triples, hepatitis C drug sales beat by $1 bln",http://www.reuters.com//article/gilead-sciences-idUSL2N0NE1Q420140422?type=companyNews
43,"  * S&P 500, Nasdaq on six-day winning streak* Netflix up after results; Facebook gains on upgrade* Allergan soars as Ackman and Valeant bid for company* Dow up 0.4 pct; S&P 500 up 0.4 pct; Nasdaq up 1 pct   (Adds Gilead earnings, updates volume)By Chuck MikolajczakNEW YORK, April 22 U.S. stocks rose on Tuesday as a host of solid earnings reports, along with strength in the healthcare sector, helped lift the S&P 500 and Nasdaq to their sixth straight advance.Netflix Inc surged 7 percent to $372.90 a day after reporting strong subscriber growth, a sign the trading favorite still had room to grow despite recent valuation concerns. With the day's gain, the stock moved to the plus side for the year after a 21 percent drop in March.The S&P healthcare index, up 1 percent, was the best performer of the 10 major S&P sectors. Allergan Inc  jumped 15.2 percent to $163.65 a day after activist investor William Ackman teamed up with Canadian drugmaker Valeant Pharmaceuticals International Inc  to bid for the company. U.S.-listed Valeant shares gained 7.5 percent to $135.41. A deal between Novartis and GlaxoSmithKline , in which the two traded over $20 billion worth of assets in an effort to cope with healthcare spending cuts and generic competition, also bolstered the healthcare sector. U.S.-listed shares of Novartis gained 1.3 percent to $86.56, while Glaxo rose 4.1 percent to $55.30.Better-than-expected earnings have lifted stocks recently, though companies have largely been exceeding reduced forecasts. Profits are seen rising 1.1 percent this quarter, down from the 6.5 percent growth rate estimated at the start of the year.""What was baked into the market, in spite of a market near an all-time high, was a sloppy earnings season,"" said Mike Serio, regional chief investment officer of Wells Fargo Private Bank in Denver. ""We've had some really good beats at this point, we've had a couple of good announcements today, you throw on the M&A activity in the drug sector, at least in the short term, everybody looks pretty excited about this market.""Dow components Travelers Cos Inc and United Technologies Corp both beat expectations, and United Tech raised the low end of its full-year profit outlook. Shares of Travelers rose 0.6 percent to $86.89 while United Tech added 0.8 percent to end at $119.19.McDonald's Corp reported earnings that fell alongside a drop in U.S. same-store sales, and its stock slipped 0.4 percent to $99.32.With 20 percent of the S&P 500 having reported results through Tuesday morning, 63 percent have topped earnings expectations, according to Thomson Reuters data, matching the long-term average. On the revenue side, 51 percent have exceeded forecasts, below the 61 percent long-term average. The Dow Jones industrial average rose 65.12 points or 0.40 percent, to end at 16,514.37. The S&P 500 gained 7.66 points or 0.41 percent, to 1,879.55. The Nasdaq Composite  added 39.912 points or 0.97 percent, to 4,161.458.After the close, Gilead Sciences Inc advanced 1.1 percent to $73.65 after the drugmaker said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.In another positive sign for equities, the Dow Jones Transportation Average, up 0.6 percent, closed at its first record high since April 2. The index got a boost from airlines such as United Continental Holdings, up 4.6 percent, and Alaska Air Group Inc, up 1.3 percent, which rose on a 2 percent drop in oil prices.Facebook Inc shares rose 2.9 percent to $63.03, helping to lift the Nasdaq 100 and the S&P 500. Credit Suisse upgraded the social networking company's stock to ""outperform"" on higher expectations for its long-term average revenue per user.Volume was light, with about 5.88 billion shares traded on U.S. exchanges, below the 6.7 billion average so far this month, according to data from BATS Global Markets.Advancing stocks outnumbered declining ones on the NYSE by 2,227 to 811, while on the Nasdaq, advancers beat decliners 1,900 to 727.   (Reporting by Chuck Mikolajczak; Editing by Nick Zieminski and Jan Paschal)",2014-04-22,GILD,"Tue Apr 22, 2014 | 5:26pm EDT","US STOCKS-Earnings, healthcare give Wall St sixth straight gain",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NE1UW20140422?type=companyNews
44,"  April 22 Gilead Sciences Inc, whose pricing policy ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.The Foster City, California-based company on Tuesday reported net income for the quarter of $2.23 billion, or $1.33  a share, up from $722 million, or 43 cents a share, a year earlier. Revenue doubled to $5 billion, beating by a wide margin the $3.98 billion average Wall Street analyst forecast, as compiled by Thomson Reuters I/B/E/S.  Gilead's decision to price the new hepatitis C drug, Sovaldi, which was approved by U.S. regulators in December, at $84,000 for a 12-week course of therapy has rankled lawmakers and insurers, spurring an outcry over the rising costs of specialty medicines.   (Reporting by Deena Beasley; Editing by Leslie Adler)",2014-04-22,GILD,"Tue Apr 22, 2014 | 4:23pm EDT","Gilead profit triples, hepatitis C drug revenue reaches $2.3 bln",http://www.reuters.com//article/gilead-sciences-idUSL2N0NE17X20140422?type=companyNews
45,"  * S&P 500, Nasdaq break six-day winning streak* Apple announces seven-for-one stock split* AT&T falls after results, but Boeing rallies* Amgen drags biotech lower, but Gilead gains* Dow off 0.1 pct; S&P 500 down 0.2 pct; Nasdaq off 0.8 pct   (Adds Apple results, split)By Chuck MikolajczakNEW YORK, April 23 U.S. stocks dipped on Wednesday to snap a six-session winning streak as gains in Boeing and Gilead were offset by slides in AT&T and the wider biotech sector.AT&T Inc fell 3.8 percent to $34.92 a day after the Dow component reported earnings that beat expectations, offset by weak service revenue growth. Verizon Communications  shed 1 percent to $47.43 while the S&P telecom sector index  dropped 2.2 percent, easily making it the session's worst-performing sector. Biotech shares pulled the Nasdaq lower. Amgen Inc  slid 5 percent to $113.32, a day after earnings missed forecasts. The Nasdaq biotech index fell 1.5 percent and NYSEArca biotech index lost 1.6 percent.""You've got some big numbers coming out from companies that have already been pretty volatile in the Nasdaq, and there is some caution against the potential for shortfalls that could restart Nasdaq on the way down,"" said Rick Meckler, president of LibertyView Capital Management in Jersey City, New Jersey.""This is traditionally not going to be a particularly strong time for earnings reports, and it's easy to take less inspiring numbers and say this market is overvalued or pass them by and say this is a seasonally low point. So it really is more about investors' own view of how high a multiple they are willing to pay.""There were bright spots within biotech. Gilead Sciences Inc  rose 1.4 percent to $73.86 and Illumina Inc  gained 3.9 percent to $153.69 after the companies posted results late Tuesday. Boeing Co reported first-quarter revenue that beat expectations and lifted its core earnings forecast to reflect a tax settlement gain, sending its stock up 2.4 percent to $130.63 and giving the biggest boost to the Dow.The Dow Jones industrial average fell 12.72 points or 0.08 percent, to end at 16,501.65. The S&P 500 lost 4.16 points or 0.22 percent, to 1,875.39. The Nasdaq Composite  dropped 34.491 points or 0.83 percent, to 4,126.967.After the closing bell, Apple Inc jumped 7.3 percent to $563 after the iPhone maker reported quarterly results, approved a seven-for-one stock split and expanded its share-buyback authorization by $30 billion. In another big move after the close, Facebook Inc  gained 4.8 percent to $64.30. Its mobile advertising business continued to accelerate in the first three months of the year, helping the social networking company top Wall Street's revenue target.Better-than-expected earnings have buoyed Wall Street lately, though companies have largely been beating reduced forecasts. Profits are seen rising 1.6 percent this quarter, down from the 6.5 percent growth rate estimated at the start of the year, according to Thomson Reuters data.Of the 141 companies in the S&P 500 that had posted results through Wednesday morning, 65.2 percent have topped expectations, above the long-term average of 63 percent. On the revenue side, 53.6 percent have exceeded forecasts, below the 61 percent long-term average.Procter & Gamble Co's earnings topped forecasts but sales were flat. The stock slipped 0.3 percent to $80.36.New home sales tumbled more than expected to an eight-month low in March. The PHLX housing sector index fell 1.1 percent, with D.R. Horton Inc off 2.2 percent at $21.35.Volume was light, with about 5.67 billion shares traded on U.S. exchanges, well below the 6.65 billion average so far this month, according to BATS Global Markets.Declining stocks outnumbered advancing ones on the NYSE by 1,566 to 1,482, while on the Nasdaq, decliners beat advancers by 1,775 to 819.    (Editing by Nick Zieminski and Jan Paschal)",2014-04-23,GILD,"Wed Apr 23, 2014 | 5:19pm EDT",US STOCKS-Wall St snaps six-day run; Apple to split stock,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NF27420140423?type=companyNews
46,"  * S&P 500, Nasdaq snap six-day winning streak* AT&T falls after results, but Boeing rallies* Amgen drags biotech lower, but Gilead gains* Dow off 0.08 pct; S&P 500 down 0.22 pct; Nasdaq off 0.83 pct   (Updates to close, adds Facebook earnings)By Chuck MikolajczakNEW YORK, April 23 U.S. stocks dipped on Wednesday to snap a six-session winning streak as gains in Boeing and Gilead were offset by slides in AT&T and the wider biotech sector.AT&T Inc fell 3.8 percent to $34.92 a day after the Dow component reported earnings that beat expectations, offset by weak service revenue growth. Verizon Communications  shed 1 percent to $47.43 while the S&P telecom sector index  dropped 2.2 percent, easily making it the session's worst-performing sector. Biotech shares pulled the Nasdaq lower. Amgen Inc  slid 5 percent to $113.32, a day after earnings missed forecasts. The Nasdaq biotech index fell 1.5 percent and NYSEArca biotech index lost 1.6 percent.""You've got some big numbers coming out from companies that have already been pretty volatile in the Nasdaq, and there is some caution against the potential for shortfalls that could restart Nasdaq on the way down,"" said Rick Meckler, president of LibertyView Capital Management in Jersey City, New Jersey.""This is traditionally not going to be a particularly strong time for earnings reports, and it's easy to take less inspiring numbers and say this market is overvalued or pass them by and say this is a seasonally low point. So it really is more about investors' own view of how high a multiple they are willing to pay."" There were bright spots within biotech. Gilead Sciences Inc  rose 1.4 percent to $73.86 and Illumina Inc  gained 3.9 percent to $153.69 after the companies posted results late Tuesday.Boeing Co reported first-quarter revenue that beat expectations and lifted its core earnings forecast to reflect a tax settlement gain, sending its stock up 2.4 percent to $130.63 and giving the biggest boost to the Dow.The Dow Jones industrial average fell 12.72 points or 0.08 percent, to 16,501.65, the S&P 500 lost 4.16 points or 0.22 percent, to 1,875.39 and the Nasdaq Composite  dropped 34.491 points or 0.83 percent, to 4,126.967. After the closing bell, Facebook Inc gained 2.2 percent to $62.69. Its mobile advertising business continued to accelerate in the first three months of the year, helping the Internet social networking company top Wall Street's revenue target.Better-than-expected earnings have boosted Wall Street lately, though companies have largely been beating reduced forecasts. Profits are seen rising 1.6 percent this quarter, down from the 6.5 percent growth rate estimated at the start of the year, according to Thomson Reuters data.Of the 141 companies in the S&P 500 that have posted results through Wednesday morning, 65.2 percent have topped expectations, above the long-term average of 63 percent. On the revenue side, 53.6 percent have exceeded forecasts, below the 61 percent long-term average.Procter & Gamble Co's earnings topped forecasts but sales were flat. The stock slipped 0.3 percent to $80.36.New home sales tumbled more than expected to an eight-month low in March. The PHLX housing sector index fell 1.1 percent, with D.R. Horton Inc off 2.2 percent at $21.35.Volume was light, with about 5.63 billion shares traded on U.S. exchanges, well below the 6.65 billion average so far this month, according to BATS Global Markets. Declining stocks outnumbered advancing ones on the NYSE by 1,566 to 1,482, while on the Nasdaq, decliners beat advancers 819 to 1,775.   (Editing by Jan Paschal and Nick Zieminski)",2014-04-23,GILD,"Wed Apr 23, 2014 | 4:38pm EDT",US STOCKS-Wall St slips to snap six-day rally; biotechs weak,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NF21A20140423?type=companyNews
47,"  * S&P 500, Nasdaq coming off six-day winning streak* AT&T falls after results, but Boeing rallies* Amgen drags biotech lower, but Gilead gains* Dow off 0.2 pct; S&P 500 down 0.2 pct; Nasdaq off 0.8 pct   (Updates to mid-afternoon, changes byline)By Chuck MikolajczakNEW YORK, April 23 U.S. stocks declined on Wednesday after a six-session winning streak as gains in Boeing and Gilead were offset by slides in AT&T and the wider biotech sector. AT&T Inc fell 3.6 percent to $35 a day after the Dow component reported adjusted earnings that beat expectations by a penny, though that was offset by weak service revenue growth. Verizon Communications shed 1.2 percent to $47.36 while the S&P telecom sector index dropped 2.1 percent, easily making it the session's worst-performing sector so far.Biotech shares tumbled, pulling the Nasdaq lower. Amgen Inc  slid 5.9 percent to $112.23 a day after the company reported earnings that missed forecasts. Biogen Idec Inc  fell 1.3 percent to $302.50 despite a strong outlook.Both the Nasdaq biotech index and NYSEArca biotech index lost 1.5 percent. ""You've got some big numbers coming out from companies that have already been pretty volatile in the Nasdaq, and there is some caution against the potential for shortfalls that could restart Nasdaq on the way down,"" said Rick Meckler, president of investment firm LibertyView Capital Management in Jersey City, New Jersey.""This is traditionally not going to be a particularly strong time for earnings reports, and it's easy to take less inspiring numbers and say this market is overvalued or pass them by and say this is a seasonally low point. So it really is more about investors' own view of how high a multiple they are willing to pay.""But there were bright spots within the sector. Gilead Sciences Inc rose 2.4 percent to $74.64 and Illumina Inc gained 5.3 percent to $155.81 after the companies posted their quarterly results late Tuesday. Boeing Co reported first-quarter revenue that beat expectations and lifted its core earnings forecast to reflect a tax settlement gain, sending its stock up 2.1 percent to $130.18 and giving the biggest boost to the Dow.    The Dow Jones industrial average fell 25.43 points or 0.15 percent, to 16,488.94. The S&P 500 slipped 4.66 points or 0.25 percent, to 1,874.89. The Nasdaq Composite  dropped 35.044 points or 0.84 percent, to 4,126.414.Better-than-expected earnings have boosted Wall Street lately, though companies have largely been beating reduced forecasts. According to Thomson Reuters data, profits are seen rising 1.6 percent this quarter, down from the 6.5 percent growth rate estimated at the start of the year.Of the 141 companies in the S&P 500 that have posted results so far, 65.2 percent have topped expectations, according to Thomson Reuters data, above the long-term average of 63 percent. On the revenue side, 53.6 percent have exceeded forecasts, below the 61 percent long-term average.Procter & Gamble Co's earnings topped analysts' forecasts but revenues were flat. The stock slipped 0.5 percent  to $80.17.New home sales dropped 14.5 percent in March, tumbling more than expected to an eight-month low. The PHLX housing sector index fell 1.2 percent, with D.R. Horton Inc off 3.3 percent at $21.13.    (Editing by Jan Paschal)",2014-04-23,GILD,"Wed Apr 23, 2014 | 2:28pm EDT",US STOCKS-Wall St slips after six-day S&P run; biotechs drop,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NF1JZ20140423?type=companyNews
48,"  * S&P 500, Nasdaq coming off six-day winning streak* AT&T falls after results, but Boeing rallies* Amgen drags biotech lower, but Gilead gains* Indexes down: Dow 0.1 pct, S&P 0.1 pct, Nasdaq 0.5 pct   (Updates to open)By Ryan VlastelicaNEW YORK, April 23 U.S. stocks edged lower on Wednesday as weakness in AT&T and biotech names inspired investors to take profits following six straight days of gains, though a rally in Boeing limited losses. AT&T Inc fell 3.4 percent to $35.07 a day after the Dow component reported adjusted earnings that beat expectations by a penny, though that was offset by weak service revenue growth. Verizon Communications fell 1.1 percent to $47.41 while the S&P telecom sector dropped 1.8 percent, by far the worst-performing sector on the day.Biotech shares fell a day after Amgen Inc reported earnings that were below forecasts. The stock fell 6 percent to $112.16 and the Nasdaq biotech index lost 1.4 percent. Biogen Idec Inc fell 1.8 percent to $300.73 despite a strong outlook.Gilead Sciences Inc late Tuesday posted a sharp profit increase, sending shares up 2.9 percent to $74.95. While the biotech results were mixed, they did point to some fundamental strength in the group, easing concerns it was overvalued. ""Earnings season has been better than expected, but revenue growth has been static, which is concerning because of its implications for margins,"" said Michael Mullaney, who oversees about $11 billion as chief investment officer at Fiduciary Trust Co in Boston. ""If margins are going to stay at record levels, we'll need revenue acceleration. Otherwise we may not see upside surprises going forward.""Boeing Co reported first-quarter revenue that beat expectations and lifted its core earnings forecast to reflect a tax settlement gain, sending shares up 2 percent to $130.15.The Dow Jones industrial average was down 18.98 points, or 0.11 percent, at 16,495.39. The Standard & Poor's 500 Index was down 1.89 points, or 0.10 percent, at 1,877.66. The Nasdaq Composite Index was down 19.09 points, or 0.46 percent, at 4,142.37. Better-than-expected corporate earnings have boosted Wall Street lately, though companies have largely been beating reduced forecasts. According to Thomson Reuters data, profits are seen rising 1.6 percent this quarter, down from the 6.5 percent growth rate estimated at the start of the year.With 28 percent of the S&P 500 having reported results, 65.2 percent have topped expectations, according to Thomson Reuters data, above the long-term average of 63 percent. On the revenue side, 53.6 percent have exceeded forecasts, below the 61 percent long-term average.Procter & Gamble Co's earnings topped analyst forecasts but revenues were flat and shares edged 0.8 percent lower to $79.93.New home sales dropped 14.5 percent in March, tumbling more than expected to an eight-month low. Housing stocks fell 1 percent, with D.R. Horton Inc off 2.3 percent to $21.33.(Editing by Nick Zieminski)",2014-04-23,GILD,"Wed Apr 23, 2014 | 11:52am EDT",US STOCKS-Wall St edges down after six-day S&P rally; AT&T falls,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NF18320140423?type=companyNews
49,"  * S&P 500, Nasdaq coming off six-day winning streak* Boeing rallies after results, outlook; AT&T drops* Biotech shares lower after results, but Gilead gains* Indexes down: Dow, S&P 500 0.1 pct, Nasdaq 0.5 pct   (Updates to open)By Ryan VlastelicaNEW YORK, April 23 U.S. stocks edged lower on Wednesday as strong results from Boeing failed to inspire investors to keep pushing equities higher following six straight days of gains. Better-than-expected corporate earnings have boosted Wall Street lately, though companies have largely been beating reduced forecasts. According to Thomson Reuters data, profits are seen rising 1.6 percent this quarter, down from the 6.5 percent growth rate estimated at the start of the year.Boeing Co reported first-quarter revenue that beat expectations and lifted its core earnings forecast to reflect a tax settlement gain, sending shares up 2.7 percent to $131.05.  However, this was offset by fellow Dow component AT&T Inc, which fell 3.4 percent to $35.07 a day after its results. ""It's nice to see Boeing rally, but expectations weren't extraordinarily high so it had a low bar to clear,"" said David Carter, chief investment officer at Lenox Wealth Advisors in New York. ""Generally valuations are still supportive for stocks, and reasonable earnings results will support continued gains.""Biotech was again in focus following a trio of key earnings releases. Gilead Sciences Inc late Tuesday posted a sharp profit increase, while Amgen Inc's earnings were below forecasts. Biogen Idec Inc posted strong results and raised its full-year earnings and revenue views.Shares of Gilead rose 1.7 percent to $74.06 while Amgen dropped 4.3 percent to $114.34. Biogen fell 1.5 percent to $301.50 and the Nasdaq biotechnology index fell 1.2 percent. While results were mixed, they did point to some fundamental strength, easing concerns the group was overvalued. The Dow Jones industrial average was down 16.89 points, or 0.10 percent, at 16,497.48. The Standard & Poor's 500 Index was down 2.59 points, or 0.14 percent, at 1,876.96. The Nasdaq Composite Index was down 19.58 points, or 0.47 percent, at 4,141.88.New home sales dropped 14.5 percent in March, tumbling more than expected to an eight-month low.Among other notable earnings, Procter & Gamble Co's  earnings topped analyst forecasts, though shares edged 0.8 percent lower to $79.93. Dow Chemical Co  rose 2 percent to $49.90 after reported better-than-expected earnings, helped by improved margins.With 28 percent of the S&P 500 having reported results through Wednesday morning, 65.2 percent have topped expectations, according to Thomson Reuters data, above the long-term average of 63 percent. On the revenue side, 53.6 percent have exceeded forecasts, below the 61 percent long-term average.    (Editing by Nick Zieminski)",2014-04-23,GILD,"Wed Apr 23, 2014 | 10:17am EDT",US STOCKS-Wall St edges lower following six-day S&P rally,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NF0W620140423?type=companyNews
50,"  * S&P 500, Nasdaq on six-day winning streak as of Tuesday* Gilead Sciences rises in premarket after results* Key earnings on tap; Apple, Facebook out after the close* Futures down: Dow 5 pts, S&P 2.1 pts, Nasdaq 7 ptsBy Ryan VlastelicaNEW YORK, April 23 U.S. stock index futures were flat on Wednesday as investors found few reasons to keep buying following six straight days of gains on both the S&P 500 and Nasdaq. * Equities have recently been boosted by corporate earnings, with a number of prominent names topping expectations, though companies have largely been beating reduced forecasts. According to Thomson Reuters data, profits are seen rising 1.1 percent this quarter, down from the 6.5 percent growth rate estimated at the start of the year.* Gilead Sciences Inc rose 3.8 percent to $75.60 in heavy premarket trading a day after the drugmaker reported a sharp increase in its quarterly profit, helped by sales of its hepatitis C drug. Gilead's results, like those of Netflix Inc , showed there was still room to grow in high-flying names that recently plunged on signs of excessive valuation.* Shares of Boeing Co rose 2.3 percent to $130.50 after the planemaker reported its first-quarter results and raised its full-year outlook for core earnings. * Procter & Gamble Co reported third-quarter sales that were slightly under expectations. The Dow component's chief executive said the company was operating ""in a slow-growth, highly competitive environment.""* More key reports are expected Wednesday, with Apple Inc  and Facebook Inc scheduled for release after the market closes.* With 20 percent of the S&P 500 having reported results through Tuesday morning, 63 percent have topped earnings expectations, according to Thomson Reuters data, matching the long-term average. On the revenue side, 51 percent have exceeded forecasts, below the 61 percent long-term average. * S&P 500 futures fell 2.1 points and were below fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures dipped 5 points and Nasdaq 100 futures lost 7 points.* Both the S&P 500 and Nasdaq closed out six straight days of gains on Tuesday. The S&P rose 3.5 percent over that period while the Nasdaq added 4 percent.* In another positive sign for equities, the Dow Jones Transportation Average rose 0.6 percent on Tuesday to close at a record high, its first since April 2. However, trading volume was light, suggesting a lack of investor conviction behind the move.* AT&T Inc late Tuesday raised its full-year revenue growth outlook, citing its acquisition of LEAP wireless in March and the popularity of a new handset pricing model that charges customers for devices separately from their wireless plans. Shares of the Dow component fell 1.4 percent to $35.78 in premarket trading.* JetBlue Airways Corp pilots late Tuesday voted by a wide margin to join the Air Line Pilots Association union, raising concerns that the move would raise the airline's costs. Shares fell 0.9 percent to $8.67 in light premarket trading.     (Editing by Chizu Nomiyama)",2014-04-23,GILD,"Wed Apr 23, 2014 | 7:41am EDT",US STOCKS-Futures flat after six straight days of gains,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0NF0GB20140423?type=companyNews
51,"  April 24 Aetna Inc. spent about $30 million during the first quarter on Sovaldi, the pricey new hepatitis C treatment from Gilead Sciences Inc., Chief Financial Officer Shawn Guertin said on Thursday during a conference call with investors.Guertin said the costs were in line with the company's expectations. Most of it was in its commercial business and in Medicare Part D, the government program in which private insurers manage drug benefits.  Medicaid-related Sovaldi costs accounted for the smallest portion of that $30 million, he said, as some states continue to develop policies on the drug and because some states where it operates do not use private insurance to pay for any pharmaceutical benefits.   (Reporting by Caroline Humer; Editing by Chizu Nomiyama) ",2014-04-24,GILD,"Thu Apr 24, 2014 | 9:30am EDT","Aetna CFO says spent $30 mln on Sovaldi in Q1, as expected",http://www.reuters.com//article/aetna-results-hepatitisc-idUSL2N0NG0U620140424?type=companyNews
52,"  (Adds analyst comment, details, background, byline, updates share price)By Deena BeasleyMay 1 Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, sending its shares up nearly 8 percent.The study found that treatment with Kalydeco and the experimental drug VX-661 for 28 days resulted in a 4.6 percentage point improvement in mean lung function for patients with two specific genetic mutations.VX-661 would be the second drug from Vertex that works by treating the underlying cause of cystic fibrosis, a rare genetic disease that impairs the lungs and digestive system.The disease is caused by defective or missing CF transmembrane conductane regulator (CFTR) proteins. Kalydeco is designed for patients with the most common CFTR mutation, while VX-661 aims to treat patients with a different mutation that affects protein function. The Phase 2 trial involved patients with both mutations who were already taking Kalydeco.""It is good data and some believe it does have an incremental positive read-through to the all-important Phase 3 data later this summer,"" said RBC Capital Markets analyst Michael Yee.That trial will answer the question of whether a combination of Vertex drugs is effective in patients with two copies of the gene mutation not currently addressed by Kalydeco - a market representing about half of the 30,000 cystic fibrosis patients in the United States. A positive result ""would be transformative to the cystic fibrosis community,"" Yee said.The most common side effects seen during the Phase 2 trial included cough, headache and upper respiratory tract infection. But ISI Group analyst Mark Schoenebaum cautioned that Vertex has not disclosed results from the mid-stage trial for patients treated with a placebo.Vertex also announced that first quarter sales of Kalydeco totaled $100 million, which fell short of the average analyst estimate of $107 million, according to Wells Fargo Securities.Separately, The company reported an adjusted first quarter loss of $1.00 per share, also below the average analyst per-share loss estimate of 67 cents, according to Thomson Reuters I/B/E/S.Vertex said it would discontinue research into treatments for hepatitis C, a market now dominated by sales of Gilead Sciences Inc's Sovaldi. Vertex late last year sold off its non-North America royalty rights to hepatitis C drug Incivek.Shares of Vertex, which closed at $68.95 in regular Nasdaq trading, were up $5.30 at $74.25 after hours.   (Reporting By Deena Beasley; Editing by David Gregorio and Alden Bentley)",2014-05-01,GILD,"Thu May 1, 2014 | 6:05pm EDT",UPDATE 1-Vertex says cystic fibrosis drugs shown to boost lung function,http://www.reuters.com//article/vertex-idUSL2N0NN1TX20140501?type=companyNews
53,"  Gilead Sciences Inc (GILD.O), maker of new hepatitis C treatment Sovaldi, on Wednesday said its board has authorized the repurchase of up to $5 billion of the company's shares.The latest authorization augments the approximate $2.9 billion remaining in Gilead's previous buy back program, which the company said is expected to be completed by September. Gilead said the new program expires three years after the completion of the current repurchase program. Immediately after the announcement, shares of Gilead jumped as much as 1.4 percent from their closing price of $78.77 on Nasdaq, then eased back to stand up 63 cents, or 0.8 percent, after hours. (Reporting By Deena Beasley; Editing by David Gregorio)",2014-05-07,GILD,"Wed May 7, 2014 | 5:44pm EDT",Gilead to buy back another $5 billion of shares,http://www.reuters.com//article/us-gilead-sciences-idUSBREA4613N20140507?type=companyNews
54,"  May 7 Gilead Sciences Inc, maker of new hepatitis C treatment Sovaldi, on Wednesday said its board has authorized the repurchase of up to $5 billion of the company's shares.The latest authorization augments the approximate $2.9 billion remaining in Gilead's previous buy back program, which the company said is expected to be completed by September. Gilead said the new program expires three years after the completion of the current repurchase program.  Immediately after the announcement, shares of Gilead jumped as much as 1.4 percent from their closing price of $78.77 on Nasdaq, then eased back to stand up 63 cents, or 0.8 percent, after hours.   (Reporting By Deena Beasley; Editing by David Gregorio)",2014-05-07,GILD,"Wed May 7, 2014 | 5:44pm EDT",Gilead to buy back another $5 billion of shares,http://www.reuters.com//article/gilead-sciences-idUSL2N0NT2DT20140507?type=companyNews
55,"   By Ryan Vlastelica | NEW YORK  NEW YORK May 15 Top hedge funds shed their stakes in high-profile Internet names such as Netflix Inc  and Groupon Inc in the first quarter, moving to peers viewed as more mature and less volatile.High-growth Internet software and biotech companies were the darlings of 2013, but their shares started to fall sharply in early March. Netflix, last year's biggest S&P 500 gainer and an important hedge fund holding, is down more than 24 percent from its closing high this year.Hedge funds invested in technology and healthcare fell 3.65 percent in April, the biggest monthly decline since October 2008 and extending March's 1.8 percent decline, according to data from Hedge Fund Research.Among prominent hedge fund managers, Carl Icahn cut his holding in Netflix by 15.8 percent in the first quarter, reducing it to about 2.2 million shares. Tiger Global Management sold its entire stake of 663,000 shares during the quarter. Netflix was up on the year for most of the first quarter, so the fund is likely to have sold at the right time.Tiger also dumped its stake of 11.46 million shares in Groupon. That position was worth $134.9 million at the end of 2013 and $89.9 million at the end of the quarter. The Internet software and services sector now accounts for about 10 percent of the top 100 long positions for equity/long short hedge funds, down from 20 percent to 25 percent in January, according to Credit Suisse data.Long/short hedge fund managers moved to short bets in Internet names amid a meltdown in the group, according to Credit Suisse. Long positions in the group now account for about 25 percent of the overall gross exposure to the group, which adds together both long and short positions. That's the lowest rate in at least three years. Some funds added to their ""momentum"" exposure, with Jana Partners increasing its stake in Groupon by almost 32 percent to 40.8 million shares.Other funds moved to technology names with less lofty valuations and that are viewed as more established. Third Point sold its stakes in both Yahoo Inc and biotech company Gilead Sciences Inc but increased its Google Inc  holdings by 31.3 percent.EBay Inc, which became a darling among top U.S. hedge funds in the fourth quarter just before billionaire activist investor Carl Icahn urged the company to spin off its PayPal business, continued to find fans in the first quarter.Omega more than tripled its stake in eBay, bringing it to 2.9 million shares, while Jana opened a stake of 3.9 million shares in the first quarter. Icahn, who backed down from his demands, disclosed a new stake in eBay, holding 27.8 million shares as of March 31.   (Reporting by Ryan Vlastelica; Additional reporting by David Gaffen and Sam Forgione; Editing by Steve Orlofsky)",2014-05-15,GILD,"Thu May 15, 2014 | 6:09pm EDT",Major U.S. hedge funds sold 'momentum' Internet names in 1st qtr,http://www.reuters.com//article/hedgefunds-filing-momentum-idUSL1N0O128Z20140515?type=companyNews
56,"  The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.The latest salvo in the war on escalating U.S. healthcare costs came from AHIP - America's Health Insurance Plans - and targeted Sovaldi, the new $84,000 hepatitis C treatment from Gilead Sciences Inc.""Sovaldi has shown tremendous results, and it's the kind of medical innovation we need to sustain. Unfortunately, the drug's maker has priced it at an astronomical level that is not sustainable for consumers, innovation, or society,"" AHIP said on its Coverage blog.Sovaldi is the first in a new wave of all-oral treatments for the liver disease that has been a tremendous advance over prior treatments. The new drug has demonstrated an ability to cure well over 90 percent of patients in just 12 weeks or less with few side effects.Prior to the Sovaldi approval, hepatitis C treatments took 24 or 48 weeks, cured about 75 percent of patients and involved many more pills as well as injectable interferon that causes flu-like symptoms and other side effects that led many people to avoid or discontinue treatment.But concern that hundreds of thousands of patients will  seek treatment with the Gilead drug that costs roughly $1,000 per pill has provided a rallying point for insurers and others seeking to rein in the skyrocketing cost of new medicines in the United States, which has no price controls on drugs, unlike Europe and other countries. In its first full quarter on the market, Sovaldi had more than $2 billion in sales, shattering previous pharmaceutical records.Cara Miller, a spokeswoman for Gilead, defended the drug's pricing in an emailed statement: ""While Sovaldi greatly enhances the standard of care for hepatitis C, it was priced such that the total regimen cost is equal to that of prior standard of care regimens.  ""Sovaldi reduces total treatment costs for HCV  taking into account the cost of medications (including those for side effects or complications) and healthcare visits  and it represents a finite cure, an important point to consider when comparing the price of a pill or bottle to the lifetime costs of treating a chronic disease.""The campaign against Gilead may also be an effort to pressure other drugmakers, such as Merck & Co, AbbVie and Bristol-Myers Squibb Co, before they set prices for their hepatitis C drugs that are expected to gain regulatory approval in the next year or two.AHIP said promising new drugs are being priced in a way that threatens Americans' access to them. ""We need to find a solution that ensures important drugs like Sovaldi are priced at sustainable levels so that we can foster even more life-saving innovation."" John Castellani, chief executive of PhRMA, the leading pharmaceutical industry trade group, said the problem is an insurance system that pushes too much of the cost of treatment onto the patient with high co-pays and deductibles for drugs.""The insurance model makes medicine seem like the most expensive part of the healthcare system,"" Castellani said. (Reporting by Bill Berkrot and Caroline Humor; Additional reporting by Ken Wills; Editing by Ken Wills)",2014-05-20,GILD,"Tue May 20, 2014 | 7:47pm EDT",U.S. health insurers say Gilead hepatitis C drug too costly,http://www.reuters.com//article/us-insurance-gilead-sciences-drugcosts-idUSKBN0E029U20140520?type=companyNews
57,"  (Adds response from Gilead Sciences in paragraphs 8-9)May 20 The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.The latest salvo in the war on escalating U.S. healthcare costs came from AHIP - America's Health Insurance Plans - and targeted Sovaldi, the new $84,000 hepatitis C treatment from Gilead Sciences Inc.""Sovaldi has shown tremendous results, and it's the kind of medical innovation we need to sustain. Unfortunately, the drug's maker has priced it at an astronomical level that is not sustainable for consumers, innovation, or society,"" AHIP said on its Coverage blog.Sovaldi is the first in a new wave of all-oral treatments for the liver disease that has been a tremendous advance over prior treatments. The new drug has demonstrated an ability to cure well over 90 percent of patients in just 12 weeks or less with few side effects. Prior to the Sovaldi approval, hepatitis C treatments took 24 or 48 weeks, cured about 75 percent of patients and involved many more pills as well as injectable interferon that causes flu-like symptoms and other side effects that led many people to avoid or discontinue treatment.But concern that hundreds of thousands of patients will  seek treatment with the Gilead drug that costs roughly $1,000 per pill has provided a rallying point for insurers and others seeking to rein in the skyrocketing cost of new medicines in the United States, which has no price controls on drugs, unlike Europe and other countries.In its first full quarter on the market, Sovaldi had more than $2 billion in sales, shattering previous pharmaceutical records. Cara Miller, a spokeswoman for Gilead, defended the drug's pricing in an emailed statement: ""While Sovaldi greatly enhances the standard of care for hepatitis C, it was priced such that the total regimen cost is equal to that of prior standard of care regimens.""Sovaldi reduces total treatment costs for HCV - taking into account the cost of medications (including those for side effects or complications) and healthcare visits - and it represents a finite cure, an important point to consider when comparing the price of a pill or bottle to the lifetime costs of treating a chronic disease."" The campaign against Gilead may also be an effort to pressure other drugmakers, such as Merck & Co, AbbVie  and Bristol-Myers Squibb Co, before they set prices for their hepatitis C drugs that are expected to gain regulatory approval in the next year or two.AHIP said promising new drugs are being priced in a way that threatens Americans' access to them. ""We need to find a solution that ensures important drugs like Sovaldi are priced at sustainable levels so that we can foster even more life-saving innovation.""John Castellani, chief executive of PhRMA, the leading pharmaceutical industry trade group, said the problem is an insurance system that pushes too much of the cost of treatment onto the patient with high co-pays and deductibles for drugs.""The insurance model makes medicine seem like the most expensive part of the healthcare system,"" Castellani said.   (Reporting by Bill Berkrot and Caroline Humor; Additional reporting by Ken Wills; Editing by Ken Wills)",2014-05-20,GILD,"Tue May 20, 2014 | 7:43pm EDT",UPDATE 1-U.S. health insurers say Gilead hepatitis C drug too costly,http://www.reuters.com//article/insurance-gilead-sciences-drugcosts-idUSL1N0O62C920140520?type=companyNews
58,"  May 20 The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.The latest salvo in the war on escalating U.S. healthcare costs came from AHIP - America's Health Insurance Plans - and targeted Sovaldi, the new $84,000 hepatitis C treatment from Gilead Sciences Inc.""Sovaldi has shown tremendous results, and it's the kind of medical innovation we need to sustain. Unfortunately, the drug's maker has priced it at an astronomical level that is not sustainable for consumers, innovation, or society,"" AHIP said on its Coverage blog.Sovaldi is the first in a new wave of all-oral treatments for the liver disease that has been a tremendous advance over prior treatments. The new drug has demonstrated an ability to cure well over 90 percent of patients in just 12 weeks or less with few side effects.Prior to the Sovaldi approval, hepatitis C treatments took 24 or 48 weeks, cured about 75 percent of patients and involved many more pills as well as injectable interferon that causes flu-like symptoms and other side effects that led many people to avoid or discontinue treatment. But concern that hundreds of thousands of patients will  seek treatment with the Gilead drug that costs roughly $1,000 per pill has provided a rallying point for insurers and others seeking to rein in the skyrocketing cost of new medicines in the United States, which has no price controls on drugs, unlike Europe and other countries.In its first full quarter on the market, Sovaldi had more than $2 billion in sales, shattering previous pharmaceutical records. Representatives from Gilead did not immediately respond to a request for comment.Drugmakers have argued that it costs billions of dollars to  develop new medicines and that high prices are necessary to sustain innovation. They also note that a treatment such as Sovaldi can save future healthcare costs by preventing liver failure, cancer or the need for a transplant. The campaign against Gilead may also be an effort to pressure other drugmakers, such as Merck & Co, AbbVie  and Bristol-Myers Squibb Co, before they set prices for their hepatitis C drugs that are expected to gain regulatory approval in the next year or two.AHIP said promising new drugs are being priced in a way that threatens Americans' access to them. ""We need to find a solution that ensures important drugs like Sovaldi are priced at sustainable levels so that we can foster even more life-saving innovation.""John Castellani, chief executive of PhRMA, the leading pharmaceutical industry trade group, said the problem is an insurance system that pushes too much of the cost of treatment onto the patient with high co-pays and deductibles for drugs.""The insurance model makes medicine seem like the most expensive part of the healthcare system,"" Castellani said.   (Reporting by Bill Berkrot and Caroline Humor; Editing by Ken Wills)",2014-05-20,GILD,"Tue May 20, 2014 | 6:53pm EDT",U.S. health insurers say Gilead hepatitis C drug too costly,http://www.reuters.com//article/insurance-gilead-sciences-drugcosts-idUSL1N0O628320140520?type=companyNews
59,"  (Repeats timeline with no changes)May 28 Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost. Before the Sovaldi outcry, U.S. insurers and doctors made limited attempts to curb the rising cost of novel medicines.Here is a timeline of drug pricing clashes:Late 2012 - France's Sanofi and U.S.-based Regeneron Pharmaceuticals drop the price on cancer drug Zaltrap after a prominent hospital, New York's Memorial Sloan Kettering Cancer Center, refuses to use it, saying it worked no better than a similar, cheaper drug.December 6, 2013 - Gilead receives approval from the U.S. Food & Drug Administration for new hepatitis C medication Sovaldi and announces it will charge $84,000 for the typical course of treatment.January 2014 - Express Scripts, which manages drug benefits programs, for the first time drops 48 brand-name drugs and pieces of equipment from its recommended list of approved drugs because there were more affordable, clinically equivalent alternatives available. It is the most comprehensive decision to drop drugs from a large formulary to date. March 4, 2014 - Molina Healthcare, a small California Medicaid insurer, starts a public campaign about the price of Sovaldi, saying it cannot afford to pay for the treatment and asking California and other states to set aside money to do so.March 21, 2014 -  U.S. Representative Henry Waxman calls for an investigation of Sovaldi pricing. Waxman, a Democrat who helped build a government buying program for HIV drugs more than two decades ago, asks Gilead to justify prices that will fall to the taxpayers who support government insurance programs including Medicaid, Medicare, the Veterans Affairs Bureau and the federal and state prison systems. Shares in Gilead and other top names in biotechnology fall on fears the industry as a whole will face resistance to ever-higher drug prices. March 31, 2014 - Global sales of Sovaldi reach $2.3 billion in the first three months on the market, a record launch for any drug. At least 30,000 patients have used the medicine. Wall Street expects sales for 2014 to top $8 billion.April 2, 2014 - California's Kaiser Permanente hospital-insurer system calls Sovaldi's price ""outrageous"" and says Gilead has not cut it a big enough discount.April 9, 2014 - The World Health Organization calls for a ""concerted effort"" to drive down the cost of new hepatitis C drugs that offer a cure but are unaffordable for most infected people worldwide. April 11, 2014 - Texas delays a decision on imposing strict limits on Sovaldi in its Medicaid health plan for the poor, at the urging of outside advisers. The move delays access to the drug in the state Medicaid program until at least August.April 17, 2014 - UnitedHealth Group Inc, the largest U.S. health insurer, makes an unusual move by detailing the unexpected costs of a single drug, Sovaldi, during the first quarter.April 18, 2014 - Biogen prices hemophilia drug Alprolix in the same range as existing, but less convenient products, in order to gain market share.May 21, 2014 - The nation's largest insurer group calls on payers and drugmakers to solve the drug pricing problem posed by Sovaldi before the U.S. government gets involved. The pharmacy industry says the insurance system needs to be reformed.     (Reporting by Caroline Humer, editing by Michele Gershberg and Peter Henderson)",2014-05-28,GILD,"Wed May 28, 2014 | 7:00am EDT",TIMELINE-RPT-Early signs of pushback over U.S. drug prices,http://www.reuters.com//article/usa-healthcare-hepatitisc-idUSL1N0OE01Y20140528?type=companyNews
60,"  Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost. Before the Sovaldi outcry, U.S. insurers and doctors made limited attempts to curb the rising cost of novel medicines.Here is a timeline of drug pricing clashes:Late 2012 - France's Sanofi and U.S.-based Regeneron Pharmaceuticals drop the price on cancer drug Zaltrap after a prominent hospital, New York's Memorial Sloan Kettering Cancer Center, refuses to use it, saying it worked no better than a similar, cheaper drug.December 6, 2013 - Gilead receives approval from the U.S. Food & Drug Administration for new hepatitis C medication Sovaldi and announces it will charge $84,000 for the typical course of treatment.January 2014 - Express Scripts, which manages drug benefits programs, for the first time drops 48 brand-name drugs and pieces of equipment from its recommended list of approved drugs because there were more affordable, clinically equivalent alternatives available. It is the most comprehensive decision to drop drugs from a large formulary to date.March 4, 2014 - Molina Healthcare, a small California Medicaid insurer, starts a public campaign about the price of Sovaldi, saying it cannot afford to pay for the treatment and asking California and other states to set aside money to do so. March 21, 2014 -  U.S. Representative Henry Waxman calls for an investigation of Sovaldi pricing. Waxman, a Democrat who helped build a government buying program for HIV drugs more than two decades ago, asks Gilead to justify prices that will fall to the taxpayers who support government insurance programs including Medicaid, Medicare, the Veterans Affairs Bureau and the federal and state prison systems. Shares in Gilead and other top names in biotechnology fall on fears the industry as a whole will face resistance to ever-higher drug prices.March 31, 2014 - Global sales of Sovaldi reach $2.3 billion in the first three months on the market, a record launch for any drug. At least 30,000 patients have used the medicine. Wall Street expects sales for 2014 to top $8 billion. April 2, 2014 - California's Kaiser Permanente hospital-insurer system calls Sovaldi's price ""outrageous"" and says Gilead has not cut it a big enough discount.April 9, 2014 - The World Health Organization calls for a ""concerted effort"" to drive down the cost of new hepatitis C drugs that offer a cure but are unaffordable for most infected people worldwide. April 11, 2014 - Texas delays a decision on imposing strict limits on Sovaldi in its Medicaid health plan for the poor, at the urging of outside advisers. The move delays access to the drug in the state Medicaid program until at least August.April 17, 2014 - UnitedHealth Group Inc, the largest U.S. health insurer, makes an unusual move by detailing the unexpected costs of a single drug, Sovaldi, during the first quarter.April 18, 2014 - Biogen prices hemophilia drug Alprolix in the same range as existing, but less convenient products, in order to gain market share.May 21, 2014 - The nation's largest insurer group calls on payers and drugmakers to solve the drug pricing problem posed by Sovaldi before the U.S. government gets involved. The pharmacy industry says the insurance system needs to be reformed. (Reporting by Caroline Humer, editing by Michele Gershberg and Peter Henderson)",2014-05-28,GILD,"Wed May 28, 2014 | 1:32am EDT",Timeline: Early signs of pushback over U.S. drug prices,http://www.reuters.com//article/us-usa-healthcare-hepatitisc-idUSKBN0E80CD20140528?type=companyNews
61,"  May 28 Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost. Before the Sovaldi outcry, U.S. insurers and doctors made limited attempts to curb the rising cost of novel medicines.Here is a timeline of drug pricing clashes:Late 2012 - France's Sanofi and U.S.-based Regeneron Pharmaceuticals drop the price on cancer drug Zaltrap after a prominent hospital, New York's Memorial Sloan Kettering Cancer Center, refuses to use it, saying it worked no better than a similar, cheaper drug.December 6, 2013 - Gilead receives approval from the U.S. Food & Drug Administration for new hepatitis C medication Sovaldi and announces it will charge $84,000 for the typical course of treatment.January 2014 - Express Scripts, which manages drug benefits programs, for the first time drops 48 brand-name drugs and pieces of equipment from its recommended list of approved drugs because there were more affordable, clinically equivalent alternatives available. It is the most comprehensive decision to drop drugs from a large formulary to date. March 4, 2014 - Molina Healthcare, a small California Medicaid insurer, starts a public campaign about the price of Sovaldi, saying it cannot afford to pay for the treatment and asking California and other states to set aside money to do so.March 21, 2014 -  U.S. Representative Henry Waxman calls for an investigation of Sovaldi pricing. Waxman, a Democrat who helped build a government buying program for HIV drugs more than two decades ago, asks Gilead to justify prices that will fall to the taxpayers who support government insurance programs including Medicaid, Medicare, the Veterans Affairs Bureau and the federal and state prison systems. Shares in Gilead and other top names in biotechnology fall on fears the industry as a whole will face resistance to ever-higher drug prices.March 31, 2014 - Global sales of Sovaldi reach $2.3 billion in the first three months on the market, a record launch for any drug. At least 30,000 patients have used the medicine. Wall Street expects sales for 2014 to top $8 billion. April 2, 2014 - California's Kaiser Permanente hospital-insurer system calls Sovaldi's price ""outrageous"" and says Gilead has not cut it a big enough discount.April 9, 2014 - The World Health Organization calls for a ""concerted effort"" to drive down the cost of new hepatitis C drugs that offer a cure but are unaffordable for most infected people worldwide. April 11, 2014 - Texas delays a decision on imposing strict limits on Sovaldi in its Medicaid health plan for the poor, at the urging of outside advisers. The move delays access to the drug in the state Medicaid program until at least August.April 17, 2014 - UnitedHealth Group Inc, the largest U.S. health insurer, makes an unusual move by detailing the unexpected costs of a single drug, Sovaldi, during the first quarter.April 18, 2014 - Biogen prices hemophilia drug Alprolix in the same range as existing, but less convenient products, in order to gain market share.May 21, 2014 - The nation's largest insurer group calls on payers and drugmakers to solve the drug pricing problem posed by Sovaldi before the U.S. government gets involved. The pharmacy industry says the insurance system needs to be reformed.     (Reporting by Caroline Humer, editing by Michele Gershberg and Peter Henderson)",2014-05-28,GILD,"Wed May 28, 2014 | 1:00am EDT",TIMELINE-Early signs of pushback over U.S. drug prices,http://www.reuters.com//article/usa-healthcare-hepatitisc-idUSL2N0NV1P620140528?type=companyNews
62,"  LONDON Britain's healthcare cost-effectiveness watchdog said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service.The National Institute for Health and Care Excellence (NICE) said it was ""minded not to recommend"" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain.The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients,"" said Carole Longson, director of the NICE Center for Health Technology Evaluation.""However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer.""Meanwhile, Gilead released more data on Sovaldi in combination with its second hepatitis C drug ledipasvir that should make it more difficult for NICE to reject. In a Japanese study of patients with the most common and often difficult to treat Genotype 1 form of the virus, the Sovaldi/ledipasvir combination demonstrated a 100 percent cure rate - 83 of 83 previously untreated patients and all 88 of those who had not been helped by prior treatment - with 12 weeks of therapy.Once ledipasvir gains approval, the combination with Sovaldi  is expected to become a one pill, once a day treatment regimen sold by Gilead.  Sovaldi is far more effective and better-tolerated than older treatments, but its high cost has provoked criticism from healthcare campaigners and insurers.The U.S. price for a 12-week course of treatment with Sovaldi is $84,000, or $1,000 for each once-daily pill. The price in Britain has been set lower at around 35,000 pounds ($58,800). Gilead and the pharmaceutical industry trade group has argued that the price is justified by the near guarantee of a cure, far fewer side effects and the treatment's ability to help patients avoid far more expensive hospitalizations for liver failure and the need for transplants as the disease progresses.($1 = 0.5956 British Pounds) (Reporting by Ben Hirschler, additional reporting by Bill Berkrot in New York; Editing by Louise Heavens and Grant McCool)",2014-06-16,GILD,"Mon Jun 16, 2014 | 12:59pm EDT",Britain's cost agency not ready to back Gilead hepatitis C drug,http://www.reuters.com//article/us-gilead-sciences-britain-idUSKBN0ER24E20140616?type=companyNews
63,"  (Adds Gilead data from Japanese study)LONDON, June 16 Britain's healthcare cost-effectiveness watchdog said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service.The National Institute for Health and Care Excellence (NICE) said it was ""minded not to recommend"" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain.""The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients,"" said Carole Longson, director of the NICE Centre for Health Technology Evaluation.""However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer."" Meanwhile, Gilead released more data on Sovaldi in combination with its second hepatitis C drug ledipasvir that should make it more difficult for NICE to reject.In a Japanese study of patients with the most common and often difficult to treat Genotype 1 form of the virus, the Sovaldi/ledipasvir combination demonstrated a 100 percent cure rate - 83 of 83 previously untreated patients and all 88 of those who had not been helped by prior treatment - with 12 weeks of therapy. Once ledipasvir gains approval, the combination with Sovaldi  is expected to become a one pill, once a day treatment regimen sold by Gilead.Sovaldi is far more effective and better-tolerated than older treatments, but its high cost has provoked criticism from healthcare campaigners and insurers. The U.S. price for a 12-week course of treatment with Sovaldi is $84,000, or $1,000 for each once-daily pill. The price in Britain has been set lower at around 35,000 pounds ($58,800).Gilead and the pharmaceutical industry trade group has argued that the price is justified by the near guarantee of a cure, far fewer side effects and the treatment's ability to help patients avoid far more expensive hospitalizations for liver failure and the need for transplants as the disease progresses.($1 = 0.5956 British Pounds)   (Reporting by Ben Hirschler, additional reporting by Bill Berkrot in New York; Editing by Louise Heavens and Grant McCool)",2014-06-16,GILD,"Mon Jun 16, 2014 | 12:50pm EDT",UPDATE 1-Britain's cost agency not ready to back Gilead hepatitis C drug,http://www.reuters.com//article/gilead-sciences-britain-idUSL5N0OX5E820140616?type=companyNews
64,"  LONDON Britain's healthcare cost-effectiveness watchdog NICE said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service.The National Institute for Health and Care Excellence (NICE) said it was ""minded not to recommend"" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain.The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients,"" said Carole Longson, director of the NICE Centre for Health Technology Evaluation. ""However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer.""Sovaldi is far more effective and better-tolerated than older treatments, but its high cost has provoked criticism from healthcare campaigners and insurers. The U.S. price for a 12-week course of treatment with Sovaldi is $84,000, or $1,000 for each once-daily pill. The price in Britain has been set lower at around 35,000 pounds ($58,800).     ($1 = 0.5956 British Pounds)  (Reporting by Ben Hirschler, editing by Louise Heavens)",2014-06-16,GILD,"Mon Jun 16, 2014 | 5:31am EDT",UK cost agency not ready to back Gilead hepatitis C drug,http://www.reuters.com//article/us-gilead-sciences-britain-idUSKBN0ER0VI20140616?type=companyNews
65,"  LONDON, June 16 Britain's healthcare cost-effectiveness watchdog NICE said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service.The National Institute for Health and Care Excellence (NICE) said it was ""minded not to recommend"" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain.""The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients,"" said Carole Longson, director of the NICE Centre for Health Technology Evaluation. ""However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer."" Sovaldi is far more effective and better-tolerated than older treatments, but its high cost has provoked criticism from healthcare campaigners and insurers. The U.S. price for a 12-week course of treatment with Sovaldi is $84,000, or $1,000 for each once-daily pill. The price in Britain has been set lower at around 35,000 pounds ($58,800).      ($1 = 0.5956 British Pounds)   (Reporting by Ben Hirschler, editing by Louise Heavens)",2014-06-16,GILD,"Mon Jun 16, 2014 | 5:23am EDT",UK cost agency not ready to back Gilead hepatitis C drug,http://www.reuters.com//article/gilead-sciences-britain-idUSL5N0OX2BA20140616?type=companyNews
66,"   By Bill Berkrot | NEW YORK  NEW YORK In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.Bristol-Myers disclosed plans for the exploratory 30-patient trial testing its three-drug combination with Sovaldi in an interview with Reuters. Eric Hughes, the leader of Bristol's global hepatitis program, said the details were due to be posted on the clinicaltrials.gov website next week. Sovaldi's $84,000 price tag for a 12-week treatment has spurred outrage among insurers, state health officials and lawmakers who fear the cost of treating millions of Americans with the progressive liver disease will top $250 billion. Insurers are pushing Gilead's rivals to offer lower prices when their hepatitis C medicines reach the market. Using the drug for a shorter course of treatment could, in theory, lower the cost, even when combined with Bristol's therapies. Rivals Merck & Co and AbbVie are also racing to develop next-generation hepatitis C treatments that cure most people of the virus in a shorter time frame.But drug pricing experts expect Gilead and its rivals may still argue that the quicker cure represents a value to patients, buffering any steep price reductions.""The position and concept of pharma is not ingredient costs or duration of treatment cost. Pharma is looking at it as cost per cure,"" said John Whang, co-president of Reimbursement Intelligence, which works with pharmaceutical companies and payers to help determine prices for medicines.The cost could come down, he said, ""but it's not going to be proportionate to the degree that the duration of treatment shortens."" The new generation of oral drugs being developed by several companies has raised hepatitis C cure rates to well above 90 percent from about 75 percent without the need for interferon or ribavirin, which caused miserable side effects that led many patients to delay or drop treatment. The drugs in clinical trials have already cut treatment time to 12 weeks from 24 to 48 weeks.  ""We got rid of the tolerability problem. We got rid of the efficacy problem. Now there is a tremendous drive to get down to shorter treatment durations,"" Bristol-Myers' Hughes said in a telephone interview.REVIVING A SOVALDI COMBO  Bristol's plan essentially revives an effort to test its drugs in combination with Sovaldi. It previously tested a single compound with Sovaldi, achieving cure rates close to 100 percent in 12 weeks. But Gilead scrapped further testing in 2012, as it  preferred to develop its own combination without a partner. Gilead's pill that combines Sovaldi with its ledipasvir is expected to gain U.S. approval this year for therapies of eight or 12 weeks, depending on the patient. The company is also testing the combination as a six-week treatment.The go-it-alone strategy has already paid off as Gilead was first to market with Sovaldi, breaking pharmaceutical industry sales records with $2.3 billion in sales within a few months. The new study, set to begin in late July, will test a trio of Bristol drugs with Sovaldi in previously untreated patients with the most common Genotype 1 form of the virus. It will involve two groups of 15 patients each - one getting four weeks of treatment and the other six. If Bristol can demonstrate cure rates in excess of 90 percent in four weeks, it plans to conduct larger trials with a more diverse patient population. ""We'll see what the data says,"" Hughes said. ""Taking this forward will be a very exciting thing.""       With Gilead not involved in the effort, Bristol will pay full price for Sovaldi to conduct the trial.Bristol would not discuss potential pricing of its regimen, since its drugs are not approved. But if treatment can be cut to four weeks from 12, the Sovaldi portion would be closer to $28,000. Other rivals are also advancing efforts to compete in what is expected to be a huge market.Merck this month agreed to pay $3.85 billion to acquire Idenix Pharmaceuticals Inc with the hope that combining the two companies' most promising drugs will produce cures in four to six weeks across the full spectrum of genotypes.U.S. and European health regulators in the last week said they would accelerate their reviews of AbbVie's four-drug regimen, meaning it could be vying for market share by early next year. (Reporting by Bill Berkrot; Editing by Michele Gershberg and Douglas Royalty)",2014-06-20,GILD,"Fri Jun 20, 2014 | 9:07am EDT",A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi,http://www.reuters.com//article/us-health-hepatitis-bristol-idUSKBN0EV0BL20140620?type=companyNews
67,"   By Bill Berkrot | NEW YORK  NEW YORK In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.Bristol-Myers disclosed plans for the exploratory 30-patient trial testing its three-drug combination with Sovaldi in an interview with Reuters. Eric Hughes, the leader of Bristol's global hepatitis program, said the details were due to be posted on the clinicaltrials.gov website next week. Sovaldi's $84,000 price tag for a 12-week treatment has spurred outrage among insurers, state health officials and lawmakers who fear the cost of treating millions of Americans with the progressive liver disease will top $250 billion. Insurers are pushing Gilead's rivals to offer lower prices when their hepatitis C medicines reach the market. Using the drug for a shorter course of treatment could, in theory, lower the cost, even when combined with Bristol's therapies. Rivals Merck & Co and AbbVie are also racing to develop next-generation hepatitis C treatments that cure most people of the virus in a shorter time frame.But drug pricing experts expect Gilead and its rivals may still argue that the quicker cure represents a value to patients, buffering any steep price reductions.""The position and concept of pharma is not ingredient costs or duration of treatment cost. Pharma is looking at it as cost per cure,"" said John Whang, co-president of Reimbursement Intelligence, which works with pharmaceutical companies and payers to help determine prices for medicines.The cost could come down, he said, ""but it's not going to be proportionate to the degree that the duration of treatment shortens."" The new generation of oral drugs being developed by several companies has raised hepatitis C cure rates to well above 90 percent from about 75 percent without the need for interferon or ribavirin, which caused miserable side effects that led many patients to delay or drop treatment. The drugs in clinical trials have already cut treatment time to 12 weeks from 24 to 48 weeks.  ""We got rid of the tolerability problem. We got rid of the efficacy problem. Now there is a tremendous drive to get down to shorter treatment durations,"" Bristol-Myers' Hughes said in a telephone interview.REVIVING A SOVALDI COMBO  Bristol's plan essentially revives an effort to test its drugs in combination with Sovaldi. It previously tested a single compound with Sovaldi, achieving cure rates close to 100 percent in 12 weeks. But Gilead scrapped further testing in 2012, as it  preferred to develop its own combination without a partner. Gilead's pill that combines Sovaldi with its ledipasvir is expected to gain U.S. approval this year for therapies of eight or 12 weeks, depending on the patient. The company is also testing the combination as a six-week treatment.The go-it-alone strategy has already paid off as Gilead was first to market with Sovaldi, breaking pharmaceutical industry sales records with $2.3 billion in sales within a few months. The new study, set to begin in late July, will test a trio of Bristol drugs with Sovaldi in previously untreated patients with the most common Genotype 1 form of the virus. It will involve two groups of 15 patients each - one getting four weeks of treatment and the other six. If Bristol can demonstrate cure rates in excess of 90 percent in four weeks, it plans to conduct larger trials with a more diverse patient population. ""We'll see what the data says,"" Hughes said. ""Taking this forward will be a very exciting thing.""       With Gilead not involved in the effort, Bristol will pay full price for Sovaldi to conduct the trial.Bristol would not discuss potential pricing of its regimen, since its drugs are not approved. But if treatment can be cut to four weeks from 12, the Sovaldi portion would be closer to $28,000. Other rivals are also advancing efforts to compete in what is expected to be a huge market.Merck this month agreed to pay $3.85 billion to acquire Idenix Pharmaceuticals Inc with the hope that combining the two companies' most promising drugs will produce cures in four to six weeks across the full spectrum of genotypes.U.S. and European health regulators in the last week said they would accelerate their reviews of AbbVie's four-drug regimen, meaning it could be vying for market share by early next year. (Reporting by Bill Berkrot; Editing by Michele Gershberg and Douglas Royalty)",2014-06-20,GILD,"Fri Jun 20, 2014 | 7:06am EDT",Exclusive: A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi,http://www.reuters.com//article/us-health-hepatitis-bristol-idUSKBN0EV11V20140620?type=companyNews
68,"   By Ransdell Pierson  Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough  treatment for hepatitis C, citing the expense to federal healthcare programs.Given the impact Sovaldis cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug, the lawmakers said in a release. ""It is unclear how Gilead set the price for Sovaldi.""Sovaldi's cost can soar to $168,000 in patients that need longer treatment periods, not including the costs of other drugs used with it, the senators said. Gilead acquired Sovaldi (sufosbuvir) in 2012 by paying more than $11 billion for Pharmasset Inc. The deal began to bear fruit after Sovaldi produced stellar results in late-stage clinical trials and was approved by U.S. regulators late last year.  The nucleotide analog inhibitor, or ""nuke,"" blocks a protein needed by the hepatitis C virus to replicate. Other companies, including Merck & Co, are developing their own nukes and other new types of hepatitis C treatments.The criticism from the two senators follows complaints from private healthcare insurers about the price of the most potent new treatment for the dangerous liver disease, which affects more than 3 million Americans. Gilead's pill, which cures patients more quickly than older drugs, and with fewer side effects, captured $2.3 billion in sales during its first full quarter on the market, a record for the drug industry.The drugmaker has defended the price, saying Sovaldi reduces overall treatment costs for hepatitis C by lowering the number of required healthcare visits and sidestepping the need for other medicines that treat side effects of older therapies. Wyden, an Oregon Democrat, and committee member Chuck Grassley, a Republican from Iowa, said in a letter to Gilead Chief Executive Officer John Martin that Sovaldi's price could also dramatically increase the cost of caring for an estimated 1.8 million prisoners infected with the hepatitis C virus. The senators said Pharmasset, before being acquired by Gilead, had expected to profitably sell the drug in the United States for $36,000, according to Securities and Exchange Commission documents. (Reporting by Ransdell Pierson in New York; Editing by Lisa Von Ahn)",2014-07-11,GILD,"Fri Jul 11, 2014 | 11:20am EDT",U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug,http://www.reuters.com//article/us-gilead-sciences-sovaldi-senators-idUSKBN0FG1JV20140711?type=companyNews
69,"  (Adds background on Sovaldi, rival drugs)By Ransdell PiersonJuly 11 Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough  treatment for hepatitis C, citing the expense to federal healthcare programs.""Given the impact Sovaldi's cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug,"" the lawmakers said in a release. ""It is unclear how Gilead set the price for Sovaldi.""Sovaldi's cost can soar to $168,000 in patients that need longer treatment periods, not including the costs of other drugs used with it, the senators said. Gilead acquired Sovaldi (sufosbuvir) in 2012 by paying more than $11 billion for Pharmasset Inc. The deal began to bear fruit after Sovaldi produced stellar results in late-stage clinical trials and was approved by U.S. regulators late last year.The nucleotide analog inhibitor, or ""nuke,"" blocks a protein needed by the hepatitis C virus to replicate. Other companies, including Merck & Co, are developing their own nukes and other new types of hepatitis C treatments. The criticism from the two senators follows complaints from private healthcare insurers about the price of the most potent new treatment for the dangerous liver disease, which affects more than 3 million Americans.Gilead's pill, which cures patients more quickly than older drugs, and with fewer side effects, captured $2.3 billion in sales during its first full quarter on the market, a record for the drug industry. The drugmaker has defended the price, saying Sovaldi reduces overall treatment costs for hepatitis C by lowering the number of required healthcare visits and sidestepping the need for other medicines that treat side effects of older therapies.Wyden, an Oregon Democrat, and committee member Chuck Grassley, a Republican from Iowa, said in a letter to Gilead Chief Executive Officer John Martin that Sovaldi's price could also dramatically increase the cost of caring for an estimated 1.8 million prisoners infected with the hepatitis C virus.The senators said Pharmasset, before being acquired by Gilead, had expected to profitably sell the drug in the United States for $36,000, according to Securities and Exchange Commission documents.   (Reporting by Ransdell Pierson in New York; Editing by Lisa Von Ahn)",2014-07-11,GILD,"Fri Jul 11, 2014 | 11:15am EDT",UPDATE 1-U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug,http://www.reuters.com//article/gilead-sciences-sovaldi-senators-idUSL2N0PM0UB20140711?type=companyNews
70,"  July 11 Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough new treatment for hepatitis C, citing the expense to federal healthcare programs.""Given the impact Sovaldi's cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug,"" the lawmakers said in a release. ""It is unclear how Gilead set the price for Sovaldi.""The criticism from the two senators follows complaints from private healthcare insurers about the price of the most potent new treatment for the dangerous liver disease, which affects more than 3 million Americans. Gilead's pill, which cures patients more quickly than older drugs, and with fewer side effects, captured more than $2 billion in sales during its first full quarter on the market, a record for the drug industry. The drugmaker has defended the price, saying Sovaldi reduces overall treatment costs for hepatitis C by lowering the number of required healthcare visits and sidestepping the need for other medicines that treat side effects of older therapies. Wyden, an Oregon Democrat, and committee member Chuck Grassley, a Republican from Iowa, said in a letter to Gilead Chief Executive Officer John Martin that Sovaldi's cost could also dramatically increase the cost of caring for an estimated 1.8 million prisoners infected with the hepatitis C virus.    (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2014-07-11,GILD,"Fri Jul 11, 2014 | 10:20am EDT",Senators ask Gilead to explain cost of Sovaldi hepatitis drug,http://www.reuters.com//article/gilead-sciences-sovaldi-senators-idUSL2N0PM0SD20140711?type=companyNews
71,"   By Bill Berkrot  Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use.Analysts had been forecasting Sovaldi sales of about $2.6 to $2.9 billion for the quarter.In its first two industry record shattering quarters on the market, Sovaldi has racked up sales of $5.8 billion despite reports that thousands of patients are still waiting for Gilead's two drugs in one pill combination treatment expected to gain U.S. approval in October. Since its December launch, Sovaldi has been prescribed for more than 80,000 patients in the United States and Europe, the company said. It said it expects to file for approval of Sovaldi in Japan in the fourth quarter.Sovaldi has been a lightning rod for a fierce debate over drug prices. Its $84,000 cost for 12-weeks of treatment that works out to $1,000 per pill has caused concerns that high demand will place a huge burden on government-run health plans and private insurers.A prominent U.S. health insurer trade group called on Gilead to lower the Sovaldi cost.    ""While it was a blockbuster quarter for Gilead, people who can't access the drug because of its price didn't fare nearly as well,"" Brendan Buck, spokesman for America's Health Insurance Plans, said in a statement.Only three U.S. states are not yet covering Sovaldi pending further review, Gilead said.  Gilead has argued that Sovaldi's price is comparable to older medicines that require far longer treatment duration with much lower cure rates and nasty side effects.""Sovaldi is a remarkable drug. We are curing people of a horrible disease in a very rapid time period,"" said Chief Operating Officer John Milligan, adding that Gilead is complying with requests from U.S. Senators for pricing information. Gilead and others are testing drug combinations that could cut treatment to as few as 4 to 6 weeks while maintaining cure rates in excess of 90 percent.While calls for price cuts have driven down Gilead's share price at times, the criticism is not all bad in the company's view. ""The controversy around Sovaldi is a constant reminder to patients that there is a new treatment option out there,"" Milligan said.Gilead shares slipped to $89.85 in extended trading from a Nasdaq close at $90.34.Gilead said its net profit soared to $3.66 billion, or $2.20 per share, from $772.6 million, or 46 cents per share, a year ago. Excluding items, the company earned $2.36 per share, topping analysts' average expectations by 57 cents, according to Thomson Reuters I/B/E/S. Gilead said it now expects 2014 revenue of $21 billion to $23 billion. Excluding Sovaldi, it had previously forecast sales of $11.3 billion to $11.5 billion.RBC Capital Markets analyst Michael Yee suggested shares were down due to a conservative forecast that implied flat Sovaldi sales in the second half. ""I don't think there's any reason for Gilead to want to parade around a huge projected number for the full year given a lot of (pricing) focus by press and government and payers,"" he said.Revenue for the quarter was $6.53 billion, topping analysts'  estimates of $5.86 billion, as Gilead's newer HIV drugs also saw solid sales growth.""What's remarkable is that their expenses didn't increase, so you see this spectacular earnings beat,"" Sanford Bernstein analyst Geoffrey Porges said.Earlier on Wednesday, Gilead won U.S. approval of its first oncology product, Zydelig (idelalisib), for the treatment of chronic lymphocytic leukemia and two other blood cancers. (Reporting by Bill Berkrot; Editing by Bernard Orr)",2014-07-23,GILD,"Wed Jul 23, 2014 | 6:50pm EDT",Gilead hepatitis C drug Sovaldi racks up $3.5 billion in quarter,http://www.reuters.com//article/us-gilead-sciences-results-idUSKBN0FS29920140723?type=companyNews
72,"  (Adds insurance group, company, analyst comment, cancer drug approval)By Bill BerkrotJuly 23 Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use.Analysts had been forecasting Sovaldi sales of about $2.6 to $2.9 billion for the quarter.In its first two industry record shattering quarters on the market, Sovaldi has racked up sales of $5.8 billion despite reports that thousands of patients are still waiting for Gilead's two drugs in one pill combination treatment expected to gain U.S. approval in October.Since its December launch, Sovaldi has been prescribed for more than 80,000 patients in the United States and Europe, the company said. It said it expects to file for approval of Sovaldi in Japan in the fourth quarter.Sovaldi has been a lightning rod for a fierce debate over drug prices. Its $84,000 cost for 12-weeks of treatment that works out to $1,000 per pill has caused concerns that high demand will place a huge burden on government-run health plans and private insurers.A prominent U.S. health insurer trade group called on Gilead to lower the Sovaldi cost. ""While it was a blockbuster quarter for Gilead, people who can't access the drug because of its price didn't fare nearly as well,"" Brendan Buck, spokesman for America's Health Insurance Plans, said in a statement.Only three U.S. states are not yet covering Sovaldi pending further review, Gilead said.Gilead has argued that Sovaldi's price is comparable to older medicines that require far longer treatment duration with much lower cure rates and nasty side effects.""Sovaldi is a remarkable drug. We are curing people of a horrible disease in a very rapid time period,"" said Chief Operating Officer John Milligan, adding that Gilead is complying with requests from U.S. Senators for pricing information. Gilead and others are testing drug combinations that could cut treatment to as few as 4 to 6 weeks while maintaining cure rates in excess of 90 percent.While calls for price cuts have driven down Gilead's share price at times, the criticism is not all bad in the company's view.""The controversy around Sovaldi is a constant reminder to patients that there is a new treatment option out there,"" Milligan said. Gilead shares slipped to $89.85 in extended trading from a Nasdaq close at $90.34.Gilead said its net profit soared to $3.66 billion, or $2.20 per share, from $772.6 million, or 46 cents per share, a year ago. Excluding items, the company earned $2.36 per share, topping analysts' average expectations by 57 cents, according to Thomson Reuters I/B/E/S.Gilead said it now expects 2014 revenue of $21 billion to $23 billion. Excluding Sovaldi, it had previously forecast sales of $11.3 billion to $11.5 billion.RBC Capital Markets analyst Michael Yee suggested shares were down due to a conservative forecast that implied flat Sovaldi sales in the second half. ""I don't think there's any reason for Gilead to want to parade around a huge projected number for the full year given a lot of (pricing) focus by press and government and payers,"" he said.Revenue for the quarter was $6.53 billion, topping analysts'  estimates of $5.86 billion, as Gilead's newer HIV drugs also saw solid sales growth.""What's remarkable is that their expenses didn't increase, so you see this spectacular earnings beat,"" Sanford Bernstein analyst Geoffrey Porges said.Earlier on Wednesday, Gilead won U.S. approval of its first oncology product, Zydelig (idelalisib), for the treatment of chronic lymphocytic leukemia and two other blood cancers.   (Reporting by Bill Berkrot; Editing by Bernard Orr)",2014-07-23,GILD,"Wed Jul 23, 2014 | 6:50pm EDT",UPDATE 2-Gilead hepatitis C drug Sovaldi racks up $3.5 bln in quarter,http://www.reuters.com//article/gilead-sciences-results-idUSL2N0PY2K320140723?type=companyNews
73,"  July 23 Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, crushing Wall Street estimates and demonstrating that the furor over its price has not curtailed early use.Analysts had been forecasting Sovaldi sales of about $2.6 billion for the quarter.In its first two industry record shattering full quarters on the market, Sovaldi has racked up about $5.8 billion in sales despite reports that thousands of patients are still waiting in the wings for Gilead's two drugs in one pill, once a day combination treatment expected to gain U.S. approval this year. Sovaldi, which won U.S. approval in December, has been a lightning rod for a fierce debate over prescription drug prices. Its $84,000 cost for a 12-week course of treatment that works out to $1,000 per pill has caused concerns that high demand will place a huge burden on government-run health plans and private health insurers. Gilead said its net profit soared to $3.66 billion, or $2.20 per share, from $772.6 million, or 46 cents per share, a year ago. Excluding one time items, the company earned $2.36 per share. Analysts on average expected $1.79, according to Thomson Reuters I/B/E/S.   (Reporting by Bill Berkrot; Editing by Bernard Orr)",2014-07-23,GILD,"Wed Jul 23, 2014 | 4:18pm EDT",Sales of Gilead hepatitis C drug Sovaldi soar in 2nd quarter,http://www.reuters.com//article/gilead-sciences-results-idUSL2N0PW25820140723?type=companyNews
74,"  The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer.The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia (CLL). It also approved Zydelig under a so-called accelerated approval program for relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma, when patients  have received at least two prior therapies.For drugs given accelerated approval, companies must conduct additional trials to confirm that the drug's apparent benefit is real.Zydelig, known generically as idealisib, will carry a boxed warning highlighting the risk of serious and potentially fatal toxicities, including liver toxicity, diarrhea, inflammation of the colon and lung, and perforation of the intestine. It will be marketed using a special risk management program.""We believe this broad boxed warning will lead docs to be cautious with this drug,"" Joseph Pantginis, an analyst at Roth Capital Partners, said in a research note.Shares of Gilead rose 0.4 percent to $89.66 in afternoon trading. Shares of Pharmacyclics Inc, which makes a rival product, Imbruvica, for chronic lymphocytic leukemia and mantle cell lymphoma and does not carry a boxed warning or risk management program, rose 8.8 percent to $105.05. Geoff Porges, an analyst at Sanford Bernstein, forecasts revenue for Zydelig growing to $1.5 billion in 2017, higher than the consensus estimate for that year of $990 million.""Gilead has global rights to the product, and are likely to commercialize it for multiple indications and subtypes of NHL as well as CLL,"" Porges said in a research report. Porges said his more optimistic view on the drug is based on its activity in indolent NHL and lead in this disease over Imbruvica and other drugs in the class. (Reporting by Toni Clarke in Washington; Editing by Susan Heavey and Steve Orlofsky)",2014-07-23,GILD,"Wed Jul 23, 2014 | 4:12pm EDT",U.S. FDA approves Gilead blood cancer drug Zydelig,http://www.reuters.com//article/us-cancer-drugs-approval-idUSKBN0FS1ST20140723?type=companyNews
75,"  The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer.The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia (CLL). It also approved Zydelig under a so-called accelerated approval program for relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma, when patients  have received at least two prior therapies.For drugs given accelerated approval, companies must conduct additional trials to confirm that the drug's apparent benefit is real.Zydelig, known generically as idealisib, will carry a boxed warning highlighting the risk of serious and potentially fatal toxicities, including liver toxicity, diarrhea, inflammation of the colon and lung, and perforation of the intestine. It will be marketed using a special risk management program.""We believe this broad boxed warning will lead docs to be cautious with this drug,"" Joseph Pantginis, an analyst at Roth Capital Partners, said in a research note.Shares of Gilead rose 0.4 percent to $89.66 in afternoon trading. Shares of Pharmacyclics Inc, which makes a rival product, Imbruvica, for chronic lymphocytic leukemia and mantle cell lymphoma and does not carry a boxed warning or risk management program, rose 8.8 percent to $105.05. Geoff Porges, an analyst at Sanford Bernstein, forecasts revenue for Zydelig growing to $1.5 billion in 2017, higher than the consensus estimate for that year of $990 million.""Gilead has global rights to the product, and are likely to commercialize it for multiple indications and subtypes of NHL as well as CLL,"" Porges said in a research report. Porges said his more optimistic view on the drug is based on its activity in indolent NHL and lead in this disease over Imbruvica and other drugs in the class. (Reporting by Toni Clarke in Washington; Editing by Susan Heavey and Steve Orlofsky)",2014-07-23,GILD,"Wed Jul 23, 2014 | 3:38pm EDT",U.S. FDA approves Gilead blood cancer drug Zydelig,http://www.reuters.com//article/us-eagle-pharms-fda-idUSKBN0FS14320140723?type=companyNews
76,"  The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer.The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia (CLL). It also approved Zydelig under a so-called accelerated approval program for relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma, when patients  have received at least two prior therapies.For drugs given accelerated approval, companies must conduct additional trials to confirm that the drug's apparent benefit is real.Zydelig, known generically as idealisib, will carry a boxed warning highlighting the risk of serious and potentially fatal toxicities, including liver toxicity, diarrhea, inflammation of the colon and lung, and perforation of the intestine. It will be marketed using a special risk management program.""We believe this broad boxed warning will lead docs to be cautious with this drug,"" Joseph Pantginis, an analyst at Roth Capital Partners, said in a research note.Shares of Gilead rose 0.4 percent to $89.66 in afternoon trading. Shares of Pharmacyclics Inc, which makes a rival product, Imbruvica, for chronic lymphocytic leukemia and mantle cell lymphoma and does not carry a boxed warning or risk management program, rose 8.8 percent to $105.05. Geoff Porges, an analyst at Sanford Bernstein, forecasts revenue for Zydelig growing to $1.5 billion in 2017, higher than the consensus estimate for that year of $990 million.""Gilead has global rights to the product, and are likely to commercialize it for multiple indications and subtypes of NHL as well as CLL,"" Porges said in a research report. Porges said his more optimistic view on the drug is based on its activity in indolent NHL and lead in this disease over Imbruvica and other drugs in the class. (Reporting by Toni Clarke in Washington; Editing by Susan Heavey and Steve Orlofsky)",2014-07-23,GILD,"Wed Jul 23, 2014 | 2:31pm EDT",U.S. FDA approves Gilead blood cancer drug Zydelig,http://www.reuters.com//article/us-cancer-drugs-approval-idUSKBN0FS20Q20140723?type=companyNews
77,"  (Adds analyst comment, competitor share reaction)July 23 The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's  Zydelig, a drug to treat three types of blood cancer.The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia (CLL).It also approved Zydelig under a so-called accelerated approval program for relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma, when patients  have received at least two prior therapies.For drugs given accelerated approval, companies must conduct additional trials to confirm that the drug's apparent benefit is real. Zydelig, known generically as idealisib, will carry a boxed warning highlighting the risk of serious and potentially fatal toxicities, including liver toxicity, diarrhea, inflammation of the colon and lung, and perforation of the intestine.It will be marketed using a special risk management program. ""We believe this broad boxed warning will lead docs to be cautious with this drug,"" Joseph Pantginis, an analyst at Roth Capital Partners, said in a research note.Shares of Gilead rose 0.4 percent to $89.66 in afternoon trading. Shares of Pharmacyclics Inc, which makes a rival product, Imbruvica, for chronic lymphocytic leukemia and mantle cell lymphoma and does not carry a boxed warning or risk management program, rose 8.8 percent to $105.05. Geoff Porges, an analyst at Sanford Bernstein, forecasts revenue for Zydelig growing to $1.5 billion in 2017, higher than the consensus estimate for that year of $990 million.""Gilead has global rights to the product, and are likely to commercialize it for multiple indications and subtypes of NHL as well as CLL,"" Porges said in a research report.Porges said his more optimistic view on the drug is based on its activity in indolent NHL and lead in this disease over Imbruvica and other drugs in the class.(Reporting by Toni Clarke in Washington; Editing by Susan Heavey and Steve Orlofsky)",2014-07-23,GILD,"Wed Jul 23, 2014 | 2:21pm EDT",UPDATE 1-U.S. FDA approves Gilead blood cancer drug Zydelig,http://www.reuters.com//article/cancer-drugs-approval-idUSL2N0PY1RU20140723?type=companyNews
78,"  July 23 The U.S. Food and Drug Administration has approved Gilead Inc's drug Zydelig to treat three types of blood cancer, the agency said on Wednesday.The FDA approved it for use in combination with Roche AG's  Rituxan for patients with relapsed chronic lymphocytic leukemia. The agency gave the drug so-called accelerated approval for patients with relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma who have received at least two prior therapies. Under the accelerated approval program, companies must conduct additional trials to confirm that the drug's apparent benefit is real. The drug will carry a boxed warning highlighting the risk of serious and potentially fatal toxicities, including toxicity, diarrhea, inflammation of the colon and lung and perforation of the intestine.    (Reporting by Toni Clarke in Washington; Editing by Susan Heavey)",2014-07-23,GILD,"Wed Jul 23, 2014 | 12:05pm EDT",U.S. FDA approves Gilead's blood cancer drug Zydelig,http://www.reuters.com//article/cancer-drugs-approval-idUSL2N0PY1HR20140723?type=companyNews
79,"   By Reuters Staff | LONDON  LONDON Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib. Ibrutinib, marketed at Imbruvica, was approved by U.S. regulators for treatment of chronic lymphocytic leukemia (CLL) in February, while Gilead's idelalisib, which has the brand name Zydelig, was approved in the United States last month. The approvals reflect a rapid pace of progress in treating CLL, a slowly progressing form of blood cancer, as scientists develop better ways to target the biological pathways involved in the disease. Last November, the U.S. Food and Drug Administration also approved Roche's Gazyva and the use of Arzerra, from GlaxoSmithKline and Genmab, was expanded in April 2014 to include CLL. ",2014-07-25,GILD,"Fri Jul 25, 2014 | 10:29am EDT",Europe backs new leukemia drugs from J&J and Gilead,http://www.reuters.com//article/us-gilead-leukemia-europe-idUSKBN0FU1IU20140725?type=companyNews
80,"  LONDON, July 25 Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib. Ibrutinib, marketed at Imbruvica, was approved by U.S. regulators for treatment of chronic lymphocytic leukaemia (CLL) in February, while Gilead's idelalisib, which has the brand name Zydelig, was approved in the United States last month. The approvals reflect a rapid pace of progress in treating CLL, a slowly progressing form of blood cancer, as scientists develop better ways to target the biological pathways involved in the disease. Last November, the U.S. Food and Drug Administration also approved Roche's Gazyva and the use of Arzerra, from GlaxoSmithKline and Genmab, was expanded in April 2014 to include CLL.    (Reporting by Ben Hirschler; editing by Tom Bergin)",2014-07-25,GILD,"Fri Jul 25, 2014 | 7:20am EDT",Europe backs new leukaemia drugs from J&J and Gilead,http://www.reuters.com//article/jj-gilead-sciences-europe-idUSL6N0Q01KD20140725?type=companyNews
81,  July 25 The European Medicines Agency:  * EU medicines agency says recommends Novo Nordisk  diabetestreatment degludec/liraglutide  * EU medicines agency says recommends Johnson & Johnson  Pharmacyclics leukaemia drug ibrutinib  * EU medicines agency says recommends Gilead Sciences  leukaemia drug  idelalisib,2014-07-25,GILD,"Fri Jul 25, 2014 | 7:13am EDT","BRIEF-EU medicines agency backs new drugs from Novo Nordisk, J&J, Gilead",http://www.reuters.com//article/ema-brief-idUSWLB008L720140725?type=companyNews
82,"   By Ryan Vlastelica | NEW YORK  NEW YORK With some of Wall Street's more volatile names set to report in the next couple of days, traders who bet on big swings in shares are hoping to see moves more like Facebook than Netflix.Netflix, along with Gilead Sciences (GILD.O) and several other stocks famous for their sharp gyrations, were unusually calm following their latest quarterly reports. However, Amazon.com and Facebook have had big days after their reports, heightening expectations for upcoming releases from Tesla Motors Inc (TSLA.O) and Expedia Inc (EXPE.O).For volatility investors, the direction of the move is not important, just the magnitude. Traders use an option strategy known as a straddle - buying a bullish call option and a bearish put option at the same strike price - in a bet that a stock will move by a certain amount. Even if a stock rises, the trader can lose money if it moves less than implied by the combined cost of the put and call options.On average, the realized stock change on earnings is about 1.5 percent lower than expected, according to derivatives strategists at Credit Suisse in New York.""Many of the companies that are typically volatile have had in-line numbers, which wouldnt result in a materially volatile stocks afterwards,"" said Doug Kass, president of Seabreeze Partners in Palm Beach, Florida.     Expedia and Tesla are both due to report results on Thursday. Over the past eight quarters, both have averaged a move of about 15 percent following results, according to Thomson Reuters data. Based on where they traded on Monday, investors expect a move of 9.4 percent for Expedia and 7.8 percent for Tesla.Investors trading options in 3D Systems Corp (DDD.N), scheduled to report on Wednesday, are looking for an 11 percent move in shares, compared with the eight-quarter median of 6 percent, according to Goldman Sachs. VOLATILITY SUCCESSES Recent days have seen more volatility among individual names. Amazon.com Inc (AMZN.O) on Friday tumbled almost 10 percent following results, while both Facebook Inc (FB.O) and Chipotle Mexican Grill (CMG.N) soared to records.Amazon lost more than $34 on the day after reporting results. The options market had priced in a $22 move. Facebook shares rose as much as $5.45, beyond the $4.92 move estimated by the options market, said Adam Sarhan, chief executive of Sarhan Capital in New York. Still, moves like these have been the exception this season, in an environment where the CBOE Volatility index .VIX is less than 13, well below its historical average of 20. Netflix Inc (NFLX.O) fell 5 percent in the week after its results, less than a third of its nearly 19 percent average move over the past eight quarters.""One might expect a little more volatility to the downside, which we havent seen,"" said Peter Cecchini, managing director and chief market strategist at Cantor Fitzgerald in New York. ""We could be in a calm before the storm, theres a lot of complacency."" Google Inc (GOOGL.O) rose 2.5 percent in the week after its results, less than half the 5.5 percent average over the past eight quarters. F5 Networks Inc (FFIV.O) rose 1.7 percent, below its 7.85 percent average. Gilead Sciences averaged a one-day move of 2.85 percent in the last six quarters; this time out, it gained just 1.1 percent.   Apple Inc (AAPL.O) rose 4.8 percent in the seven sessions following earnings, according to Thomson Reuters data, below the 6.4 percent average over the past eight quarters.""Last quarter the people who played an Apple straddle really got rewarded,"" said Dennis Dick, proprietary trader at Bright Trading LLC in Las Vegas. Apple gained 11.4 percent in the week after results. ""This time they bid it up too much, and those people got beat up.""Sarhan said that selling volatility in high-growth names can still be dangerous, even in a quiet market. ""Youre going into a situation where you know these names have had big moves in the past,"" he said.  (Editing by Nick Zieminski)",2014-07-29,GILD,"Tue Jul 29, 2014 | 10:39am EDT",A mixed quarter for bets on U.S. stock volatility,http://www.reuters.com//article/us-markets-usa-volatility-analysis-idUSKBN0FY1HK20140729?type=companyNews
83,"  Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.On Monday, Vertex sent a letter to doctors who treat patients with liver wasting disease to inform them that it would not be available after Oct. 14, a company spokesman confirmed on Wednesday.Vertex said in May during a conference call with analysts that it would withdraw from the hepatitis C market but had not said when it would stop making the drug. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion. Sales began to decline at the end of 2012 as patients began to wait for promising new drugs from competitors, which hit the market at the end of 2013.  The spokesman said the move was due to dwindling patients for the drug and the new treatments that are available. In the first half of the year, Gilead sold about $6 billion of Sovaldi, which has a high cure rate without the risk of the side effects older treatments carried. Johnson & Johnson markets the Vertex hepatitis C treatment outside of the United States.Vertex shares were up 3.7 percent to $88.58 on Wednesday.  (Reporting by Caroline Humer; Editing by Nick Zieminski)",2014-08-13,GILD,"Wed Aug 13, 2014 | 2:43pm EDT",Vertex to end sales of hepatitis C drug Incivek,http://www.reuters.com//article/us-vertex-hepatitisc-idUSKBN0GD1S520140813?type=companyNews
84,"  Aug 13 Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.On Monday, Vertex sent a letter to doctors who treat patients with liver wasting disease to inform them that it would not be available after Oct. 14, a company spokesman confirmed on Wednesday.Vertex said in May during a conference call with analysts that it would withdraw from the hepatitis C market but had not said when it would stop making the drug. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion. Sales began to decline at the end of 2012 as patients began to wait for promising new drugs from competitors, which hit the market at the end of 2013. The spokesman said the move was due to dwindling patients for the drug and the new treatments that are available. In the first half of the year, Gilead sold about $6 billion of Sovaldi, which has a high cure rate without the risk of the side effects older treatments carried. Johnson & Johnson markets the Vertex hepatitis C treatment outside of the United States.Vertex shares were up 3.7 percent to $88.58 on Wednesday.   (Reporting by Caroline Humer; Editing by Nick Zieminski)",2014-08-13,GILD,"Wed Aug 13, 2014 | 2:42pm EDT",Vertex to end sales of hepatitis C drug Incivek,http://www.reuters.com//article/vertex-hepatitisc-idUSL2N0QJ1YT20140813?type=companyNews
85,"  Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi.Gilead's shares rose as much as 3 percent in early trading.""While this outcome was widely expected, it is good nonetheless as it removes a 'disaster scenario',"" Cowen & Co analyst Phil Nadeau said, raising his price target to $105 from $95.Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012.  Gilead started selling sofosbuvir under the brand name Sovaldi in December.The arbitration panel on Thursday determined that Roche failed to establish any of its claims and is not entitled to any damages or other relief, Gilead said in a regulatory filing on Friday. Sovaldi, which costs $84,000 for 12 weeks of treatment, had sales of $3.5 billion in the second quarter ended June.The cost of Sovaldi, which cures well in excess of 90 percent of patients in as little as 8 weeks of treatment, has drawn sharp criticism from insurers and government officials. Gilead's shares were up 1 pct at $97.70 in late morning trading on the Nasdaq. Up to Thursday's close, the stock had risen 28 percent this year. (Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)",2014-08-15,GILD,"Fri Aug 15, 2014 | 12:14pm EDT",Gilead says panel rejects Roche's claims on hepatitis C drug,http://www.reuters.com//article/us-gilead-roche-patent-idUSKBN0GF13D20140815?type=companyNews
86,"  Aug 15 Gilead Sciences Inc said an arbitration panel has ruled in its favor, rejecting patent infringement claims from Roche Holding AG, related to Gilead's hepatitis C drug, Sovaldi.Roche initiated arbitration proceedings against Gilead in 2013, asserting exclusive rights over sofosbuvir by virtue of its 2004 collaboration agreement with Pharmasset Inc. Gilead bought Pharmasset in 2012.Gilead started selling sofosbuvir under the brand name Sovaldi in December. The arbitration panel on Thursday determined that Roche failed to establish any of its claims and is not entitled to any damages or other relief, Gilead said in a regulatory filing on Friday. (1.usa.gov/Xmtn2P) Sovaldi, which costs $84,000 for 12-weeks of treatment, had sales of $3.5 billion in the second quarter ended June. Gilead shares were up 1 pct in premarket trade. They had closed at $96.36 on Thursday on the Nasdaq.   (Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)",2014-08-15,GILD,"Fri Aug 15, 2014 | 8:10am EDT",Gilead says wins favorable ruling on hep C drug,http://www.reuters.com//article/gilead-roche-patent-idUSL4N0QL3HU20140815?type=companyNews
87,"  Aug 15 Achillion Pharmaceuticals Inc  said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.The mid-stage trial tested Achillion's drug, ACH-3102, in 12 patients in combination with Gilead Sciences Inc's  Sovaldi, also known as sofosbuvir. Achillion said it would begin treating 12 additional patients for six weeks with a once-daily dose of ACH-3102 and sofosbuvir. The trial excluded the older hepatitis C drug ribavirin, which can cause rashes, anemia and other side effects. Achillion shares rose about 10 percent to $9.25 in premarket trading.   (Reporting by Anand Basu in Bangalore; Editing by Simon Jennings)",2014-08-15,GILD,"Fri Aug 15, 2014 | 8:06am EDT",Achillion's hepatitis C drug cures all patients in mid-stage trial,http://www.reuters.com//article/achillion-hepatitisc-idUSL4N0QL3IO20140815?type=companyNews
88,"  LONDON, Sept 8 GlaxoSmithKline and Gilead Sciences release:* First-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study * Plan to seek approval for this combination indication by submitting data from Ambition study to regulators  * GSK and Gilead jointly sponsored study  Further company coverage:    (Reporting by Ben Hirschler)",2014-09-08,GILD,"Mon Sep 8, 2014 | 9:08am EDT","BRIEF-GSK, Gilead drug combo helps in pulmonary arterial hypertension",http://www.reuters.com//article/pressreleasegskannouncesfirst-brief-idUSFWN0R800G20140908?type=companyNews
89,"   By Deena Beasley | LOS ANGELES  LOS ANGELES The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.Gregg Alton, Gilead's executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month. The total cost of the current treatment is $95,000, which includes Sovaldi and two older medicines, ribavirin and interferon, according to Gilead. The price of the new drug would be based on that cost, Alton said in an interview. ""We are going to price this fixed-dose regimen based on those costs,"" Alton said. ""We do plan on launching a better product without having a significant premium.""Health insurers, U.S. state authorities and congressional lawmakers have pleaded with Gilead to offer a greater discount for Sovaldi as the cost of treating more than 3 million U.S. patients are expected to reach hundreds of billions of dollars. The drugmaker is expected to rake in nearly $12 billion in hepatitis C drug sales worldwide in 2014. Sovaldi sales have been unprecedented for any drug in its first year on the market. ""The blank check mindset we've seen from Gilead is a threat to our entire health care system, and we hope they will pursue more sustainable pricing in the future,"" said Brendan Buck, a spokesman for the insurance industry's largest lobbying group, America's Health Insurance Plans.Gilead expects savings for some patients in its pricing scheme. It said that nearly half of hepatitis C patients - previously untreated, healthier individuals - can be cured after eight weeks of using the new pill, compared with 12 weeks for the current Sovaldi regimen. That would effectively cut the treatment cost by one-third for such patients.  U.S. health regulators are due to decide by Oct. 10 whether to approve the new drug, a pill that combines Sovaldi with the experimental therapy ledipasvir and eliminates the need for other treatments. It has been shown to cure up to 99 percent of patients versus 90 percent for Sovaldi plus ribavirin and interferon, which also cause hard-to-tolerate side effects.LOWER AVERAGE COST? But the fact that a shorter treatment time for some will equate to a lower drug price may disappoint some investors. ISI Group analyst Mark Schoenebaum on Friday lowered his average price estimate per patient to $85,000 from $100,000 to account for it. RBC Capital Markets analyst Michael Yee estimates that the new Gilead drug will be priced at $95,000 for 12 weeks, while Sanford Bernstein's Geoff Porges anticipated a list price of $100,000.Alton noted that the new drug will be priced below the current cost of Sovaldi plus Olysio, a daily protease inhibitor sold by Johnson & Johnson. Although it is not FDA-approved, some doctors have been prescribing Sovaldi in combination with Olysio, costing up to $150,000.But J. Mario Molina, chief executive officer at insurer Molina Healthcare Inc, says the drug should cost no more than $45,000 per patient, based on his estimate of how many patients it may save from severe liver disease.    ""Yes, it will save lives and prevent people from having a liver transplant, but not very many,"" Molina said. ""If I said, you give me $9 million and I will give you $4 million or $5 million back, would you do that? That's what Gilead is doing."" Hepatitis C kills more than 15,000 Americans each year, mostly from illnesses such as cirrhosis and liver cancer, according to the U.S. Centers for Disease Control and Prevention.The often-undiagnosed virus is transmitted through contaminated blood. While infection rates have dropped since the early 1990s - due in part to the introduction of blood and organ screening - many older adults remain at risk. The CDC has called for baby boomers to be routinely tested.Gilead estimates that around 400,000 Americans diagnosed with the virus are currently under a doctor's care.""We are probably looking at 150,000 being treated this year, maybe slightly more - say 200,000 - next year,"" Alton said. He estimates it will take three years to treat the diagnosed population, including newly identified patients, and about 20 years for hepatitis C to be eradicated. (Reporting by Deena Beasley; Editing by Michele Gershberg and Lisa Shumaker)",2014-09-12,GILD,"Fri Sep 12, 2014 | 6:52pm EDT","Gilead to raise price for new hepatitis C drug above $84,000",http://www.reuters.com//article/us-gilead-sovaldi-idUSKBN0H72KR20140912?type=companyNews
90,"   By Deena Beasley | LOS ANGELES, Sept 12  LOS ANGELES, Sept 12 The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.Gregg Alton, Gilead's executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month.The total cost of the current treatment is $95,000, which includes Sovaldi and two older medicines, ribavirin and interferon, according to Gilead. The price of the new drug would be based on that cost, Alton said in an interview.""We are going to price this fixed-dose regimen based on those costs,"" Alton said. ""We do plan on launching a better product without having a significant premium.""Health insurers, U.S. state authorities and congressional lawmakers have pleaded with Gilead to offer a greater discount for Sovaldi as the cost of treating more than 3 million U.S. patients are expected to reach hundreds of billions of dollars.The drugmaker is expected to rake in nearly $12 billion in hepatitis C drug sales worldwide in 2014. Sovaldi sales have been unprecedented for any drug in its first year on the market.""The blank check mindset we've seen from Gilead is a threat to our entire health care system, and we hope they will pursue more sustainable pricing in the future,"" said Brendan Buck, a spokesman for the insurance industry's largest lobbying group, America's Health Insurance Plans. Gilead expects savings for some patients in its pricing scheme. It said that nearly half of hepatitis C patients - previously untreated, healthier individuals - can be cured after eight weeks of using the new pill, compared with 12 weeks for the current Sovaldi regimen. That would effectively cut the treatment cost by one-third for such patients.U.S. health regulators are due to decide by Oct. 10 whether to approve the new drug, a pill that combines Sovaldi with the experimental therapy ledipasvir and eliminates the need for other treatments. It has been shown to cure up to 99 percent of patients versus 90 percent for Sovaldi plus ribavirin and interferon, which also cause hard-to-tolerate side effects.LOWER AVERAGE COST?  But the fact that a shorter treatment time for some will equate to a lower drug price may disappoint some investors. ISI Group analyst Mark Schoenebaum on Friday lowered his average price estimate per patient to $85,000 from $100,000 to account for it.RBC Capital Markets analyst Michael Yee estimates that the new Gilead drug will be priced at $95,000 for 12 weeks, while Sanford Bernstein's Geoff Porges anticipated a list price of $100,000.Alton noted that the new drug will be priced below the current cost of Sovaldi plus Olysio, a daily protease inhibitor sold by Johnson & Johnson. Although it is not FDA-approved, some doctors have been prescribing Sovaldi in combination with Olysio, costing up to $150,000. But J. Mario Molina, chief executive officer at insurer Molina Healthcare Inc, says the drug should cost no more than $45,000 per patient, based on his estimate of how many patients it may save from severe liver disease.""Yes, it will save lives and prevent people from having a liver transplant, but not very many,"" Molina said. ""If I said, you give me $9 million and I will give you $4 million or $5 million back, would you do that? That's what Gilead is doing.""Hepatitis C kills more than 15,000 Americans each year, mostly from illnesses such as cirrhosis and liver cancer, according to the U.S. Centers for Disease Control and Prevention.The often-undiagnosed virus is transmitted through contaminated blood. While infection rates have dropped since the early 1990s - due in part to the introduction of blood and organ screening - many older adults remain at risk. The CDC has called for baby boomers to be routinely tested.Gilead estimates that around 400,000 Americans diagnosed with the virus are currently under a doctor's care.""We are probably looking at 150,000 being treated this year, maybe slightly more - say 200,000 - next year,"" Alton said.He estimates it will take three years to treat the diagnosed population, including newly identified patients, and about 20 years for hepatitis C to be eradicated.   (Reporting by Deena Beasley; Editing by Michele Gershberg and Lisa Shumaker)",2014-09-12,GILD,"Fri Sep 12, 2014 | 6:46pm EDT","Gilead to raise price for new hepatitis C drug above $84,000",http://www.reuters.com//article/gilead-sovaldi-idUSL1N0RD21N20140912?type=companyNews
91,"  (Repeats story published Friday with no changes)By Deena BeasleyLOS ANGELES, Sept 13 The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.Gregg Alton, Gilead's executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month.The total cost of the current treatment is $95,000, which includes Sovaldi and two older medicines, ribavirin and interferon, according to Gilead. The price of the new drug would be based on that cost, Alton said in an interview.""We are going to price this fixed-dose regimen based on those costs,"" Alton said. ""We do plan on launching a better product without having a significant premium.""Health insurers, U.S. state authorities and congressional lawmakers have pleaded with Gilead to offer a greater discount for Sovaldi as the cost of treating more than 3 million U.S. patients are expected to reach hundreds of billions of dollars.The drugmaker is expected to rake in nearly $12 billion in hepatitis C drug sales worldwide in 2014. Sovaldi sales have been unprecedented for any drug in its first year on the market. ""The blank check mindset we've seen from Gilead is a threat to our entire health care system, and we hope they will pursue more sustainable pricing in the future,"" said Brendan Buck, a spokesman for the insurance industry's largest lobbying group, America's Health Insurance Plans.Gilead expects savings for some patients in its pricing scheme. It said that nearly half of hepatitis C patients - previously untreated, healthier individuals - can be cured after eight weeks of using the new pill, compared with 12 weeks for the current Sovaldi regimen. That would effectively cut the treatment cost by one-third for such patients.U.S. health regulators are due to decide by Oct. 10 whether to approve the new drug, a pill that combines Sovaldi with the experimental therapy ledipasvir and eliminates the need for other treatments. It has been shown to cure up to 99 percent of patients versus 90 percent for Sovaldi plus ribavirin and interferon, which also cause hard-to-tolerate side effects. LOWER AVERAGE COST? But the fact that a shorter treatment time for some will equate to a lower drug price may disappoint some investors. ISI Group analyst Mark Schoenebaum on Friday lowered his average price estimate per patient to $85,000 from $100,000 to account for it.RBC Capital Markets analyst Michael Yee estimates that the new Gilead drug will be priced at $95,000 for 12 weeks, while Sanford Bernstein's Geoff Porges anticipated a list price of $100,000.Alton noted that the new drug will be priced below the current cost of Sovaldi plus Olysio, a daily protease inhibitor sold by Johnson & Johnson. Although it is not FDA-approved, some doctors have been prescribing Sovaldi in combination with Olysio, costing up to $150,000. But J. Mario Molina, chief executive officer at insurer Molina Healthcare Inc, says the drug should cost no more than $45,000 per patient, based on his estimate of how many patients it may save from severe liver disease.""Yes, it will save lives and prevent people from having a liver transplant, but not very many,"" Molina said. ""If I said, you give me $9 million and I will give you $4 million or $5 million back, would you do that? That's what Gilead is doing.""Hepatitis C kills more than 15,000 Americans each year, mostly from illnesses such as cirrhosis and liver cancer, according to the U.S. Centers for Disease Control and Prevention.The often-undiagnosed virus is transmitted through contaminated blood. While infection rates have dropped since the early 1990s - due in part to the introduction of blood and organ screening - many older adults remain at risk. The CDC has called for baby boomers to be routinely tested.Gilead estimates that around 400,000 Americans diagnosed with the virus are currently under a doctor's care.""We are probably looking at 150,000 being treated this year, maybe slightly more - say 200,000 - next year,"" Alton said.He estimates it will take three years to treat the diagnosed population, including newly identified patients, and about 20 years for hepatitis C to be eradicated.   (Reporting by Deena Beasley; Editing by Michele Gershberg and Lisa Shumaker)",2014-09-13,GILD,"Sat Sep 13, 2014 | 7:00am EDT","RPT-Gilead to raise price for new hepatitis C drug above $84,000",http://www.reuters.com//article/gilead-sovaldi-idUSL1N0RD2PC20140913?type=companyNews
92,"   By Aditya Kalra and Zeba Siddiqui | NEW DELHI/MUMBAI  NEW DELHI/MUMBAI U.S. drugmaker Gilead Sciences Inc GILD.O has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations.Approximately 150 million people in the world live with chronic hepatitis C infection, most of them in low and middle-income countries, and the new licenses are designed to give many of them access to an otherwise unaffordable drug.As with AIDS 15 years ago, modern drugs are transforming the ability to fight hepatitis C, and Sovaldi has been hailed as a breakthrough in treating the liver-destroying virus.Sovaldi, chemically known as sofosbuvir, is a far more effective and better-tolerated treatment than older injection regimens, but Gilead has come under fire over its U.S. price tag, with cost presenting a huge barrier in poor countries.Gilead said it would also launch its own branded Sovaldi in India at a price of $300 a month. The drug is normally given for either three or six months and costs $84,000 for a 12-week course in the United States. Gilead's next-generation version is going to be even more expensive.Gilead's licensing agreement with firms including India's Cipla CIPL.NS and Ranbaxy Laboratories RANB.NS clears the way for the launch of cheap generic versions of the drug in 91 developing countries, including India, which make up 54 percent of the total global hepatitis-infected population.Cadila Healthcare CADI.NS, Sequent Scientific SEQU.BO, Strides Arcolab STAR.NS, Hetero Drugs and Mylan Laboratories, owned by U.S.-based Mylan MYL.O, are the others who will now be able to make and sell the Sovaldi generic, Gilead said in a statement on Monday. All companies will be allowed to set their own prices for the generic drug and will pay Gilead a royalty on their sales, it said.""We need to have enough companies to have a competitive marketplace,"" Gregg Alton, Gilead's executive vice president, corporate and medical affairs, told a news conference in the Indian capital.Sovaldi is already on track to be one of the world's biggest-selling drugs, with sales in 2014 - its first full year on the market - set to exceed $11 billion, according to consensus forecasts compiled by Thomson Reuters Cortellis. IMPROVE ACCESS Campaigners, however, were critical of the licensing deals, saying they would not ensure access to several middle-income countries where health authorities would still struggle to provide treatment to patients.There are no plans to expand the list (of 91 countries) right now, Alton said, noting that the drug would be sold at a price higher than $300 for a month's supply in better-off developing countries, such as China and Brazil.Critics also argue that many poor countries do not have patent protection for Sovaldi, so the medicine could be sold in these places without the agreement of Gilead, at a lower price. ""There are no patents on sofosbuvir in India and several other countries that these generic companies could have sold to,"" said Tahir Amin, director of intellectual property at I-MAK.org, a group of lawyers and scientists that has opposed a patent on Sovaldi in India.Bhavesh Shah, vice-president of international marketing at Hetero Drugs, said Gilead's price would serve as the ""benchmark"" for the Sovaldi generic. The launch of the generic version is expected by the second or third quarter of 2015.The World Health Organization said this year that it wanted a ""concerted effort"" to drive down the cost of new hepatitis C drugs that offer a cure, but are unaffordable for most infected people worldwide, adding to pressure on Gilead to do more to improve access to Sovaldi.In Egypt, Gilead offered in March to supply the medicine at a 99 percent discount to the U.S. price. The north Arfican country has the world's highest prevalence of hepatitis C.The new licensing pact will also cover Gilead's next-generation version of Sovaldi, which would combine sofosbuvir with the experimental therapy ledipasvir. U.S. regulators are due to decide by Oct. 10 whether to approve this new combination. (Editing by Sumeet Chatterjee and David Clarke)",2014-09-15,GILD,"Mon Sep 15, 2014 | 9:14am EDT",Gilead signs hepatitis C pact to cut drug cost for poor,http://www.reuters.com//article/us-gilead-sciences-india-idUSKBN0HA0TT20140915?type=companyNews
93,"  * Generic Sovaldi to be available in 91 developing countries* Companies allowed to set own prices for Sovaldi* Gilead plans to sell Sovaldi in India for $300 a month   (Adds detail, background)By Aditya Kalra and Zeba SiddiquiNEW DELHI/MUMBAI, Sept 15 U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations.Approximately 150 million people in the world live with chronic hepatitis C infection, most of them in low and middle-income countries, and the new licences are designed to give many of them access to an otherwise unaffordable drug.As with AIDS 15 years ago, modern drugs are transforming the ability to fight hepatitis C, and Sovaldi has been hailed as a breakthrough in treating the liver-destroying virus.Sovaldi, chemically known as sofosbuvir, is a far more effective and better-tolerated treatment than older injection regimens, but Gilead has come under fire over its U.S. price tag, with cost presenting a huge barrier in poor countries.Gilead said it would also launch its own branded Sovaldi in India at a price of $300 a month. The drug is normally given for either three or six months and costs $84,000 for a 12-week course in the United States. Gilead's next-generation version is going to be even more expensive. Gilead's licensing agreement with firms including India's Cipla and Ranbaxy Laboratories clears the way for the launch of cheap generic versions of the drug in 91 developing countries, including India, which make up 54 percent of the total global hepatitis-infected population.Cadila Healthcare, Sequent Scientific, Strides Arcolab, Hetero Drugs and Mylan Laboratories, owned by U.S.-based Mylan, are the others who will now be able to make and sell the Sovaldi generic, Gilead said in a statement on Monday.All companies will be allowed to set their own prices for the generic drug and will pay Gilead a royalty on their sales, it said.""We need to have enough companies to have a competitive marketplace,"" Gregg Alton, Gilead's executive vice president, corporate and medical affairs, told a news conference in the Indian capital. Sovaldi is already on track to be one of the world's biggest-selling drugs, with sales in 2014 - its first full year on the market - set to exceed $11 billion, according to consensus forecasts compiled by Thomson Reuters Cortellis.IMPROVE ACCESS Campaigners, however, were critical of the licensing deals, saying they would not ensure access to several middle-income countries where health authorities would still struggle to provide treatment to patients. ""There are no plans to expand the list (of 91 countries) right now,"" Alton said, noting that the drug would be sold at a price higher than $300 for a month's supply in better-off developing countries, such as China and Brazil.Critics also argue that many poor countries do not have patent protection for Sovaldi, so the medicine could be sold in these places without the agreement of Gilead, at a lower price.""There are no patents on sofosbuvir in India and several other countries that these generic companies could have sold to,"" said Tahir Amin, director of intellectual property at I-MAK.org, a group of lawyers and scientists that has opposed a patent on Sovaldi in India.Bhavesh Shah, vice-president of international marketing at Hetero Drugs, said Gilead's price would serve as the ""benchmark"" for the Sovaldi generic. The launch of the generic version is expected by the second or third quarter of 2015.The World Health Organisation said this year that it wanted a ""concerted effort"" to drive down the cost of new hepatitis C drugs that offer a cure, but are unaffordable for most infected people worldwide, adding to pressure on Gilead to do more to improve access to Sovaldi.In Egypt, Gilead offered in March to supply the medicine at a 99 percent discount to the U.S. price. The north Arfican country has the world's highest prevalence of hepatitis C.The new licensing pact will also cover Gilead's next-generation version of Sovaldi, which would combine sofosbuvir with the experimental therapy ledipasvir. U.S. regulators are due to decide by Oct. 10 whether to approve this new combination.    (Additional reporting by Ben Hirschler in London; Editing by Sumeet Chatterjee and David Goodman)",2014-09-15,GILD,"Mon Sep 15, 2014 | 9:04am EDT",UPDATE 2-Gilead signs hepatitis C pact to cut drug cost for poor,http://www.reuters.com//article/gilead-sciences-india-idUSL3N0RG34B20140915?type=companyNews
94,"  NEW DELHI/MUMBAI, Sept 15 U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd  and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now be able to make and sell the Sovaldi generic, the company said in a statement. The companies will be allowed to set their own prices for the generic drug, and will pay a royalty on their earned sales to Gilead, it said.  Gilead's Sovaldi, chemically sofosbuvir, is hailed as a  breakthrough in treating hepatitis C, but the company has come under fire over its product's $1,000-per-pill price tag in the United States.   (Reporting by Aditya Kalra in NEW DELHI and Zeba Siddiqui in Mumbai; Editing by Sunil Nair)",2014-09-15,GILD,"Mon Sep 15, 2014 | 6:06am EDT","Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others",http://www.reuters.com//article/gilead-sciences-india-idUSL3N0RG2M920140915?type=companyNews
95,"  Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening.The mid-stage study evaluated the drug, simtuzumab, in combination with chemotherapy, against a placebo plus chemotherapy, in previously untreated patients with advanced pancreatic cancer. The study failed its main goal of improving progression-free-survival (PFS). There was no statistically significant difference in PFS between patients on simtuzumab and those on the placebo, Gilead said on Wednesday.Simtuzumab is also being tested for use in colorectal cancer, myelofibrosis, idiopathic pulmonary fibrosis and liver fibrosis. Last week, Gilead said the next generation version of its $84,000 hepatitis C drug, Sovaldi, already under fire for its record-breaking costs, was going to be even more expensive.  Separately, the biotechnology company also licensed Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the drug in 91 developing nations. Foster City, California-based Gilead's stock was little changed at $105.14 in premarket trading on Wednesday. The stock closed at $104.76 on Tuesday.  (Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila and Simon Jennings)",2014-09-17,GILD,"Wed Sep 17, 2014 | 1:42pm EDT",Gilead's experimental drug fails mid-stage study,http://www.reuters.com//article/us-health-gilead-cancer-idUSKBN0HC0W920140917?type=companyNews
96,"  Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed.The study, encompassing data from May through August 2014, suggests that another surge of patients will begin therapy when newer treatments of similar effectiveness and shorter duration are introduced later in the year. U.S. health regulators are due to decide by Oct. 10 whether to approve a new treatment, a pill that combines Sovaldi with the experimental therapy ledipasvir and eliminates the need for other treatments. The research revealed Sovaldi therapy discontinuation rates of 8.1 percent, approximately four times higher than those in trials, CVS said on Wednesday. Patients who were completely new to Hepatitis C treatment were also more likely to discontinue therapy, the study found. The CVS Health Research Institute analyzed discontinuation rates for nearly 2,000 patients who filled prescriptions for Sovaldi since December. The patients were managed by CVS Caremark, the CVS Health pharmacy benefit management business.Hepatitis C kills more than 15,000 Americans each year, mostly from illnesses such as cirrhosis and liver cancer, according to the U.S. Centers for Disease Control and Prevention.  (Reporting by Natalie Grover in Bangalore; Editing by Simon Jennings)",2014-09-17,GILD,"Wed Sep 17, 2014 | 8:41am EDT",Study shows downward trend in Sovaldi utilization,http://www.reuters.com//article/us-gilead-sciences-study-idUSKBN0HC19620140917?type=companyNews
97,"  Sept 17 Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed.The study, encompassing data from May through August 2014, suggests that another surge of patients will begin therapy when newer treatments of similar effectiveness and shorter duration are introduced later in the year.U.S. health regulators are due to decide by Oct. 10 whether to approve a new treatment, a pill that combines Sovaldi with the experimental therapy ledipasvir and eliminates the need for other treatments. The research revealed Sovaldi therapy discontinuation rates of 8.1 percent, approximately four times higher than those in trials, CVS said on Wednesday. Patients who were completely new to Hepatitis C treatment were also more likely to discontinue therapy, the study found. The CVS Health Research Institute analyzed discontinuation rates for nearly 2,000 patients who filled prescriptions for Sovaldi since December. The patients were managed by CVS Caremark, the CVS Health pharmacy benefit management business.Hepatitis C kills more than 15,000 Americans each year, mostly from illnesses such as cirrhosis and liver cancer, according to the U.S. Centers for Disease Control and Prevention.   (Reporting by Natalie Grover in Bangalore; Editing by Simon Jennings)",2014-09-17,GILD,"Wed Sep 17, 2014 | 8:38am EDT",Study shows downward trend in Sovaldi utilization,http://www.reuters.com//article/gilead-sciences-study-idUSL3N0RI40S20140917?type=companyNews
98,"  (Adds details, background, shares)Sept 17 Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening.The mid-stage study evaluated the drug, simtuzumab, in combination with chemotherapy, against a placebo plus chemotherapy, in previously untreated patients with advanced pancreatic cancer. The study failed its main goal of improving progression-free-survival (PFS). There was no statistically significant difference in PFS between patients on simtuzumab and those on the placebo, Gilead said on Wednesday.Simtuzumab is also being tested for use in colorectal cancer, myelofibrosis, idiopathic pulmonary fibrosis and liver fibrosis. Last week, Gilead said the next generation version of its $84,000 hepatitis C drug, Sovaldi, already under fire for its record-breaking costs, was going to be even more expensive. Separately, the biotechnology company also licensed Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the drug in 91 developing nations.Foster City, California-based Gilead's stock was little changed at $105.14 in premarket trading on Wednesday. The stock closed at $104.76 on Tuesday.   (Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila and Simon Jennings)",2014-09-17,GILD,"Wed Sep 17, 2014 | 6:47am EDT",UPDATE 1-Gilead's experimental drug fails mid-stage study,http://www.reuters.com//article/gilead-sciences-study-idUSL3N0RI3E920140917?type=companyNews
99,"  Sept 17 Gilead Sciences Inc said its experimental drug did not significantly improve the length of time that patients with a type of pancreatic cancer lived without the disease worsening.The mid-stage study was evaluating the drug, simtuzumab, in combination with chemotherapy against a placebo plus chemotherapy, in previously untreated patients with advanced pancreatic cancer.  (Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila) ",2014-09-17,GILD,"Wed Sep 17, 2014 | 6:19am EDT",Gilead's experimental cancer drug fails in mid-stage study,http://www.reuters.com//article/idUSL3N0RI3CQ20140917?type=companyNews
100,"  * Indexes up: Dow 0.5 pct, S&P 0.61 pct, Nasdaq 0.76 pctBy Chuck MikolajczakNEW YORK, Sept 24 Biotech stocks are moving higher on Wednesday, bouncing back from a two-day drop, helped by gains in Gilead Sciences after trial results for the company's HIV treatment.Gilead said its HIV tablet containing tenofovir alafenamide was found better than its approved drug, Stribild, in two mid-stage studies, sending shares up 2.5 percent to $108.06.Of the 119 stocks that comprise the Nasdaq biotech index, only 10 were in negative territory. The gains helped lift the biotech index 2.4 percent, putting it on track for its best day in two months. Also moving higher were Biogen Idec, up 4 percent to $345.50 and Vertex Pharmaceuticals, up 4.9 percent to $109.95.* S&P 500 was rising 9.89 points, or 0.5 percent. * Nasdaq Comp was gaining 34.30 points, or 0.76 percent.* Dow industrials was adding 103.91 points, or 0.61 percent. * Russell 2000 was adding 5.8 points, or 0.52 percent.* S&P MidCap was adding 2.41 points, or 0.17 percent.* S&P SmallCap was gaining 2.95 points, or 0.46 percent.   (Reporting by Chuck Mikolajczak; Editing by Meredith Mazzilli)",2014-09-24,GILD,"Wed Sep 24, 2014 | 1:48pm EDT",US STOCKS-Biotechs climb after two-day drop,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0RP1WP20140924?type=companyNews
101,"  Gilead Sciences Inc said its HIV tablet containing tenofovir alafenamide was found better than its approved drug, Stribild, in two mid-stage studies.The company's shares rose 1.3 percent to $106.77 in early trading on the Nasdaq on Wednesday. In one study, 93 percent of patients taking the drug containing tenofovir alafenamide experienced a reduction in HIV virus in their blood, compared with 92 percent of those taking Stribild. In the second study, 91.6 percent of patients taking the tenofovir alafenamide drug had reduced HIV virus levels in their blood, compared with 88 percent of those taking Stribild. RBC Capital Markets analysts said the data was positive as it increased confidence in Gilead's long-term revenue potential from its HIV drug pipeline, beyond 2018. Gilead's revenue from HIV drugs is expected to peak at $11.7 billion in 2018, Morningstar analysts said in a note earlier this month. They said there was a 70 percent probability that the drug containing tenofovir alafenamide would be approved. Gilead said on Wednesday it planned to apply for U.S. and European regulatory approval for the drug in the fourth quarter. Separately, the company said it had applied for approval for its hepatitis C treatment in Japan.  (Reporting by Amrutha Penumudi in Bangalore; Editing by Kirti Pandey)",2014-09-24,GILD,"Wed Sep 24, 2014 | 10:25am EDT",Gilead's HIV drug shows potential in two mid-stage studies,http://www.reuters.com//article/us-gilead-sciences-hivdrug-idUSKCN0HJ1H520140924?type=companyNews
102,"  Sept 24 Gilead Sciences Inc said its HIV tablet containing tenofovir alafenamide was found better than its approved drug, Stribild, in two mid-stage studies.The company's shares rose 1.3 percent to $106.77 in early trading on the Nasdaq on Wednesday.In one study, 93 percent of patients taking the drug containing tenofovir alafenamide experienced a reduction in HIV virus in their blood, compared with 92 percent of those taking Stribild. In the second study, 91.6 percent of patients taking the tenofovir alafenamide drug had reduced HIV virus levels in their blood, compared with 88 percent of those taking Stribild.RBC Capital Markets analysts said the data was positive as it increased confidence in Gilead's long-term revenue potential from its HIV drug pipeline, beyond 2018. Gilead's revenue from HIV drugs is expected to peak at $11.7 billion in 2018, Morningstar analysts said in a note earlier this month. They said there was a 70 percent probability that the drug containing tenofovir alafenamide would be approved. Gilead said on Wednesday it planned to apply for U.S. and European regulatory approval for the drug in the fourth quarter.Separately, the company said it had applied for approval for its hepatitis C treatment in Japan.    (Reporting by Amrutha Penumudi in Bangalore; Editing by Kirti Pandey)",2014-09-24,GILD,"Wed Sep 24, 2014 | 10:20am EDT",Gilead's HIV drug shows potential in two mid-stage studies,http://www.reuters.com//article/gilead-sciences-hivdrug-idUSL3N0RP4IW20140924?type=companyNews
103,"   By Natalie Huet | PARIS  PARIS France will tax drugmakers whose costly hepatitis C drugs threaten to throw off course its healthcare budget, the government has said, heaping pressure on pharmaceutical companies like Gilead Sciences to cut their prices.The Socialist government said it had designed a ""progressive contribution scheme"" ensuring all patients can access new and more effective treatments against the liver-destroying virus, while limiting the burden of these drugs on state finances.The government will selectively tax drugmakers when the total cost to the state from their hepatitis C drugs exceeds a certain amount each year, Health Minister Marisol Touraine said, as she unveiled the country's 2015 social security budget bill on Monday.If social security spending on hepatitis C drugs exceeds 450 million euros ($567 million) in 2014, the makers of those drugs will be taxed based on the revenue they had reaped in excess of that cap, the ministry said in a presentation. In 2015, the tax will apply beyond a 700 million euro cap, it added.Details of the new tax should be presented to lawmakers in October and a vote on the budget is due by the end of the year. Some 200,000 people in France are infected with hepatitis C and treatments for the virus could cost the state-run healthcare system as much as 1 billion euros this year, according to reports in newspapers Le Monde and Les Echos. The ministry declined to comment on any estimates.LOWER CURE RATES   With its move, France is raising pressure on U.S. biotechnology company Gilead, which obtained regulatory approval for its hepatitis C drug Sovaldi in Europe last January, but is still negotiating its official price in France with representatives of the economy and health ministries. A representative for Gilead in Europe could not immediately be reached for comment. Gilead has argued that Sovaldi's price is comparable to older medicines that require longer treatment duration with much lower cure rates and nasty side effects.Sovaldi cures well in excess of 90 percent of patients in as little as eight weeks of treatment. But its price has fueled sharp criticism from governments and private insurers alike. Sovaldi currently costs around 56,000 euros ($70,000) in France and $84,000 in the United States for 12 weeks of treatment. The U.S. price works out to as much as $1,000 per pill.Sovaldi is on track to be one of the world's biggest-selling drugs, set to rake in close to $12 billion in revenue in 2014 - its first full year on the market - according to forecasts compiled by Thomson Reuters Cortellis. Rivals Merck & Co and AbbVie are also racing to develop next-generation hepatitis C treatments that cure most people of the virus in a shorter timeframe.Hepatitis C virus, or HCV, is spread through blood, often via contaminated needles, and causes cirrhosis and liver cancer. Approximately 150 million people in the world live with the infection, most of them in low and middle-income countries. (Editing by Andrew Callus and David Holmes)",2014-09-30,GILD,"Tue Sep 30, 2014 | 7:38am EDT",France uses tax to put pressure on hepatitis C drug prices,http://www.reuters.com//article/us-france-deficit-gilead-idUSKCN0HP15N20140930?type=companyNews
104,"  * State spending on hep C drugs to be capped each year* Tax to hit firms whose drugs throw spending off course* Move heaps pressure on Gilead to cut Sovaldi's priceBy Natalie HuetPARIS, Sept 30 France will tax drugmakers whose costly hepatitis C drugs threaten to throw off course its healthcare budget, the government has said, heaping pressure on pharmaceutical companies like Gilead Sciences to cut their prices.The Socialist government said it had designed a ""progressive contribution scheme"" ensuring all patients can access new and more effective treatments against the liver-destroying virus, while limiting the burden of these drugs on state finances.The government will selectively tax drugmakers when the total cost to the state from their hepatitis C drugs exceeds a certain amount each year, Health Minister Marisol Touraine said, as she unveiled the country's 2015 social security budget bill on Monday.If social security spending on hepatitis C drugs exceeds 450 million euros ($567 million) in 2014, the makers of those drugs will be taxed based on the revenue they had reaped in excess of that cap, the ministry said in a presentation. In 2015, the tax will apply beyond a 700 million euro cap, it added.Details of the new tax should be presented to lawmakers in October and a vote on the budget is due by the end of the year.Some 200,000 people in France are infected with hepatitis C and treatments for the virus could cost the state-run healthcare system as much as 1 billion euros this year, according to reports in newspapers Le Monde and Les Echos. The ministry declined to comment on any estimates.LOWER CURE RATES With its move, France is raising pressure on U.S. biotechnology company Gilead, which obtained regulatory approval for its hepatitis C drug Sovaldi in Europe last January, but is still negotiating its official price in France with representatives of the economy and health ministries. A representative for Gilead in Europe could not immediately be reached for comment. Gilead has argued that Sovaldi's price is comparable to older medicines that require longer treatment duration with much lower cure rates and nasty side effects.Sovaldi cures well in excess of 90 percent of patients in as little as eight weeks of treatment. But its price has fuelled sharp criticism from governments and private insurers alike.Sovaldi currently costs around 56,000 euros ($70,000) in France and $84,000 in the United States for 12 weeks of treatment. The U.S. price works out to as much as $1,000 per pill.Sovaldi is on track to be one of the world's biggest-selling drugs, set to rake in close to $12 billion in revenue in 2014 - its first full year on the market - according to forecasts compiled by Thomson Reuters Cortellis.Rivals Merck & Co and AbbVie are also racing to develop next-generation hepatitis C treatments that cure most people of the virus in a shorter timeframe.Hepatitis C virus, or HCV, is spread through blood, often via contaminated needles, and causes cirrhosis and liver cancer. Approximately 150 million people in the world live with the infection, most of them in low and middle-income countries. ($1 = 0.7939 euro)   (Editing by Andrew Callus and David Holmes)",2014-09-30,GILD,"Tue Sep 30, 2014 | 7:33am EDT",France uses tax to put pressure on hepatitis C drug prices,http://www.reuters.com//article/france-deficit-gilead-idUSL6N0RV27X20140930?type=companyNews
105,"   By Deena Beasley  U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12-week course of treatment to rid patients of the liver-destroying viral infection.The daily pill, to be sold under the brand name Harvoni, combines Gilead's $84,000 pill Sovaldi with another drug, ledipasvir, and eliminates the need for two older, side-effect-laden treatments that needed to be taken along with Sovaldi.Gilead, which has faced a backlash from health insurers over the high cost of its hepatitis C treatments, said the current regimen of Sovaldi plus the older drugs, interferon and ribavirin, has a cost of $94,726.The company emphasized that the price of the new drug is less than the current regimen, but insurers and other payers said it is still unsustainable.""Unfortunately, we believe that the price being demanded is still inappropriately high for a product targeting such a large group of patients,"" said David Whitrap, spokesman for Express Scripts Holding Co, the largest manager of pharmacy benefit programs in the United States. ""New innovations do not always require inappropriate, premium pricing.""Hepatitis C, estimated to infect about 3.2 million Americans, is a viral disease that causes inflammation of the liver that can lead to liver failure. Gilead said nearly half of patients infected with the most common type of hepatitis C - previously untreated, healthier individuals - can be cured after eight weeks of taking Harvoni, compared with 12 weeks for the current Sovaldi regimen.The cost of treating those patients with the new pill for eight weeks is $63,000.Wall Street analysts note that the price of Harvoni is lower than the $130,000 or more now needed to treat certain hepatitis C patients with Sovaldi and Olysio, a newer antiviral drug sold by Johnson & Johnson. ""The price of $94,000 is very attractive,"" said RBC Capital Markets analyst Michael Yee. ""At eight weeks of therapy, the cost is about $63,000, which is 30 percent cheaper than Sovaldi.""Deutsche Bank analyst Robyn Karnauskas said Harvoni's pricing came in slightly below her expectations, but is ""rational and strongly supportive of sustained market share.""Bristol-Myers Squibb Co said on Tuesday it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs. AbbVie Inc is slated to hear from the FDA later this year on its application to market an all-oral hepatitis C regimen.""As the additional hepatitis C drugs are approved over the next few months, we're looking forward to driving more competition in this space,"" Express Scripts said.Gilead is expected to reap nearly $12 billion in hepatitis C drug sales worldwide in 2014. Sovaldi sales have been unprecedented for any first-year drug. Gilead shares closed 2 percent lower at $103.73 on Friday. (Additional reporting by Bill Berkrot in New York; editing by Tom Brown and Matthew Lewis)",2014-10-10,GILD,"Fri Oct 10, 2014 | 4:36pm EDT","U.S. FDA approves Gilead's $94,500 hepatitis C drug",http://www.reuters.com//article/us-gilead-fda-hepatitis-idUSKCN0HZ1YG20141010?type=companyNews
106,"  (Adds pharmacy benefit manager comment, analyst comment, background)By Deena BeasleyOct 10 U.S. regulators on Friday approved a new hepatitis C pill from Gilead Sciences Inc, which said it will charge $94,500 for an improved 12-week course of treatment to rid patients of the liver-destroying viral infection.The daily pill, to be sold under the brand name Harvoni, combines Gilead's $84,000 pill Sovaldi with another drug, ledipasvir, and eliminates the need for two older, side-effect-laden treatments that needed to be taken along with Sovaldi.Gilead, which has faced a backlash from health insurers over the high cost of its hepatitis C treatments, said the current regimen of Sovaldi plus the older drugs, interferon and ribavirin, has a cost of $94,726.The company emphasized that the price of the new drug is less than the current regimen, but insurers and other payers said it is still unsustainable.""Unfortunately, we believe that the price being demanded is still inappropriately high for a product targeting such a large group of patients,"" said David Whitrap, spokesman for Express Scripts Holding Co, the largest manager of pharmacy benefit programs in the United States. ""New innovations do not always require inappropriate, premium pricing."" Hepatitis C, estimated to infect about 3.2 million Americans, is a viral disease that causes inflammation of the liver that can lead to liver failure.Gilead said nearly half of patients infected with the most common type of hepatitis C - previously untreated, healthier individuals - can be cured after eight weeks of taking Harvoni, compared with 12 weeks for the current Sovaldi regimen.The cost of treating those patients with the new pill for eight weeks is $63,000. Wall Street analysts note that the price of Harvoni is lower than the $130,000 or more now needed to treat certain hepatitis C patients with Sovaldi and Olysio, a newer antiviral drug sold by Johnson & Johnson.""The price of $94,000 is very attractive,"" said RBC Capital Markets analyst Michael Yee. ""At eight weeks of therapy, the cost is about $63,000, which is 30 percent cheaper than Sovaldi.""Deutsche Bank analyst Robyn Karnauskas said Harvoni's pricing came in slightly below her expectations, but is ""rational and strongly supportive of sustained market share."" Bristol-Myers Squibb Co said on Tuesday it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs.AbbVie Inc is slated to hear from the FDA later this year on its application to market an all-oral hepatitis C regimen.""As the additional hepatitis C drugs are approved over the next few months, we're looking forward to driving more competition in this space,"" Express Scripts said.Gilead is expected to reap nearly $12 billion in hepatitis C drug sales worldwide in 2014. Sovaldi sales have been unprecedented for any first-year drug.Gilead shares closed 2 percent lower at $103.73 on Friday.   (Additional reporting by Bill Berkrot in New York; editing by Tom Brown and Matthew Lewis)",2014-10-10,GILD,"Fri Oct 10, 2014 | 4:32pm EDT","UPDATE 2-U.S. FDA approves Gilead's $94,500 hepatitis C drug",http://www.reuters.com//article/gilead-fda-hepatitis-idUSL2N0S51WN20141010?type=companyNews
107,"  Oct 10 U.S. regulators on Friday approved Gilead Sciences Inc's all-oral hepatitis C drug, clearing the way for the company to increase its revenue from sales of treatments for the liver-destroying viral infection.The new drug, to be sold under the brand name Harvoni, combines Gilead's $1,000-per-pill Sovaldi, with another drug, ledipasvir, and eliminates the need for two older treatments that needed to be taken along with Sovaldi.Gilead did not immediately respond to a request for comment on its plans for pricing Harvoni. The company has said that nearly half of hepatitis C patients - previously untreated, healthier individuals - can be cured after eight weeks of using the new pill, compared with 12 weeks for the current Sovaldi regimen.The launch late last year of Sovaldi sparked a backlash from health insurers reluctant to reimburse for the $84,000 course of treatment, even though it can cure most patients. Gilead is expected to rake in nearly $12 billion in hepatitis C drug sales worldwide in 2014. Sovaldi sales have been unprecedented for any drug in its first year on the market. Hepatitis C, estimated to infect about 3.2 million Americans, is a viral disease that causes inflammation of the liver that can lead to liver failure.(Reporting By Deena Beasley; Editing by Tom Brown)",2014-10-10,GILD,"Fri Oct 10, 2014 | 1:58pm EDT",U.S. FDA approves Gilead's all-oral hepatitis C drug,http://www.reuters.com//article/gilead-fda-hepatitis-idUSL2N0RP1MU20141010?type=companyNews
108,"   By Deena Beasley  Gilead Sciences Inc (GILD.O), maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.The company, which received U.S. regulatory approval earlier this month for new hepatitis C drug Harvoni, said total product sales for the quarter more than doubled to $5.97 billion from $2.71 billion a year earlier. Third-quarter Sovaldi sales totaled $2.8 billion, which fell short of the average Wall Street estimate of $2.97 billion, according to Deutsche Bank. Second quarter-sales of the drug, which was launched last December and has drawn criticism from insurers over its cost, totaled $3.48 billion.Shares of Gilead, which closed at $113.45 on Nasdaq, fell 4 percent to $109 in after-hours trading. So far this year, the shares have gained around 48 percent.""There's a lot of warehousing going on for the launch of the new all-oral Harvoni,"" said RBC Capital Markets analyst Michael Yee. ""But we expect a significant increase in hepatitis C sales in 2015 as the all-oral was just launched a couple of weeks ago."" A 12-week course of Harvoni is priced at $94,500, but Gilead has said many patients will be cured of the virus after just eight weeks of treatment.""We're seeing a broader group of physicians writing (Harvoni) scripts than with Sovaldi,"" Gilead Chief Operating Officer John Milligan said during a conference call. ""With regard to payers, we're feeling reasonably confident with their reaction."" Yee forecasts $15 billion in worldwide hepatitis C sales for Gilead next year.Gilead, also the world's largest producer of branded HIV drugs, reported a quarterly net profit of $2.73 billion, or $1.67 per share, compared with $788.6 million, or 47 cents per share, a year ago.Excluding one-time items, Gilead said it earned $1.84 per share. The company raised the lower end of its 2014 product sales outlook to $22 billion from $21 billion, but left the upper end unchanged at $23 billion. Wall Street analysts, on average, have forecast 2014 sales of $24.3 billion, according to Deutsche Bank.Gilead also increased its estimate for 2014 sales, general and administrative costs to between $2.7 billion and $2.8 billion from a previous estimate of $2.3 billion to $2.4 billion, citing a change in accounting for a U.S. tax. (Additional reporting by Bill Berkrot; Editing by Bernard Orr)",2014-10-28,GILD,"Tue Oct 28, 2014 | 6:19pm EDT","Gilead third-quarter Sovaldi sales dip, but net profit triples",http://www.reuters.com//article/us-gilead-sciences-results-idUSKBN0IH26K20141028?type=companyNews
109,"  (Adds company comment, updates share price)By Deena BeasleyOct 28 Gilead Sciences Inc, maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.The company, which received U.S. regulatory approval earlier this month for new hepatitis C drug Harvoni, said total product sales for the quarter more than doubled to $5.97 billion from $2.71 billion a year earlier.Third-quarter Sovaldi sales totaled $2.8 billion, which fell short of the average Wall Street estimate of $2.97 billion, according to Deutsche Bank. Second quarter-sales of the drug, which was launched last December and has drawn criticism from insurers over its cost, totaled $3.48 billion.Shares of Gilead, which closed at $113.45 on Nasdaq, fell 4 percent to $109 in after-hours trading. So far this year, the shares have gained around 48 percent. ""There's a lot of warehousing going on for the launch of the new all-oral Harvoni,"" said RBC Capital Markets analyst Michael Yee. ""But we expect a significant increase in hepatitis C sales in 2015 as the all-oral was just launched a couple of weeks ago.""A 12-week course of Harvoni is priced at $94,500, but Gilead has said many patients will be cured of the virus after just eight weeks of treatment.""We're seeing a broader group of physicians writing (Harvoni) scripts than with Sovaldi,"" Gilead Chief Operating Officer John Milligan said during a conference call. ""With regard to payers, we're feeling reasonably confident with their reaction."" Yee forecasts $15 billion in worldwide hepatitis C sales for Gilead next year.Gilead, also the world's largest producer of branded HIV drugs, reported a quarterly net profit of $2.73 billion, or $1.67 per share, compared with $788.6 million, or 47 cents per share, a year ago. Excluding one-time items, Gilead said it earned $1.84 per share.The company raised the lower end of its 2014 product sales outlook to $22 billion from $21 billion, but left the upper end unchanged at $23 billion. Wall Street analysts, on average, have forecast 2014 sales of $24.3 billion, according to Deutsche Bank.Gilead also increased its estimate for 2014 sales, general and administrative costs to between $2.7 billion and $2.8 billion from a previous estimate of $2.3 billion to $2.4 billion, citing a change in accounting for a U.S. tax.(Additional reporting by Bill Berkrot; Editing by Bernard Orr)",2014-10-28,GILD,"Tue Oct 28, 2014 | 6:17pm EDT","UPDATE 2-Gilead third-quarter Sovaldi sales dip, but net profit triples",http://www.reuters.com//article/gilead-sciences-results-idUSL1N0SN2NY20141028?type=companyNews
110,"  Oct 28 Gilead Sciences Inc, maker of $84,000 hepatitis C drug Sovaldi, on Tuesday said third quarter net profit more than tripled and product sales doubled, despite a dip in Sovaldi sales as doctors and patients awaited a recently approved combination pill.The company, which received U.S. regulatory approval earlier this month for new hepatitis C drug Harvoni, said total product sales for the quarter more than doubled to $5.97 billion from $2.71 billion a year earlier.Third-quarter Sovaldi sales totaled $2.8 billion. Wall Street analysts, on average, had expected $2.97 billion, according to Deutsche Bank. Second quarter-sales of the drug, which was launched last December totaled $3.48 billion. The company reported a quarterly net profit of $2.73 billion, or $1.67 per share, compared with $788.6 million, or 47 cents per share, a year ago. Excluding items, Gilead earned $1.84 per share during the quarter. (Reporting By Deena Beasley; Editing by Bernard Orr)",2014-10-28,GILD,"Tue Oct 28, 2014 | 4:27pm EDT",Gilead third-quarter profit triples as sales more than double,http://www.reuters.com//article/gilead-sciences-results-idUSL1N0SN1HS20141028?type=companyNews
111,"  Oct 29 Express Scripts Holding Co :  * Says may change drug formulary in mid-2015 to favor expected new hepatitis cdrugs given ""unsustainable"" high cost of gilead's  sovaldi  * Says changing formulary in mid year, instead of waiting to January, would be an unusual step, but necessary given sovaldi's high price  * Gilead shares fall 3.3 percent in morning trading  * Says hopes AbbVie has different (price) approach than Gilead for its  expected new hepatitis c drug",2014-10-29,GILD,"Wed Oct 29, 2014 | 9:41am EDT","BRIEF-Express Scripts says may change formulary in mid-2015 due to ""unsustainable"" cost of Gilead's Sovaldi",http://www.reuters.com//article/expressscripts-brief-idUSWEN00E8U20141029?type=companyNews
112,"   By Bill Berkrot | NEW YORK  NEW YORK Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak.Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation (ALF). Some of the drugs will address advanced fibrosis and cirrhosis, which are the scarring that virtually all liver diseases cause without effective treatments. Each of these drugs, once approved, could reach annual sales of as much as $10 billion, industry analysts said.  Most of the treatments are now in early Phase I or Phase II clinical trials, with more informative interim data on several expected over the course of the next year.Gilead, which was first to market with its hepatitis C cure Sovaldi late last year and has been racking up about $3 billion in sales each quarter, is a solid bet to be among the leaders in the next wave of liver therapies, experts said.""The Gilead program is encouraging,"" said Dr. Naga Chalasani, director of gastroenterology and hepatology at Indiana University Hospital in Indianapolis, who is participating in clinical trials of promising drugs from Gilead and others.Drugmakers are working to address the fatty liver disease known as NASH, or nonalcoholic steatohepatitis. Without treatment, NASH can progress to liver-destroying cirrhosis and potentially cancer.ALF estimates that non-alcoholic fatty liver disease, including NASH, affects up to 30 percent of people in the United States. It can be caused by bad diets and alcohol abuse, and has also been tied to diabetes.""We have no treatment for that condition other than tell a patient they need to lose weight,"" said Dr. Mauricio Lisker-Melman, director of the hepatology program at Washington University School of Medicine in St Louis.   Intercept Pharmaceuticals has attracted the most attention. Just released final data from a mid-stage clinical trial showed its obeticholic acid halted NASH progression and improved liver scarring in primarily moderately ill patients. ""For now, no one else has demonstrated an antifibrotic effect in this population, and I believe we are ahead of the pack in that sense,"" said Intercept Chief Executive Mark Pruzanski.Intercept plans to begin a Phase III trial with at least 1,000 more seriously ill patients next year. Dr. Scott Friedman, dean for therapeutic discovery at Mt. Sinai Hospital in New York, who has worked with virtually all the companies in the field, said most were first testing drugs in patients whose liver damage is not advanced.""Gilead has sort of leapfrogged that,"" Friedman said, tackling more serious damage, as its simtuzumab targets fibrotic scarring directly, rather than inflammation or other drivers of disease. Reversing cirrhosis and improving liver function is ""the highest bar I can think of in this business, and it would be spectacular,"" he said. Gilead faces competition from several smaller companies with promising drugs in development, including Intercept, France's Genfit, Israel's Galmed, Galectin Therapeutics, Conatus Pharmaceuticals and Raptor Pharmaceuticals, specialists said.Gilead's antibody simtuzumab blocks an enzyme called LOXL2 that is directly involved in laying down bands of collagen that form the scar tissue behind cirrhosis. The collagen bands, which result from a wide variety of assaults on the liver, including alcohol and drug abuse, cross link haphazardly to destroy the liver's architecture and function.Gilead expects to have a strong indication of whether its drug is working when one-year data from a two-year Phase II study becomes available next year.""We have a very active research program,"" saidMani Subramanian, head of liver disease clinical research at Gilead. ""We're targeting everything: metabolic issues, inflammation and fibrosis directly.""He acknowledged challenges faced by drugmakers trying to address more advanced liver disease: ""It's been a graveyard for drugs that try to reverse fibrosis,"" Subramanian said.  NOT FOR FAINT OF HEART  Chalasani at Indiana University Hospital estimated there may be 20 different drugs being tried by various drug companies that seem to be good targets.But betting on them is not for the faint of heart. Intercept's shares shot from about $72 to over $400 in a matter of days in January after it was announced the trial of its drug would meet the intended goal. On the flip side, Galectin lost nearly two thirds of its value in July, when its NASH drug using a different approach had a setback in a Phase I trial. Conatus is first testing its drug, emricasan, in patients facing acute liver failure, which has a 50 percent mortality rate in 28 days. Chief Executive Steven Mento said the goal was to ""rescue these patients and prevent catastrophic organ failure."" The company plans to work its way back, testing on less severely ill patients. The drug targets inflammation and excessive cell death seen as drivers of the disease. Dr. David Bernstein, chief of hepatology at North Shore University Hospital in Manhasset, N.Y., called the Conatus drug exciting and the initial trial a sensible approach.  ""There's limited downside because there's nothing else that can be done anyway,"" said Bernstein, who expects to be involved in future emricasan trials. ""If you can reverse cirrhosis, you really will change the impact of liver disease worldwide.""Drugs that succeed in reversing cirrhosis ""can be as big a class as the class of statins,"" said Conatus's Mento, referring to cholesterol drugs, such as Pfizer's Lipitor, which alone at its peak had annual sales of about $13 billion. Raptor, by contrast, is developing a drug for NASH in children, a growing problem that has left liver specialists fearing an obese generation that could require liver transplants in the prime of life. Raptor is testing a drug already approved for use in children for an extremely rare kidney disease. ""In terms of safety, it's well established,"" said Raptor President and CEO designate Julie Anne Smith. It is now engaged in a year-long mid-stage trial of 169 children whose NASH was confirmed by liver biopsy with data expected in the first half of next year. Companies are waiting for the U.S. Food and Drug Administration to outline what it will take to approve a NASH drug. ""The FDA is struggling with what constitutes a meaningful improvement with a patient,"" Gilead's Subramanian said.Goals such as reducing fat buildup or modestly improving fibrosis would likely be simpler and quicker to achieve, for example, than avoiding need for liver transplants.  The FDA is working ""to identify clinically meaningful endpoints for NASH and related liver diseases to help guide drug development,"" it said in a statement.The uncertainty from the FDA also creates risks for investors and has led some analysts to focus on other liver therapies. RBC Capital Markets analyst Michael Yee favors companies taking on hepatitis B, such as Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals, Gilead and Isis Pharmaceuticals in partnership with GlaxoSmithKline. And one private company not to be ignored, OnCore Biopharma, founded by former Pharmasset executives, including the inventor of Gilead's Sovaldi.  While finding a cure for hepatitis B will not be easy, trials would mirror those for hepatitis C, with a simple blood test yielding clear results in months rather than years.  (Reporting by Bill Berkrot. Editing by Michele Gershberg and John Pickering)",2014-11-09,GILD,"Sun Nov 9, 2014 | 8:07am EST","After hepatitis C cure, companies target next big liver disease market",http://www.reuters.com//article/us-health-liver-insight-idUSKCN0IT0IO20141109?type=companyNews
113,"   By Bill Berkrot | NEW YORK  NEW YORK Nov 9 Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak.Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation (ALF). Some of the drugs will address advanced fibrosis and cirrhosis, which are the scarring that virtually all liver diseases cause without effective treatments. Each of these drugs, once approved, could reach annual sales of as much as $10 billion, industry analysts said.Most of the treatments are now in early Phase I or Phase II clinical trials, with more informative interim data on several expected over the course of the next year.Gilead, which was first to market with its hepatitis C cure Sovaldi late last year and has been racking up about $3 billion in sales each quarter, is a solid bet to be among the leaders in the next wave of liver therapies, experts said.""The Gilead program is encouraging,"" said Dr. Naga Chalasani, director of gastroenterology and hepatology at Indiana University Hospital in Indianapolis, who is participating in clinical trials of promising drugs from Gilead and others.Drugmakers are working to address the fatty liver disease known as NASH, or nonalcoholic steatohepatitis. Without treatment, NASH can progress to liver-destroying cirrhosis and potentially cancer.ALF estimates that non-alcoholic fatty liver disease, including NASH, affects up to 30 percent of people in the United States. It can be caused by bad diets and alcohol abuse, and has also been tied to diabetes.""We have no treatment for that condition other than tell a patient they need to lose weight,"" said Dr. Mauricio Lisker-Melman, director of the hepatology program at Washington University School of Medicine in St Louis.Intercept Pharmaceuticals has attracted the most attention. Just released final data from a mid-stage clinical trial showed its obeticholic acid halted NASH progression and improved liver scarring in primarily moderately ill patients. ""For now, no one else has demonstrated an antifibrotic effect in this population, and I believe we are ahead of the pack in that sense,"" said Intercept Chief Executive Mark Pruzanski. Intercept plans to begin a Phase III trial with at least 1,000 more seriously ill patients next year.Dr. Scott Friedman, dean for therapeutic discovery at Mt. Sinai Hospital in New York, who has worked with virtually all the companies in the field, said most were first testing drugs in patients whose liver damage is not advanced.""Gilead has sort of leapfrogged that,"" Friedman said, tackling more serious damage, as its simtuzumab targets fibrotic scarring directly, rather than inflammation or other drivers of disease. Reversing cirrhosis and improving liver function is ""the highest bar I can think of in this business, and it would be spectacular,"" he said.Gilead faces competition from several smaller companies with promising drugs in development, including Intercept, France's Genfit, Israel's Galmed, Galectin Therapeutics, Conatus Pharmaceuticals and Raptor Pharmaceuticals, specialists said.Gilead's antibody simtuzumab blocks an enzyme called LOXL2 that is directly involved in laying down bands of collagen that form the scar tissue behind cirrhosis. The collagen bands, which result from a wide variety of assaults on the liver, including alcohol and drug abuse, cross link haphazardly to destroy the liver's architecture and function.Gilead expects to have a strong indication of whether its drug is working when one-year data from a two-year Phase II study becomes available next year. ""We have a very active research program,"" said Mani Subramanian, head of liver disease clinical research at Gilead. ""We're targeting everything: metabolic issues, inflammation and fibrosis directly."" He acknowledged challenges faced by drugmakers trying to address more advanced liver disease: ""It's been a graveyard for drugs that try to reverse fibrosis,"" Subramanian said.NOT FOR FAINT OF HEART Chalasani at Indiana University Hospital estimated there may be 20 different drugs being tried by various drug companies that seem to be good targets.But betting on them is not for the faint of heart. Intercept's shares shot from about $72 to over $400 in a matter of days in January after it was announced the trial of its drug would meet the intended goal. On the flip side, Galectin lost nearly two thirds of its value in July, when its NASH drug using a different approach had a setback in a Phase I trial.Conatus is first testing its drug, emricasan, in patients facing acute liver failure, which has a 50 percent mortality rate in 28 days. Chief Executive Steven Mento said the goal was to ""rescue these patients and prevent catastrophic organ failure."" The company plans to work its way back, testing on less severely ill patients. The drug targets inflammation and excessive cell death seen as drivers of the disease. Dr. David Bernstein, chief of hepatology at North Shore University Hospital in Manhasset, N.Y., called the Conatus drug exciting and the initial trial a sensible approach.""There's limited downside because there's nothing else that can be done anyway,"" said Bernstein, who expects to be involved in future emricasan trials. ""If you can reverse cirrhosis, you really will change the impact of liver disease worldwide.""Drugs that succeed in reversing cirrhosis ""can be as big a class as the class of statins,"" said Conatus's Mento, referring to cholesterol drugs, such as Pfizer's Lipitor, which alone at its peak had annual sales of about $13 billion.Raptor, by contrast, is developing a drug for NASH in children, a growing problem that has left liver specialists fearing an obese generation that could require liver transplants in the prime of life.Raptor is testing a drug already approved for use in children for an extremely rare kidney disease. ""In terms of safety, it's well established,"" said Raptor President and CEO designate Julie Anne Smith. It is now engaged in a year-long mid-stage trial of 169 children whose NASH was confirmed by liver biopsy with data expected in the first half of next year.Companies are waiting for the U.S. Food and Drug Administration to outline what it will take to approve a NASH drug. ""The FDA is struggling with what constitutes a meaningful improvement with a patient,"" Gilead's Subramanian said.Goals such as reducing fat buildup or modestly improving fibrosis would likely be simpler and quicker to achieve, for example, than avoiding need for liver transplants.The FDA is working ""to identify clinically meaningful endpoints for NASH and related liver diseases to help guide drug development,"" it said in a statement.The uncertainty from the FDA also creates risks for investors and has led some analysts to focus on other liver therapies. RBC Capital Markets analyst Michael Yee favors companies taking on hepatitis B, such as Arrowhead Research Corp , Canada's Tekmira Pharmaceuticals, Gilead and Isis Pharmaceuticals in partnership with GlaxoSmithKline. And one private company not to be ignored, OnCore Biopharma, founded by former Pharmasset executives, including the inventor of Gilead's Sovaldi.While finding a cure for hepatitis B will not be easy, trials would mirror those for hepatitis C, with a simple blood test yielding clear results in months rather than years.    (Reporting by Bill Berkrot. Editing by Michele Gershberg and John Pickering)",2014-11-09,GILD,"Sun Nov 9, 2014 | 8:00am EST","INSIGHT-After hep C cure, companies target next big liver disease market",http://www.reuters.com//article/health-liver-idUSL1N0SW3A520141109?type=companyNews
114,"  * Gilead climbs after Merck's hepatitis C drug trial results* Dow transportation average hits new high* Cable companies fall after Obama net neutrality statement* Indexes up: Dow 0.2 pct, S&P 0.2 pct, Nasdaq 0.2 pct   (Updates to early afternoon)By Caroline ValetkevitchNEW YORK, Nov 10 U.S. stocks edged higher in afternoon trading on Monday, lifting the Dow and S&P 500 to intraday highs after the indexes advanced for a third straight week, helped by railroad shares. The Dow Jones transportation average was up 1 percent, also hitting another intraday record high, led by gains in railroad shares including Union Pacific, which was up 1.9 percent and among the top gainers on the S&P 500.Results late Friday from Berkshire Hathaway   showed profit from the BNSF railroad rose about 5 percent. Berkshire Class B shares were up 0.7 percent at $144.59, also among the top gainers in the S&P 500.Oil prices extended recent losses, with U.S. crude oil prices falling below $78 a barrel, helping shares of some consumer companies. Wal-Mart, due to report results on Thursday, climbed 1.5 percent.""It's been a very sharp rally off a very sharp correction, no reason it shouldn't go higher but all it takes is one very determined seller to start a cascade of selling,"" said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, New York.The Dow Jones industrial average rose 27.1 points, or 0.15 percent, to 17,601.03, the S&P 500 gained 4.53 points, or 0.22 percent, to 2,036.45 and the Nasdaq Composite  added 10.68 points, or 0.23 percent, to 4,643.21. The bulk of U.S. third-quarter earnings are in, though a handful of high-profile retailers have yet to report.The Dow has gained 7.3 percent while the S&P 500  has risen 7.7 percent over the past three weeks, the best three-week performance for both indexes since October 2011.Gilead Sciences rose 0.8 percent after data from a midstage study showed Merck's attempt to shorten hepatitis C treatment by adding Gilead's Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 0.6 percent at $59.Shares of cable providers fell after U.S. President Barack Obama said the Federal Communications Commission should reclassify broadband to regulate it more like a public utility. Comcast lost 3.5 percent.Advancing issues outnumbered declining ones on the NYSE by 1,630 to 1,379, for a 1.18-to-1 ratio on the upside; on the Nasdaq, 1,492 issues rose and 1,130 fell for a 1.32-to-1 ratio favoring advancers.   (Additional reporting by Chuck Mikolajczak; Editing by Bernadette Baum and Nick Zieminski)",2014-11-10,GILD,"Mon Nov 10, 2014 | 1:30pm EST",US STOCKS-Wall Street climbs to new highs; transports rally,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T01LZ20141110?type=companyNews
115,"  * Gilead climbs after Merck's hepatitis C drug trial results* McDonald's sales fall in October* Cable companies fall after Obama net neutrality statement* Indexes up: Dow 0.16 pct, S&P 0.25 pct, Nasdaq 0.3 pct   (Updates to midday)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stocks rose modestly on Monday, as an absence of major market catalysts gave investors little reason to make big bets after the Dow and S&P 500 advanced for a third straight week to record highs. Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's and network equipment maker Cisco Systems.""Sort of a reluctant rally on the day,"" said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, New York.""It's been a very sharp rally off a very sharp correction, no reason it shouldn't go higher but all it takes is one very determined seller to start a cascade of selling."" McDonald's Corp rose 0.3 percent to $95.41 after its worldwide sales at restaurants open at least 13 months fell 0.5 percent in October but still beat expectations.Gilead Sciences rose 1.7 percent to $108.27 after data from a midstage study showed Merck's attempt to shorten hepatitis C treatment by adding Gilead's Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 1.1 percent to $58.69. Thomson Reuters data showed that of 448 companies in the S&P 500 to report earnings, 74.6 percent beat expectations, above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 10 percent over the year-ago period.The Dow has gained 7.3 percent while the S&P 500  has risen 7.7 percent over the past three weeks, the best three-week performance for both indexes since October 2011.The Dow Jones industrial average rose 27.67 points, or 0.16 percent, to 17,601.6, the S&P 500 gained 5.08 points, or 0.25 percent, to 2,037 and the Nasdaq Composite  added 13.93 points, or 0.3 percent, to 4,646.47.Shares in cable providers fell after U.S. President Barack Obama said the Federal Communications Commission should reclassify broadband to regulate it more like a public utility. Comcast lost 3.5 percent to $53.21, Time Warner  fell 3.9 percent to $138.06, and Cablevision  shed 2 percent to $18.55.Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue as housing demand strengthened. Its shares rose 3.9 percent to $33.47.       (Editing by Bernadette Baum and Nick Zieminski)",2014-11-10,GILD,"Mon Nov 10, 2014 | 11:58am EST",US STOCKS-Wall Street climbs modestly after three-week run,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T01AD20141110?type=companyNews
116,"  * Gilead climbs after Merck's hepatitis C drug trial results* McDonald's sales fall in October* Cable companies fall after Obama's net neutrality statement* Indexes up: Dow 0.16 pct, S&P 0.27 pct, Nasdaq 0.42 pct   (Adds detail on cable stocks, updates prices)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stocks edged higher on Monday, as a dearth of major market catalysts left little incentive for investors to make big bets after the Dow and S&P 500 advanced for a third straight week to record highs. Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's and network equipment maker Cisco Systems.""We have had a nice run and last week we did see the markets largely go into neutral and take a bit of a pause,"" said Peter Kenny, chief market strategist at Clearpool Group in New York.""Earnings season is coming to a close, there are no economic data releases for the next two days, we've gotten more or less the framing for the market."" McDonald's Corp rose 0.3 percent to $95.35 after its worldwide sales at restaurants open at least 13 months fell 0.5 percent in October but still beat expectations.Gilead Sciences rose 1.8 percent to $108.38 after data from a midstage study showed Merck's attempt to shorten hepatitis C treatment by adding Gilead's Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 2 percent to $58.18. Thomson Reuters data showed that of 448 companies in the S&P 500 to report earnings, 74.6 percent beat expectations, above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 10 percent over the year-ago period.The Dow gained 7.3 percent while the S&P 500  was up 7.7 percent over the past three weeks, the best three-week performance for both indexes since October 2011.The Dow Jones industrial average rose 28.32 points, or 0.16 percent, to 17,602.25, the S&P 500 gained 5.48 points, or 0.27 percent, to 2,037.4 and the Nasdaq Composite  added 19.36 points, or 0.42 percent, to 4,651.89.Shares in cable providers fell after U.S. President Barack Obama said the Federal Communications Commission should reclassify broadband to regulate it more like a public utility. Comcast lost 2.9 percent to $53.58, Time Warner  fell 3.1 percent to $139.16, and Cablevision  shed 1.5 percent to $18.63.Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue as housing demand strengthened. Its shares rose 3.6 percent to $33.38.       (Editing by Bernadette Baum and Nick Zieminski)",2014-11-10,GILD,"Mon Nov 10, 2014 | 11:06am EST",US STOCKS-Wall Street edges higher after three-week run,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T013Y20141110?type=companyNews
117,"  * Gilead climbs after Merck's hep C drug trial results* McDonald's sales fall in October* Dow off 0.05 pct, S&P up 0.01 pct, Nasdaq off 0.08 pct   (Updates to market open)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stocks were little changed on Monday, as investors paused in the absence of major market catalysts after the Dow and S&P 500 advanced for a third straight week to fresh record highs.Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's and network equipment maker Cisco Systems. ""We have had a nice run and last week we did see the markets largely go into neutral and take a bit of a pause,"" said Peter Kenny, chief market strategist at Clearpool Group in New York.""Earnings season is coming to a close, there are no economic data releases for the next two days, we've gotten more or less the framing for the market.""McDonald's Corp rose 0.3 percent to $95.35 after its worldwide sales at restaurants open at least 13 months fell 0.5 percent in October but still beat expectations. Gilead Sciences rose 2.1 percent to $108.70 as the biggest boost to the S&P 500 and Nasdaq 100 after data from a midstage study showed Merck's attempt to shorten hepatitis C treatment to just four weeks by adding Gilead's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 2.7 percent to $57.73 as the biggest drag on the Dow and S&P.Thomson Reuters data showed that of 442 companies in the S&P 500 to report earnings, 74.2 percent beat expectations, above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 9.8 percent over the year-ago period.The Dow gained 7.3 percent while the S&P 500  was up 7.7 percent over the past three weeks, the best three-week performance for both indexes since October 2011. The Dow Jones industrial average fell 8.67 points, or 0.05 percent, to 17,565.26, the S&P 500 gained 0.26 points, or 0.01 percent, to 2,032.18 and the Nasdaq Composite  dropped 3.52 points, or 0.08 percent, to 4,629.01.Alibaba Group shares were up 1.5 percent at $116.26 ahead of ""Singles Day"" in China on Nov. 11, which has become the largest day of online sales in the world.Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue as housing demand strengthened. Its shares rose 2.8 percent to $33.12, lifting the PHLX housing index 1.1 percent.GoPro shares fell 2.7 percent to $76.90 after the company filed a common stock offering of up to $800 million.(Editing by Bernadette Baum)",2014-11-10,GILD,"Mon Nov 10, 2014 | 9:56am EST",US STOCKS-Wall Street little changed after three-week rally,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T00VQ20141110?type=companyNews
118,"  * Gilead climbs after Merck's hep C drug trial results* McDonald's sales fall in October* Futures up: Dow 17 pts, S&P 1.75 pts, Nasdaq 9.5 pts   (Adds quote, updates prices)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stocks were poised for a flat open on Monday, after the Dow and S&P 500 advanced for a third straight week to fresh record highs.Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's as well as network equipment maker Cisco Systems. ""We have had a nice run and last week we did see the markets largely go into neutral and take a bit of a pause,"" said Peter Kenny, chief market strategist at Clearpool Group in New York.""Earnings season is coming to a close, there are no economic data releases for the next two days, we've gotten more or less the framing for the market.""McDonald's Corp said worldwide sales at restaurants open at least 13 months fell 0.5 percent in October, hurt by stiff competition in the United States, economic and political upheaval in Europe and the fallout from a supplier scandal in China. According to Thomson Reuters data through Friday, of 442 companies in the S&P 500 to report earnings, 74.2 percent beat Wall Street expectations, well above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 9.8 percent over the year-ago period.The Dow has risen 7.3 percent while the S&P 500  is up 7.7 percent over past three weeks, the best three-week performance for both indexes since October 2011.S&P 500 e-mini futures were up 1.75 points and fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract, indicated a flat open. Dow Jones industrial average e-mini futures rose 17 points and Nasdaq 100 e-mini futures added 9.5 points. Alibaba Group shares were up 2.1 percent at $116.99 in premarket trading ahead of ""Singles Day"" in China on Nov. 11, which has become the largest day of online sales in the world.Gilead Sciences rose 2.5 percent to $109.10 before the opening bell after data from a midstage study showed Merck's  attempt to shorten hepatitis C treatment to just four weeks by adding Gilead's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy. Merck shares were down 2.9 percent to $57.65.Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue after it sold more homes at higher prices as housing demand strengthened. Its shares rose 2.4 percent to $33 in light premarket trading.GoPro shares slumped 6.8 percent to $73.67 in premarket after the company said it filed a common stock offering of up to $800 million.(Editing by Bernadette Baum)",2014-11-10,GILD,"Mon Nov 10, 2014 | 9:05am EST",US STOCKS-Wall Street set to open flat after three-week run,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T00S320141110?type=companyNews
119,"  * Gilead climbs after Merck's hep C drug trial results* Retailers due to post earnings this week* Futures up: Dow 17 pts, S&P 2.5 pts, Nasdaq 10.25 pts   (Adds premarket movers)By Chuck MikolajczakNEW YORK, Nov 10 U.S. stock index futures edged higher on Monday, after the Dow and S&P 500 advanced for a third straight week to fresh record highs.* Earnings season begins to wind down this week, with 16 S&P 500 companies expected to report quarterly results, including retailers Wal-Mart and Macy's as well as network equipment maker Cisco Systems. * McDonald's Corp said worldwide sales at restaurants open at least 13 months fell 0.5 percent in October, hurt by stiff competition in the United States, economic and political upheaval in Europe and the fallout from a supplier scandal in China.* According to Thomson Reuters data through Friday, of 442 companies in the S&P 500 to report earnings, 74.2 percent beat Wall Street expectations, well above the 63 percent beat rate since 1994 and 67 percent for the past four quarters. Earnings are expected to grow 9.8 percent over the year-ago period.* The Dow has risen 7.3 percent while the S&P 500  is up 7.7 percent over past three weeks, the best three-week performance for both indexes since October 2011. * Alibaba Group shares were up 2.1 percent to $116.99 in premarket trading ahead of ""Singles Day"" in China on Nov. 11, which has become the largest day of online sales in the world. Volume of nearly 700,000 shares made the stock the most actively traded among New York Stock Exchange-listed issues.* Gilead Sciences rose 3 percent to $109.60 before the opening bell after data from a midstage study showed Merck's  attempt to shorten hepatitis C treatment to just four weeks by adding Gilead's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy.* Toll Brothers Inc, the largest U.S. luxury homebuilder, reported a 29 percent jump in quarterly revenue after it sold more homes at higher prices as housing demand strengthened. Its shares rose 2.4 percent to $32.99 in light premarket trading. * KKR & Co plans to sell its North Dakota Bakken oil deposit worth less than $500 million as part of an ongoing downsizing plan, according to people familiar with the matter.* S&P 500 e-minis were up 2.5 points, or 0.12 percent, with 125,321 contracts changing hands.* Nasdaq 100 e-minis were up 10.25 points, or 0.25 percent, in volume of 20,479 contracts.* Dow e-minis were up 17 points, or 0.1 percent, with 20,021 contracts changing hands.   (Editing by Bernadette Baum)",2014-11-10,GILD,"Mon Nov 10, 2014 | 8:21am EST",US STOCKS-Futures inch up after three-week rally; Alibaba active,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0T00MM20141110?type=companyNews
120,"  (Repeats for additional subscribers)By Bill BerkrotNEW YORK Nov 10 Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak.Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation (ALF). Some of the drugs will address advanced fibrosis and cirrhosis, which are the scarring that virtually all liver diseases cause without effective treatments. Each of these drugs, once approved, could reach annual sales of as much as $10 billion, industry analysts said.Most of the treatments are now in early Phase I or Phase II clinical trials, with more informative interim data on several expected over the course of the next year.Gilead, which was first to market with its hepatitis C cure Sovaldi late last year and has been racking up about $3 billion in sales each quarter, is a solid bet to be among the leaders in the next wave of liver therapies, experts said.""The Gilead program is encouraging,"" said Dr. Naga Chalasani, director of gastroenterology and hepatology at Indiana University Hospital in Indianapolis, who is participating in clinical trials of promising drugs from Gilead and others.Drugmakers are working to address the fatty liver disease known as NASH, or nonalcoholic steatohepatitis. Without treatment, NASH can progress to liver-destroying cirrhosis and potentially cancer.ALF estimates that non-alcoholic fatty liver disease, including NASH, affects up to 30 percent of people in the United States. It can be caused by bad diets and alcohol abuse, and has also been tied to diabetes.""We have no treatment for that condition other than tell a patient they need to lose weight,"" said Dr. Mauricio Lisker-Melman, director of the hepatology program at Washington University School of Medicine in St Louis.Intercept Pharmaceuticals has attracted the most attention. Just released final data from a mid-stage clinical trial showed its obeticholic acid halted NASH progression and improved liver scarring in primarily moderately ill patients. ""For now, no one else has demonstrated an antifibrotic effect in this population, and I believe we are ahead of the pack in that sense,"" said Intercept Chief Executive Mark Pruzanski. Intercept plans to begin a Phase III trial with at least 1,000 more seriously ill patients next year.Dr. Scott Friedman, dean for therapeutic discovery at Mt. Sinai Hospital in New York, who has worked with virtually all the companies in the field, said most were first testing drugs in patients whose liver damage is not advanced.""Gilead has sort of leapfrogged that,"" Friedman said, tackling more serious damage, as its simtuzumab targets fibrotic scarring directly, rather than inflammation or other drivers of disease. Reversing cirrhosis and improving liver function is ""the highest bar I can think of in this business, and it would be spectacular,"" he said.Gilead faces competition from several smaller companies with promising drugs in development, including Intercept, France's Genfit, Israel's Galmed, Galectin Therapeutics, Conatus Pharmaceuticals and Raptor Pharmaceuticals, specialists said.Gilead's antibody simtuzumab blocks an enzyme called LOXL2 that is directly involved in laying down bands of collagen that form the scar tissue behind cirrhosis. The collagen bands, which result from a wide variety of assaults on the liver, including alcohol and drug abuse, cross link haphazardly to destroy the liver's architecture and function. Gilead expects to have a strong indication of whether its drug is working when one-year data from a two-year Phase II study becomes available next year.""We have a very active research program,"" said Mani Subramanian, head of liver disease clinical research at Gilead. ""We're targeting everything: metabolic issues, inflammation and fibrosis directly."" He acknowledged challenges faced by drugmakers trying to address more advanced liver disease: ""It's been a graveyard for drugs that try to reverse fibrosis,"" Subramanian said.NOT FOR FAINT OF HEART Chalasani at Indiana University Hospital estimated there may be 20 different drugs being tried by various drug companies that seem to be good targets.But betting on them is not for the faint of heart. Intercept's shares shot from about $72 to over $400 in a matter of days in January after it was announced the trial of its drug would meet the intended goal. On the flip side, Galectin lost nearly two thirds of its value in July, when its NASH drug using a different approach had a setback in a Phase I trial.Conatus is first testing its drug, emricasan, in patients facing acute liver failure, which has a 50 percent mortality rate in 28 days. Chief Executive Steven Mento said the goal was to ""rescue these patients and prevent catastrophic organ failure."" The company plans to work its way back, testing on less severely ill patients. The drug targets inflammation and excessive cell death seen as drivers of the disease. Dr. David Bernstein, chief of hepatology at North Shore University Hospital in Manhasset, N.Y., called the Conatus drug exciting and the initial trial a sensible approach.""There's limited downside because there's nothing else that can be done anyway,"" said Bernstein, who expects to be involved in future emricasan trials. ""If you can reverse cirrhosis, you really will change the impact of liver disease worldwide.""Drugs that succeed in reversing cirrhosis ""can be as big a class as the class of statins,"" said Conatus's Mento, referring to cholesterol drugs, such as Pfizer's Lipitor, which alone at its peak had annual sales of about $13 billion.Raptor, by contrast, is developing a drug for NASH in children, a growing problem that has left liver specialists fearing an obese generation that could require liver transplants in the prime of life.Raptor is testing a drug already approved for use in children for an extremely rare kidney disease. ""In terms of safety, it's well established,"" said Raptor President and CEO designate Julie Anne Smith. It is now engaged in a year-long mid-stage trial of 169 children whose NASH was confirmed by liver biopsy with data expected in the first half of next year.Companies are waiting for the U.S. Food and Drug Administration to outline what it will take to approve a NASH drug. ""The FDA is struggling with what constitutes a meaningful improvement with a patient,"" Gilead's Subramanian said.Goals such as reducing fat buildup or modestly improving fibrosis would likely be simpler and quicker to achieve, for example, than avoiding need for liver transplants.The FDA is working ""to identify clinically meaningful endpoints for NASH and related liver diseases to help guide drug development,"" it said in a statement.The uncertainty from the FDA also creates risks for investors and has led some analysts to focus on other liver therapies. RBC Capital Markets analyst Michael Yee favors companies taking on hepatitis B, such as Arrowhead Research Corp , Canada's Tekmira Pharmaceuticals, Gilead and Isis Pharmaceuticals in partnership with GlaxoSmithKline. And one private company not to be ignored, OnCore Biopharma, founded by former Pharmasset executives, including the inventor of Gilead's Sovaldi.While finding a cure for hepatitis B will not be easy, trials would mirror those for hepatitis C, with a simple blood test yielding clear results in months rather than years.    (Reporting by Bill Berkrot. Editing by Michele Gershberg and John Pickering)",2014-11-10,GILD,"Mon Nov 10, 2014 | 7:00am EST","RPT - INSIGHT-After hep C cure, companies target next big liver disease market",http://www.reuters.com//article/health-liver-idUSL1N0SX39H20141110?type=companyNews
121,"   By Bill Berkrot  Nov 9 An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, according to interim data from a midstage study.Several companies have been working to find ways to further reduce the number of weeks of treatment needed, while keeping cure rates above 90 percent.A just approved pill called Harvoni that combines Sovaldi  with another Gilead drug requires eight weeks of treatment for many patients, and longer for tougher to treat patients.In the ongoing Merck trial of previously untreated patients, only 38.7 percent had no detectable sign of the liver destroying virus after four weeks of treatment with Sovaldi and Merck's grazoprevir/elbasvir combination. Nineteen of the 31 patients in the four-week treatment arm relapsed prior to the planned end of the study, which is 12 weeks after completion of dosing. The preliminary data was set to be presented on Monday at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston.The best result so far in the multi-arm, three-drug study called C-Swift was observed with eight weeks of treatment of patients with cirrhosis in which 94.7 percent had no detectable virus. They will be deemed cured if the virus has not reappeared 12 weeks after stopping treatment. With a six-week regimen in non-cirrhotics, 86.7 percent of patients had no sign of virus up to 8 weeks after completing treatment, according to the interim results.""These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types,"" Dr. Eric Lawitz, the study's lead investigator, said in a statement. The three drugs each work in a different way to help prevent the virus from replicating. But following failure of the 4-week experiment, Merck said it will turn its attention to studying a combination of three of its own drugs in development rather than involving the Gilead medicine in future studies.The hepatitis C field has been moving at a lightning pace. Only a handful of years ago, patients needed 48 weeks of treatment with drugs that had harsh side effects and only cured about 40 percent of patients.The new all-oral treatments eliminate the need for injectable interferon and its flu-like side effects, as well as another older drug called ribavirin that caused anemia and other problems, while dramatically increasing cure rates and reducing treatment duration.    (Reporting by Bill Berkrot; Editing by Chris Reese)",2014-11-10,GILD,"Sun Nov 9, 2014 | 7:03pm EST",Merck 4-week hep C regimen with Gilead's Sovaldi comes up short,http://www.reuters.com//article/merck-co-hepatitis-idUSL1N0SX36J20141110?type=companyNews
122,"   By Ransdell Pierson  Gilead Sciences Inc on Tuesday said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and had failed to benefit from prior treatments.The data bolsters the attractiveness of Harvoni, a combination drug that U.S. regulators approved last month and whose $95,000 cost for a course of treatment has raised complaints from insurers and politicians. The Gilead study involved 155 patients with cirrhosis and the most common genotype 1 form of the liver virus. They previously had failed to benefit from standard older treatments that included protease inhibitors as well as interferon and ribavirin, drugs that can cause harsh side effects and must be taken for almost a year.  All patients received Harvoni, a once-daily pill containing Gilead's Sovaldi and ledipasvir. The combination eliminates the need to take interferon and ribavirin with Sovaldi.In one group taking Harvoni alone for 24 weeks, the cure rate was 97 percent. It was 96 percent for patients who received Harvoni plus ribavirin for 12 weeks. Three far smaller Gilead studies evaluated Sovaldi, a so-called nucleotide, in combination with the company's experimental NS5A inhibitor GS-5816, with and without ribavirin for eight or 12 weeks.Of patients taking the combination for 12 weeks without ribavirin, sustained cures were seen in 100 percent of genotype 1 patients, with and without cirrhosis, and in 88 percent of those with the less common genotype 3 form of the virus, with cirrhosis. Shares of Gilead were up 1.4 percent at $108.54 in morning trading. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2014-11-11,GILD,"Tue Nov 11, 2014 | 11:29am EST",Gilead hepatitis C drug highly effective in cirrhosis patients,http://www.reuters.com//article/us-gilead-sciences-hepatitis-idUSKCN0IV1P420141111?type=companyNews
123,"   By Ransdell Pierson  Nov 11 Gilead Sciences Inc on Tuesday said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and had failed to benefit from prior treatments.The data bolsters the attractiveness of Harvoni, a combination drug that U.S. regulators approved last month and whose $95,000 cost for a course of treatment has raised complaints from insurers and politicians.The Gilead study involved 155 patients with cirrhosis and the most common genotype 1 form of the liver virus. They previously had failed to benefit from standard older treatments that included protease inhibitors as well as interferon and ribavirin, drugs that can cause harsh side effects and must be taken for almost a year. All patients received Harvoni, a once-daily pill containing Gilead's Sovaldi and ledipasvir. The combination eliminates the need to take interferon and ribavirin with Sovaldi. In one group taking Harvoni alone for 24 weeks, the cure rate was 97 percent. It was 96 percent for patients who received Harvoni plus ribavirin for 12 weeks.Three far smaller Gilead studies evaluated Sovaldi, a so-called nucleotide, in combination with the company's experimental NS5A inhibitor GS-5816, with and without ribavirin for eight or 12 weeks. Of patients taking the combination for 12 weeks without ribavirin, sustained cures were seen in 100 percent of genotype 1 patients, with and without cirrhosis, and in 88 percent of those with the less common genotype 3 form of the virus, with cirrhosis.Shares of Gilead were up 1.4 percent at $108.54 in morning trading.   (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)",2014-11-11,GILD,"Tue Nov 11, 2014 | 11:26am EST",Gilead hepatitis C drug highly effective in cirrhosis patients,http://www.reuters.com//article/gilead-sciences-hepatitis-idUSL2N0T10Z020141111?type=companyNews
124,"  PARIS Nov 20 France has negotiated a big discount for Gilead Sciences Inc's controversial new hepatitis C drug Sovaldi, under a government deal that ensures it will be fully reimbursable by health-funding schemes.The Economic Committee for Health Products (CEPS) has fixed the price of a box of Sovaldi at 13,667 euros before tax, a reduction of 5,000 euros on the original price and ""the lowest price in Europe"", the Health Ministry said on Thursday.Twelve weeks of treatment will now cost 41,000 euros ($51,373) before tax, against 56,000 euros previously. In the United States, where Sovaldi's high price has sparked controversy and pushed up insurance companies' costs, a 12-week course costs $84,000, or $1,000 per pill.Some 200,000 people in France have hepatitis C and the total cost of treatment to the national health fund is 800 million euros a year. Sovaldi has racked up record sales despite a fierce debate over its price and concerns that high demand will place a huge burden on government-run health plans and private insurers. Last month, U.S. regulators approved the sale of a new hepatitis C pill from Gilead, called Harvoni, which will cost $94,500 for an improved 12-week course of treatment to rid patients of the liver-destroying viral infection.Harvoni has just won temporary approval for sale in France at 16,000 euros a box but negotiations are taking place with the French government aiming for a lower price.  ($1 = 0.7981 euro)   (Reporting by Gregory Blachier; Writing by Mark John and Ben Hirschler; Editing by Hugh Lawson)",2014-11-20,GILD,"Thu Nov 20, 2014 | 8:20am EST","France pegs Gilead hepatitis C drug at ""lowest price in Europe""",http://www.reuters.com//article/health-hepatitis-gilead-solvadi-idUSL6N0TA2TA20141120?type=companyNews
125,"   By Caroline Humer  Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's  Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday.Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels, according to the report from the IMS Institute for Healthcare Informatics. The increase also reflected a slowdown in the introduction of cheaper generic versions of branded medicines.By 2018, IMS expects spending to rise to $1.3 trillion due to new breakthrough therapies.Hepatitis C drugs will add about $100 billion in total spending in the next few years, while cancer spending will rise to $100 billion and diabetes care will account for another $78 billion. Cancer drugs contributing to the high cost include Roche Holding AG's Perjeta and Kadcyla, Pharmacyclics Inc's Imbruvica and Amgen's Kyprolis. Drugmakers have come under pressure over high U.S. prices, particularly Sovaldi's list price of $1,000 per pill. State Medicaid offices and private insurers say the prices are too high to bear, while drugmakers defend them as reflecting the wider cost of developing medicines, many of which they say will never make a profit.U.S. spending accounts for about one-third of the total drug spend and is due to rise 11.7 percent in 2014 before the growth rate slows to an annual 5 percent increase after 2015. IMS's spending figures do not take into account manufacturer rebates, coupons and discounts, particularly in the United States, which will lower spending by about one half a percentage point during that time period, or $60 billion to $80 billion. In the 2009 to 2013 period, there was an estimated $63 billion in rebates, IMS said.""Within the U.S. market, we are seeing in aggregate higher levels of rebate, especially in the diabetes and respiratory therapy areas,"" said Murray Aitken, executive director of the IMS Institute for Healthcare Informatics. Rebates typically increase for drugs that are about to go off patent, then disappear once they are off patent, Aitken said. He declined to discuss specific drugs such as Lantus, which Sanofi said recently was coming under intense price pressure from U.S. insurers, and is due to go off patent in 2015.  (Reporting by Caroline Humer; Editing by Leslie Adler)",2014-11-20,GILD,"Thu Nov 20, 2014 | 12:03am EST","Drug spending tops $1 trillion on hepatitis C, cancer therapies: study",http://www.reuters.com//article/us-pharmaceuticals-study-spending-idUSKCN0J40AC20141120?type=companyNews
126,"   By Caroline Humer  Nov 20 Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's  Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday.Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels, according to the report from the IMS Institute for Healthcare Informatics. The increase also reflected a slowdown in the introduction of cheaper generic versions of branded medicines.By 2018, IMS expects spending to rise to $1.3 trillion due to new breakthrough therapies. Hepatitis C drugs will add about $100 billion in total spending in the next few years, while cancer spending will rise to $100 billion and diabetes care will account for another $78 billion. Cancer drugs contributing to the high cost include Roche Holding AG's Perjeta and Kadcyla, Pharmacyclics Inc's Imbruvica and Amgen's Kyprolis.Drugmakers have come under pressure over high U.S. prices, particularly Sovaldi's list price of $1,000 per pill. State Medicaid offices and private insurers say the prices are too high to bear, while drugmakers defend them as reflecting the wider cost of developing medicines, many of which they say will never make a profit. U.S. spending accounts for about one-third of the total drug spend and is due to rise 11.7 percent in 2014 before the growth rate slows to an annual 5 percent increase after 2015.IMS's spending figures do not take into account manufacturer rebates, coupons and discounts, particularly in the United States, which will lower spending by about one half a percentage point during that time period, or $60 billion to $80 billion. In the 2009 to 2013 period, there was an estimated $63 billion in rebates, IMS said. ""Within the U.S. market, we are seeing in aggregate higher levels of rebate, especially in the diabetes and respiratory therapy areas,"" said Murray Aitken, executive director of the IMS Institute for Healthcare Informatics.Rebates typically increase for drugs that are about to go off patent, then disappear once they are off patent, Aitken said.He declined to discuss specific drugs such as Lantus, which Sanofi said recently was coming under intense price pressure from U.S. insurers, and is due to go off patent in 2015.    (Reporting by Caroline Humer; Editing by Leslie Adler)",2014-11-20,GILD,"Thu Nov 20, 2014 | 12:00am EST","Drug spending tops $1 trln on hepatitis C, cancer therapies -study",http://www.reuters.com//article/pharmaceuticals-study-spending-idUSL2N0T913820141120?type=companyNews
127,"  (Adds details on drug, other Bristol-Myers, rival treatments)Nov 26 Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve the use of its experimental treatment for hepatitis C, daclatasvir, in combination with other antiviral drugs.Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York-based company's experimental medicines.But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen. Bristol-Myers said the FDA has asked it for data involving use of daclatasvir with other drugs, and that the company is in discussions with the agency about the scope of the required information.Most notably, it is testing daclatasvir in combination with Gilead Sciences Inc's Sovaldi, a blockbuster treatment that is used on its own or as a component of a combination treatment called Harvoni that was recently introduced by Gilead and is expected to quickly become the market leader. Bristol-Myers' combination of daclatasvir and asunaprevir,  however, was approved in July for use in Japan, which it long considered a prime market for the treatment. One strain of the hepatitis C virus, Genotype 1b, is prevalent in Japan, where intolerance to interferon, an older medicine, is particularly high. In late-stage clinical trials, the combination treatment cured about 85 percent of patients with 24 weeks of therapy. The combinations being developed by rival drugmakers have demonstrated cure rates well in excess of 90 percent with just 12 weeks of therapy, and they are pursuing even shorter treatment durations.Bristol-Myers, meanwhile, is studying a three-drug regimen that, based on earlier studies, is expected to cure more people in 12 weeks and would compete more favorably with rival treatments. The U.S. marketing application for the company's three-drug combination is expected to be filed next year.Shares of Bristol-Myers were little changed in afternoon trading on Wednesday.       (Reporting by Ransdell Pierson; Editing by Paul Simao)",2014-11-26,GILD,"Wed Nov 26, 2014 | 1:05pm EST",UPDATE 1-FDA declines to approve Bristol-Myers hepatitis drug,http://www.reuters.com//article/bristol-myers-hepatitis-idUSL2N0TG1C720141126?type=companyNews
128,"   By Brendan Pierson  Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc  of charging ""exorbitant"" prices for its blockbuster hepatitis C drug Sovaldi.The lawsuit, filed Tuesday in federal court in Philadelphia by the Southeastern Pennsylvania Transportation Authority, seeks an unspecified amount of money damages.Sovaldi, a highly effective treatment for hepatitis C, costs $1,000 per pill in the United States, or $84,000 for a typical 12-week course. The drug sells for much less in some other countries. The lawsuit claims that Gilead's pricing is an abuse of its patent monopoly on the drug and violates federal antitrust laws.Gilead's ""limited rights as a patent holder do not translate into a license to price gouge consumers,"" the lawsuit said. The transportation authority, which said it has paid more than $2.4 million for Sovaldi for its employees, is seeking to represent a class of everyone in the United States who has paid for Sovaldi or has not been able to afford needed Sovaldi treatment. Sovaldi has brought in more than $8.5 billion for Gilead in the first three quarters of 2014, just under half the company's total sales.Gilead did not immediately respond to an email seeking comment.The case is Southeastern Pennsylvania Transportation Authority, individually and on behalf of all others similarly situated, v. Gilead Sciences Inc, U.S. District Court, Eastern District of Pennsylvania, No. 2:14-cv-06978.",2014-12-10,GILD,"Wed Dec 10, 2014 | 4:03pm EST",Gilead sued over 'exorbitant' hepatitis C drug prices,http://www.reuters.com//article/health-sovaldi-idUSL1N0TU2DC20141210?type=companyNews
129,"   By Brendan Pierson  Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging ""exorbitant"" prices for its blockbuster hepatitis C drug Sovaldi.The lawsuit, filed Tuesday in federal court in Philadelphia by the Southeastern Pennsylvania Transportation Authority, seeks an unspecified amount of money damages.Sovaldi, a highly effective treatment for hepatitis C, costs $1,000 per pill in the United States, or $84,000 for a typical 12-week course. The drug sells for much less in some other countries.The lawsuit claims that Gilead's pricing is an abuse of its patent monopoly on the drug and violates federal antitrust laws. Gilead's ""limited rights as a patent holder do not translate into a license to price gouge consumers,"" the lawsuit said.The transportation authority, which said it has paid more than $2.4 million for Sovaldi for its employees, is seeking to represent a class of everyone in the United States who has paid for Sovaldi or has not been able to afford needed Sovaldi treatment.  Sovaldi has brought in more than $8.5 billion for Gilead in the first three quarters of 2014, just under half the company's total sales.Gilead did not immediately respond to an email seeking comment. The case is Southeastern Pennsylvania Transportation Authority, individually and on behalf of all others similarly situated, v. Gilead Sciences Inc, U.S. District Court, Eastern District of Pennsylvania, No. 2:14-cv-06978. (Reporting by Brendan Pierson,; Editing by Alexia Garamfalvi and Richard Chang)",2014-12-10,GILD,"Wed Dec 10, 2014 | 3:57pm EST",Gilead sued over 'exorbitant' hepatitis C drug prices,http://www.reuters.com//article/us-health-sovaldi-idUSKBN0JO29M20141210?type=companyNews
130,"   By Brendan Pierson  Dec 10 Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc  of charging ""exorbitant"" prices for its blockbuster hepatitis C drug Sovaldi.The lawsuit, filed Tuesday in federal court in Philadelphia by the Southeastern Pennsylvania Transportation Authority, seeks an unspecified amount of money damages.Sovaldi, a highly effective treatment for hepatitis C, costs $1,000 per pill in the United States, or $84,000 for a typical 12-week course. The drug sells for much less in some other countries. The lawsuit claims that Gilead's pricing is an abuse of its patent monopoly on the drug and violates federal antitrust laws.Gilead's ""limited rights as a patent holder do not translate into a license to price gouge consumers,"" the lawsuit said. The transportation authority, which said it has paid more than $2.4 million for Sovaldi for its employees, is seeking to represent a class of everyone in the United States who has paid for Sovaldi or has not been able to afford needed Sovaldi treatment. Sovaldi has brought in more than $8.5 billion for Gilead in the first three quarters of 2014, just under half the company's total sales.Gilead did not immediately respond to an email seeking comment.The case is Southeastern Pennsylvania Transportation Authority, individually and on behalf of all others similarly situated, v. Gilead Sciences Inc, U.S. District Court, Eastern District of Pennsylvania, No. 2:14-cv-06978.   (Reporting by Brendan Pierson,; Editing by Alexia Garamfalvi and Richard Chang)",2014-12-10,GILD,"Wed Dec 10, 2014 | 3:55pm EST",Gilead sued over 'exorbitant' hepatitis C drug prices,http://www.reuters.com//article/health-sovaldi-idUSL1N0TU27W20141210?type=companyNews
131,"  U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus.The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening. The U.S. Food and Drug Administration approved the regimen, which will be sold under the brand name Viekira Pak, for patients with genotype 1 form of the virus, the most common  type of hepatitis C and the most difficult to treat.  Gilead's Sovaldi, which was approved a year ago, had been selling at the rate of about $3 billion per quarter due to huge pent up demand. Sovaldi is now combined with another Gilead drug and sold as Harvoni, which is taken as one pill once a day for  12 weeks at a cost of about $94,500. Some patients can take it for just eight weeks, which costs about $63,000. The AbbVie regimen has demonstrated similarly impressive efficacy to Gilead's, with cure rates above 90 percent, and minimal negative side effects.  But Gilead, which has come under intense pressure from U.S. health insurers, politicians and pharmacy benefit managers over the high cost of its treatment, is widely expected to dominate the market, given its convenience advantage of fewer pills and  drugs, unless AbbVie undercuts Harvoni on pricing.AbbVie did not immediately announce the price of its treatment. The AbbVie treatment is awaiting a European approval decision expected in the first quarter of 2015 after an advisory committee gave it a positive recommendation.Hepatitis C, estimated to infect about 3.2 million Americans and at least 130 million people worldwide, is a progressive viral disease that if left untreated can lead to cirrhosis and liver failure, cancer or need for at transplant. The new all-oral treatment options eliminate the need for injectable interferon, for years a mainstay of heptatitis C therapy, but one that caused miserable side effects, such as flu-like symptoms.         (Reporting by Bill Berkrot and Caroline Humer; Editing by Chizu Nomiyama)",2014-12-19,GILD,"Fri Dec 19, 2014 | 6:47pm EST",U.S. FDA approves AbbVie all-oral hepatitis C treatment,http://www.reuters.com//article/us-abbvie-hepatitis-idUSKBN0JX2AG20141219?type=companyNews
132,"  An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc.U.S. health regulators earlier on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead.    (Reporting by Caroline Humer)",2014-12-19,GILD,"Fri Dec 19, 2014 | 6:47pm EST","AbbVie says newly approved hepatitis C treatment costs $83,319",http://www.reuters.com//article/us-abbvie-hepatitis-prices-idUSKBN0JX2J420141219?type=companyNews
133,"  (Adds no price available yet, details on hepatitis c)Dec 19 U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus.The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening. The U.S. Food and Drug Administration approved the regimen, which will be sold under the brand name Viekira Pak, for patients with genotype 1 form of the virus, the most common  type of hepatitis C and the most difficult to treat.Gilead's Sovaldi, which was approved a year ago, had been selling at the rate of about $3 billion per quarter due to huge pent up demand. Sovaldi is now combined with another Gilead drug and sold as Harvoni, which is taken as one pill once a day for  12 weeks at a cost of about $94,500. Some patients can take it for just eight weeks, which costs about $63,000. The AbbVie regimen has demonstrated similarly impressive efficacy to Gilead's, with cure rates above 90 percent, and minimal negative side effects.But Gilead, which has come under intense pressure from U.S. health insurers, politicians and pharmacy benefit managers over the high cost of its treatment, is widely expected to dominate the market, given its convenience advantage of fewer pills and  drugs, unless AbbVie undercuts Harvoni on pricing. AbbVie did not immediately announce the price of its treatment. The AbbVie treatment is awaiting a European approval decision expected in the first quarter of 2015 after an advisory committee gave it a positive recommendation.Hepatitis C, estimated to infect about 3.2 million Americans and at least 130 million people worldwide, is a progressive viral disease that if left untreated can lead to cirrhosis and liver failure, cancer or need for at transplant.The new all-oral treatment options eliminate the need for injectable interferon, for years a mainstay of heptatitis C therapy, but one that caused miserable side effects, such as flu-like symptoms.           (Reporting by Bill Berkrot and Caroline Humer; Editing by Chizu Nomiyama)",2014-12-19,GILD,"Fri Dec 19, 2014 | 3:28pm EST",UPDATE 1-U.S. FDA approves AbbVie all-oral hepatitis C treatment,http://www.reuters.com//article/abbvie-hepatitis-idUSL1N0U31ZV20141219?type=companyNews
134,"  Dec 19 U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus.The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening. The U.S. Food and Drug Administration approved the regimen, which will be sold under the brand name Viekira Pak, for patients with genotype 1 form of the virus, the most common  type of hepatitis C and the most difficult to treat. Gilead's Sovaldi, which was approved a year ago, had been selling at the rate of about $3 billion per quarter due to huge pent up demand. Sovaldi is now combined with another Gilead drug and sold as Harvoni, which is taken as one pill once a day for  12 weeks at a cost of about $94,500. Some patients can take it for just eight weeks, which costs about $63,000. The AbbVie regimen has demonstrated similarly impressive efficacy to Gilead's, with cure rates above 90 percent, and minimal negative side effects. But Gilead, which has come under intense pressure from U.S. health insurers, politicians and pharmacy benefit managers over the high cost of its treatment, is widely expected to dominate the market, given its convenience advantage of fewer pills and  drugs, unless AbbVie undercuts Harvoni on pricing.   (Reporting by Bill Berkrot and Caroline Humer; Editing by Chizu Nomiyama)",2014-12-19,GILD,"Fri Dec 19, 2014 | 3:02pm EST",U.S. FDA approves AbbVie all-oral hepatitis C treatment,http://www.reuters.com//article/abbvie-hepatitis-idUSL1N0U13C120141219?type=companyNews
135,"  (Adds price for 12-week treatment)By Caroline HumerDec 19 U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences.Gilead's Sovaldi treatment stole headlines last year with its $84,000 price tag and set off a national debate about whether drug prices have climbed too high.AbbVie's newly approved regimen is also less costly than  Gilead's newest one-pill regimen that combines Sovaldi with another drug and costs $94,500 for 12 weeks. With Gilead's newly improved Harvoni, some patients can take the treatment for just eight weeks, which sells for about $63,000.Some insurers and analysts had said that AbbVie might price its drug, which will be sold under the brand name Viekira Pak,  lower than Gilead because of pricing pressure.Gilead has come under intense pressure from U.S. health insurers, politicians and pharmacy benefit managers over the high cost of Sovaldi and more recently, Harvoni. It argues the price is justified because the treatment cures nearly all patients of the liver-destroying virus. An AbbVie spokeswoman said the company considered many factors in setting the price such as the cost effectiveness of the treatment and its value in offsetting other short and long term costs.The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening. The U.S. Food and Drug Administration approved the regimen for patients with genotype 1 form of the virus, the most common type of hepatitis C and the most difficult to treat. It was not immediately clear how the AbbVie pricing would impact Harvoni sales, which is widely expected to dominate the market given its advantage of fewer pills.Gilead's Sovaldi, which was approved a year ago, had been selling at the rate of about $3 billion per quarter due to huge pent up demand.The AbbVie regimen has demonstrated similar efficacy to Gilead's, with cure rates of 95 to 100 percent, the company said, and minimal negative side effects. AbbVie said that 95 percent of patients will require a 12 week treatment.Enanta Pharmaceuticals Inc, which helped develop the Abbvie drug, saw its shares rise 4.2 percent in after-hours trading while AbbVie's shares gained 1.1 percent.       (Reporting by Bill Berkrot and Caroline Humer in New York and Amrutha Penumudi in Bengalaru; Editing by Chizu Nomiyama and Diane Craft)",2014-12-20,GILD,"Fri Dec 19, 2014 | 8:02pm EST","UPDATE 2-U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks",http://www.reuters.com//article/abbvie-hepatitis-idUSL1N0U31ZV20141220?type=companyNews
136,"   By Caroline Humer  The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's treatments after trying for nearly a year to win a deeper discount.Express Scripts' move reignited investor concerns that pharmaceutical companies will have to bow to pricing pressure from U.S. insurers and lawmakers over novel medications whose cost can reach hundreds of thousands of dollars for some diseases.Gilead shares dropped 13 percent, or about $14.54, in Monday trading to $93.88, though it was still far above the $65 level reached in April, when insurers launched a major outcry over its multibillion-dollar hepatitis C business. Shares in major biotechnology companies such as Amgen, Biogen and Celgene fell more than 2 percent.Express Scripts opposed the $84,000 price tag of Gilead Sciences' Sovaldi treatment since its approval a year ago. It said the $1,000-a-day pill, shown to cure hepatitis C in most patients, was unaffordable.Private insurers generally receive discounts of as much as 20 percent, but Gilead has resisted, bringing in $3 billion in quarterly revenue for Sovaldi this year. The company maintains that Sovaldi, and a next-generation version called Harvoni that was approved in October, will save the U.S. healthcare system the costs of caring for advanced liver disease in many patients.Gilead spokeswoman Cara Miller said on Monday in an e-mailed statement that the company is continuing to negotiate with Express Scripts.AbbVie's Viekira Pak drug was approved on Friday by U.S. regulators and the company set a list price of $83,319. But it has agreed to a significantly lower price than Gilead for Express Scripts' National Preferred Formulary, a list of approved and covered drugs for 25 million Americans, Express Scripts Chief Medical Officer Steve Miller said in an interview.""This is unprecedented,"" Miller said, explaining that the pricing on specialty drugs of this type tend to be much closer even when a competitor enters the market. He did not provide a specific dollar figure, but said AbbVie had narrowed the price gap to resemble what Western European countries pay for  Sovaldi, which runs from $51,373 in France to $66,000 in Germany. WIDENING TREATMENT An estimated 3.2 million people in the United States have hepatitis C. Most insurance plans have paid for Gilead's drugs only for patients with advanced liver disease to limit their exposure to its cost. Express Scripts said the AbbVie agreement will allow it to extend treatment to all hepatitis C patients. Dr. Camilla Graham, co-director of the viral hepatitis center at Beth Israel Deaconess medical center in Boston, said she is hopeful other insurers will follow suit. ""My first thought when I saw this was 'Finally, we have a solution to this public health crisis,'"" Graham said. A significant portion of patients with hepatitis C receive medical care through government-paid programs, including Medicare for the elderly and disabled, Medicaid for the poor and the U.S. Department of Defense.State Medicaid agencies have also limited access to Gilead's Sovaldi, saying it is too expensive even after they receive a legally mandated 23 percent discount.Matt Salo, executive director of the National Association of Medicaid Directors, said he is ""hopeful but cautious"" about the state agencies' ability to extract further rebates on top of the discount from Gilead and AbbVie.America's Health Insurance Plans, the insurance industry's largest lobbying group, also hopes to see Gilead's prices drop now that there is competition in the market, said spokesman Brendan Buck.  EXCEPTIONS MADE FOR SOVALDI The AbbVie regimen consists of a cocktail of anti-viral drugs to be taken as three pills in the morning and one in the evening. The regimen requires some patients also to take ribavirin. The U.S. Food and Drug Administration approved the regimen for patients with genotype 1 form of the virus, the most common type of hepatitis C and the most difficult to treat.Express Scripts said starting Jan. 1, 2015, it would pay for the AbbVie drug only for patients who have genotype 1. Express Scripts will no longer cover Gilead's Harvoni, a one-pill treatment for patients with genotype 1 that costs $94,500 for a 12-week course. It will cover Sovaldi in cases where patients have other types of the disease. The AbbVie regimen is also not recommended for patients whose livers are not functioning and in people who have not benefited from using older treatments. An Express Scripts spokesman said the company will make exceptions for those patients to allow them to take Gilead's medications.Mario Molina, chief executive officer of Molina Healthcare Inc., a small Medicaid insurer in California that has criticized Gilead's high prices, said on Monday that he sees more competition on drug prices ahead.""I think that this is the beginning,"" Molina said, describing the move as ""a harbinger of things to come."" (Reporting by Caroline Humer; Editing by Michele Gershberg, Meredith Mazzilli and Dan Grebler)",2014-12-22,GILD,"Mon Dec 22, 2014 | 5:37pm EST",Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival,http://www.reuters.com//article/us-express-scripts-abbvie-hepatitisc-idUSKBN0K007620141222?type=companyNews
137,"  * Energy shares continue decline as oil falls* Gilead falls as Express Scripts picks AbbVie treatment* Dow boosted by gains at Intel, IBM; S&P ends at record* Indexes up: Dow 0.9 pct, S&P 0.4 pct, Nasdaq 0.3 pct   (Updates to close)By Ryan VlastelicaNEW YORK, Dec 22 U.S. stocks rose for a fourth straight session on Monday as large-cap technology shares gained and gave an outsized boost to the Dow, though continued weakness in crude oil weighed on the energy sector. The S&P 500 ended at a record, though trading was quiet with many market participants out ahead of the upcoming Christmas holiday. About 6 billion shares traded on all U.S. platforms, according to BATS exchange data, compared with the month-to-date average of 7.86 billion.Tech was the strongest sector of the day, with the S&P information technology sector up 1.1 percent. Intel Corp rose 2.3 percent to $37.21, providing the biggest boost to the Dow, while IBM rose 1.8 percent to $161.44 and Cisco Systems rose 1.6 percent to $28.22. Priceline Group rose 3.6 percent to $1,149.38.""I wouldn't put a lot of weight on this week's trading, given year-end maneuvers and how slow it is,"" said Rex Macey, chief allocation officer at Wilmington Trust Investment Advisors in Atlanta, Georgia. ""While I'm comfortable with the level of the broader market, I don't think there are obvious bargains. Some may say oil stocks are bargains now, but it's too soon to say."" Crude oil sank 3.2 percent after Saudi Arabia's powerful oil minister said OPEC would not cut production at any price. The S&P energy index fell 1 percent as one of the day's weakest sectors; Chesapeake Energy  fell 7.3 percent to $18.42 while Southwestern Energy  was off 5.5 percent at $29.31.Crude oil is coming off four straight weeks of declines, and has fallen in 11 of the past 12 completed weeks.The S&P rose 3.4 percent last week, boosted by a 5 percent jump over three sessions, after the U.S. Federal Reserve said it would take a ""patient"" approach toward raising interest rates and oil prices appeared to stabilize. The Dow Jones industrial average rose 154.57 points, or 0.87 percent, to 17,959.37, the S&P 500 gained 7.89 points, or 0.38 percent, to 2,078.54 and the Nasdaq Composite  added 16.04 points, or 0.34 percent, to 4,781.42.Gilead slumped 14 percent to $92.90 as the biggest drag on both the S&P and Nasdaq 100. Express Scripts , the nation's largest pharmacy benefit manager, said it would no longer cover Gilead's treatments after it lined up a cheaper price from AbbVie Inc for its newly approved hepatitis C treatment.Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs which showed promise in separate studies. Shares surged 10 percent to $15.61.Advancing issues outnumbered declining ones on the NYSE by 1,806 to 1,291, for a 1.40-to-1 ratio on the upside; on the Nasdaq, 1,682 issues rose and 1,072 fell for a 1.57-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 73 new 52-week highs and 5 new lows; the Nasdaq Composite was recording 144 new highs and 36 new lows.   (Editing by Meredith Mazzilli)",2014-12-22,GILD,"Mon Dec 22, 2014 | 4:20pm EST",US STOCKS-Wall St up for fourth straight day; S&P ends at record,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0U61RK20141222?type=companyNews
138,"  (Adds Molina CEO quote)By Caroline HumerDec 22 The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's  newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's  treatments after trying for nearly a year to win a deeper discount.Express Scripts' move reignited investor concerns that pharmaceutical companies will have to bow to pricing pressure from U.S. insurers and lawmakers over novel medications whose cost can reach hundreds of thousands of dollars for some diseases.Gilead shares dropped 13 percent, or about $14.54, in Monday trading to $93.88, though it was still far above the $65 level reached in April, when insurers launched a major outcry over its multibillion-dollar hepatitis C business. Shares in major biotechnology companies such as Amgen, Biogen  and Celgene fell more than 2 percent.Express Scripts opposed the $84,000 price tag of Gilead Sciences' Sovaldi treatment since its approval a year ago. It said the $1,000-a-day pill, shown to cure hepatitis C in most patients, was unaffordable.Private insurers generally receive discounts of as much as 20 percent, but Gilead has resisted, bringing in $3 billion in quarterly revenue for Sovaldi this year. The company maintains that Sovaldi, and a next-generation version called Harvoni that was approved in October, will save the U.S. healthcare system the costs of caring for advanced liver disease in many patients.Gilead spokeswoman Cara Miller said on Monday in an e-mailed statement that the company is continuing to negotiate with Express Scripts.AbbVie's Viekira Pak drug was approved on Friday by U.S. regulators and the company set a list price of $83,319.But it has agreed to a significantly lower price than Gilead for Express Scripts' National Preferred Formulary, a list of approved and covered drugs for 25 million Americans, Express Scripts Chief Medical Officer Steve Miller said in an interview. ""This is unprecedented,"" Miller said, explaining that the pricing on specialty drugs of this type tend to be much closer even when a competitor enters the market. He did not provide a specific dollar figure, but said AbbVie had narrowed the price gap to resemble what Western European countries pay for  Sovaldi, which runs from $51,373 in France to $66,000 in Germany.WIDENING TREATMENT An estimated 3.2 million people in the United States have hepatitis C. Most insurance plans have paid for Gilead's drugs only for patients with advanced liver disease to limit their exposure to its cost. Express Scripts said the AbbVie agreement will allow it to extend treatment to all hepatitis C patients.Dr. Camilla Graham, co-director of the viral hepatitis center at Beth Israel Deaconess medical center in Boston, said she is hopeful other insurers will follow suit. ""My first thought when I saw this was 'Finally, we have a solution to this public health crisis,'"" Graham said.A significant portion of patients with hepatitis C receive medical care through government-paid programs, including Medicare for the elderly and disabled, Medicaid for the poor and the U.S. Department of Defense.State Medicaid agencies have also limited access to Gilead's Sovaldi, saying it is too expensive even after they receive a legally mandated 23 percent discount.Matt Salo, executive director of the National Association of Medicaid Directors, said he is ""hopeful but cautious"" about the state agencies' ability to extract further rebates on top of the discount from Gilead and AbbVie. America's Health Insurance Plans, the insurance industry's largest lobbying group, also hopes to see Gilead's prices drop now that there is competition in the market, said spokesman Brendan Buck.EXCEPTIONS MADE FOR SOVALDI The AbbVie regimen consists of a cocktail of anti-viral drugs to be taken as three pills in the morning and one in the evening. The regimen requires some patients also to take ribavirin. The U.S. Food and Drug Administration approved the regimen for patients with genotype 1 form of the virus, the most common type of hepatitis C and the most difficult to treat.Express Scripts said starting Jan. 1, 2015, it would pay for the AbbVie drug only for patients who have genotype 1. Express Scripts will no longer cover Gilead's Harvoni, a one-pill treatment for patients with genotype 1 that costs $94,500 for a 12-week course. It will cover Sovaldi in cases where patients have other types of the disease.The AbbVie regimen is also not recommended for patients whose livers are not functioning and in people who have not benefited from using older treatments. An Express Scripts spokesman said the company will make exceptions for those patients to allow them to take Gilead's medications.Mario Molina, chief executive officer of Molina Healthcare Inc., a small Medicaid insurer in California that has criticized Gilead's high prices, said on Monday that he sees more competition on drug prices ahead.""I think that this is the beginning,"" Molina said, describing the move as ""a harbinger of things to come.""   (Reporting by Caroline Humer; Editing by Michele Gershberg, Meredith Mazzilli and Dan Grebler)",2014-12-22,GILD,"Mon Dec 22, 2014 | 4:12pm EST",UPDATE 3-Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival,http://www.reuters.com//article/express-scripts-abbvie-hepatitisc-idUSL1N0U61N420141222?type=companyNews
139,     ,2014-12-22,GILD,"Mon Dec 22, 2014 | 3:19pm EST","UPDATE 2-Express Scripts to cover AbbVie hepatitis C drug, drops Gilead treatment",http://www.reuters.com//article/express-scripts-abbvie-hepatitisc-idUSL1N0U60QF20141222?type=companyNews
140,"  * U.S. shares higher on year-end buying     * ECB QE hopes, Greek political relief boost European shares     * Gilead weighs on S&P, Nasdaq 100     * Oil prices resume declines   (Adds close of European stock markets, investor quote, updates prices)     By Sam Forgione     NEW YORK, Dec 22 Equity markets worldwide edged higher on Monday after rising expectations for more European stimulus supported shares in the region, while year-end buying underpinned U.S. stocks.     U.S. stocks inched up, but some profit-taking after the S&P 500's best weekly performance in nearly two months capped gains. Anticipation of outright government bond buying from the European Central Bank and greater political stability in Greece boosted European bourses.      ""You've got the normal seasonality of the market supported by strong fundamentals,"" said Philip Orlando, chief equity market strategist at Federated in New York, on the gains in U.S. stocks.     Asian markets set the tone with gains of 1 percent following  Wall Street's strong finish last week.     The dollar edged higher against a basket of major currencies, reversing an earlier dip in thin pre-holiday trading.      Trading volume is expected to be light this week due to the Christmas holiday, which could increase volatility. U.S. equity markets will open for an abbreviated session on Wednesday and close on Thursday for Christmas.     In the euro zone, Belgium's Luc Coene became the latest ECB policymaker to back outright government bond buying to stimulate the region's economy, while declines in oil prices ramped up expectations that the ECB could announce more stimulus measures to fight deflation.      ""Even the Germans would have to wince and accept a certain degree of quantitative easing given the deflationary expectations associated with lower oil prices,"" said Clem Miller, portfolio manager at Wilmington Trust Investment Advisors in Wilmington, Delaware.     Expectations grew that Greece could avoid destabilizing snap elections after Prime Minister Antonis Samaras made a surprise offer to bring pro-European independents into the government if they backed his choice for a new president, boosting Greek shares.      MSCI's all-country world index was last up 0.33 percent at 419.57. Europe's broad FTSEurofirst 300 index  closed up 0.44 percent, at 1,367.     The Dow Jones industrial average was last up 0.61 percent at 17,914.07, while the S&P 500 was up 0.21 percent at 2,075.06. The Nasdaq Composite was last up 0.26 percent, to 4,777.67.     A plunge in shares of Gilead Sciences dragged on the S&P and Nasdaq 100 indexes, while the Dow was lifted by gains in large-cap tech shares.      Yields on benchmark 10-year U.S. Treasury notes  were slightly down from Friday's levels at 2.16 percent after the government's sale of $27 billion new two-year notes, the first offer of $104 billion in new supply this week.       The U.S. dollar index, which measures the greenback against a basket of six major currencies, was last up 0.05 percent at 89.638.     Brent crude was last down $1.25, or 2.04 percent, at $60.13 a barrel. U.S. crude settled down $1.87, or 3.27 percent, at $55.26 per barrel.      Spot gold prices fell $12.44 to $1,182.91 an ounce on a dip in oil prices.    (Additional reporting by Marc Jones and Sudip Kar-Gupta in London and Chuck Mikolajczak in New York; Editing by Dan Grebler and Chizu Nomiyama)   ",2014-12-22,GILD,"Mon Dec 22, 2014 | 3:13pm EST","GLOBAL MARKETS-Shares higher on year-end buying, ECB stimulus hints",http://www.reuters.com//article/markets-global-idUSL1N0U61BI20141222?type=companyNews
141,"  * Energy shares continue decline as oil falls 3 percent* Gilead falls as Express Scripts picks AbbVie treatment* Dow boosted by gains at Intel, IBM* Indexes up: Dow 0.6 pct, S&P 0.1 pct, Nasdaq 0.2 pct   (Updates prices)By Ryan VlastelicaNEW YORK, Dec 22 U.S. stocks rose on Monday, putting major indexes on track for a fourth straight daily gain, with gains in large-cap tech shares giving an outsized boost to the Dow. Major indexes remained near record levels, but trading was quiet this week given the upcoming Christmas holiday. The stock market will be closed on Thursday and close early on Wednesday.Energy shares continued their recent downward trend as crude oil sank 3.3 percent on the day after Saudi Arabia's powerful oil minister said OPEC would not cut production at any price. The S&P energy index fell 1.2 percent as the day's weakest sector; Chevron Corp lost 1 percent to $111.76 while Halliburton Co was off 2.2 percent at $39.61.Crude oil is on track for its fifth straight weekly decline and has fallen in 12 of the past 13 weeks. ""A decline like this means oil hasn't stabilized or found a bottom,"" said Rex Macey, chief allocation officer at Wilmington Trust Investment Advisors in Atlanta, Georgia. ""While I'm comfortable with the level of the broader market, I don't think there are obvious bargains. Some may say oil stocks are bargains now, but it's too soon to say.""Gilead slumped 12 percent to $95.01 as the biggest drag on both the S&P and Nasdaq 100 indexes. Express Scripts, the nation's largest pharmacy benefit manager, said it would no longer cover Gilead's treatments after it lined up a cheaper price from AbbVie Inc for its newly approved hepatitis C treatment.The benchmark S&P index rose 3.4 percent last week, boosted by a 5 percent jump over three sessions, after the U.S. Federal Reserve said it would take a ""patient"" approach toward raising interest rates and oil prices appeared to stabilize. At 2:42 p.m. (1943 GMT) the Dow Jones industrial average  rose 105.64 points, or 0.59 percent, to 17,910.44, the S&P 500 gained 3.38 points, or 0.16 percent, to 2,074.03 and the Nasdaq Composite added 9.24 points, or 0.19 percent, to 4,774.62.Tech shares lifted the Dow, with Intel Corp up 2.2 percent to $37.16 and IBM up 1.7 percent to $161.19. Cisco Systems rose 1.4 percent to $28.17.Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs which showed promise in separate studies. Shares surged 10 percent to $15.61.Advancing issues outnumbered declining ones on the NYSE by 1,651 to 1,408, for a 1.17-to-1 ratio on the upside; on the Nasdaq, 1,538 issues rose and 1,197 fell for a 1.28-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 66 new 52-week highs and 5 new lows; the Nasdaq Composite was recording 129 new highs and 31 new lows.     (Editing by Meredith Mazzilli)",2014-12-22,GILD,"Mon Dec 22, 2014 | 2:50pm EST",US STOCKS-Wall St on track for four-day rally; tech lifts Dow,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0U61J320141222?type=companyNews
142,"   By Caroline Humer  (Story refiles to correct typographical error in first paragraph to Sovaldi instead of Solvadi)U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Sovaldi from Gilead Sciences.Gilead's Sovaldi treatment stole headlines last year with its $84,000 price tag and set off a national debate about whether drug prices have climbed too high.AbbVie's newly approved regimen is also less costly than  Gilead's newest one-pill regimen that combines Sovaldi with another drug and costs $94,500 for 12 weeks.With Gilead's newly improved Harvoni, some patients can take the treatment for just eight weeks, which sells for about $63,000.  Some insurers and analysts had said that AbbVie might price its drug, which will be sold under the brand name Viekira Pak,  lower than Gilead because of pricing pressure.Gilead has come under intense pressure from U.S. health insurers, politicians and pharmacy benefit managers over the high cost of Sovaldi and more recently, Harvoni. It argues the price is justified because the treatment cures nearly all patients of the liver-destroying virus.An AbbVie spokeswoman said the company considered many factors in setting the price such as the cost effectiveness of the treatment and its value in offsetting other short and long term costs. The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening. The U.S. Food and Drug Administration approved the regimen for patients with genotype 1 form of the virus, the most common type of hepatitis C and the most difficult to treat. It was not immediately clear how the AbbVie pricing would impact Harvoni sales, which is widely expected to dominate the market given its advantage of fewer pills. Gilead's Sovaldi, which was approved a year ago, had been selling at the rate of about $3 billion per quarter due to huge pent up demand. The AbbVie regimen has demonstrated similar efficacy to Gilead's, with cure rates of 95 to 100 percent, the company said, and minimal negative side effects. AbbVie said that 95 percent of patients will require a 12 week treatment. Enanta Pharmaceuticals Inc, which helped develop the Abbvie drug, saw its shares rise 4.2 percent in after-hours trading while AbbVie's shares gained 1.1 percent.     (Reporting by Bill Berkrot and Caroline Humer in New York and Amrutha Penumudi in Bengalaru; Editing by Chizu Nomiyama and Diane Craft)",2014-12-22,GILD,"Mon Dec 22, 2014 | 1:14pm EST","U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks",http://www.reuters.com//article/us-abbvie-hepatitis-idUSKBN0K01MV20141222?type=companyNews
143,"  * Energy shares continue decline as oil falls 3 percent* Gilead falls as Express Scripts picks AbbVie treatment* Dow boosted by gains at Intel, IBM* Indexes up: Dow 0.6 pct, S&P 0.1 pct, Nasdaq 0.2 pct   (Updates to afternoon trading)By Ryan VlastelicaNEW YORK, Dec 22 U.S. stocks edged higher on Monday, with investors holding off on making big bets after the S&P 500's best week in nearly two months, while the Dow was lifted by gains in large-cap tech shares.Major indexes remained near record levels, but trading was expected to be quiet this week given the upcoming Christmas holiday. The stock market will be closed on Thursday and close early on Wednesday. Energy shares continued their recent downward trend as crude oil sank 3 percent on the day after Saudi Arabia's powerful oil minister said OPEC would not cut production at any price. The S&P energy index fell 1.6 percent as the day's weakest sector; Chevron Corp lost 1.3 percent to $111.44 while Halliburton Co was off 1.9 percent at $39.70.Crude oil is on track for its fifth-straight weekly decline and has fallen in 12 of the past 13 weeks.""A decline like this means oil hasn't stabilized or found a bottom,"" said Rex Macey, chief allocation officer at Wilmington Trust Investment Advisors in Atlanta, Georgia. ""While I'm comfortable with the level of the broader market, I don't think there are obvious bargains. Some may say oil stocks are bargains now, but it's too soon to say."" Gilead slumped more than 12 percent to $94.80 as the biggest drag on both the S&P and Nasdaq 100 indexes. Express Scripts, the nation's largest pharmacy benefit manager, said it would no longer cover Gilead's treatments after it lined up a cheaper price from AbbVie Inc for its newly approved hepatitis C treatment.The benchmark S&P index rose 3.4 percent last week, boosted by a 5 percent jump over three sessions, after the U.S. Federal Reserve said it would take a ""patient"" approach toward raising interest rates and oil prices appeared to stabilize.At 12:54 p.m. the Dow Jones industrial average rose 98.45 points, or 0.55 percent, to 17,903.25, the S&P 500  gained 1.64 points, or 0.08 percent, to 2,072.29 and the Nasdaq Composite added 9.01 points, or 0.19 percent, to 4,774.39. Tech shares lifted the Dow, with Intel Corp up 2.1 percent to $37.14 and IBM up 2 percent to $161.66. Cisco Systems rose 1.4 percent to $28.17.Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs which showed promise in separate studies. Shares surged 15 percent to $16.39.Advancing issues outnumbered declining ones on the NYSE by 1,526 to 1,498, for a 1.02-to-1 ratio on the upside; on the Nasdaq, 1,473 issues rose and 1,212 fell for a 1.22-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 60 new 52-week highs and 5 new lows; the Nasdaq Composite was recording 120 new highs and 27 new lows.(Editing by Meredith Mazzilli)",2014-12-22,GILD,"Mon Dec 22, 2014 | 1:09pm EST",US STOCKS-Wall St edges up after three-day run; tech lifts Dow,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0U619820141222?type=companyNews
144,"  (Corrects typographical error in first paragraph to Sovaldi instead of Solvadi)By Caroline HumerDec 19 U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Sovaldi from Gilead Sciences.Gilead's Sovaldi treatment stole headlines last year with its $84,000 price tag and set off a national debate about whether drug prices have climbed too high.AbbVie's newly approved regimen is also less costly than  Gilead's newest one-pill regimen that combines Sovaldi with another drug and costs $94,500 for 12 weeks. With Gilead's newly improved Harvoni, some patients can take the treatment for just eight weeks, which sells for about $63,000.Some insurers and analysts had said that AbbVie might price its drug, which will be sold under the brand name Viekira Pak,  lower than Gilead because of pricing pressure.Gilead has come under intense pressure from U.S. health insurers, politicians and pharmacy benefit managers over the high cost of Sovaldi and more recently, Harvoni. It argues the price is justified because the treatment cures nearly all patients of the liver-destroying virus. An AbbVie spokeswoman said the company considered many factors in setting the price such as the cost effectiveness of the treatment and its value in offsetting other short and long term costs.The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening. The U.S. Food and Drug Administration approved the regimen for patients with genotype 1 form of the virus, the most common type of hepatitis C and the most difficult to treat. It was not immediately clear how the AbbVie pricing would impact Harvoni sales, which is widely expected to dominate the market given its advantage of fewer pills.Gilead's Sovaldi, which was approved a year ago, had been selling at the rate of about $3 billion per quarter due to huge pent up demand.The AbbVie regimen has demonstrated similar efficacy to Gilead's, with cure rates of 95 to 100 percent, the company said, and minimal negative side effects. AbbVie said that 95 percent of patients will require a 12 week treatment.Enanta Pharmaceuticals Inc, which helped develop the Abbvie drug, saw its shares rise 4.2 percent in after-hours trading while AbbVie's shares gained 1.1 percent.       (Reporting by Bill Berkrot and Caroline Humer in New York and Amrutha Penumudi in Bengalaru; Editing by Chizu Nomiyama and Diane Craft)",2014-12-22,GILD,"Mon Dec 22, 2014 | 1:06pm EST","REFILE-UPDATE 2-U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks",http://www.reuters.com//article/abbvie-hepatitis-idUSL1N0U61A620141222?type=companyNews
145,"   By Natalie Grover  Data from Achillion Pharmaceuticals Inc's hepatitis C drug trials showed the company could develop a shorter-duration treatment rivaling offerings from Gilead Sciences Inc and Abbvie Inc.The company said on Monday it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies.The biotechnology company's shares rose as much as 17 percent to $16.77, their highest in more than seven years.Data from the first study, testing a combination of Achillion's NS5A inhibitor, ACH-3102, and Gilead's blockbuster Sovaldi, showed signs that the virus disappeared within four weeks, following a six-week course of therapy.  Gilead's Harvoni, which combines Sovaldi with the company's own NS5A inhibitor, achieves this response only after eight weeks of therapy.The main goal of Achillion's ongoing mid-stage study is to achieve a sustained virological response 12 weeks after therapy that would constitute a cure.The market for hepatitis C drugs has developed at a lightening pace in recent years, with several companies working on producing newer drugs to treat the disease that affects about 150 million around the world. The U.S. health regulator on Friday approved Abbvie's hep C cocktail.  In a separate early-stage study, Achillion's nucleotide inhibitor, ACH-3422, also demonstrated potent antiviral activity.William Blair's Katherine Xu said the company's ACH-3422 was slower to exert its effects than Sovaldi, adding that its nucleotide inhibitor needs to be equally effective for Achillion to attract takeover interest. Achillion, one of the few companies developing hepatitis C drugs independently, said it planned to start mid-stage studies to evaluate the combination next year.Wells Fargo's Brian Abrahams said an all-Achillion combination could still have an edge over competition as ACH-3102's high barrier to resistance will offset ACH-3422's slower effect. (Editing by Saumyadeb Chakrabarty)",2014-12-22,GILD,"Mon Dec 22, 2014 | 12:16pm EST",Achillion data shows promise of shorter-duration hep C treatment,http://www.reuters.com//article/us-achillion-hepc-idUSKBN0K00ZB20141222?type=companyNews
146,"  * GDP, durable goods data on tap* Gilead bounces in premarket after selloff* Futures up: Dow 40 pts, S&P 3.75 pts, Nasdaq 9 pts   (Adds data on premarket actives)By Chuck MikolajczakNEW YORK, Dec 23 U.S. stock index futures edged higher on Tuesday, a day after the Dow and S&P 500 closed at fresh records, and ahead of a raft of economic data.* Major Wall Street indexes have risen for four straight sessions, pushing the benchmark S&P index  to its 50th record high of the year. The S&P has risen 5.4 percent over that period, its best 4-day run since July 2010. The rally comes on the heels of a selloff, sparked by a slump in oil prices that saw the index drop nearly 5 percent from its prior record high set on Dec. 5. * Investors will eye a slew of economic data, including the final reading for third-quarter gross domestic product (GDP) and durable goods at 8:30 a.m. (1330 GMT). Economists expect the GDP to show the U.S. economy grew at a 4.3 percent annual pace, up from the prior estimate of 3.9 percent. Durable goods orders are forecast to show a 2.9 percent increase.* The Thomson Reuters/University of Michigan's final December reading on consumer sentiment is scheduled for release at 9:55 a.m (1455 GMT). New home sales data for November as well as the November reading for personal income and spending are expected at 10 a.m. (1500 GMT). * Trading volume is expected to be light this week due to the Christmas holiday, which could increase volatility. U.S. equity markets will open for an abbreviated session Wednesday and be closed on Thursday.* Gilead Sciences Inc was the most actively traded issue on the Nasdaq premarket, up 0.8 percent to $93.65. On Monday, the drugmaker slumped more than 14 percent, its biggest drop in nearly 14 years, after Express Scripts Holding Co  said it lined up a cheaper price for AbbVie Inc's  newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead's rival treatments.* China Finance Online Co Ltd jumped 20.9 percent to $6.43 before the opening bell after the web-based financial services company posted quarterly results. Volume of over 87,000 shares represented about 6 percent of its 10-day daily average. Futures snapshot at 8:02:* S&P 500 e-minis were up 3.75 points, or 0.18 percent, with 52,186 contracts changing hands.* Nasdaq 100 e-minis were up 9 points, or 0.21 percent, on volume of 7,310 contracts.* Dow e-minis were up 40 points, or 0.22 percent, with 7,551 contracts changing hands.   (Editing by Chizu Nomiyama and Jeffrey Benkoe)",2014-12-23,GILD,"Tue Dec 23, 2014 | 8:15am EST",US STOCKS-Futures edge up after latest record; data on tap,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0U70LR20141223?type=companyNews
147,"   By Deena Beasley | LOS ANGELES  LOS ANGELES Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's   rival treatments after trying for nearly a year to win a deeper discount. [ID: nL1N0U61N4]The move threatens to undermine profits at Gilead, and was viewed by Wall Street as a sign that other major biotechnology players, including Amgen Inc and Biogen Inc, will face steeper U.S. pricing pressure from insurers. Other drugmakers without potentially transformative new products, such as Shire Plc, Novo Nordisk and Theravance Inc , may also be particularly vulnerable, analysts said. Neither Shire, Novo Nordisk nor Theravance responded to requests for comment.Express Scripts will further expand the number of medicines it won't cover for 2016, including treatments for common illnesses such as diabetes, pulmonary hypertension and arthritis, said Chief Medical Officer Dr Steve Miller, in an interview earlier this month. In some cases, Express Scripts could drop coverage for newer specialty medicines in the biotechnology field, he said. The timing on specific drugs will depend on when new competing drugs with similar clinical benefits are approved for the U.S. market.Express Scripts first began excluding drugs from its largest national reimbursement list for 2014, with 44 medications, and increased that number to 66 for 2015.The prospect of having their drugs dropped from Express Scripts' biggest ""formulary"" list of covered medicines has prompted some leading pharmaceutical makers to discount their prices, Miller said.Express Scripts is acting on behalf of clients who need to rein in healthcare costs, and estimates that the move has so far saved such employers more than $1 billion in annual spending, Miller said.Employers ""are by necessity asking us to take a more aggressive stance because the affordability of their benefits is really at risk,"" Miller said. ""We are going to be opportunistic"" in looking for savings in the future.Gilead shares dropped more than 14 percent in Monday trading to $92.90. Shares in Amgen, Biogen and Celgene CELG.O fell more than 2 percent. CVS HEALTH The second largest U.S. pharmacy benefits manager, CVS Health Corp, has said it will exclude 95 prescription products from its reimbursement list next year, up from 72 in 2014. It expects the practice will save its plan sponsors over $3.5 billion between 2012 and 2015.The drugs most under scrutiny include more expensive, ""me-too"" products, in categories where several drugmakers compete for similar patients. Both Novo Nordisk and Sanofi SA  are developing slightly longer-lasting insulins.Amgen, AbbVie and Johnson & Johnson, respectively sell Enbrel, Humira and Remicade - all rheumatoid arthritis drugs that work in a similar way. Companies like Teva Pharmaceuticals Industries and Actavis want to switch patients to more expensive versions of their multiple sclerosis and Alzheimer's drugs, respectively, before the arrival of cheap generic competitors.The effect is already being felt by such Big Pharma players as AstraZeneca Plc and Sanofi. Both companies warned recently that the need to offer U.S. price discounts on some of their biggest brand-name medicines will hurt 2015 sales. Insurers are pushing back against prices in other categories, including blood thinners and even HIV drugs and multiple sclerosis treatments, where there are multiple options for doctors and patients, observers said.""The extent of this becoming a broader problem is tied to whether we get great new drugs for things like asthma, (high cholesterol), Alzheimer's and cancer,"" said Sanford Bernstein analyst Ronny Gal. ""If there is a limited pool of money and a bunch of new drugs, the pressure on older drugs will increase.""DIMINISHING RETURNS In recent years, the introduction of far cheaper generic versions of medicines like Pfizer Inc's Lipitor to reduce cholesterol and Merck & Co's asthma drug Singulair helped insurers save on reimbursement costs. But that wave of patent expiries has slowed considerably.In the meantime, a new crop of novel, and in some cases, highly effective treatments for cancer and hepatitis C are costing them tens of billions of dollars more to reimburse. The influx of generics ""allowed the system to actually see drug price deflation,"" said Asher Anolic, manager of Fidelity's Select Pharmaceuticals Portfolio. ""At the same time, others are launching innovative new drugs ... Based on those dynamics I get more concerned. Where is the give in the system? It's on the legacy products.""Anolic said his Fidelity fund focuses on drugmakers with highly differentiated portfolios of treatments. Its top holdings as of Sept 30 included Actavis, AbbVie, Novartis AG  and Bristol-Myers Squibb Co.""When you look at the industry as a whole, we will probably see less profitability,"" said Nils Behnke, a partner at consulting firm Bain & Co. ""Mid-sized companies with a broader portfolio of little products, 'me-too' products - they will have a hard time.""Murray Aitken, vice president at healthcare information company IMS Health, estimates that 2014 spending on new and innovative brand-name drugs will total about $20 billion compared with about $3 billion in 2012.Industry executives say newer health plans, whether purchased by individual consumers or offered through an employer, will further accelerate efforts to limit drug prices because they require patients to pay a higher share of prescription costs.Pharmacy benefits companies like Express Scripts say they will cover an excluded medicine if that specific treatment is deemed medically necessary for a patient. Some groups have expressed concern that patient care might be compromised.The Pharmaceutical Research and Manufacturers of America, a leading drug industry trade group, said such practices hurt patients by limiting access to a range of appropriate medicines and potentially discriminating against certain conditions.But insurers say that the high price of new drugs set by manufacturers has already deterred some patients from following doctor's orders.""Plan sponsors, because of the rapid rise in cost, are many times having to ask the consumer to pay more"" for their medicines, said Express Scripts' Miller. ""If you can't afford your healthcare, you don't take it.""",2014-12-23,GILD,"Tue Dec 23, 2014 | 8:03am EST",Express Scripts presses for more drug savings with coverage list,http://www.reuters.com//article/health-usa-expressscripts-idUSL1N0U70ML20141223?type=companyNews
148,"  * GDP, durable goods data on tap* Gilead bounces in premarket after selloff* Futures up: Dow 28 pts, S&P 2.25 pts, Nasdaq 6.75 ptsBy Chuck MikolajczakNEW YORK, Dec 23 U.S. stock index futures were little changed on Tuesday, after the Dow and S&P 500 closed at fresh records and ahead of a raft of economic data.* Major Wall Street indexes have risen for four straight sessions, pushing the benchmark S&P index to its 50th record high of the year. The S&P has risen 5.4 percent over that period, its best 4-day run since July 2010. The sharp rally comes on the heels of a selloff that saw the index drop nearly 5 percent from its prior record high set on Dec. 5. * Investors will eye a slew of economic data on Tuesday, including the final reading for third-quarter gross domestic product and durable goods at 8:30 a.m. (1330 GMT). Expectations call for GDP to show the U.S. economy grew at a 4.3 percent annual pace, up from the prior estimate of 3.9 percent. Durable goods orders are expected to show a 2.9 percent increase.* The Thomson Reuters/University of Michigan's final December reading on consumer sentiment is scheduled for release at 9:55 a.m (1455 GMT). New home sales data for November as well as the November reading for personal income and spending are expected at 10 a.m. (1500 GMT).* Trading volume is expected to be light this week due to the Christmas holiday, which could increase volatility. U.S. equity markets will open for an abbreviated session Wednesday and be closed on Thursday. * Gilead Sciences rose 1.2 percent in premarket trade. The drugmaker slumped more than 14 percent in the prior session, its biggest drop in nearly 14 years, after Express Scripts said it lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead's rival treatments.* China Finance jumped 15.8 percent to $6.16 before the opening bell after the web-based financial services company posted quarterly results. * In Europe, a pullback on the Greek stock market on fears of early elections kept a lid on gains in the region's equities. Trading was light in Asia with Japan on holiday and markets moved only marginally. MSCI's broadest index of Asia-Pacific shares outside Japan eased 0.3 percent.Futures snapshot at 7:23 a.m. EST (1223 GMT):* S&P 500 e-minis were up 2.25 points, or 0.11 percent, with 44,713 contracts changing hands.* Nasdaq 100 e-minis were up 6.75 points, or 0.16 percent, in volume of 6,150 contracts.* Dow e-minis were up 28 points, or 0.16 percent, with 6,284 contracts changing hands.   (Reporting by Chuck Mikolajczak; Editing by Chizu Nomiyama)",2014-12-23,GILD,"Tue Dec 23, 2014 | 7:38am EST",US STOCKS-Futures little changed after latest record; data on tap,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0U70KP20141223?type=companyNews
149,"   By Deena Beasley | LOS ANGELES  LOS ANGELES Express Scripts (ESRX.O), the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year.On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's (ABBV.N) newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's (GILD.O) rival treatments after trying for nearly a year to win a deeper discount.The move threatens to undermine profits at Gilead, and was viewed by Wall Street as a sign that other major biotechnology players, including Amgen Inc (AMGN.O) and Biogen Inc (BIIB.O), will face steeper U.S. pricing pressure from insurers. Other drugmakers without potentially transformative new products, such as Shire Plc (SHP.L), Novo Nordisk NOVN.VX and Theravance Inc (THRX.O), may also be particularly vulnerable, analysts said. Neither Shire, Novo Nordisk nor Theravance responded to requests for comment.Express Scripts will further expand the number of medicines it won't cover for 2016, including treatments for common illnesses such as diabetes, pulmonary hypertension and arthritis, said Chief Medical Officer Dr Steve Miller, in an interview earlier this month. In some cases, Express Scripts could drop coverage for newer specialty medicines in the biotechnology field, he said. The timing on specific drugs will depend on when new competing drugs with similar clinical benefits are approved for the U.S. market.Express Scripts first began excluding drugs from its largest national reimbursement list for 2014, with 44 medications, and increased that number to 66 for 2015.The prospect of having their drugs dropped from Express Scripts' biggest ""formulary"" list of covered medicines has prompted some leading pharmaceutical makers to discount their prices, Miller said.Express Scripts is acting on behalf of clients who need to rein in healthcare costs, and estimates that the move has so far saved such employers more than $1 billion in annual spending, Miller said.Employers ""are by necessity asking us to take a more aggressive stance because the affordability of their benefits is really at risk,"" Miller said. ""We are going to be opportunistic in looking for savings in the future.Gilead shares dropped more than 14 percent in Monday trading to $92.90. Shares in Amgen, Biogen and Celgene CELG.O fell more than 2 percent.CVS HEALTH  The second largest U.S. pharmacy benefits manager, CVS Health Corp (CVS.N), has said it will exclude 95 prescription products from its reimbursement list next year, up from 72 in 2014. It expects the practice will save its plan sponsors over $3.5 billion between 2012 and 2015.The drugs most under scrutiny include more expensive, ""me-too"" products, in categories where several drugmakers compete for similar patients. Both Novo Nordisk and Sanofi SA (SASY.PA) are developing slightly longer-lasting insulins. Amgen, AbbVie and Johnson & Johnson (JNJ.N), respectively sell Enbrel, Humira and Remicade - all rheumatoid arthritis drugs that work in a similar way. Companies like Teva Pharmaceuticals Industries (TEVA.N)and Actavis ACT.N want to switch patients to more expensive versions of their multiple sclerosis and Alzheimer's drugs, respectively, before the arrival of cheap generic competitors.The effect is already being felt by such Big Pharma players as AstraZeneca Plc (AZN.L) and Sanofi. Both companies warned recently that the need to offer U.S. price discounts on some of their biggest brand-name medicines will hurt 2015 sales. Insurers are pushing back against prices in other categories, including blood thinners and even HIV drugs and multiple sclerosis treatments, where there are multiple options for doctors and patients, observers said. ""The extent of this becoming a broader problem is tied to whether we get great new drugs for things like asthma, (high cholesterol), Alzheimer's and cancer,"" said Sanford Bernstein analyst Ronny Gal. ""If there is a limited pool of money and a bunch of new drugs, the pressure on older drugs will increase."" DIMINISHING RETURNS In recent years, the introduction of far cheaper generic versions of medicines like Pfizer Inc's (PFE.N) Lipitor to reduce cholesterol and Merck & Co's (MRK.N) asthma drug Singulair helped insurers save on reimbursement costs. But that wave of patent expiries has slowed considerably. In the meantime, a new crop of novel, and in some cases, highly effective treatments for cancer and hepatitis C are costing them tens of billions of dollars more to reimburse.The influx of generics ""allowed the system to actually see drug price deflation,"" said Asher Anolic, manager of Fidelity's Select Pharmaceuticals Portfolio. ""At the same time, others are launching innovative new drugs ... Based on those dynamics I get more concerned. Where is the give in the system? It's on the legacy products."" Anolic said his Fidelity fund focuses on drugmakers with highly differentiated portfolios of treatments. Its top holdings as of Sept 30 included Actavis, AbbVie, Novartis AG NOVN.VX and Bristol-Myers Squibb Co (BMY.N).""When you look at the industry as a whole, we will probably see less profitability,"" said Nils Behnke, a partner at consulting firm Bain & Co. ""Mid-sized companies with a broader portfolio of little products, 'me-too' products - they will have a hard time.""Murray Aitken, vice president at healthcare information company IMS Health (IMS.N), estimates that 2014 spending on new and innovative brand-name drugs will total about $20 billion compared with about $3 billion in 2012. Industry executives say newer health plans, whether purchased by individual consumers or offered through an employer, will further accelerate efforts to limit drug prices because they require patients to pay a higher share of prescription costs.Pharmacy benefits companies like Express Scripts say they will cover an excluded medicine if that specific treatment is deemed medically necessary for a patient. Some groups have expressed concern that patient care might be compromised. The Pharmaceutical Research and Manufacturers of America, a leading drug industry trade group, said such practices hurt patients by limiting access to a range of appropriate medicines and potentially discriminating against certain conditions.But insurers say that the high price of new drugs set by manufacturers has already deterred some patients from following doctor's orders.""Plan sponsors, because of the rapid rise in cost, are many times having to ask the consumer to pay more"" for their medicines, said Express Scripts' Miller. ""If you can't afford your healthcare, you don't take it."" (Reporting by Deena Beasley; Editing by Michele Gershberg and John Pickering)",2014-12-23,GILD,"Tue Dec 23, 2014 | 7:25am EST",Exclusive: Express Scripts presses for more drug savings with coverage list,http://www.reuters.com//article/us-health-usa-expressscripts-idUSKBN0K10A620141223?type=companyNews
150,"  * Trading volume light in holiday week* Gilead Sciences rises on analyst upgrade* Energy sector loses early gains as oil turns lower* Dow off 0.09 pct, S&P 500 up 0.09 pct, Nasdaq flat   (Updates to market close)By Chuck MikolajczakNEW YORK, Dec 29 U.S. stocks were little changed in thin trading on Monday as the S&P 500 notched its latest record high, but gains were curbed when an early rally in energy prices lost momentum.Equities have trended to the upside of late, buoyed by data showing an improving economy and the U.S. Federal Reserve's  commitment to be ""patient"" about raising interest rates. After the S&P 500 gained nearly 6 percent over the prior eight sessions, it notched its 53rd record close of the year on Monday. The S&P energy index advanced 0.3 percent, pulling back from a gain of more than 1 percent as Brent and U.S. crude oil turned lower. Brent settled down $1.57 at $57.88 and U.S. crude settled down $1.12 at $53.61 a barrel.In contrast to the fall in oil prices, consumer discretionary names were among the day's best performers, up 0.7 percent. General Motors rose 2.6 percent to $34.60. The S&P 500 retail sector rose 0.8 percent as Macy's Inc advanced 1.8 percent to $65.22 and Amazon.com was up 1 percent to $312.04.""The nearer-term picture is, consumers are enjoying lower gas prices, it's almost as if it is an alleviation of taxes,"" said Andre Bakhos, managing director at Janlyn Capital LLC in Bernardsville, New Jersey. ""Someone is getting hurt in this while the consumer is benefiting, and at some point it could come back to bite the market and the economy.""The Dow Jones industrial average fell 15.48 points, or 0.09 percent, to 18,038.23, the S&P 500 gained 1.8 points, or 0.09 percent, to 2,090.57 and the Nasdaq Composite  added 0.05 points to 4,806.91.The speed and scale of the rally could cap further upside, especially in the final trading week of the year, when many market participants are out on holiday and catalysts are limited. Volume is expected to remain light, which could exacerbate volatility. The stock market will be closed on Thursday for New Year's Day. About 4.78 billion shares traded on U.S. exchanges on Monday, well below the 7.18 billion average this month, according to BATS Global Markets.Gilead Sciences Inc rose 3.7 percent to $97.30 as one of the S&P 500's biggest percentage gainers after Morgan Stanley upgraded the stock to ""overweight"" from ""equal-weight.""LiveDeal Inc jumped 19.1 percent to $3.92 on volume of 13.6 million shares, to dwarf its 50-day average of about 455,000 shares, after the company reported 2014 results.NYSE advancing issues outnumbered decliners 1,800 to 1,299, for a 1.39-to-1 ratio; on the Nasdaq, 1,438 issues rose and 1,320 fell for a 1.09-to-1 ratio favoring advancers.The S&P 500 posted 68 new 52-week highs and 5 new lows; the Nasdaq Composite recorded 160 new highs and 39 new lows.   (Reporting by Chuck Mikolajczak; Editing by Nick Zieminski)",2014-12-29,GILD,"Mon Dec 29, 2014 | 4:41pm EST",US STOCKS-Wall St little changed but S&P hits record,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0UD1DF20141229?type=companyNews
151,"  * Trading volume light in holiday week* Gilead Sciences rises on analyst upgrade* Oil turns sharply lower, energy cuts gains* Dow off 0.05 pct, S&P 500 up 0.1 pct, Nasdaq off 0.09 pct   (Updates to mid-afternoon trading, changes byline)By Chuck MikolajczakNEW YORK, Dec 29 U.S. stocks were little changed in a quiet session on Monday as a decline in oil prices weighed on the energy sector, although the S&P 500 was on track to notch yet another record high. Equities have trended to the upside of late, buoyed by data showing an improving economy and the U.S. Federal Reserve's  commitment to take a ""patient"" approach toward raising interest rates. The S&P 500 has gained 5.9 percent over the prior seven sessions, notching its 52nd record close of the year on Friday.The S&P energy index lost 0.2 percent, after climbing more than 1 percent as Brent and U.S. crude oil  turned lower. Brent was last off 2.8 percent at $57.80 while WTI lost 2.6 percent to $53.30.In contrast to the fall in energy names, consumer discretionary names were among the day's biggest gainers, with the sector up 0.5 percent. General Motors rose 2.3 percent to $34.51 while retail names were also strong on the day. The S&P 500 retail sector rose 0.6 percent while Macy's Inc advanced 2 percent to $65.30 and Amazon.com  was up 0.7 percent to $311.30. ""The nearer-term picture is, consumers are enjoying lower gas prices, it's almost as if it is an alleviation of taxes,"" said Andre Bakhos, managing director at Janlyn Capital LLC in Bernardsville, New Jersey.""Someone is getting hurt in this while the consumer is benefiting, and at some point it could come back to bite the market and the economy.""The Dow Jones industrial average fell 9.51 points, or 0.05 percent, to 18,044.2, the S&P 500 gained 2.18 points, or 0.1 percent, to 2,090.95 and the Nasdaq Composite  dropped 4.14 points, or 0.09 percent, to 4,802.72. The speed and scale of the rally could limit upside, especially in the final trading week of the year, when many market participants are out on holiday and catalysts are limited. Volume is expected to remain light, which could exacerbate volatility. The stock market will be closed on Thursday for New Year's Day.Gilead Sciences Inc rose 2.7 percent to $96.36 as one of the S&P 500's biggest percentage gainers after Morgan Stanley upgraded the stock to ""overweight"" from ""equal-weight.""LiveDeal Inc jumped 18.5 percent to $3.90 on volume of 9.6 million shares, many times its 50-day average of about 455,000 shares and on track for its most active day since May 28. The move came after the company reported its 2014 results.Advancing issues outnumbered declining ones on the NYSE by 1,708 to 1,351, for a 1.26-to-1 ratio; on the Nasdaq, 1,366 issues fell and 1,334 advanced for a 1.02-to-1 ratio favoring decliners.The S&P 500 was posting 65 new 52-week highs and 5 new lows; the Nasdaq Composite was recording 143 new highs and 35 new lows.     (Reporting by Chuck Mikolajczak; Editing by Nick Zieminski)",2014-12-29,GILD,"Mon Dec 29, 2014 | 2:13pm EST",US STOCKS-Wall St little changed as energy pares gains,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0UD12A20141229?type=companyNews
152,"  * Trading volume light in holiday week* Gilead Sciences rises on analyst upgrade* Oil turns sharply lower, energy cuts gains* Dow flat, S&P 500 up 0.2 pct, Nasdaq up 0.1 pct   (Updates to afternoon trading)By Ryan VlastelicaNEW YORK, Dec 29 U.S. stocks edged higher in a thinly-traded session on Monday as the market's recent upward bias continued and put the Dow on track for an eighth straight daily advance. Equities have trended to the upside of late, with the S&P 500 up 5.9 percent over the past seven sessions, ending at its 52nd record close of the year on Friday. The Dow's seven-session streak is its longest since March 2013, when it rose for ten straight sessions.The speed and scale of the rally could limit upside, especially in the final trading week of the year, when many market participants are out on holiday and there are few catalysts. Volume is expected to remain light, which could leave the market more susceptible to big swings. The stock market will be closed on Thursday for New Year's Day.""Everything is a go right now, but there's no reason to expect we'll start seeing big moves this week. I don't see anything ... that could derail or upset the market,"" said Mark Martiak, senior wealth strategist at Premier Wealth/First Allied Securities in New York. Consumer discretionary names were among the day's biggest gainers, with the sector up 0.6 percent. General Motors rose 2.2 percent to $34.46 while retail names were also strong on the day. The S&P 500 retail sector rose 0.6 percent while Macy's Inc added 1.3 percent to $64.90 and Amazon.com was up 1.3 percent to $313.15.The S&P energy index rose 0.1 percent, well off its highs of the day as crude oil turned lower. Oil fell 1.8 percent, continuing a recent bout of extended weakness, after earlier rising as much as 1.85 percent. Crude has fallen in 12 of the past 13 weeks. Gilead Sciences Inc rose 3.1 percent to $96.63 as one of the S&P 500's biggest percentage gainers after Morgan Stanley upgraded the stock to ""overweight"" from ""equal-weight.""LiveDeal Inc jumped 23 percent to $4.07 on volume of 9.6 million shares, many times its 50-day average of about 455,000 shares and on track for its most active day since May 28. The move came after the company reported its 2014 results.At 12:20 p.m. (1720 GMT), the Dow Jones industrial average  fell 1.44 points, or 0.01 percent, to 18,052.27, the S&P 500 gained 3.2 points, or 0.15 percent, to 2,091.97 and the Nasdaq Composite added 4.02 points, or 0.08 percent, to 4,810.88.Advancing issues outnumbered declining ones on the NYSE by 1,815 to 1,181, for a 1.54-to-1 ratio; on the Nasdaq, 1,401 issues rose and 1,237 fell for a 1.13-to-1 ratio favoring advancers.The S&P 500 was posting 63 new 52-week highs and 5 new lows; the Nasdaq Composite was recording 124 new highs and 28 new lows.   (Editing by Nick Zieminski)",2014-12-29,GILD,"Mon Dec 29, 2014 | 12:29pm EST",US STOCKS-Wall St edges up in quiet session,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0UD0WP20141229?type=companyNews
153,"   By Bill Berkrot and Caroline Humer  CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception.The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows a move last month by CVS rival Express Scripts Holding that favored AbbVie's regimen after negotiating a price discount below what Gilead had been charging its commercial customers.Express Scripts, the nation's largest pharmacy benefit manager, said it would cover AbbVie's Viekira Pak and exclude Gilead's Sovaldi and combination drug Harvoni. The decision had sent Gilead shares sharply lower at the time.On Monday, Gilead shares were up 2.5 percent following the CVS announcement, while AbbVie shares were down 2.2 percent.Gilead has come under intense criticism for the high price of its first-to-market all-oral treatment; Sovaldi costs about $1,000 per pill. Harvoni combines Sovaldi with another drug into a one-pill, once-a-day treatment with cure rates well above 90 percent. A 12-week course of treatment with Harvoni costs about $93,500, although some patients may need just eights weeks of therapy costing about $63,000.It was not yet known whether Gilead agreed to a substantially discounted price to secure CVS coverage. Gilead did not immediately return a call seeking comment.Express Scripts said it is still negotiating with Gilead on behalf of its plans. ""Our actions have changed how pharmaceutical innovation will be rewarded in the future,""  spokesman Brian Henry said.  RBC Capital Markets analyst Michael Yee said the CVS move ""removes near-term uncertainty for many investors who feared CVS would also strike a deal with AbbVie and put more pressure on Gilead.""AbbVie declined to say whether it was still in talks with CVS.CVS said the Gilead drugs would be exclusive on its standard commercial formulary, as well as those for exchanges created under the Affordable Care Act, Medicare Part D and Medicaid. ""Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C,"" CVS spokeswoman Christine Cramer said in a statement.The recently approved AbbVie regimen has similarly high cure rates, but involves more drugs and pills per day. Many patients must also take the older drug ribavirin, which can cause anemia and other side effects.Gilead shares were up $2.28 at $97.19, while AbbVie shares were down $1.45 at $64.44. (Reporting by Caroline Humer and Bill Berkrot in New York; Editing by Jeffrey Benkoe and Leslie Adler)",2015-01-05,GILD,"Mon Jan 5, 2015 | 2:28pm EST",CVS to cover Gilead hepatitis C treatment over AbbVie regimen,http://www.reuters.com//article/us-gilead-cvs-idUSKBN0KE1FK20150105?type=companyNews
154,"  (Recasts with attribution from CVS; adds Express Scripts, analyst comment, background)By Bill Berkrot and Caroline HumerJan 5 CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception.The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows a move last month by CVS rival Express Scripts Holding  that favored AbbVie's regimen after negotiating a price discount below what Gilead had been charging its commercial customers.Express Scripts, the nation's largest pharmacy benefit manager, said it would cover AbbVie's Viekira Pak and exclude Gilead's Sovaldi and combination drug Harvoni. The decision had sent Gilead shares sharply lower at the time.On Monday, Gilead shares were up 2.5 percent following the CVS announcement, while AbbVie shares were down 2.2 percent. Gilead has come under intense criticism for the high price of its first-to-market all-oral treatment; Sovaldi costs about $1,000 per pill. Harvoni combines Sovaldi with another drug into a one-pill, once-a-day treatment with cure rates well above 90 percent.A 12-week course of treatment with Harvoni costs about $93,500, although some patients may need just eights weeks of therapy costing about $63,000.It was not yet known whether Gilead agreed to a substantially discounted price to secure CVS coverage. Gilead did not immediately return a call seeking comment. Express Scripts said it is still negotiating with Gilead on behalf of its plans. ""Our actions have changed how pharmaceutical innovation will be rewarded in the future,""  spokesman Brian Henry said.RBC Capital Markets analyst Michael Yee said the CVS move ""removes near-term uncertainty for many investors who feared CVS would also strike a deal with AbbVie and put more pressure on Gilead."" AbbVie declined to say whether it was still in talks with CVS.CVS said the Gilead drugs would be exclusive on its standard commercial formulary, as well as those for exchanges created under the Affordable Care Act, Medicare Part D and Medicaid.""Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C,"" CVS spokeswoman Christine Cramer said in a statement.The recently approved AbbVie regimen has similarly high cure rates, but involves more drugs and pills per day. Many patients must also take the older drug ribavirin, which can cause anemia and other side effects.Gilead shares were up $2.28 at $97.19, while AbbVie shares were down $1.45 at $64.44.   (Reporting by Caroline Humer and Bill Berkrot in New York; Editing by Jeffrey Benkoe and Leslie Adler)",2015-01-05,GILD,"Mon Jan 5, 2015 | 2:07pm EST",UPDATE 1-CVS to cover Gilead hepatitis C treatment over AbbVie regimen,http://www.reuters.com//article/gilead-cvs-idUSL1N0UK1B920150105?type=companyNews
155,"  (Adds details, background, share price)By Deena BeasleyJan 8 Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.Anthem said the deal effectively lowers its hepatitis C treatment costs. ""We were able to achieve a very competitive rate and a freeze on retail pricing for 2015,"" the insurer said in an emailed statement. ""That does favorably impact plan costs for 2015.""Gilead has come under fire for the high cost of Harvoni, as well as predecessor drug Sovaldi, which was launched in late 2013 at a price of $1,000 per pill. Harvoni has a list price of $94,500 for 12 weeks of treatment, or $1,125 per daily pill. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the largest manager of prescription drug plans for U.S. employers, subsequently chose AbbVie's drug as the exclusive option for patients in its largest commercial plan, covering 25 million people.Anthem said Harvoni is covered for members of its affiliated health plans who are infected with genotype 1 hepatitis C, the strain that accounts for around 75 percent of all chronic hepatitis C infections in the United States.The insurer attributed its decision to favorable pricing and clinical differences, including the fact that Harvoni does not require additional medication, and offers a less complex treatment regimen than the AbbVie drug. CVS Health Corp, the nation's second-largest pharmacy benefit manager, said this week it had selected Gilead's drugs as its exclusive option for patients on commercial plans as well as those covered under its healthcare exchange plans, Medicare and Medicaid.Anthem declined to comment on the number of customers affected by its deal with Gilead but said it affects patients covered under its commercial/employer-based plan. Anthem said hepatitis C drugs sit on the highest coverage tiers, which means patients are required to pay for a certain percentage of the drug cost. Deutsche Bank analyst Robyn Karnauskas said Anthem is a client of Express Scripts, covering between 8.5 million and 13.5 million patients.""We see the Anthem deal as positive, however note that discounts are now key to play in the HCV space,"" Karnauskas said in a research note. She models hepatitis C sales for Gilead using a 30 percent discount to list prices.Shares of Gilead, which rose nearly 3 percent in regular trading, were up another 2.1 percent at $104.49 after hours.More than three million people in the United States are believed to be infected with hepatitis C.   (Reporting by Deena Beasley; Editing by James Dalgleish)",2015-01-08,GILD,"Thu Jan 8, 2015 | 5:45pm EST",UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs,http://www.reuters.com//article/anthem-gilead-hepatitis-idUSL1N0UN2LD20150108?type=companyNews
156,"  Jan 8 Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.Anthem said the deal effectively lowers its hepatitis C treatment costs. ""We were able to achieve a very competitive rate and a freeze on retail pricing for 2015,"" the insurer said in an emailed statement. ""That does favorably impact plan costs for 2015.""Gilead has come under fire for the high cost of Harvoni, as well as predecessor drug Sovaldi, which was launched in late 2013 at a price of $1,000 per pill. Harvoni has a list price of $94,500 for 12 weeks of treatment, or $1,125 per daily pill. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, subsequently chose AbbVie's drug as the exclusive option for patients in its largest commercial plan, covering 25 million people. CVS Health Corp, the nation's second-largest pharmacy benefit manager announced earlier this week it had selected Gilead's drugs as its exclusive option for patients on commercial plans as well as those covered under its healthcare exchange plans, Medicare and Medicaid. More than three million people in the United States are believed to be infected with hepatitis C.   (Reporting by Deena Beasley; Editing by James Dalgleish)",2015-01-08,GILD,"Thu Jan 8, 2015 | 5:03pm EST",Anthem selects Gilead as primary supplier of hepatitis C drugs,http://www.reuters.com//article/anthem-gilead-hepatitis-idUSL1N0UN2IV20150108?type=companyNews
157,"  (Corrects Anthem ticker symbol in text)By Deena BeasleyJan 8 Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.Anthem said the deal effectively lowers its hepatitis C treatment costs. ""We were able to achieve a very competitive rate and a freeze on retail pricing for 2015,"" the insurer said in an emailed statement. ""That does favorably impact plan costs for 2015.""Gilead has come under fire for the high cost of Harvoni, as well as predecessor drug Sovaldi, which was launched in late 2013 at a price of $1,000 per pill. Harvoni has a list price of $94,500 for 12 weeks of treatment, or $1,125 per daily pill. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the largest manager of prescription drug plans for U.S. employers, subsequently chose AbbVie's drug as the exclusive option for patients in its largest commercial plan, covering 25 million people.Anthem said Harvoni is covered for members of its affiliated health plans who are infected with genotype 1 hepatitis C, the strain that accounts for around 75 percent of all chronic hepatitis C infections in the United States.The insurer attributed its decision to favorable pricing and clinical differences, including the fact that Harvoni does not require additional medication, and offers a less complex treatment regimen than the AbbVie drug. CVS Health Corp, the nation's second-largest pharmacy benefit manager, said this week it had selected Gilead's drugs as its exclusive option for patients on commercial plans as well as those covered under its healthcare exchange plans, Medicare and Medicaid.Anthem declined to comment on the number of customers affected by its deal with Gilead but said it affects patients covered under its commercial/employer-based plan. Anthem said hepatitis C drugs sit on the highest coverage tiers, which means patients are required to pay for a certain percentage of the drug cost. Deutsche Bank analyst Robyn Karnauskas said Anthem is a client of Express Scripts, covering between 8.5 million and 13.5 million patients.""We see the Anthem deal as positive, however note that discounts are now key to play in the HCV space,"" Karnauskas said in a research note. She models hepatitis C sales for Gilead using a 30 percent discount to list prices.Shares of Gilead, which rose nearly 3 percent in regular trading, were up another 2.1 percent at $104.49 after hours.More than three million people in the United States are believed to be infected with hepatitis C.   (Reporting by Deena Beasley; Editing by James Dalgleish)",2015-01-09,GILD,"Fri Jan 9, 2015 | 11:33am EST",CORRECTED-UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs,http://www.reuters.com//article/anthem-gilead-hepatitis-idUSL1N0UN2LD20150109?type=companyNews
158,"  Shares of Gilead Sciences Inc closed down 6 percent on Tuesday, after a pharmacy benefit manager said it would cover both Gilead and rival AbbVie Inc's hepatitis C offering, renewing concerns of pricing pressure.Investors interpreted this as further discounting of hep C drugs, signaled by an increasing willingness by drugmakers to offer rebates, Sanford Bernstein's Geoffrey Porges wrote in a note.Express Scripts, the largest U.S. pharmacy benefit manager, dropped Gilead's hep C drugs in December in favor of AbbVie's newly approved alternative at a cheaper price.Meanwhile, CVS Health Corp, the second-largest pharmacy benefit manager, and health insurer Anthem Inc inked deals with Gilead to cover Harvoni.On Monday, St. Paul, Minnesota-based pharmacy benefit manager Prime Therapeutics LLC, which serves over 25 million people, said it would cover both Gilead's Harvoni and AbbVie's Viekira Pak.  ""There has been a substantial reduction in the net price of both of these drugs just in the past few weeks, so sometimes it pays not to go first,"" said Peter Wickersham, Prime's senior vice president of Integrated Care and Specialty.While exact rebate rates will unlikely be disclosed we would hesitate to read too much into the claims from Prime, and we do not believe they alter expectations about hep C pricing, Porges said. ""It is possible that neither Gilead nor AbbVie felt the need to offer a deep rebate to Prime for exclusivity.""Prime is not known for exclusionary formularies in contrast with CVS and Express Scripts, and consequently, both drugmakers may have been less pressured with Prime than they were with CVS and Express Scripts, he said.  AbbVie's shares closed down 3.6 percent on the New York Stock Exchange on Tuesday. (Reporting by Natalie Grover in Bengaluru)",2015-01-13,GILD,"Tue Jan 13, 2015 | 6:42pm EST","Gilead, AbbVie hit by fresh concerns on Hep C discounting",http://www.reuters.com//article/us-gilead-sciences-abbvie-prime-therapeu-idUSKBN0KM2HF20150113?type=companyNews
159,"   By Susan Kelly and Bill Berkrot  Express Scripts, the largest U.S. pharmacy benefit manager, on Tuesday said cost savings on expensive cancer treatments could be achieved if the company were involved earlier in the decision-making process. Express Scripts, which has become more aggressive in negotiating discounts on drugs for insurance plans and employers, in December stopped covering Gilead Sciences Inc's hepatitis C treatments after lining up a cheaper price for AbbVie's newly-approved alternative.Gilead's Sovaldi and follow-up combination pill Harvoni have been shown to cure hepatitis C in more than 90 percent of patients. But Express deemed the more than $90,000 price for 12 weeks of Harvoni treatment unaffordable. The move reignited investor concerns that drugmakers will have to bow to pricing pressure from U.S. insurers and lawmakers over novel medications whose cost can reach hundreds of thousands of dollars for some diseases.For cancer patients, treatment decisions typically go through health insurance plans first, and medicines are not changed once people have begun their regimens, Express Scripts Chief Executive George Paz said at the J.P. Morgan Healthcare conference in San Francisco. He said PBMs should be included in the decision-making process at a much earlier stage.   ""The big opportunity out there is really in cancer,"" Paz said. ""If we can get out in front of that, that is a huge opportunity."" Paz said he is also focused on a new crop of cholesterol-lowering drugs expected to hit the market this year, and is talking to companies about market share, positioning and pricing. ""They are pretty astonishing, but they are also very expensive,"" Paz said of the drugs which target a protein known as PCSK9. Manufacturers include Amgen Inc and Regeneron Pharmaceuticals Inc in partnership with Sanofi. The key is to determine which are real breakthrough treatments and which are me too drugs, Paz said.Amgen said it was talking to payers about its evolocumab, and believes they can only exclude a drug from formularies if there is no clinical difference between rival medicines.""If not, payers will have to leave choices to physicians,"" said Tony Hooper, Amgen's head of commercial operations. Regeneron Chief Executive Officer Len Schleifer was asked if he was concerned about Paz's comments that PCSK9 drugs were in his sights.""It's not a worry. It's a reality that we will deal with,"" Schleifer said. ""I think there will be fair pricing and healthy competition in the marketplace."" (Reporting by Susan Kelly in Chicago and Bill Berkrot in New York; Editing by Christian Plumb, Bernard Orr)",2015-01-13,GILD,"Tue Jan 13, 2015 | 4:29pm EST",Express Scripts sees opportunity to lower cancer treatment cost,http://www.reuters.com//article/us-healthcare-expressscripts-drugprices-idUSKBN0KM28K20150113?type=companyNews
160,"  (Adds Amgen, Regeneron comments)By Susan Kelly and Bill BerkrotJan 13 Express Scripts, the largest U.S. pharmacy benefit manager, on Tuesday said cost savings on expensive cancer treatments could be achieved if the company were involved earlier in the decision-making process.Express Scripts, which has become more aggressive in negotiating discounts on drugs for insurance plans and employers, in December stopped covering Gilead Sciences Inc's  hepatitis C treatments after lining up a cheaper price for AbbVie's newly-approved alternative.Gilead's Sovaldi and follow-up combination pill Harvoni have been shown to cure hepatitis C in more than 90 percent of patients. But Express deemed the more than $90,000 price for 12 weeks of Harvoni treatment unaffordable. The move reignited investor concerns that drugmakers will have to bow to pricing pressure from U.S. insurers and lawmakers over novel medications whose cost can reach hundreds of thousands of dollars for some diseases.For cancer patients, treatment decisions typically go through health insurance plans first, and medicines are not changed once people have begun their regimens, Express Scripts Chief Executive George Paz said at the J.P. Morgan Healthcare conference in San Francisco. He said PBMs should be included in the decision-making process at a much earlier stage.""The big opportunity out there is really in cancer,"" Paz said. ""If we can get out in front of that, that is a huge opportunity."" Paz said he is also focused on a new crop of cholesterol-lowering drugs expected to hit the market this year, and is talking to companies about market share, positioning and pricing.""They are pretty astonishing, but they are also very expensive,"" Paz said of the drugs which target a protein known as PCSK9. Manufacturers include Amgen Inc and Regeneron Pharmaceuticals Inc in partnership with Sanofi . The key is to determine which are real breakthrough treatments and which are ""me too"" drugs, Paz said. Amgen said it was talking to payers about its evolocumab, and believes they can only exclude a drug from formularies if there is no clinical difference between rival medicines.""If not, payers will have to leave choices to physicians,"" said Tony Hooper, Amgen's head of commercial operations.Regeneron Chief Executive Officer Len Schleifer was asked if he was concerned about Paz's comments that PCSK9 drugs were in his sights.""It's not a worry. It's a reality that we will deal with,"" Schleifer said. ""I think there will be fair pricing and healthy competition in the marketplace.""   (Reporting by Susan Kelly in Chicago and Bill Berkrot in New York; Editing by Christian Plumb, Bernard Orr)",2015-01-13,GILD,"Tue Jan 13, 2015 | 4:28pm EST",UPDATE 1-Express Scripts sees opportunity to lower cancer treatment cost,http://www.reuters.com//article/healthcare-expressscripts-drugprices-idUSL1N0US1Z120150113?type=companyNews
161,"   By Sumeet Chatterjee | MUMBAI  MUMBAI India's patent office has rejected an application from U.S.-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.The application had been opposed by Indian generic drugmaker Natco Pharma Ltd and New York-based Initiative for Medicines, Access & Knowledge (I-MAK) on the grounds that the drug, chemically called sofosbuvir, is not inventive enough compared with a previous formulation, according to patent office order documents seen by Reuters on Wednesday.India's patent laws allow a third party to dispute the validity of a pending patent application.The patent office's order said Gilead's request for Sovaldi, which is normally given for either three or six months and costs $84,000 for a 12-week course in the United States, was rejected on the basis that ""minor changes in the molecule"" did not improve efficacy of the drug. The rejection will allow the Indian generic companies to make and sell versions of the drug in country where a majority of people live on less than $2 a day and health insurance is scarce.Gilead could not immediately be reached for comment. Natco Chief Executive Rajeev Nannapaneni was not available outside regular Indian business hours.Foreign drugmakers in India, a global hub for making generic drugs, have been frustrated by a series of decisions on patents and pricing, with the government looking to improve healthcare access. Market access and patent protection for U.S. drugs are expected to feature when Indian Prime Minister Narendra Modi hosts President Barack Obama later this month for India's annual Republic Day celebrations.The patent office's order comes amid a growing clamor by healthcare campaigners and doctors to ensure Sovaldi and other new hepatitis C pills are affordable in developing countries. In a bid to make Sovaldi available in 91 developing nations including in India, Gilead licensed the drug, hailed by doctors as a breakthrough in treating the liver-destroying disease, to seven India-based drugmakers in April last year.Campaigners, however, were critical of the licensing deals, saying they would not ensure access to several middle-income countries where health authorities would still struggle to provide treatment to patients.  (Reporting by Sumeet Chatterjee; Editing by David Holmes)",2015-01-14,GILD,"Wed Jan 14, 2015 | 11:51am EST",India rejects Gilead's Hepatitis C drug patent request,http://www.reuters.com//article/us-gilead-india-patent-idUSKBN0KN1ZE20150114?type=companyNews
162,"   By Sumeet Chatterjee | MUMBAI  MUMBAI Jan 14 India's patent office has rejected an application from U.S.-based Gilead Sciences Inc  for its hepatitis C drug Sovaldi, paving the way for local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.The application had been opposed by Indian generic drugmaker Natco Pharma Ltd and New York-based Initiative for Medicines, Access & Knowledge (I-MAK) on the grounds that the drug, chemically called sofosbuvir, is not inventive enough compared with a previous formulation, according to patent office order documents seen by Reuters on Wednesday.India's patent laws allow a third party to dispute the validity of a pending patent application.The patent office's order said Gilead's request for Sovaldi, which is normally given for either three or six months and costs $84,000 for a 12-week course in the United States, was rejected on the basis that ""minor changes in the molecule"" did not improve efficacy of the drug. The rejection will allow the Indian generic companies to make and sell versions of the drug in country where a majority of people live on less than $2 a day and health insurance is scarce.Gilead could not immediately be reached for comment. Natco Chief Executive Rajeev Nannapaneni was not available outside regular Indian business hours. Foreign drugmakers in India, a global hub for making generic drugs, have been frustrated by a series of decisions on patents and pricing, with the government looking to improve healthcare access.Market access and patent protection for U.S. drugs are expected to feature when Indian Prime Minister Narendra Modi hosts President Barack Obama later this month for India's annual Republic Day celebrations. The patent office's order comes amid a growing clamour by healthcare campaigners and doctors to ensure Sovaldi and other new hepatitis C pills are affordable in developing countries.In a bid to make Sovaldi available in 91 developing nations including in India, Gilead licensed the drug, hailed by doctors as a breakthrough in treating the liver-destroying disease, to seven India-based drugmakers in April last year.Campaigners, however, were critical of the licensing deals, saying they would not ensure access to several middle-income countries where health authorities would still struggle to provide treatment to patients.    (Reporting by Sumeet Chatterjee; Editing by David Holmes)",2015-01-14,GILD,"Wed Jan 14, 2015 | 11:45am EST",India rejects Gilead's Hepatitis C drug patent request,http://www.reuters.com//article/gilead-india-patent-idUSL3N0UT4PB20150114?type=companyNews
163,"   By Caroline Humer  Kite Pharma Inc plans to open conversations with insurers this year to lay the groundwork for an experimental cancer treatment that could cost hundreds of thousands of dollars if it works and is approved by regulators, top executives said this week.The possible treatment has yet to start a broad clinical trial, but the urgency comes as biotech and pharma companies consider how to navigate pushback by health insurers against Gilead Sciences Inc on the price of its hepatitis C treatment.""We learn from mistakes,"" Kite Chief Executive Officer Arie Belldegrun said in an interview at the J.P. Morgan Healthcare Conference when asked how it would garner support for an immunotherapy cancer treatment that may cost hundreds of thousands of dollars.Such treatments are in early development but are being closely watched as they could offer substantially higher cure rates than current cancer regimens. Insurer pushback on drug prices hit its stride in December when AbbVie Inc. introduced a competitor to Gilead and the nation's largest benefit manager Express Scripts dropped coverage of Gilead's drug on its largest pharmacy plan covering 25 million people. Gilead, which charges less for the treatment outside of the United States, has since been dropping its price, according to Wall Street analysts. When asked at the conference about analyst reports that it had cut its price by 30 percent, Gilead did not comment. Kite will soon begin a broad clinical trial on the immunotherapy cancer treatment in which cells are drawn from a person, sent to the lab to be treated, and then reintroduced into the individual's bloodstream. The trial is due to be completed by the second half of 2016.Kite Chief Financial Officer Cynthia Butitta said that its financial models set a base case price at $150,000 per treatment, but that the actual price will depend more on survival rates and the drug's efficacy. Analysts have estimated the costs at up to $300,000 per treatment. The company's new marketing head starts next month and will begin conversations with insurers about the trials and the treatment's possible benefits. ""We're starting that effort this year,"" Butitta said.Kite, which recently signed a collaboration deal with Amgen Inc is one of several companies developing this type of immunotherapy cancer treatment along with Novartis AG, BlueBird Bio Inc and Juno Therapeutics Inc. (Reporting by Caroline Humer in San Francisco; Editing by Christian Plumb)",2015-01-15,GILD,"Thu Jan 15, 2015 | 2:16pm EST",Kite CEO plans to learn from Gilead's pricing playbook,http://www.reuters.com//article/us-healthcare-kite-pharma-idUSKBN0KO2EF20150115?type=companyNews
164,"   By Caroline Humer and Bill Berkrot  Aetna Inc, the third-largest U.S. health insurer, said it negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to nearly 11 million commercial customers.Aetna, which posted an updated coverage policy on its website on Friday, said it believes the price it received for Gilead's Sovaldi, and a newer combination treatment called Harvoni, is ""competitive with other recently announced agreements for this class of therapy."" It would not detail the size of the discount. Gilead shares closed up 3.4 percent at $100.71 after the Aetna deal was announced. Aetna shares closed 2.3 percent higher at $92.56.    Aetna and other insurers have pushed back against the high price of new hepatitis C treatments and other drugs, questioning their affordability after Gilead's Sovaldi was priced at $84,000 per treatment when it became the first new all-oral treatment to reach the market in late 2013. U.S. health regulators late last month approved Viekira Pak from AbbVie Inc, the first competitor to Gilead's drugs. Within a few days, Express Scripts, the largest U.S. pharmacy benefits manager, dropped coverage of Gilead's treatments in most cases in favor of the AbbVie therapy, citing a substantial discount.  Both breakthrough treatments for the first time can cure the liver-wasting disease in more than 90 percent of patients without the miserable side effects of older medicines. More than 3 million people in the United States are estimated to have hepatitis C.Since Express Scripts' move, insurers have pressed both AbbVie and Gilead for discounts on their hepatitis C treatments to keep them on reimbursement lists. CVS Health, Anthem and Humana chose Gilead drugs as their preferred treatment, while pharmacy benefits company Prime Therapeutics kept both on its list.Wall Street analysts estimate the drugmakers have provided discounts of 30 percent or more. Gilead and AbbVie would not comment on the price reductions. Some industry experts see Gilead and AbbVie gaining in terms of the number of patients treated now that they have conceded on price. Many insurers had limited use of the new hepatitis C drugs to the sickest patients to contain costs.""The floodgates (of patients) could start to open over time this year,"" said RBC Capital Markets analyst Michael Yee. He has forecast $15 billion for Gilead worldwide hepatitis C sales in 2015 and sees room for upside.  ""That number starts to go up as we start seeing some of the prescription numbers come out,"" he said.Len Yaffe, portfolio manager of the StockDoc Partners healthcare fund, expects $18 billion in Gilead hepatitis C sales this year as more patients are covered for treatment.Gilead's new two-drug treatment, Harvoni, taken as one pill once a day, is expected to replace Sovaldi use. It has a list price of $94,500 for 12 weeks. AbbVie's Viekira Pak, which involves more pills and drugs, and in most cases must be taken with the older medicine ribavirin, has a list price of $83,319 per treatment. (Reporting by Caroline Humer and Bill Berkrot; Editing by Michele Gershberg, Alan Crosby)",2015-01-16,GILD,"Fri Jan 16, 2015 | 6:10pm EST","Aetna backs Gilead's hepatitis C treatment, gets discount",http://www.reuters.com//article/us-healthcare-aetna-hepatitisc-idUSKBN0KP28O20150116?type=companyNews
165,"  (Adds portfolio manager, analyst comment, updates shares)By Caroline Humer and Bill BerkrotJan 16 Aetna Inc, the third-largest U.S. health insurer, said it negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to nearly 11 million commercial customers.Aetna, which posted an updated coverage policy on its website on Friday, said it believes the price it received for Gilead's Sovaldi, and a newer combination treatment called Harvoni, is ""competitive with other recently announced agreements for this class of therapy."" It would not detail the size of the discount.Gilead shares closed up 3.4 percent at $100.71 after the Aetna deal was announced. Aetna shares closed 2.3 percent higher at $92.56.Aetna and other insurers have pushed back against the high price of new hepatitis C treatments and other drugs, questioning their affordability after Gilead's Sovaldi was priced at $84,000 per treatment when it became the first new all-oral treatment to reach the market in late 2013. U.S. health regulators late last month approved Viekira Pak from AbbVie Inc, the first competitor to Gilead's drugs. Within a few days, Express Scripts, the largest U.S. pharmacy benefits manager, dropped coverage of Gilead's treatments in most cases in favor of the AbbVie therapy, citing a substantial discount.Both breakthrough treatments for the first time can cure the liver-wasting disease in more than 90 percent of patients without the miserable side effects of older medicines. More than 3 million people in the United States are estimated to have hepatitis C. Since Express Scripts' move, insurers have pressed both AbbVie and Gilead for discounts on their hepatitis C treatments to keep them on reimbursement lists. CVS Health, Anthem  and Humana chose Gilead drugs as their preferred treatment, while pharmacy benefits company Prime Therapeutics kept both on its list.Wall Street analysts estimate the drugmakers have provided discounts of 30 percent or more. Gilead and AbbVie would not comment on the price reductions.Some industry experts see Gilead and AbbVie gaining in terms of the number of patients treated now that they have conceded on price. Many insurers had limited use of the new hepatitis C drugs to the sickest patients to contain costs. ""The floodgates (of patients) could start to open over time this year,"" said RBC Capital Markets analyst Michael Yee. He has forecast $15 billion for Gilead worldwide hepatitis C sales in 2015 and sees room for upside.""That number starts to go up as we start seeing some of the prescription numbers come out,"" he said.Len Yaffe, portfolio manager of the StockDoc Partners healthcare fund, expects $18 billion in Gilead hepatitis C sales this year as more patients are covered for treatment.Gilead's new two-drug treatment, Harvoni, taken as one pill once a day, is expected to replace Sovaldi use. It has a list price of $94,500 for 12 weeks. AbbVie's Viekira Pak, which involves more pills and drugs, and in most cases must be taken with the older medicine ribavirin, has a list price of $83,319 per treatment.   (Reporting by Caroline Humer and Bill Berkrot; Editing by Michele Gershberg, Alan Crosby)",2015-01-16,GILD,"Fri Jan 16, 2015 | 6:06pm EST","UPDATE 2-Aetna backs Gilead's hepatitis C treatment, gets discount",http://www.reuters.com//article/healthcare-aetna-hepatitisc-idUSL1N0UV1VE20150116?type=companyNews
166,"  (Refiles to take out errant word in first paragraph.)By Caroline HumerJan 16 Aetna Inc, the third-largest U.S. health insurer, said it has negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to nearly 11 million commercial customers.Aetna, which posted an updated coverage policy on its website on Friday, said in a statement that it believes its price is ""competitive with other recently announced agreements for this class of therapy."" Aetna and other insurers have pushed back against the high price of hepatitis C treatments and other drugs, questioning their affordability after Gilead's first drug, Sovaldi, was priced at $84,000 per treatment, or roughly $1,000 per pill, in late 2013.The agreement followed a clinical review of other FDA-approved therapies for hepatitis C, which includes the late December approval of AbbVie Inc.'s competing treatment. Since that approval, AbbVie and Gilead have given discounts to their list prices of 30 percent or more, according to analysts. Aetna declined to comment on the size of the discount. The company said it is not updating its 2015 financial guidance at this time.The agreement follows similar announcements by pharmacy benefit managers Express Scripts Inc and CVS Health . (Reporting by Caroline Humer; Editing by Alan Crosby)",2015-01-16,GILD,"Fri Jan 16, 2015 | 5:44pm EST","REFILE-Aetna backs Gilead's hepatitis C treatment, gets discount",http://www.reuters.com//article/healthcare-aetna-hepatitisc-idUSL1N0UV2GA20150116?type=companyNews
167,"  (Corrects to remove errant word its in first paragraph.)By Caroline HumerJan 16 Aetna Inc, the third-largest U.S. health insurer, said it has negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to its nearly 11 million commercial customers.Aetna, which posted an updated coverage policy on its website on Friday, said in a statement that it believes its price is ""competitive with other recently announced agreements for this class of therapy."" Aetna and other insurers have pushed back against the high price of hepatitis C treatments and other drugs, questioning their affordability after Gilead's first drug, Sovaldi, was priced at $84,000 per treatment, or roughly $1,000 per pill, in late 2013.The agreement followed a clinical review of other FDA-approved therapies for hepatitis C, which includes the late December approval of AbbVie Inc.'s competing treatment. Since that approval, AbbVie and Gilead have given discounts to their list prices of 30 percent or more, according to analysts. Aetna declined to comment on the size of the discount. The company said it is not updating its 2015 financial guidance at this time.The agreement follows similar announcements by pharmacy benefit managers Express Scripts Inc and CVS Health . (Reporting by Caroline Humer; Editing by Alan Crosby)",2015-01-16,GILD,"Fri Jan 16, 2015 | 5:35pm EST","CORRECTED (OFFICIAL)-Aetna backs Gilead's hepatitis C treatment, gets discount",http://www.reuters.com//article/healthcare-aetna-hepatitisc-idUSL1N0UV2F820150116?type=companyNews
168,"  (Company corrected number of customers to 11 million from 20 million in first paragraph.)By Caroline HumerJan 16 Aetna Inc, the third-largest U.S. health insurer, said it has negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to its nearly 11 million commercial customers.Aetna, which posted an updated coverage policy on its website on Friday, said in a statement that it believes its price is ""competitive with other recently announced agreements for this class of therapy."" Aetna and other insurers have pushed back against the high price of hepatitis C treatments and other drugs, questioning their affordability after Gilead's first drug, Sovaldi, was priced at $84,000 per treatment, or roughly $1,000 per pill, in late 2013.The agreement followed a clinical review of other FDA-approved therapies for hepatitis C, which includes the late December approval of AbbVie Inc.'s competing treatment. Since that approval, AbbVie and Gilead have given discounts to their list prices of 30 percent or more, according to analysts. Aetna declined to comment on the size of the discount. The company said it is not updating its 2015 financial guidance at this time.The agreement follows similar announcements by pharmacy benefit managers Express Scripts Inc and CVS Health . (Reporting by Caroline Humer; Editing by Alan Crosby)",2015-01-16,GILD,"Fri Jan 16, 2015 | 5:15pm EST","CORRECTED (OFFICIAL)-Aetna backs Gilead's hepatitis C treatment, gets discount",http://www.reuters.com//article/healthcare-aetna-hepatitisc-idUSL1N0UV2DI20150116?type=companyNews
169,"   By Caroline Humer  Jan 16 Aetna Inc, the third-largest U.S. health insurer, said it has negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to its nearly 20 million commercial customers.Aetna, which posted an updated coverage policy on its website on Friday, said in a statement that it believes its price is ""competitive with other recently announced agreements for this class of therapy.""Aetna and other insurers have pushed back against the high price of hepatitis C treatments and other drugs, questioning their affordability after Gilead's first drug, Sovaldi, was priced at $84,000 per treatment, or roughly $1,000 per pill, in late 2013. The agreement followed a clinical review of other FDA-approved therapies for hepatitis C, which includes the late December approval of AbbVie Inc.'s competing treatment. Since that approval, AbbVie and Gilead have given discounts to their list prices of 30 percent or more, according to analysts.Aetna declined to comment on the size of the discount. The company said it is not updating its 2015 financial guidance at this time. The agreement follows similar announcements by pharmacy benefit managers Express Scripts Inc and CVS Health . (Reporting by Caroline Humer; Editing by Alan Crosby)",2015-01-16,GILD,"Fri Jan 16, 2015 | 2:34pm EST",Aetna backs Gilead's hepatitis C treatment and gets discount,http://www.reuters.com//article/healthcare-aetna-hepatitisc-idUSL1N0UV1RJ20150116?type=companyNews
170,"   By Sumeet Chatterjee | MUMBAI  MUMBAI U.S.-based Gilead Sciences Inc  will appeal the Indian patent office's rejection of its application for hepatitis C drug Sovaldi, a move that could allow local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.The rejection relates to the patent application covering the metabolites, or small molecules, of sofosbuvir, the chemical name of Sovaldi.Indian drugmaker Natco Pharma and the Initiative for Medicines, Access & Knowledge (I-MAK) had opposed Gilead's application on the grounds that the drug is not inventive enough compared with a previous formulation. ""Gilead strongly defends its intellectual property. The company will be appealing the decision as well as exploring additional procedural options,"" the company said in a statement on Friday. It did not elaborate.The patent office order said Gilead's request was rejected as ""minor changes in the molecule"" did not improve efficacy of the drug, which is normally given for either three or six months and costs $84,000 for a 12-week course in the United States. The rejection will allow Indian generic companies to make and sell cheaper versions in a country where a majority of the people live on less than $2 a day and health insurance is scarce. In a bid to make Sovaldi available in 91 developing nations including in India, Gilead licensed the drug, hailed by doctors as a breakthrough in treating the liver-destroying disease, to seven India-based drugmakers in April 2014.""These proceedings do not impact our commitment to enabling access to our hepatitis C medicines in India and other developing countries, and our generic licensing program with our Indian partners continues as normal,"" the Gilead statement said.Mdecins Sans Frontires (MSF) said the entry for additional generic drugmakers after the patent office order should increase competition needed to bring prices down, especially in countries that have been excluded from the licence agreement.",2015-01-16,GILD,"Fri Jan 16, 2015 | 7:34am EST",Gilead to appeal India patent ruling on hepatitis C drug,http://www.reuters.com//article/gilead-sciences-india-patent-idUSL1N0UV0MQ20150116?type=companyNews
171,"  MUMBAI Jan 16 U.S.-based Gilead Sciences Inc  will appeal the Indian patent office's rejection of its application for hepatitis C drug Sovaldi, a move that could allow local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.The rejection relates to the patent application covering the metabolites, or small molecules, of sofosbuvir, the chemical name of Sovaldi.Indian drugmaker Natco Pharma and the Initiative for Medicines, Access & Knowledge (I-MAK) had opposed Gilead's application on the grounds that the drug is not inventive enough compared with a previous formulation.""Gilead strongly defends its intellectual property. The company will be appealing the decision as well as exploring additional procedural options,"" the company said in a statement on Friday. It did not elaborate. The patent office order said Gilead's request was rejected as ""minor changes in the molecule"" did not improve efficacy of the drug, which is normally given for either three or six months and costs $84,000 for a 12-week course in the United States. The rejection will allow Indian generic companies to make and sell cheaper versions in a country where a majority of the people live on less than $2 a day and health insurance is scarce.In a bid to make Sovaldi available in 91 developing nations including in India, Gilead licensed the drug, hailed by doctors as a breakthrough in treating the liver-destroying disease, to seven India-based drugmakers in April 2014. ""These proceedings do not impact our commitment to enabling access to our hepatitis C medicines in India and other developing countries, and our generic licensing program with our Indian partners continues as normal,"" the Gilead statement said.Mdecins Sans Frontires (MSF) said the entry for additional generic drugmakers after the patent office order should increase competition needed to bring prices down, especially in countries that have been excluded from the licence agreement.        (Reporting by Sumeet Chatterjee; Editing by Prateek Chatterjee)",2015-01-16,GILD,"Fri Jan 16, 2015 | 5:42am EST",Gilead to appeal India patent ruling on hepatitis C drug,http://www.reuters.com//article/gilead-sciences-india-patent-idUSL3N0UV3FU20150116?type=companyNews
172,"  Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus.EnvisionRx said Gilead's Sovaldi and its newer two-drug combination pill Harvoni would be available on its formulary, with other hepatitis C drugs, such as AbbVie's Viekira Pak, allowed only as an exception in some cases.It was not disclosed how much of a price discount EnvisionRx negotiated from Gilead to secure the agreement.""The safety and efficacy profile of Gilead's HCV products, coupled with the most competitive pricing in the drug class, have solidified EnvisionRx's choice to place Gilead's products in an exclusive and preferred formulary position,"" said EnvisionRx President Dawn Sherman in a statement.Express Scripts Holding, the largest U.S. pharmacy benefits manager (PBM) which had complained about the high cost of Gilead's first to market treatment, fired the first shot in the hepatitis C price war days after the AbbVie rival treatment was approved. It gave Viekira Pak preference on its formulary, excluding Gilead's drugs.Gilead then locked up formulary exclusivity for Harvoni with CVS Health, the second largest U.S. PBM. PBMs negotiate drug pricing for employers and health plans. Health insurers have also chosen sides after negotiating their own discount deals following the Express Scripts move.Aetna, Anthem and Humana chose Gilead drugs as their preferred treatment, while PBM Prime Therapeutics kept both on its list. Both treatments have demonstrated an ability to cure well over 90 percent of patients, although Gilead's Harvoni involves fewer drugs than Viekira.Harvoni, which combines Sovaldi with another drug, has a list price of $94,500 for 12 weeks of treatment. Viekira Pak  was listed at about $83,300. Analysts believe the companies have been providing discounts of up to 30 percent, although the specific negotiated rebates have not been disclosed. EnvisionRx provides services for Medicare Part D plans as well as government paid or subsidized insurance through Medicaid, CHIP and individual exchange plans. (Reporting by Bill Berkrot and Caroline Humer; editing by Gunna Dickson)",2015-01-26,GILD,"Mon Jan 26, 2015 | 2:42pm EST",PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary,http://www.reuters.com//article/us-gilead-envision-hepatitis-idUSKBN0KZ2AH20150126?type=companyNews
173,"  Jan 26 Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus.EnvisionRx said Gilead's Sovaldi and its newer two-drug combination pill Harvoni would be available on its formulary, with other hepatitis C drugs, such as AbbVie's Viekira Pak, allowed only as an exception in some cases.It was not disclosed how much of a price discount EnvisionRx negotiated from Gilead to secure the agreement.""The safety and efficacy profile of Gilead's HCV products, coupled with the most competitive pricing in the drug class, have solidified EnvisionRx's choice to place Gilead's products in an exclusive and preferred formulary position,"" said EnvisionRx President Dawn Sherman in a statement.Express Scripts Holding, the largest U.S. pharmacy benefits manager (PBM) which had complained about the high cost of Gilead's first to market treatment, fired the first shot in the hepatitis C price war days after the AbbVie rival treatment was approved. It gave Viekira Pak preference on its formulary, excluding Gilead's drugs. Gilead then locked up formulary exclusivity for Harvoni with CVS Health, the second largest U.S. PBM.PBMs negotiate drug pricing for employers and health plans. Health insurers have also chosen sides after negotiating their own discount deals following the Express Scripts move. Aetna, Anthem and Humana chose Gilead drugs as their preferred treatment, while PBM Prime Therapeutics kept both on its list.Both treatments have demonstrated an ability to cure well over 90 percent of patients, although Gilead's Harvoni involves fewer drugs than Viekira. Harvoni, which combines Sovaldi with another drug, has a list price of $94,500 for 12 weeks of treatment. Viekira Pak  was listed at about $83,300.Analysts believe the companies have been providing discounts of up to 30 percent, although the specific negotiated rebates have not been disclosed.EnvisionRx provides services for Medicare Part D plans as well as government paid or subsidized insurance through Medicaid, CHIP and individual exchange plans.(Reporting by Bill Berkrot and Caroline Humer; editing by Gunna Dickson)",2015-01-26,GILD,"Mon Jan 26, 2015 | 2:39pm EST",PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary,http://www.reuters.com//article/gilead-envision-hepatitis-idUSL1N0V51KU20150126?type=companyNews
174,"   By Caroline Humer  UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc.Gilead and AbbVie have been battling for hepatitis C market share since the approval in December for an AbbVie drug that challenges Gilead's blockbusters. Insurers and pharmacy benefit managers have been striking deals for preferred or exclusive status in exchange for discounts for 2015.UnitedHealth's drug coverage list, which is effective Feb. 1, applies to all of the company's commercial, fully insured customers who use its Optum RX pharmacy benefit manager and self-insured customers such as large employers who follow the drug list.The update to the formulary, available on the company's website, also applies to its Medicaid, Medicare and military contracts. ""We are constantly working to deliver value and manage costs for customers and consumers throughout our business,"" UnitedHealth spokesman Tyler Mason said in a statement. Gilead declined to comment. Gilead set off a firestorm last year when it launched a breakthrough treatment for hepatitis C called Sovaldi that carries an $84,000-per-treatment price tag.Insurers, including UnitedHealth, were taken by surprise by its cost and called it out as an unexpected hit to profits last year.  Express Scripts, a pharmacy benefit manager, pushed back against the price of Sovaldi and Gilead's follow-up drug Harvoni, which has a list price of $93,400. It backed AbbVie's Viekira Pak, saying it had gotten a significant discount.Analysts and investors say the treatments are being discounted by at least 30 percent. The companies have declined to comment.UnitedHealth is the last of the top three U.S. insurers to strike a deal with either Gilead or AbbVie. Reuters reported two weeks ago that Aetna Inc had backed Gilead, as have Anthem Inc and Humana Inc. Pharmacy benefit manager CVS Health also went with Gilead while smaller competitor Prime Therapeutics kept both on its list. The state of Missouri earlier this week said it had selected AbbVie's Viekira Pak for Medicaid patients who meet certain criteria, and said the agreement would reduce treatment costs by 30 to 40 percent.UnitedHealth has 45 million medical customers. Of those, 18 million are employed by companies that are self-insured and use UnitedHealth to administer their plan benefits; not all those employers follow UnitedHealth's commercial drug guideline or use UnitedHealth for their drug benefits.Gilead shares, which closed down 2.5 percent at $102.45, were trading slightly higher in after-hours activity at $103.11. (Reporting by Caroline Humer; Additional reporting by Bill Berkrot; Editing by Alan Crosby and Leslie Adler)",2015-01-28,GILD,"Wed Jan 28, 2015 | 5:36pm EST",UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment,http://www.reuters.com//article/us-unitedhealth-gilead-hepatitisc-idUSKBN0L12JP20150128?type=companyNews
175,"  (Adds background on other insurers)By Caroline HumerJan 28 UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc.Gilead and AbbVie have been battling for hepatitis C market share since the approval in December for an AbbVie drug that challenges Gilead's blockbusters. Insurers and pharmacy benefit managers have been striking deals for preferred or exclusive status in exchange for discounts for 2015.UnitedHealth's drug coverage list, which is effective Feb. 1, applies to all of the company's commercial, fully insured customers who use its Optum RX pharmacy benefit manager and self-insured customers such as large employers who follow the drug list.The update to the formulary, available on the company's website, also applies to its Medicaid, Medicare and military contracts. ""We are constantly working to deliver value and manage costs for customers and consumers throughout our business,"" UnitedHealth spokesman Tyler Mason said in a statement.Gilead declined to comment.Gilead set off a firestorm last year when it launched a breakthrough treatment for hepatitis C called Sovaldi that carries an $84,000-per-treatment price tag. Insurers, including UnitedHealth, were taken by surprise by its cost and called it out as an unexpected hit to profits last year.Express Scripts, a pharmacy benefit manager, pushed back against the price of Sovaldi and Gilead's follow-up drug Harvoni, which has a list price of $93,400. It backed AbbVie's Viekira Pak, saying it had gotten a significant discount. Analysts and investors say the treatments are being discounted by at least 30 percent. The companies have declined to comment.UnitedHealth is the last of the top three U.S. insurers to strike a deal with either Gilead or AbbVie. Reuters reported two weeks ago that Aetna Inc had backed Gilead, as have Anthem Inc and Humana Inc. Pharmacy benefit manager CVS Health also went with Gilead while smaller competitor Prime Therapeutics kept both on its list.The state of Missouri earlier this week said it had selected AbbVie's Viekira Pak for Medicaid patients who meet certain criteria, and said the agreement would reduce treatment costs by 30 to 40 percent.UnitedHealth has 45 million medical customers. Of those, 18 million are employed by companies that are self-insured and use UnitedHealth to administer their plan benefits; not all those employers follow UnitedHealth's commercial drug guideline or use UnitedHealth for their drug benefits.Gilead shares, which closed down 2.5 percent at $102.45, were trading slightly higher in after-hours activity at $103.11.   (Reporting by Caroline Humer; Additional reporting by Bill Berkrot; Editing by Alan Crosby and Leslie Adler)",2015-01-28,GILD,"Wed Jan 28, 2015 | 5:31pm EST",UPDATE 2-UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment,http://www.reuters.com//article/unitedhealth-gilead-hepatitisc-idUSL1N0V72OS20150128?type=companyNews
176,"  Jan 28 UnitedHealth Group Inc on Wednesday backed Gilead Sciences Inc's hepatitis C treatment Harvoni on its 2015 commercial drug coverage list over a new competitor, Viekira Pak from AbbVie Inc.The drug coverage list, which is effective Feb. 1, applies to all of the firm's commercial fully insured customers who use its Optum RX pharmacy benefit manager and self-insured customers such as large employers who follow the drug list.The update to the formulary, available on the company's website, applies to its Medicaid, Medicare and military contracts as well. ""We are constantly working to deliver value and manage costs for customers and consumers throughout our business,"" UnitedHealth Group spokesman Tyler Mason said in a statement. Gilead declined to comment. (Reporting by Caroline Humer; Editing by Leslie Adler)",2015-01-28,GILD,"Wed Jan 28, 2015 | 4:16pm EST",UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment,http://www.reuters.com//article/unitedhealth-gilead-hepatitisc-idUSL1N0V72GD20150128?type=companyNews
177,"  (Adds analyst comment)By Bill BerkrotJan 30 AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a ""meaningful share"" of the U.S. market, where it is competing against Gilead Sciences .AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which could grow as more countries begin using Viekira Pak.""We expect it to remain a large and attractive opportunity for many years to come,"" Gonzalez said.AbbVie shares fell 3.6 percent to $60.85 as investors were disappointed by the Viekira forecast.""It was carefully worded in the most optimistic way possible,"" BMO analyst Alex Arfaei said. An exit rate of above $3 billion in 2015, ""indicates that sales in 2015 will be below $3 billion."" With Merck expected to launch its rival treatment in 2016, he said, ""we expect additional price competition in this market.""Some analysts have forecast annual Gilead hepatitis C sales in excess of $15 billion.AbbVie and Gilead have been competing to nail down managed care contracts since Viekira Pak's December U.S. approval after Express Scripts Holding, the largest pharmacy benefit manager (PBM), negotiated a lower price from AbbVie and excluded Gilead's hepatitis treatments from its list of covered drugs. Gilead came under intense criticism for the $84,000 cost of its Sovaldi hepatitis C treatment and more expensive Harvoni combination pill.CVS Health, the second largest PBM, and the largest health insurers have since chosen Gilead's drugs for preferential coverage.AbbVie said more than 40 percent of people who receive insurance coverage from a managed care company, such as CVS or Aetna, will have access to Viekira Pak, including 20 percent with exclusive coverage. More than half of all U.S. managed care lives are now under contract, Gonzalez estimated. He said AbbVie was working on several contracts expected to be finalized within 30 days.""Up to this point we are pleased with our formulary position and we believe we have the potential to capture meaningful share of the U.S. HCV market,"" he added.Analysts have estimated that discounts offered for preferred drug status have exceeded 30 percent off list price. AbbVie declined to disclose details of its contracts.""We priced and rebated consistent with the value of our product and what we thought was appropriate for the market,"" Gonzalez said.He said AbbVie offered the greatest discounts to plans willing to allow Viekira access to patients regardless of  severity of their liver damage.The company said 1,100 Viekira prescriptions were written through Jan. 16. It reported $48 million in Viekira sales in December, largely from inventory stocking.   (Additional reporting by Caroline Humer; Editing by Paul Simao and Phil Berlowitz)",2015-01-30,GILD,"Fri Jan 30, 2015 | 1:24pm EST",UPDATE 2-AbbVie expects hep C drug sales to top $3 billion per year,http://www.reuters.com//article/abbvie-results-hepatitis-idUSL1N0V91BB20150130?type=companyNews
178,"   By Bill Berkrot  AbbVie Inc's (ABBV.N) chief executive said on Friday the company's new hepatitis C treatment Viekira Pak has the potential to capture a ""meaningful share"" of the U.S. market, where it is competing against Gilead Sciences (GILD.O).AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which could grow beyond that as more countries begin using Viekira Pak, which is a combination of several pills.""We expect it to remain a large and attractive opportunity for many years to come,"" Gonzalez said.Some analysts have forecast annual sales of Gilead's hepatitis C franchise in excess of $15 billion.AbbVie and Gilead have been in a fierce battle to nail down managed care contracts since Viekira Pak's December U.S. approval after Express Scripts Holding (ESRX.O), the largest pharmacy benefit manager (PBM), negotiated a lower price from AbbVie and excluded Gilead's hepatitis treatments from its list of covered drugs.Gilead came under intense criticism for the $84,000 cost of its Sovaldi oral hepatitis C drug and more expensive Harvoni combination pill. CVS Health (CVS.N), the second largest PBM, and the largest health insurers have since chosen Gilead's drugs for preferential coverage.AbbVie said more than 40 percent of people who receive insurance coverage from a managed care company, such as CVS or Aetna (AET.N), will have access to Viekira Pak, including 20 percent with exclusive coverage.More than half of all U.S. managed care lives are now under contract, Gonzalez estimated. He said AbbVie was working on several contracts expected to be finalized over the next 30 days. ""Up to this point we are pleased with our formulary position and we believe we have the potential to capture meaningful share of the U.S. HCV market,"" he added.Analysts have estimated that discounts offered for preferred drug status have exceeded 30 percent off list price. AbbVie declined to disclose details of its contracts.""We priced and rebated consistent with the value of our product and what we thought was appropriate for the market,"" Gonzalez said. He said AbbVie offered the greatest discounts to plans willing to allow Viekira Pak access to patients regardless of  severity of their liver damage.The company said 1,100 Viekira prescriptions were written through Jan. 16. It reported $48 million in Viekira sales in December, largely from inventory stocking.""This level of Viekira prescription generation is well within our expectations for this stage of the U.S. launch,"" Gonzalez said.Internationally, Viekira is selling in Germany, Britain, Canada, Austria and Sweden. ""We are on the cusp of beginning promotion in several other countries,"" Gonzalez said.   (Additional reporting by Caroline Humer; Editing by Paul Simao)",2015-01-30,GILD,"Fri Jan 30, 2015 | 12:29pm EST",AbbVie expects more than $3 billion in annual hepatitis C drug sales,http://www.reuters.com//article/us-abbvie-results-hepatitis-idUSKBN0L31O920150130?type=companyNews
179,"  Jan 30 AbbVie Inc's top executive said on Friday that the company's new hepatitis C treatment Viekira Pak has the potential to capture a ""meaningful share"" of the U.S. market, where it is competing against Gilead Sciences Inc .AbbVie Chief Executive Officer Richard Gonzalez told investors that more than 40 percent of managed care covered lives will have access to Viekira Pak and that it was the only drug covered for more than 20 percent of managed care lives. The company, which has been in a market share battle with Gilead, said that 1,100 prescriptions were written through Jan. 16. ""This is well within our expectations at this stage of the launch,"" Gonzalez said. He said that the company expects an annualized sales run rate of more than $3 billion by the end of 2015. It started shipping the drug in late December.   (Reporting by Bill Berkrot, writing by Caroline Humer)",2015-01-30,GILD,"Fri Jan 30, 2015 | 9:36am EST",AbbVie says it will take meaningful share of hepatitis C market,http://www.reuters.com//article/abbvie-results-hepatitis-idUSWEN00EPJ20150130?type=companyNews
180,"   By Deena Beasley  Gilead Sciences Inc (GILD.O) on Tuesday said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price, and the drugmaker's shares slid more than 5 percent.Gilead executives disclosed the discounts on a conference call after the company said strong sales of the drugs, Harvoni and Sovaldi, helped boost net profit more than four-fold in the latest quarter, beating Wall Street forecasts.The executives said the ""gross to net"" adjustment for the company's hepatitis C drug sales will average 46 percent in 2015, up sharply from 22 percent at the end of 2014.Many Wall Street analysts had projected hepatitis C sales based on discounts of 25 percent to 30 percent.Foster City, California-based Gilead also said it would start paying a quarterly dividend and devote $15 billion more to a share buyback plan.In late 2013, Gilead prompted howls of protests about prescription drug prices when it launched Sovaldi at a price of $1,000 a pill. But since AbbVie Inc (ABBV.N) launched a rival hepatitis C treatment late last year, both companies have fought for market share by offering rebates to group payers.  Chief Operating Officer John Milligan said Gilead ""will continue taking steps necessary"" to provide wide access to its hepatitis C drugs, which have been shown to cure nearly all treated patients.Sales of Sovaldi totaled $1.73 billion for the quarter, while sales of follow-on drug Harvoni totaled $2.11 billion. Analysts, on average, had forecast Sovaldi sales of $2.05 billion and Harvoni sales of $1.58 billion, according to Deutsche Bank.Gilead estimated that so far, 141,000 Americans have been started on one of its hepatitis C products, and it expects 250,000 to be treated this year. As many as 3.2 million people in the United States are estimated to be infected with the hepatitis C virus, which can lead to severe liver disease. For full year 2015, Gilead projected total product sales of $26 billion to $27 billion, short of the average Wall Street estimate of $28.6 billion.""The guidance is conservative,"" said RBC Capital Markets analyst Michael Yee. ""They probably don't want to be parading around huge sales for the course of the year as everyone is sensitive to this and everyone is watching them.""Gilead reported quarterly net income of $3.49 billion, or $2.18 per share, up from $791 million, or 47 cents per share, a year earlier. Excluding one-time items, Gilead earned $2.43 per share, outstripping the average Wall Street estimate of $2.22 per share, according to Thomson Reuters I/B/E/S.The company said it would pay a quarterly dividend of 43 cents a share starting in the second quarter this year. Yee said that implies a yield of 1.6 percent. Gilead also announced a new $15 billion share buyback, in addition to $3 billion outstanding in its current buyback plan.The dividend and expanded share buyback ""reflect the confidence we have in our business and our robust balance sheet,"" said Chief Financial Officer Robin Washington. ""This doesn't prevent us in any way from investing in the pipeline, or M&A.""After the trading session's close, Gilead shares tumbled 5.4 percent to $101.44 on Nasdaq. (Reporting By Deena Beasley; Editing by Grant McCool and David Gregorio)",2015-02-03,GILD,"Tue Feb 3, 2015 | 6:45pm EST","Gilead boosts hepatitis C drug discounts, shares slide",http://www.reuters.com//article/us-gilead-sciences-results-idUSKBN0L72HU20150203?type=companyNews
181,"  (Adds analyst comment, company comment, byline, updates share price)By Deena BeasleyFeb 3 Gilead Sciences Inc on Tuesday said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price, and the drugmaker's shares slid more than 5 percent.Gilead executives disclosed the discounts on a conference call after the company said strong sales of the drugs, Harvoni and Sovaldi, helped boost net profit more than four-fold in the latest quarter, beating Wall Street forecasts.The executives said the ""gross to net"" adjustment for the company's hepatitis C drug sales will average 46 percent in 2015, up sharply from 22 percent at the end of 2014.Many Wall Street analysts had projected hepatitis C sales based on discounts of 25 percent to 30 percent.Foster City, California-based Gilead also said it would start paying a quarterly dividend and devote $15 billion more to a share buyback plan. In late 2013, Gilead prompted howls of protests about prescription drug prices when it launched Sovaldi at a price of $1,000 a pill. But since AbbVie Inc launched a rival hepatitis C treatment late last year, both companies have fought for market share by offering rebates to group payers.Chief Operating Officer John Milligan said Gilead ""will continue taking steps necessary"" to provide wide access to its hepatitis C drugs, which have been shown to cure nearly all treated patients.Sales of Sovaldi totaled $1.73 billion for the quarter, while sales of follow-on drug Harvoni totaled $2.11 billion. Analysts, on average, had forecast Sovaldi sales of $2.05 billion and Harvoni sales of $1.58 billion, according to Deutsche Bank. Gilead estimated that so far, 141,000 Americans have been started on one of its hepatitis C products, and it expects 250,000 to be treated this year. As many as 3.2 million people in the United States are estimated to be infected with the hepatitis C virus, which can lead to severe liver disease.For full year 2015, Gilead projected total product sales of $26 billion to $27 billion, short of the average Wall Street estimate of $28.6 billion.""The guidance is conservative,"" said RBC Capital Markets analyst Michael Yee. ""They probably don't want to be parading around huge sales for the course of the year as everyone is sensitive to this and everyone is watching them."" Gilead reported quarterly net income of $3.49 billion, or $2.18 per share, up from $791 million, or 47 cents per share, a year earlier.Excluding one-time items, Gilead earned $2.43 per share, outstripping the average Wall Street estimate of $2.22 per share, according to Thomson Reuters I/B/E/S.The company said it would pay a quarterly dividend of 43 cents a share starting in the second quarter this year. Yee said that implies a yield of 1.6 percent. Gilead also announced a new $15 billion share buyback, in addition to $3 billion outstanding in its current buyback plan.The dividend and expanded share buyback ""reflect the confidence we have in our business and our robust balance sheet,"" said Chief Financial Officer Robin Washington. ""This doesn't prevent us in any way from investing in the pipeline, or M&A.""After the trading session's close, Gilead shares tumbled 5.4 percent to $101.44 on Nasdaq.   (Reporting By Deena Beasley; Editing by Grant McCool and David Gregorio)",2015-02-03,GILD,"Tue Feb 3, 2015 | 6:41pm EST","UPDATE 2-Gilead boosts hepatitis C drug discounts, shares slide",http://www.reuters.com//article/gilead-sciences-results-idUSL1N0VD2V920150203?type=companyNews
182,  Feb 3 Gilead Sciences Inc * Estimates 2015 gross to net hepatitis C drug adjustments at 46 percent versus 22 percent at end 2014  Source text for Eikon:  Further company coverage:    (Reporting By Deena Beasley)  ,2015-02-03,GILD,"Tue Feb 3, 2015 | 6:10pm EST",BRIEF-Gilead Sciences estimates 2015 gross to net hepatitis C drug adjustments at 46 percent versus 22 percent at end 2014,http://www.reuters.com//article/idUSL1N0VD2W020150203?type=companyNews
183,"  Feb 3 Gilead Sciences Inc posted strong quarterly sales of its hepatitis C drugs Harvoni and Sovaldi, sending the drugmaker's net profit up more than four-fold for the quarter.The Foster City, California-based company on Tuesday reported quarterly net income of $3.49 billion, or $2.18 per share, compared with $791 million, or 47 cents per share, a year earlier. Excluding one-time items, Gilead earned $2.43 per share, outstripping the average Wall Street estimate of $2.22 per share, according to Thomson Reuters I/B/E/S. Sales of Sovaldi, the $1,000 pill for hepatitis C which ignited a fierce debate over prescription drug prices, totaled $1.73 billion for the quarter, while sales of follow-on drug Harvoni totaled $2.11 billion. Analysts, on average, had forecast Sovaldi sales of $2.05 billion and Harvoni sales of $1.58 billion, according to Deutsche Bank. For full-year 2015, Gilead projected total product sales of $26 billion and $27 billion, which falls short of the average Wall Street estimate of $28.6 billion.      (Reporting By Deena Beasley; Editing by Grant McCool)",2015-02-03,GILD,"Tue Feb 3, 2015 | 4:28pm EST","Gilead 4th-qtr profit quadruples, $3.84 bln in hep C drug sales",http://www.reuters.com//article/gilead-sciences-results-idUSL1N0VD1Z820150203?type=companyNews
184,"  Pharmacy benefit manager Catamaran Corp said on Tuesday that it will back Gilead Sciences Inc's Harvoni and Sovaldi as exclusive hepatitis C treatments on its drug coverage lists.Gilead has been striking deals with pharmacy benefit managers and insurers since AbbVie Inc late last year launched a competing product called Viekera Pak that produces similar high cure rates for hepatitis C.The agreement puts Catamaran among the majority of payers which have announced deals for preferred or exclusive status fpr the Gilead drug, including Aetna Inc and UnitedHealth Group Inc. Catamaran said its agreement is based on clinical outcomes and delivered through its BriovaRx specialty pharmacy. It said patients would be monitored for full adherence to the drug regimen.The company declined to provide further information about the structure of the agreement, which it said is designed to ensure that the high-cost therapies deliver their promised results. Harvoni, a combination pill that includes Sovaldi, has a list price of $94,500 while Sovaldi alone sells for $84,000 per treatment. AbbVie's treatment, which comes in a blister pack with multiple pills to be taken each day, lists for $83,319. Analysts and investors have estimated that the price war between AbbVie and Gilead has resulted in discounts and rebates of around 30 percent, but both companies have declined to comment on these figures.  (Reporting by Caroline Humer; Editing by Grant McCool)",2015-02-03,GILD,"Tue Feb 3, 2015 | 1:56pm EST",Catamaran backs Gilead's hepatitis C treatment over AbbVie competitor,http://www.reuters.com//article/us-catamaran-gilead-idUSKBN0L727V20150203?type=companyNews
185,"  Feb 3 Pharmacy benefit manager Catamaran Corp  said on Tuesday that it will back Gilead Sciences Inc's  Harvoni and Sovaldi as exclusive hepatitis C treatments on its drug coverage lists.Gilead has been striking deals with pharmacy benefit managers and insurers since AbbVie Inc late last year launched a competing product called Viekera Pak that produces similar high cure rates for hepatitis C.The agreement puts Catamaran among the majority of payers which have announced deals for preferred or exclusive status fpr the Gilead drug, including Aetna Inc and UnitedHealth Group Inc. Catamaran said its agreement is based on clinical outcomes and delivered through its BriovaRx specialty pharmacy. It said patients would be monitored for full adherence to the drug regimen. The company declined to provide further information about the structure of the agreement, which it said is designed to ensure that the high-cost therapies deliver their promised results. Harvoni, a combination pill that includes Sovaldi, has a list price of $94,500 while Sovaldi alone sells for $84,000 per treatment. AbbVie's treatment, which comes in a blister pack with multiple pills to be taken each day, lists for $83,319. Analysts and investors have estimated that the price war between AbbVie and Gilead has resulted in discounts and rebates of around 30 percent, but both companies have declined to comment on these figures.   (Reporting by Caroline Humer; Editing by Grant McCool)",2015-02-03,GILD,"Tue Feb 3, 2015 | 1:52pm EST",Catamaran backs Gilead's hepatitis C treatment over AbbVie competitor,http://www.reuters.com//article/catamaran-gilead-idUSL1N0VD20S20150203?type=companyNews
186,"  Aetna Inc (AET.N), the third largest U.S. health insurer, raised its 2015 profit forecast after negotiating a price cut from Gilead Sciences Inc (GILD.O) on hepatitis C treatments for this year. Aetna said the increased outlook was also due to momentum in its business early in the year after a strong finish to 2014. It boosted its full-year operating earnings forecast to at least $7.00 per share, up from $6.90. Aetna also reported quarterly profit in line with estimates.The stock rose more than 1 percent.Aetna reported an improved medical benefit ratio of 83 percent for the fourth quarter, compared with 83.9 percent a year earlier. The ratio is the amount an insurer spends on medical claims compared with its income from premiums.The company said the costs of medical care have remained moderate and that it expects its medical benefit ratio to be between 82 percent and 83 percent. Its comments on spending were in line with larger competitors UnitedHealth Group Inc (UNH.N) and Anthem Inc (ANTM.N). The company said the medical benefit ratio for commercial plans, its largest business, deteriorated to 82 percent from 81.7 percent, due to higher-than-expected medical costs in small businesses and expenses associated with the new hepatitis C treatments.Last year Aetna was among insurance companies and other payers who said that the $84,000 cost per treatment for Gilead's new hepatitis C drug, which hit the market late in 2013, was unaffordable. When AbbVie Inc (ABBV.N) launched a competing drug at the end of 2014, insurers, pharmacy benefit managers and others started negotiating for discounts from Gilead. Aetna said last month it had secured a lower cost and would back Gilead's Harvoni drug as its preferred treatment over AbbVie's.Aetna's membership rose to 23.5 million at the end of 2014 from 22.2 million a year earlier, helped by growth in new insurance created by the national healthcare reform law, often called Obamacare. Aetna said it added 560,000 members from the Obamacare exchanges at the end of 2014 and expects that to increase to 800,000 by the end of the first quarter, helped by expansion into Georgia.The company reported operating earnings of $1.22 per share for the quarter, largely in line with average analyst estimate, according to Thomson Reuters I/B/E/S. Revenue of $14.77 billion beat the average estimate of $14.60 billion.The company's shares rose $1.01 to $93.23 on the New York Stock Exchange. (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Don Sebastian and Jeffrey Benkoe)",2015-02-03,GILD,"Tue Feb 3, 2015 | 11:59am EST",Health insurer Aetna raises 2015 profit forecast,http://www.reuters.com//article/us-centene-results-idUSKBN0L710U20150203?type=companyNews
187,"  (Adds details from call on outlook)Feb 3 Aetna Inc, the third largest U.S. health insurer, raised its 2015 profit forecast after negotiating a price cut from Gilead Sciences Inc on hepatitis C treatments for this year.Aetna said the increased outlook was also due to momentum in its business early in the year after a strong finish to 2014. It boosted its full-year operating earnings forecast to at least $7.00 per share, up from $6.90. Aetna also reported quarterly profit in line with estimates.The stock rose more than 1 percent.Aetna reported an improved medical benefit ratio of 83 percent for the fourth quarter, compared with 83.9 percent a year earlier. The ratio is the amount an insurer spends on medical claims compared with its income from premiums. The company said the costs of medical care have remained moderate and that it expects its medical benefit ratio to be between 82 percent and 83 percent. Its comments on spending were in line with larger competitors UnitedHealth Group Inc  and Anthem Inc.The company said the medical benefit ratio for commercial plans, its largest business, deteriorated to 82 percent from 81.7 percent, due to higher-than-expected medical costs in small businesses and expenses associated with the new hepatitis C treatments. Last year Aetna was among insurance companies and other payers who said that the $84,000 cost per treatment for Gilead's new hepatitis C drug, which hit the market late in 2013, was unaffordable. When AbbVie Inc launched a competing drug at the end of 2014, insurers, pharmacy benefit managers and others started negotiating for discounts from Gilead. Aetna said last month it had secured a lower cost and would back Gilead's Harvoni drug as its preferred treatment over AbbVie's.Aetna's membership rose to 23.5 million at the end of 2014 from 22.2 million a year earlier, helped by growth in new insurance created by the national healthcare reform law, often called Obamacare. Aetna said it added 560,000 members from the Obamacare exchanges at the end of 2014 and expects that to increase to 800,000 by the end of the first quarter, helped by expansion into Georgia.The company reported operating earnings of $1.22 per share for the quarter, largely in line with average analyst estimate, according to Thomson Reuters I/B/E/S.Revenue of $14.77 billion beat the average estimate of $14.60 billion.The company's shares rose $1.01 to $93.23 on the New York Stock Exchange.   (Reporting by Caroline Humer in New York and Amrutha Penumudi in Bengaluru; Editing by Don Sebastian and Jeffrey Benkoe)",2015-02-03,GILD,"Tue Feb 3, 2015 | 11:57am EST",UPDATE 3-Health insurer Aetna raises 2015 profit forecast,http://www.reuters.com//article/aetna-results-idUSL4N0VD4KT20150203?type=companyNews
188,"  * Crude down sharply after 4-day rally* ADP employment falls short of expectations* Merck down after earnings, Disney climbs* Indexes: Dow up 0.1 pct, S&P off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)By Caroline ValetkevitchNEW YORK, Feb 4 The S&P 500 and Nasdaq eased on Wednesday in the wake of a two-day rally as energy shares followed oil prices lower and Gilead and other biotech names declined.Walt Disney kept the Dow in positive territory.  Disney shares jumped 8 percent to $101.64 after quarterly profit topped analysts' expectations. The S&P 500 energy index was off 1.8 percent as oil prices declined after a four-day surge of nearly 20 percent. U.S. crude was down 8.2 percent following a new build in U.S. crude stockpiles.The day's dip in stocks follows a 2-day gain of 2.8 percent for the S&P 500, driven largely by the jump in energy shares.""It does seem as if the trading world has focused in on the price of crude oil as being the best barometer of what's going on in terms of economic activity,"" said Eric Kuby, chief investment officer of North Star Investment Management Corp in  Chicago.Leading biotechnology shares lower was Gilead Sciences , whose stock dropped 7.7 percent to $98.82, a day after the drugmaker said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers. The news fueled concerns the sector would face increasing price pressure. The Nasdaq Biotech Index was down 1.5 percent. Gilead was also the biggest drag on the S&P 500 and Nasdaq.Also in the healthcare space, Merck shares lost 2.8 percent to $59.32 after the drugmaker reported slightly disappointing fourth quarter sales.At 2:15 p.m., the Dow Jones industrial average rose 22.09 points, or 0.13 percent, to 17,688.49, the S&P 500  lost 6.22 points, or 0.3 percent, to 2,043.81 and the Nasdaq Composite dropped 3.37 points, or 0.07 percent, to 4,724.37. Shares of cable and telecom operators jumped after Federal Communications Commission Chairman Tom Wheeler, in an op-ed on Wired.com, said he aims to establish the ""strongest open Internet protections ever proposed by the FCC"" that would apply to both wireless and wired broadband providers.  Shares of Comcast were up 3.1 percent at $57.10.Helping the shares was the regulator's assertion that he would not regulate rates for network operators even under the new rules, said MoffettNathanson analyst Craig Moffett.Shares of Apple were up 1.1 percent at $119.95 and its market capitalization topped $700 billion.On the economic front, U.S. labor market data disappointed. The ADP National Employment Report showed private employers added 213,000 jobs in January, short of the 225,000 estimate.Declining issues outnumbered advancing ones on the NYSE by 1,967 to 1,083, for a 1.82-to-1 ratio; on the Nasdaq, 1,510 issues fell and 1,185 advanced, for a 1.27-to-1 ratio favoring decliners.The benchmark S&P 500 was posting 34 new 52-week highs and 3 new lows; the Nasdaq Composite was recording 70 new highs and 27 new lows.    (Additonal reporting by Sinead Carew; Editing by Chizu Nomiyama and Nick Zieminski)",2015-02-04,GILD,"Wed Feb 4, 2015 | 2:35pm EST","US STOCKS-S&P, Nasdaq slip after 2-day run up; energy drops with oil",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VE24N20150204?type=companyNews
189,"  * Crude falls after 4-day rally* ADP employment falls short of expectations* Merck down after earnings, Disney climbs* Indexes: Dow up 0.1 pct, S&P off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)By Caroline ValetkevitchNEW YORK, Feb 4 The S&P 500 and Nasdaq eased on Wednesday, in the wake of a two-day rally, as Gilead and other biotech names declined and energy shares reversed course with oil prices.Walt Disney kept the Dow in positive territory.  Disney shares jumped 8.3 percent to $101.86 after quarterly profit topped analysts' expectations. Leading biotechnology shares lower was Gilead Sciences , whose stock dropped 7.5 percent, a day after the drugmaker said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price.The news fueled concerns the sector would face increasing price pressure, The Nasdaq Biotech Index was down 1.4 percent. Gilead was also the biggest drag on the S&P 500 and Nasdaq.Also in the healthcare space, Merck shares lost 4 percent after the drugmaker reported slightly disappointing fourth quarter sales. The S&P 500 energy index was off 1.5 percent as oil prices declined after a four-day surge of nearly 20 percent. U.S. crude was down 5.3 percent at $50.23 following a new build in U.S. crude stockpiles.The day's dip move follows a 2-day gain of 2.8 percent for the S&P 500, driven largely by a jump in energy shares.""It does seem as if the trading world has focused in on the price of crude oil as being the best barometer of what's going on in terms of economic activity,"" said Eric Kuby, chief investment officer, North Star Investment Management Corp., Chicago. At 12:49 p.m., the Dow Jones industrial average rose 9.49 points, or 0.05 percent, to 17,675.89, the S&P 500  lost 7.08 points, or 0.35 percent, to 2,042.95 and the Nasdaq Composite dropped 10.55 points, or 0.22 percent, to 4,717.19.Shares of cable and telecom operators rose sharply after Federal Communications Commission Chairman Tom Wheeler, in an op-ed published on Wired.com, said he aims to establish the ""strongest open Internet protections ever proposed by the FCC"" that would apply, for the first time, to both wireless and wired broadband providers. Shares of Comcast  were up 2.4 percent.On the economic front, U.S. labor market data disappointed. The ADP National Employment Report showed private employers added 213,000 jobs in January, short of the 225,000 estimate.Declining issues outnumbered advancing ones on the NYSE by 1,894 to 1,095, for a 1.73-to-1 ratio; on the Nasdaq, 1,465 issues fell and 1,182 advanced, for a 1.24-to-1 ratio favoring decliners.The S&P 500 was posting 31 new 52-week highs and 2 new lows; the Nasdaq Composite was recording 68 new highs and 23 new lows.     (Additonal reporting by Sinead Carew; Editing by Chizu Nomiyama and Nick Zieminski)",2015-02-04,GILD,"Wed Feb 4, 2015 | 1:05pm EST","US STOCKS-S&P, Nasdaq down after 2-day run up; biotechs, energy fall",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VE1UA20150204?type=companyNews
190,"  Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C drugs, fueling worries that the broader sector would face increasing price pressure.The Nasdaq Biotechnology index fell as much as 3.85 percent, putting it on track for its biggest daily decline since Dec. 23 as biotech companies are seen to be under the most pressure to cut prices for their expensive-to-develop drugs.Gilead weighed most heavily on the biotechnology sector with a 8.9 percent drop in its shares but the biggest losers in the index were Pacific Biosciences of California, which fell 17.6 percent, followed by Achillion Pharmaceuticals Inc, which lost 15.7 percent. Myriad Genetics dropped 11 percent.""Investors are in shock"" about Gilead's disclosure in its 2015 guidance that it expects to have to offer average discounts of 46 percent for the year, Bernstein analyst Geoffrey Porges said in a research note, much deeper than the 25 percent he had expected.More traditional drug companies were also hurt as investors worried they would not be immune to the pressure from insurance companies to cut prices. The Standard & Poor's 500 healthcare sector index fell 1.3 percent and was the second worst S&P sector, weighed down by companies including Merck & Co, which was down 4 percent, and AbbVie Inc, which fell 6.9 percent.   (Reporting by Sinead Carew; Editing by Richard Chang)",2015-02-04,GILD,"Wed Feb 4, 2015 | 11:44am EST",Gilead drags healthcare shares down on drug price worries,http://www.reuters.com//article/us-stocks-healthcare-idUSKBN0L81YM20150204?type=companyNews
191,"  Feb 4 Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc  said it gave health insurers steeper-than-expected discounts on its hepatitis C drugs, fueling worries that the broader sector would face increasing price pressure.The Nasdaq Biotechnology index fell as much as 3.85 percent, putting it on track for its biggest daily decline since Dec. 23 as biotech companies are seen to be under the most pressure to cut prices for their expensive-to-develop drugs.Gilead weighed most heavily on the biotechnology sector with a 8.9 percent drop in its shares but the biggest losers in the index were Pacific Biosciences of California, which fell 17.6 percent, followed by Achillion Pharmaceuticals Inc , which lost 15.7 percent. Myriad Genetics  dropped 11 percent.""Investors are in shock"" about Gilead's disclosure in its 2015 guidance that it expects to have to offer average discounts of 46 percent for the year, Bernstein analyst Geoffrey Porges said in a research note, much deeper than the 25 percent he had expected.More traditional drug companies were also hurt as investors worried they would not be immune to the pressure from insurance companies to cut prices. The Standard & Poor's 500 healthcare sector index fell 1.3 percent and was the second worst S&P sector, weighed down by companies including Merck & Co, which was down 4 percent, and AbbVie Inc, which fell 6.9 percent.  (Reporting by Sinead Carew; Editing by Richard Chang)",2015-02-04,GILD,"Wed Feb 4, 2015 | 11:38am EST",Gilead drags healthcare shares down on drug price worries,http://www.reuters.com//article/stocks-healthcare-idUSL1N0VE1K520150204?type=companyNews
192,"   By Natalie Grover  Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.Achillion's shares rose as much as 19 percent to $12.85 on Monday on investor's hopes that an all-Achillion combination could be as effective as Gilead's and AbbVie Inc's current therapies.The estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent years, with several companies including Gilead, AbbVie and Merck & Co Inc working on faster, more potent ways to cure the liver-destroying virus, which affects more than 170 million globally.The new-generation hepatitis C regimens use a two- to three-drug combination  a nucleotide analog inhibitor or ""nuke"" and a NS5A inhibitor in Gilead's case  to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.Gilead's regimen Harvoni, with its own NS5A inhibitor and Sovaldi as the ""nuke"", needs to be taken for at least eight weeks. Launched in October, its sales touched $2.11 billion in the quarter ended Dec. 31. AbbVie's three-drug cocktail Viekira Pak, which won U.S. approval in December, must be taken for at least 12 weeks.Achillion's ongoing mid-stage study tests its NS5A inhibitor, ACH-3102, with Sovaldi in previously untreated genotype 1 hepatitis C patients over six and eight weeks of therapy. The main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy. Monday's data shows Achillion's NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.The question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair's Katherine Xu said. Achillion, one of the few companies developing hepatitis C therapies independently, plans to begin a mid-stage study this year to evaluate its proprietary doublet.The all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank's Alethia Young estimated. She expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.Harvoni's list price is $93,400 and Viekira Pak is estimated to cost $83,319. (Editing by Ted Kerr and Savio D'Souza)",2015-02-09,GILD,"Mon Feb 9, 2015 | 12:41pm EST",Promising data bodes well for all-Achillion hep C treatment,http://www.reuters.com//article/us-achillion-gilead-idUSKBN0LD16U20150209?type=companyNews
193,"  * Achillion Pharma jumps on hepatitis C drug-trial results* Qualcomm up, nears deal with China on antitrust dispute* Indexes down: Dow 0.44 pct, S&P 0.29 pct, Nasdaq 0.22 pct   (Updates to afternoon trade, commentary)By Sinead CarewNEW YORK, Feb 9 U.S. stocks fell on Monday due to increased tensions over Greek debt negotiations and disappointing Chinese economic data on top of investor uncertainty about interest rates.Rising oil prices helped offset the pressure by boosting the energy sector, while utilities shares declined as investors opted instead for fixed income investments.Greece's Prime Minister Alexis Tsipras had ruled out any extension of its international bailout on Sunday and announced moves to reverse some of the reforms imposed by its lenders. European Commission President Jean-Claude Juncker said on Monday Greeks should not expect the euro zone to accept these latest terms. Investors are waiting for the Greek situation to be resolved and found some reassurance the market did not collapse after the weekend's news, said Ken Polcari, director of the NYSE floor division at O'Neil Securities in New York.""In the end, he's going to be the one to blink,"" he said, referring to Greece's Tsipras. ""If the market was really concerned then you'd see much more to the downside.""National Bank of Greece's U.S.-listed shares fell 5.7 percent to $1.12.China's exports fell 3.3 percent from a year ago while imports tumbled 19.9 percent, far worse than expectations, raising concerns about the world's second-largest economy. U.S. Treasury debt prices rose on Monday as global investors sought shelter in safe-haven sovereign debt.. This hurt utilities stocks, seen as the safest equity sector.""I have a feeling it's an interest-rate sensitive play,"" said Terry Morris, senior vice president and senior equity manager for National Penn Investors Trust Company in Reading, Pennsylvania.Oil prices climbed for a third straight session, lifting the S&P energy sector 0.5 percent after OPEC forecast greater demand for crude this year than previously thought. The Dow Jones industrial average fell 77.55 points, or 0.44 percent, to 17,746.74, the S&P 500 lost 5.97 points, or 0.29 percent, to 2,049.5 and the Nasdaq Composite  dropped 10.63 points, or 0.22 percent, to 4,733.77.Achillion Pharmaceuticals jumped 12.4 percent to $12.16 on news that its experimental hepatitis C drug, used in combination with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus after six weeks of therapy. Gilead shares rose 1 percent to $98.44.Qualcomm shares gained 1.2 percent and helped boost the Nasdaq after a source told Reuters the company is likely to pay China a $1 billion fine, ending a 14-month government investigation into anti-competitive practices.Despite some high-profile misses from multinationals, Thomson Reuters data through Monday morning showed 72.6 percent of the 328 S&P 500 companies in the S&P 500 that reported earnings beat expectations, above the 69 percent beat rate for the past four quarters.Declining issues outnumbered advancing ones on the NYSE by 1,652 to 1,391, for a 1.19-to-1 ratio on the downside; on the Nasdaq, 1,601 issues fell and 1,095 advanced for a 1.46-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 11 new 52-week highs and 3 new lows; the Nasdaq Composite was recording 43 new highs and 21 new lows.   (Additional reporting by Chuck Mikolajczak; Editing by Bernadette Baum, Nick Zieminski and Meredith Mazzilli)",2015-02-09,GILD,"Mon Feb 9, 2015 | 3:04pm EST","US STOCKS-Wall St down on China, Greek worry; energy gains",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VJ1YD20150209?type=companyNews
194,"  * Achillion Pharma jumps on hepatitis C drug-trial results* Qualcomm up, nears deal with China on antitrust dispute* Indexes down: Dow 0.28 pct, S&P 0.12 pct, Nasdaq 0.02 pct   (Updates to afternoon trade, commentary)By Sinead CarewNEW YORK, Feb 9 U.S. stocks pared their losses on Monday as investors took increased tensions over Greek debt negotiations and disappointing Chinese economic data in stride, helped by a rise in oil prices that boosted energy stocks.After Greece's Prime Minister Alexis Tsipras ruled out any extension of its international bailout on Sunday and announced moves to reverse some of the reforms imposed by its lenders European Commission President Jean-Claude Juncker said Greeks should not expect the euro zone to accept the latest terms proposed by Greece.Investors are waiting for the Greek situation to be resolved and found some reassurance the market did not collapse after the weekend's news, said Ken Polcari, director of the NYSE floor division at O'Neil Securities in New York. ""In the end, he's going to be the one to blink,"" he said, referring to Greece's Tsipras. ""If the market was really concerned then you'd see much more to the downside.""China's exports fell 3.3 percent from a year ago while imports tumbled 19.9 percent, well short of expectations, raising concerns about the world's second-largest economy.""China is a negative and Greece is a negative, certainly Greece is something investors have lived with for a while,"" said Rick Meckler, president of LibertyView Capital Management in Jersey City, New Jersey. National Bank of Greece's U.S.-listed shares dropped 7 percent to $1.12.Oil prices climbed for a third straight session, lifting the S&P energy sector 0.6 percent. OPEC forecast greater demand for crude this year than previously thought and projected less supply from countries outside the group.The Dow Jones industrial average fell 49.52 points, or 0.28 percent, to 17,774.77, the S&P 500 lost 2.39 points, or 0.12 percent, to 2,053.08 and the Nasdaq Composite  dropped 1.05 points, or 0.02 percent, to 4,743.35. Achillion Pharmaceuticals jumped 12.4 percent to $12.16. Its experimental hepatitis C drug, used in combination with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus after six weeks of therapy. Gilead shares rose 1 percent to $98.44.Qualcomm shares gained 1.8 percent after a source told Reuters it is likely to pay China a $1 billion fine, ending a 14-month government investigation into anti-competitive practices.Hasbro rose 7.7 percent. The toymaker reported a nearly 31 percent quarterly profit increase and authorized additional share repurchases.Despite some high-profile misses from multinationals, Thomson Reuters data through Monday morning shows 72.6 percent of the 328 companies in the S&P 500 that have reported earnings have topped expectations, above the 69-percent beat rate for the past four quarters.NYSE advancing issues outnumbered decliners 1,530 to 1,482, for a 1.03-to-1 ratio; on the Nasdaq, 1,343 issues fell and 1,309 advanced, a 1.03-to-1 ratio favoring decliners.The S&P 500 was posting 11 new 52-week highs and 2 lows; the Nasdaq Composite was recording 40 new highs and 20 lows.      (Additional reporting by Chuck Mikolajczak, Editing by Bernadette Baum and Nick Zieminski)",2015-02-09,GILD,"Mon Feb 9, 2015 | 1:24pm EST","US STOCKS-Wall St down on China, Greek worry; energy gains",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VJ1OX20150209?type=companyNews
195,"  * Study shows Achillion's inhibitor looks best-in-class: analyst* All-Achillion combination could rival Gilead, AbbVie treatments* Achillion to begin testing its own combination this year* Shares rise as much as 19 pct   (Adds detail, analyst comment; updates shares)By Natalie GroverFeb 9 Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.Achillion's shares rose as much as 19 percent to $12.85 on Monday on investor's hopes that an all-Achillion combination could be as effective as Gilead's and AbbVie Inc's current therapies. The estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent years, with several companies including Gilead, AbbVie and Merck & Co Inc  working on faster, more potent ways to cure the liver-destroying virus, which affects more than 170 million globally.The new-generation hepatitis C regimens use a two- to three-drug combination - a nucleotide analog inhibitor or ""nuke"" and a NS5A inhibitor in Gilead's case - to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.Gilead's regimen Harvoni, with its own NS5A inhibitor and Sovaldi as the ""nuke"", needs to be taken for at least eight weeks. Launched in October, its sales touched $2.11 billion in the quarter ended Dec. 31. AbbVie's three-drug cocktail Viekira Pak, which won U.S. approval in December, must be taken for at least 12 weeks.Achillion's ongoing mid-stage study tests its NS5A inhibitor, ACH-3102, with Sovaldi in previously untreated genotype 1 hepatitis C patients over six and eight weeks of therapy.The main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy. Monday's data shows Achillion's NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.The question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair's Katherine Xu said.Achillion, one of the few companies developing hepatitis C therapies independently, plans to begin a mid-stage study this year to evaluate its proprietary doublet.The all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank's Alethia Young estimated. She expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.Harvoni's list price is $93,400 and Viekira Pak is estimated to cost $83,319.   (Editing by Ted Kerr and Savio D'Souza)",2015-02-09,GILD,"Mon Feb 9, 2015 | 12:39pm EST",UPDATE 2-Promising data bodes well for all-Achillion hep C treatment,http://www.reuters.com//article/achillion-study-idUSL4N0VJ4S520150209?type=companyNews
196,"  * Achillion Pharma jumps on hep C drug-trial results* Qualcomm up, nears deal with China on antitrust dispute* Indexes off: Dow 0.33 pct, S&P 0.18 pct, Nasdaq 0.24 pct   (Updates to late morning trade)By Chuck MikolajczakNEW YORK, Feb 9 U.S. stocks slipped on Monday, on the heels of disappointing Chinese economic data and increased tensions over Greek debt negotiations, though the decline was limited by another gain in oil prices.China's exports fell 3.3 percent from a year ago while imports tumbled 19.9 percent, well short of expectations, raising concerns about the health of the world's second-largest economy.""China is a negative and Greece is a negative, certainly Greece is something investors have lived with for a while and it's not a huge surprise,"" said Rick Meckler, president of investment firm LibertyView Capital Management in Jersey City, New Jersey. Greece's Prime Minister Alexis Tsipras ruled out any extension of its international bailout on Sunday and announced moves to reverse some of the reforms imposed by its lenders.  On Monday, European Commission President Jean-Claude Juncker said Greeks should not expect the euro zone to accept the latest terms proposed by Greece.National Bank of Greece's U.S.-listed shares dropped 9.9 percent to $1.09.Losses were capped as oil prices climbed for a third straight session and lifted the S&P energy sector 0.7 percent. OPEC forecast greater demand for crude this year than previously thought and projected less supply from countries outside the group. ""It's a little bit of a reverse of what we had before, which was consumer-driven stocks did well and the market in general did well but energy did poorly,"" said Meckler.The Dow Jones industrial average fell 59.18 points, or 0.33 percent, to 17,765.11, the S&P 500 lost 3.74 points, or 0.18 percent, to 2,051.73 and the Nasdaq Composite  dropped 11.21 points, or 0.24 percent, to 4,733.19.McDonald's lost 1.5 percent to $92.58. Same-restaurant sales fell a steeper-than-expected 1.8 percent in January. Achillion Pharmaceuticals jumped 10.8 percent to $12. Its experimental hepatitis C drug, when used in combination with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus after six weeks of therapy. Gilead shares edged up 0.1 percent to $97.60.Qualcomm shares gained 2.8 percent to $68.71, the biggest boost to the Nasdaq 100. A source told Reuters the chipmaker is likely to pay China a record fine of around $1 billion, ending a 14-month government investigation into anti-competitive practices.Hasbro rose 6.7 percent to $59.49 after the toymaker reported a nearly 31 percent rise in quarterly profit and authorized additional share repurchases of $500 million.Despite some high-profile earnings misses from large multinationals, Thomson Reuters data through Monday morning shows 72.6 percent of the 328 companies in the S&P 500 that have reported earnings have topped expectations. The beat rate for the past four quarters was 69 percent and fourth-quarter earnings are expected to grow 6.5 percent.Advancing issues outnumbered declining ones on the NYSE by 1,461 to 1,448, for a 1.01-to-1 ratio on the upside; on the Nasdaq, 1,375 issues fell and 1,184 advanced for a 1.16-to-1 ratio favoring decliners.The benchmark S&P 500 index posted 9 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 34 new highs and 16 new lows.     (Editing by Bernadette Baum and Nick Zieminski)",2015-02-09,GILD,"Mon Feb 9, 2015 | 11:29am EST","US STOCKS-Wall St dips on China, Greek worry; energy gains",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VJ1C220150209?type=companyNews
197,"  * Achillion Pharma jumps on hepatitis C drug trial results* Qualcomm near deal with China on antitrust dispute, shares climb* Indexes off: Dow 0.34 pct, S&P 0.2 pct, Nasdaq 0.24 pct   (Updates to market open)By Chuck MikolajczakNEW YORK, Feb 9 U.S. stocks slipped on Monday, on the heels of disappointing Chinese economic data and signs of increased tensions surrounding Greek debt negotiations.China's exports fell 3.3 percent from a year ago while imports tumbled 19.9 percent, well short of expectations, raising concerns about the world's second-largest economy. Greece's Prime Minister Alexis Tsipras on Sunday ruled out any extension of its international bailout and announced moves to reverse some of the reforms imposed by its lenders.  On Monday, European Commission President Jean-Claude Juncker said Greeks should not expect the euro zone to accept the latest terms proposed by Greece.National Bank of Greece U.S.-listed shares dropped 7.4 percent to $1.12.""We are seeing heightened nervousness over the Greek elections and the policies that could make or break its EU membership,"" said Andre Bakhos, managing director at Janlyn Capital LLC in Bernardsville, New Jersey.""In addition, the Chinese economic data disappointed and added to the economic global weakness we have been seeing."" The Dow Jones industrial average fell 60.57 points, or 0.34 percent, to 17,763.72, the S&P 500 lost 4.08 points, or 0.2 percent, to 2,051.39 and the Nasdaq Composite  dropped 11.23 points, or 0.24 percent, to 4,733.17.U.S. stocks fell on Friday as stronger than anticipated monthly payrolls heightened expectations the U.S. Federal Reserve may hike interest rates by mid-year, but the three major indexes managed to notch gains for the week.McDonald's lost 0.9 percent to $93.12. Same-restaurant sales fell a steeper-than-expected 1.8 percent in January. Achillion Pharmaceuticals jumped 15 percent to $12.44. Its experimental hepatitis C drug, when used in combination with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus after six weeks of therapy. Gilead shares edged up 0.1 percent to $97.60.Qualcomm shares gained 3.6 percent to $68.71, the biggest boost to the Nasdaq 100. A source told Reuters the chipmaker is likely to pay China a record fine of around $1 billion, ending a 14-month government investigation into anti-competitive practices.Hasbro rose 4.7 percent to $58.38 after the second-largest U.S. toymaker reported a nearly 31 percent rise in quarterly profit and authorized additional share repurchases of $500 million.Despite some high-profile earnings misses from large multinationals, Thomson Reuters data through Friday show 73 percent of the 322 companies in the S&P 500 that have reported earnings have topped expectations. The beat rate for the past four quarters was 69 percent and fourth-quarter earnings are expected to grow 6.4 percent.Advancing issues outnumbered declining ones on the NYSE by 1,394 to 1,362, for a 1.02-to-1 ratio; on the Nasdaq, 1,251 issues fell and 1,032 advanced, a 1.21-to-1 ratio favoring decliners.The benchmark S&P 500 posted 4 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 19 new highs and 9 new lows.      (Editing by Bernadette Baum and Nick Zieminski)",2015-02-09,GILD,"Mon Feb 9, 2015 | 9:59am EST",US STOCKS-Wall St dips after China data; Greek worry continues,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VJ12320150209?type=companyNews
198,"  * Achillion Pharma jumps on hepatitis C drug trial results* Qualcomm near deal with China on antitrust dispute* Futures off: Dow 105 pts, S&P 12 pts, Nasdaq 24 pts   (Adds quote, updates prices)By Chuck MikolajczakNEW YORK, Feb 9 U.S. stocks were poised for a lower open on Monday, on the heels  of disappointing economic data out of China and signs of rising tensions surrounding Greek debt negotiations.Greece's Prime Minister Alexis Tsipras on Sunday ruled out any extension of its international bailout and announced moves to reverse some of the reforms imposed by its lenders. National Bank of Greece U.S.-listed shares dropped 10.7 percent to $1.08.China's exports fell 3.3 percent from a year ago while imports tumbled 19.9 percent, well short of expectations and raising concerns about the strength of the world's second-largest economy. ""We are seeing heightened nervousness over the Greek elections and the policies that could make or break its EU membership,"" said Andre Bakhos, managing director at Janlyn Capital LLC in Bernardsville, New Jersey.""In addition, the Chinese economic data disappointed and added to the economic global weakness we have been seeing.""U.S. stocks fell on Friday as stronger than anticipated monthly payrolls heightened expectations the U.S. Federal Reserve may hike interest rates by mid-year, but the three major indexes managed to notch gains for the week. S&P 500 e-mini futures were down 12.5 points and fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract, indicated a lower open. Dow Jones industrial average e-mini futures fell 105 points and Nasdaq 100 e-mini futures lost 24 points.McDonald's lost 1.1 percent to $93 in premarket trade after the fast-food restaurant chain's same-restaurant sales fell a steeper-than-expected 1.8 percent in January.Achillion Pharmaceuticals jumped 10.4 percent to $11.94. Its experimental hepatitis C drug, when used in combination with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus after six weeks of therapy. Gilead shares shed 0.4 percent to $97.05 in premarket. Qualcomm shares gained 2.1 percent to $67.72 in premarket trade. A source told Reuters the chipmaker is likely to pay China a record fine of around $1 billion, ending a 14-month government investigation into anti-competitive practices.Hasbro Inc rose 3.2 percent to $57.50 in premarket trade after the second-largest U.S. toymaker reported a nearly 31 percent rise in quarterly profit and authorized additional share repurchases of $500 million.Hotel, energy and financial services conglomerate Loews Corp  reported a 13 percent fall in quarterly profit from continuing operations, mainly due to lower investment income.Despite some high-profile earnings misses from large multinational companies, Thomson Reuters data through Feb. 6 shows that 73 percent of the 322 companies in the S&P 500 that have reported earnings have topped expectations. The beat rate for the past four quarters stands at 69 percent and fourth quarter earnings are expected to grow 6.4 percent.Earnings are expected from 68 S&P 500 components this week, including Cisco Systems and Whole Foods Market.(Editing by Bernadette Baum and Nick Zieminski)",2015-02-09,GILD,"Mon Feb 9, 2015 | 9:00am EST","US STOCKS-Wall St to open lower on China data, Greek worry",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0VJ0S620150209?type=companyNews
199,"   By Bill Berkrot | NEW YORK  NEW YORK Gilead Sciences Inc said on Tuesday it expects the number of hepatitis C patients treated in Europe with its Sovaldi drug to increase dramatically this year, and that approvals for the newer combination pill, Harvoni, could come quickly.The company, which has come under intense criticism in the United States for the high price of its treatments for the liver destroying virus, is negotiating price cuts in Europe in exchange for patient volume promises.Unlike the United States, where it is left to insurers and pharmacy benefit managers to negotiate price cuts for expensive drugs, price controls on medicines have long been a reality in Europe.Gilead President and Chief Operating Officer John Milligan said about 17,000 hepatitis C patients were treated in France last year under a temporary utilization program.""This year they will increase that budget allotment fairly dramatically in return for some price/volume concessions. If they commit to certain volumes, we'll commit to certain price concessions,"" Milligan said at the Bio CEO&Investor conference in New York. Similar arrangements have been made in Spain and in Italy, which has among the highest prevalence of hepatitis C in Europe, he said.""Italy has committed to volumes this year that I believe are about three times the volume they have ever treated,"" Milligan said.Sovaldi must be used with at least one other drug to produce cure rates well in excess of 90 percent.  The company's Harvoni drug, which combines Sovaldi with another Gilead anti-viral medicine into a one pill once a day treatment, won U.S. approval late last year. Gilead is currently in talks on gaining patient access to Harvoni in Europe, which could accelerate 2015 sales that many analysts expect to exceed $12 billion worldwide.""Negotiations for approvals of Harvoni are going very, very fast,"" Milligan said. ""Payers see the value of it and see that  more patients can benefit than ever before. That means we can bring more patients onto Harvoni sooner than we anticipated."" Some investors have expressed concern that short duration treatments will ultimately limit hepatitis C drug sales, compared with Gilead's HIV drugs that patients may have to take for decades.Milligan estimates it will take six years to exhaust the estimated 1.6 million patients already diagnosed in the United States alone.""On top of that, about an equal number need to be diagnosed,"" he said. ""So it plays out over a much longer period of time."" (Reporting by Bill Berkrot. Editing by Andre Grenon)",2015-02-10,GILD,"Tue Feb 10, 2015 | 4:42pm EST",Gilead expects big increase in Europeans treated with hep C drug,http://www.reuters.com//article/us-gilead-hepatitis-europe-idUSKBN0LE2T720150210?type=companyNews
200,"   By Bill Berkrot | NEW YORK  NEW YORK Feb 10 Gilead Sciences Inc  said on Tuesday it expects the number of hepatitis C patients treated in Europe with its Sovaldi drug to increase dramatically this year, and that approvals for the newer combination pill, Harvoni, could come quickly.The company, which has come under intense criticism in the United States for the high price of its treatments for the liver destroying virus, is negotiating price cuts in Europe in exchange for patient volume promises.Unlike the United States, where it is left to insurers and pharmacy benefit managers to negotiate price cuts for expensive drugs, price controls on medicines have long been a reality in Europe.Gilead President and Chief Operating Officer John Milligan said about 17,000 hepatitis C patients were treated in France last year under a temporary utilization program. ""This year they will increase that budget allotment fairly dramatically in return for some price/volume concessions. If they commit to certain volumes, we'll commit to certain price concessions,"" Milligan said at the Bio CEO&Investor conference in New York.Similar arrangements have been made in Spain and in Italy, which has among the highest prevalence of hepatitis C in Europe, he said.""Italy has committed to volumes this year that I believe are about three times the volume they have ever treated,"" Milligan said. Sovaldi must be used with at least one other drug to produce cure rates well in excess of 90 percent.The company's Harvoni drug, which combines Sovaldi with another Gilead anti-viral medicine into a one pill once a day treatment, won U.S. approval late last year. Gilead is currently in talks on gaining patient access to Harvoni in Europe, which could accelerate 2015 sales that many analysts expect to exceed $12 billion worldwide. ""Negotiations for approvals of Harvoni are going very, very fast,"" Milligan said. ""Payers see the value of it and see that  more patients can benefit than ever before. That means we can bring more patients onto Harvoni sooner than we anticipated.""Some investors have expressed concern that short duration treatments will ultimately limit hepatitis C drug sales, compared with Gilead's HIV drugs that patients may have to take for decades.Milligan estimates it will take six years to exhaust the estimated 1.6 million patients already diagnosed in the United States alone.""On top of that, about an equal number need to be diagnosed,"" he said. ""So it plays out over a much longer period of time.""   (Reporting by Bill Berkrot. Editing by Andre Grenon)",2015-02-10,GILD,"Tue Feb 10, 2015 | 4:38pm EST",Gilead expects big increase in Europeans treated with hep C drug,http://www.reuters.com//article/gilead-hepatitis-europe-idUSL1N0VK2JG20150210?type=companyNews
201,"   By Bill Berkrot  Ninety-seven percent of hepatitis C patients also infected with HIV were cured of the liver-destroying virus after 12 weeks of treatment with Bristol-Myers Squibb's daclatasvir and Gilead Sciences' Sovaldi, according to data from a study presented on Thursday.The results could help put Bristol's hepatitis C program back on track in the United States, following a setback last year.In the Ally-2 study, including new patients and those not helped by prior treatment, 149 of 153 were deemed cured of hepatitis C regardless of what other anti-viral regimens they were on for HIV, the virus that causes AIDS.""The results of Ally-2 signaled that nearly all HIV-HCV coinfected patients in the study could be cured of hepatitis C with a 12-week regimen on daclatasvir and sofosbuvir,"" Dr. David Wyles, the study's lead investigator, said in a statement, using the chemical name for Sovaldi.There were no reported serious side effects related to the hepatitis drugs, and patients did not require any alteration of HIV medications over potential drug-drug interactions. ""This is a paramount consideration for clinicians treating this patient population,"" added Wyles, who presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI) meeting in Seattle.About 300,000 Americans with HIV also suffer from hepatitis C, according to the Centers for Disease Control and Prevention, making them prone to more rapid progression to liver damage. Daclatasvir is approved in Europe, Brazil and Japan as part of combination therapy, but has fallen behind rivals in the world's most lucrative market. In November, the U.S. Food and Drug Administration declined to approve daclatasvir in combination with other antiviral drugs.The company had sought FDA permission to market daclatasvir in combination with another Bristol drug, asunaprevir. But Bristol abandoned its U.S. marketing application for asunaprevir due to potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen.The FDA asked for new data on daclatasvir with other drugs, which the Ally results could help satisfy. Sovaldi is part of Gilead's market-leading hepatitis C franchise and half of its own one-pill-per-day combination treatment Harvoni.All 26 patients in the Ally-2 study with the less common genotypes 2, 3 and 4 of the virus were cured by the combination. A shorter eight-week regimen tested among 50 patients led to a 75 percent cure rate. (Reporting by Bill Berkrot; Editing by James Dalgleish)",2015-02-26,GILD,"Thu Feb 26, 2015 | 3:20pm EST",Bristol hep C drug helps cure 97 percent of HIV coinfected patients: study,http://www.reuters.com//article/us-bristolmyers-hepatitis-idUSKBN0LU2E720150226?type=companyNews
202,"   By Bill Berkrot  Feb 26 Ninety-seven percent of hepatitis C patients also infected with HIV were cured of the liver-destroying virus after 12 weeks of treatment with Bristol-Myers Squibb's daclatasvir and Gilead Sciences'  Sovaldi, according to data from a study presented on Thursday.The results could help put Bristol's hepatitis C program back on track in the United States, following a setback last year.In the Ally-2 study, including new patients and those not helped by prior treatment, 149 of 153 were deemed cured of hepatitis C regardless of what other anti-viral regimens they were on for HIV, the virus that causes AIDS.""The results of Ally-2 signaled that nearly all HIV-HCV coinfected patients in the study could be cured of hepatitis C with a 12-week regimen on daclatasvir and sofosbuvir,"" Dr. David Wyles, the study's lead investigator, said in a statement, using the chemical name for Sovaldi. There were no reported serious side effects related to the hepatitis drugs, and patients did not require any alteration of HIV medications over potential drug-drug interactions.""This is a paramount consideration for clinicians treating this patient population,"" added Wyles, who presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI) meeting in Seattle. About 300,000 Americans with HIV also suffer from hepatitis C, according to the Centers for Disease Control and Prevention, making them prone to more rapid progression to liver damage.Daclatasvir is approved in Europe, Brazil and Japan as part of combination therapy, but has fallen behind rivals in the world's most lucrative market. In November, the U.S. Food and Drug Administration declined to approve daclatasvir in combination with other antiviral drugs. The company had sought FDA permission to market daclatasvir in combination with another Bristol drug, asunaprevir. But Bristol abandoned its U.S. marketing application for asunaprevir due to potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen.The FDA asked for new data on daclatasvir with other drugs, which the Ally results could help satisfy.Sovaldi is part of Gilead's market-leading hepatitis C franchise and half of its own one-pill-per-day combination treatment Harvoni.All 26 patients in the Ally-2 study with the less common genotypes 2, 3 and 4 of the virus were cured by the combination. A shorter eight-week regimen tested among 50 patients led to a 75 percent cure rate.   (Reporting by Bill Berkrot; Editing by James Dalgleish)",2015-02-26,GILD,"Thu Feb 26, 2015 | 3:15pm EST",Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study,http://www.reuters.com//article/bristolmyers-hepatitis-idUSL1N0W02MF20150226?type=companyNews
203,"  * Natco says deal covers 91 developing nations* Natco to pay Gilead royalties on sales of drugs   (Adds comments from Delhi Network of Positive People, BDR Pharma MD, stock price)MUMBAI, March 2 India's Natco Pharma Ltd  said on Monday it has agreed a deal with Gilead Sciences Inc to supply generic copies of the U.S. drugmaker's chronic hepatitis C medicines, including $1,000-a-pill drug Sovaldi, in 91 developing nations.Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.Sovaldi, chemically known as sofosbuvir, is a far more effective and better-tolerated treatment than older injection products, and racked up $1.7 billion in sales for Gilead in the fourth quarter alone.But the firm has come under fire over the drug's price tag, its cost presenting a huge barrier in poorer countries. About 150 million people in the world live with chronic hepatitis C infection, most of them in low- and middle-income countries. Drugs under the deal with Natco include sofosbuvir (Sovaldi), a combination of ledipasvir and sofosbuvir - a follow-on drug called Harvoni - and a treatment known as GS-5816, which is in late-stage clinical trials, Natco said in a statement.As with the other deals, Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead.Natco had earlier joined the New York-based Initiative for Medicines, Access & Knowledge (I-MAK), the Delhi Network of Positive People, and privately-held BDR Pharmaceuticals International Ltd in filing opposition to a patent on Sovaldi in India. A Natco spokesman did not immediately respond to a request seeking further details on the deal announced on Monday.In early reactions, some of those who had opposed a patent for Sovaldi said the Natco deal hadn't altered their position. ""We do not think this weakens our case. The drug's prices may be low under the deals, but they can be much lower without a patent, so we will continue to oppose it,"" said Vikas Ahuja, President of the Delhi Network of Positive People.BDR Pharma Managing Director Dharmesh Shah declined to comment on Natco's Gilead deal, but said he was not seeking a similar contract.Natco shares were up 3 percent at 0837 GMT on Monday, while the wider Mumbai market was down 0.2 percent.(Reporting by Zeba Siddiqui; Editing by Subhranshu Sahu and Kenneth Maxwell)",2015-03-02,GILD,"Mon Mar 2, 2015 | 3:47am EST",UPDATE 1-India's Natco Pharma ties up with Gilead on hepatitis C drugs,http://www.reuters.com//article/natco-pharma-gilead-sciences-deals-idUSL4N0W42NA20150302?type=companyNews
204,"  MUMBAI, March 2 India's Natco Pharma Limited  said on Monday it signed a licensing deal with Gilead Sciences Inc to make and sell generic versions of the U.S. drugmaker's chronic hepatitis C medicines.Drugs under the deal include sofosbuvir, a combination of ledipasvir and sofosbuvir, and GS-5816, which is in late-stage clinical trials, Natco said in a statement.  Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.   (Reporting by Zeba Siddiqui in Mumbai; Editing by Subhranshu Sahu) ",2015-03-02,GILD,"Mon Mar 2, 2015 | 1:40am EST",India's Natco Pharma ties up with Gilead on hepatitis C drugs,http://www.reuters.com//article/natco-pharma-gilead-sciences-deals-idUSL4N0W42L120150302?type=companyNews
205,"  U.S. regulators have accepted Bristol-Myers Squibb Co's re-submitted marketing application for an experimental hepatitis C treatment after the drugmaker was forced last year to withdraw its initial request.Bristol-Myers on Thursday said the U.S. Food and Drug Administration will review daclatasvir, its so-called NS5A inhibitor, for use in combination with Gilead Sciences Inc's potent and widely used Sovaldi treatment. It said the FDA is expected to make its decision within six months.Bristol-Myers originally had sought FDA permission to market daclatasvir in combination with another Bristol drug, asunaprevir. But it abandoned that application due to potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen.  Bristol-Myers then went back to the drawing board, collecting data from a separate large trial in which daclatasvir was tested with Sovaldi in patients with a different and less-common strain of hepatitis C, called genotype 3. In that late-stage trial, 90 percent of previously untreated patients had no trace of the virus after 12 weeks of treatment. Daclatasvir is already approved in Europe, Brazil and Japan as part of a combination therapy.  (Reporting by Ransdell Pierson; Editing by Chris Reese and Christian Plumb)",2015-03-12,GILD,"Thu Mar 12, 2015 | 4:44pm EDT",FDA to review re-submitted Bristol-Myers hepatitis C drug,http://www.reuters.com//article/us-bristol-myers-gilead-sciences-idUSKBN0M82HC20150312?type=companyNews
206,"  (Adds details on Bristol-Myers drugs, trial with Sovaldi)March 12 U.S. regulators have accepted Bristol-Myers Squibb Co's re-submitted marketing application for an experimental hepatitis C treatment after the drugmaker was forced last year to withdraw its initial request.Bristol-Myers on Thursday said the U.S. Food and Drug Administration will review daclatasvir, its so-called NS5A inhibitor, for use in combination with Gilead Sciences Inc's  potent and widely used Sovaldi treatment. It said the FDA is expected to make its decision within six months. Bristol-Myers originally had sought FDA permission to market daclatasvir in combination with another Bristol drug, asunaprevir. But it abandoned that application due to potential competition from more potent drugs, leaving the FDA without data to gauge the effectiveness of daclatasvir as part of a combination regimen. Bristol-Myers then went back to the drawing board, collecting data from a separate large trial in which daclatasvir was tested with Sovaldi in patients with a different and less-common strain of hepatitis C, called genotype 3. In that late-stage trial, 90 percent of previously untreated patients had no trace of the virus after 12 weeks of treatment.Daclatasvir is already approved in Europe, Brazil and Japan as part of a combination therapy.   (Reporting by Ransdell Pierson; Editing by Chris Reese and Christian Plumb)",2015-03-12,GILD,"Thu Mar 12, 2015 | 4:34pm EDT",UPDATE 1-FDA to review re-submitted Bristol-Myers hepatitis C drug,http://www.reuters.com//article/bristol-myers-gilead-sciences-idUSL1N0WE2EI20150312?type=companyNews
207,"  (Removes reference to Nasdaq intraday record in paragraph 2)* Dollar dips but oversupply worry weighs on oil* Gilead Pharma shares fall, biotech index down* Indexes: Dow up 0.34 pct, S&P up 0.18 pct, Nasdaq off 0.01 pctBy Chuck MikolajczakNEW YORK, March 23 U.S. stocks were little changed on Monday on the heels of a rally in the prior week, as investors weighed fluctuations in the dollar and its impact on other markets, including crude prices.The Nasdaq was less than 0.5 percent of a closing record set on March 10, 2000. Equity market gains ebbed and flowed, tracking the behavior of energy stocks as crude oil prices were caught between the weakness in the U.S. dollar and concerns about oversupply. The S&P 500 energy sector was up 0.1 percent after earlier gaining as much as 0.9 percent.The action in the dollar has closely affected stocks of late as traders anticipate monetary policy tightening by the Federal Reserve some time later this year. The 20-day correlation between the dollar index and the S&P 500 sits at -0.79. The dollar index was down 0.9 percent on the day.The recent dollar strength ""is probably already at the point where it is going to have a significant impact to earnings,"" said Stephen Massocca, chief investment officer at Wedbush Equity Management LLC in San Francisco. While the dollar's rise has been beneficial for consumers, its rapid strengthening has been a problem for a large portion of the market, such as commodities firms and exporters.""Given what is going on with commodity prices and what is going on with energy prices, if anything the inflation news is getting better, not worse,"" said Massocca.The Dow Jones industrial average rose 62.07 points, or 0.34 percent, to 18,189.72, the S&P 500 gained 3.81 points, or 0.18 percent, to 2,111.91 and the Nasdaq Composite  dropped 0.37 points, or 0.01 percent, to 5,026.05. Brent slipped 0.3 percent, while U.S. crude  added 0.2 percent even after top exporter Saudi Arabia said it would only mull cutting output if producers outside OPEC do so as well.Kansas City Southern shares dropped 7.8 percent to $106.70 as the worst performer on the S&P 500 after the railroad cut its full year revenue forecast.Gilead Sciences shares fell 1.9 percent to $100.33 after a report said nine patients taking its hepatitis C drugs along with a heart treatment developed abnormally slow heartbeats and one died.The Nasdaq Biotech index fell for the first time in nine sessions, down 2.3 percent, after running up nearly 20 percent from its February low.Advancing issues outnumbered declining ones on the NYSE by 1,965 to 1,030, for a 1.91-to-1 ratio; on the Nasdaq, 1,593 issues rose and 1,104 fell for a 1.44-to-1 ratio.The benchmark S&P 500 index was posting 61 new 52-week highs and 1 new lows; the Nasdaq Composite was recording 137 new highs and 30 new lows.     (Editing by Bernadette Baum)",2015-03-23,GILD,"Mon Mar 23, 2015 | 3:04pm EDT",CORRECTED-US STOCKS-Wall St little changed as energy retreats,http://www.reuters.com//article/markets-stocks-usa-idUSL2N0WP1FA20150323?type=companyNews
208,"  Gilead Sciences Inc shares slid 2 percent on Monday after the company warned about potentially fatal risks for patients being treated with its top-selling hepatitis c drugs who also take the potent heart drug amiodarone.Gilead said it sent cautionary emails to healthcare providers on Friday to notify them of nine cases in which patients treated with its Harvoni or Sovaldi, while also taking amiodarone, suffered a slow heart beat condition known as symptomatic bradycardia. One of the patients died.The condition was seen almost immediately in six of the patients. Three of the nine required the placement of a pacemaker and seven had also been taking a beta blocker, which slows heart rates.The labels on the hepatitis C drugs already contain a warning against co-administration with amiodarone and particularly in patients also taking beta blockers. AbbVie's  rival hepatitis C treatment Viekira Pak carries a similar warning.""We believe this disclosure will have little or no effect on demand for Harvoni and Sovaldi,"" Sanford Bernstein analyst Geoffrey Porges said in a research note. ""First, the underlying patient numbers on amiodarone are relatively small. Second, there is no inherent reason that hepatitis C-infected individuals should have much higher rates of treatment with amiodarone, so the exclusion of co-administration is unlikely to materially affect the dynamics of the market,"" he said.Sovaldi had fourth quarter sales of $1.7 billion, while the newer combination treatment Harvoni, which includes Sovaldi, had sales of $2.1 billion for the period. Gilead, in a statement, said ""it remains confident in the safety profiles of Sovaldi and Harvoni"" and will continue to monitor their safety in collaboration with health regulators and the medical community.Amiodarone is an older drug used to keep the heart beating normally in patients with life threatening rhythm disorders, such as ventricular tachycardia or ventricular fibrillation. It has a history of potentially dangerous toxicities. The new hepatitis C drugs represent a major breakthrough as they can cure well over 90 percent of patients who have the liver destroying virus with virtually none of the troubling side effects of older treatments.Gilead shares were down $2.05, or 2 percent, at $100.24 on Nasdaq.   (Reporting by Bill Berkrot; Editing by Tom Brown)",2015-03-23,GILD,"Mon Mar 23, 2015 | 2:32pm EDT",Gilead shares dip after warning about hepatitis C drug interaction,http://www.reuters.com//article/us-gilead-warning-idUSKBN0MJ22E20150323?type=companyNews
209,"  March 23 Gilead Sciences Inc shares slid 2 percent on Monday after the company warned about potentially fatal risks for patients being treated with its top-selling hepatitis c drugs who also take the potent heart drug amiodarone.Gilead said it sent cautionary emails to healthcare providers on Friday to notify them of nine cases in which patients treated with its Harvoni or Sovaldi, while also taking amiodarone, suffered a slow heart beat condition known as symptomatic bradycardia. One of the patients died.The condition was seen almost immediately in six of the patients. Three of the nine required the placement of a pacemaker and seven had also been taking a beta blocker, which slows heart rates.The labels on the hepatitis C drugs already contain a warning against co-administration with amiodarone and particularly in patients also taking beta blockers. AbbVie's   rival hepatitis C treatment Viekira Pak carries a similar warning. ""We believe this disclosure will have little or no effect on demand for Harvoni and Sovaldi,"" Sanford Bernstein analyst Geoffrey Porges said in a research note.""First, the underlying patient numbers on amiodarone are relatively small. Second, there is no inherent reason that hepatitis C-infected individuals should have much higher rates of treatment with amiodarone, so the exclusion of co-administration is unlikely to materially affect the dynamics of the market,"" he said. Sovaldi had fourth quarter sales of $1.7 billion, while the newer combination treatment Harvoni, which includes Sovaldi, had sales of $2.1 billion for the period.Gilead, in a statement, said ""it remains confident in the safety profiles of Sovaldi and Harvoni"" and will continue to monitor their safety in collaboration with health regulators and the medical community. Amiodarone is an older drug used to keep the heart beating normally in patients with life threatening rhythm disorders, such as ventricular tachycardia or ventricular fibrillation. It has a history of potentially dangerous toxicities.The new hepatitis C drugs represent a major breakthrough as they can cure well over 90 percent of patients who have the liver destroying virus with virtually none of the troubling side effects of older treatments.Gilead shares were down $2.05, or 2 percent, at $100.24 on Nasdaq.     (Reporting by Bill Berkrot; Editing by Tom Brown)",2015-03-23,GILD,"Mon Mar 23, 2015 | 2:31pm EDT",Gilead shares dip after warning about hepatitis C drug interaction,http://www.reuters.com//article/gilead-warning-idUSL2N0WP1EK20150323?type=companyNews
210,     ,2015-03-23,GILD,"Mon Mar 23, 2015 | 10:20am EDT","US STOCKS-Stocks up as dollar adds to losses, oil gains",http://www.reuters.com//article/markets-stocks-usa-idUSL2N0WP0SK20150323?type=companyNews
211,"   By Ben Hirschler | LONDON  LONDON Gilead Sciences is seeking to convince governments and multilateral agencies worldwide that hepatitis C can be eliminated with a demonstration project in Georgia offering free drugs to all those who need them.The unprecedented program will make the Caucasian country a testbed for uprooting the liver-destroying disease, using Gilead's highly effective but costly pill Sovaldi, plus its newer product Harvoni once approved.Georgia has the world's third highest prevalence of hepatitis C, after Egypt and Mongolia, with nearly 7 percent of adults carrying the virus. It also has a wide range of viral variations and different types of patients.What is more, the country is a manageable size, with a population of around 5 million, and has viral screening systems, making it ideal for scientific study, according to Gregg Alton, the U.S. drugmaker's head of corporate and medical affairs. ""It is a nice country for us to evaluate,"" he said in a telephone interview on Wednesday from the European Association for the Study of the Liver annual meeting in Vienna.The scheme, which has the backing of the U.S. Centers for Disease Control and Prevention, will cover an initial 5,000 patients in 2015, with a second phase treating up to 20,000 a year.Gilead's hepatitis C drugs, and rival products from the likes of AbbVie, can cure hepatitis C but are out of reach at Western prices to patients in poor countries, with a single Sovaldi pill costing $1,000 in the United States. While Gilead has slashed the price for several low-income countries to $300 per bottle of 28 pills, it also wants to involve international donors in a broad eradication drive.""We will take the Georgia data to other countries around the world to really make the case that investment can fundamentally change the disease over time,"" Alton said. Alton admits the scheme may prompt other governments to ask for free drugs as well, but he said it was unrealistic to simply give away product globally. Instead, he wants to see international funding along the lines of the Global Fund to Fight AIDS, Tuberculosis and Malaria.""Gilead cannot cure hepatitis C globally on our backs alone. There have to be other players that come in and make that investment,"" he said. (Editing by William Hardy)",2015-04-22,GILD,"Wed Apr 22, 2015 | 11:58am EDT",Gilead uses Georgia as free-drug testbed for hepatitis C elimination,http://www.reuters.com//article/us-health-hepatitis-gilead-georgia-idUSKBN0ND1XU20150422?type=companyNews
212,"   By Saqib Iqbal Ahmed and Sinead Carew | NEW YORK, April 24  NEW YORK, April 24 Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector.Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co, Boston Scientific Corp , Merck & Co, Pfizer Inc, Gilead Sciences Inc and Celgene Corp.So far, companies that have reported in this sector have seen positive moves in share prices, and many investors say they think healthcare stocks have room to run.But options traders are not taking chances. Options on a key healthcare exchange-traded fund (ETF) are set near their most defensive posture ever.So far this year, the S&P healthcare sector index  has risen 8.7 percent, leading all other S&P sector indexes. Since 2008, it has increased 179 percent while the broader S&P 500 is up 135 percent. On Thursday, healthcare's strong performance helped push the S&P 500 to an intraday record and the Nasdaq composite index to its all-time closing high.Investors have been drawn to healthcare stocks by a spate of mergers and expectations for more buyouts on top of major drug launches and strong demand from an aging population. ""It's kind of tough to punch holes into the healthcare bull story,"" said Sven Borho, founding general partner at health specialist fund OrbiMed Advisors LLC, in New York.""What worries me is the long stretch of outperformance relative to the rest of the market,"" he said. Even so, ""it's not that healthcare valuations broadly have gone off the roof.""The sector is trading at 18.8 times earnings estimates for the year ahead compared to S&P's P/E ratio of 17.5. Traders in the options market, however, are preparing for possible downside. Activity in puts, which can be used to hedge against a drop in shares, has picked up noticeably in April for the Health Care Select Sector SPDR ETF.The average daily puts volume has risen to 16,000, from 9,000 for the first three months of 2015. For every call option, usually used for bullish bets, there are 4.6 put options open, the highest ratio since early 2007, right after their launch, according to options analytics firm Trade Alert.""It's really just a function of investors looking to protect their gains,"" said Max Breier, senior equity derivatives trader at BMO Capital Markets. ""In a market cap-weighted ETF like the XLV, if you get a number of the top-weighted names kind of disappointing at once you can get a pretty violent reaction,"" Breier said. Companies reporting next week include Bristol-Meyers Squibb Co, Boston Scientific Corp, Merck & Co, Pfizer Inc, Gilead Sciences Inc and Celgene Corp.Medical device maker Boston Scientific is the second-best S&P healthcare performer with a 39-percent share price gain so far this year. The most accurate analysts say it could meet earnings per share estimates for 20.4 cents per share or miss by a thread, according to StarMine.Gilead could beat analysts' $2.30 EPS estimate by over 22 cents while Bristol-Meyers and Celgene could beat their EPS estimates by about a penny, according to StarMine.Shares are more likely to react to comments about drug studies or pricing than to results, Borho said.Wall Street analysts expect the S&P healthcare sector to report a 10.2 percent first-quarter earnings increase, compared with 7.2 percent expected on April 1 and 12.4 percent in October, Reuters data showed.Other big events investors will watch next week include  first-quarter GDP numbers and the Federal Reserve's statement after its two-day policy meeting on Wednesday. Apple Inc  reports earnings on Monday afternoon in a week when oil companies are expected to report grim results.    (Editing by Nick Zieminski)",2015-04-24,GILD,"Fri Apr 24, 2015 | 2:59pm EDT",Wall St Week Ahead-Investors seek protection against healthcare stock decline,http://www.reuters.com//article/markets-stocks-usa-weekahead-idUSL1N0XL1CL20150424?type=companyNews
213,"   By Deena Beasley | LOS ANGELES  LOS ANGELES Gilead Sciences Inc on Thursday said its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs, as it topped Wall Street estimates.Gilead signaled that, with its hepatitis C franchise established, it is a good time for the company to consider business development opportunities. ""We want to stick very closely to therapeutic areas we are in today,"" Gilead Chief Operating Officer John Milligan said on a conference call.Excluding items, Gilead earned $2.94 per share in the first quarter, beating the average Wall Street estimate of $2.32, according to Thomson Reuters I/B/E/S. The company's shares, which fell 1.8 percent in regular trading, rose 2 percent to $102.52 after hours.Product sales rose 52 percent to $7.41 billion, including $4.55 billion for hepatitis C drugs Sovaldi and Harvoni. Analysts had expected hepatitis C sales of $3.54 billion, according to Deutsche Bank.""It was an extremely strong quarter,"" said RBC Capital Markets analyst Michael Yee, noting that the sales guidance ""signals confidence in the year."" Gilead said it now expects full-year product sales of $28 billion to $29 billion, up from a previous estimate of $26 billion to $27 billion.In late 2013, Gilead prompted howls of protest about prescription drug prices when it launched Sovaldi at $1,000 a pill, and later Harvoni at an even higher price. But since AbbVie Inc launched a rival treatment late last year, both have fought for market share by offering rebates to group payers.Gilead said earlier this year that its ""gross-to-net"" adjustment for hepatitis C sales would average 46 percent in 2015. The company declined to revisit that estimate on Thursday. Gilead said more than 70,000 U.S. patients and 20,000 European patients were started on its hepatitis C drugs in the first quarter. Because the drugs cure nearly all patients, the market opportunity is limited.Around 3.3 million Americans are believed to be infected with the liver-destroying hepatitis C virus, but only about half of them are aware that they are infected. Gilead posted net income of $4.3 billion, or $2.76 per share, up from $2.2 billion, or $1.33 per share, a year earlier.     Cash on hand at the end of the quarter totaled $14.5 billion.""They could pretty much buy anything,"" said Sanford Bernstein analyst Geoffrey Porges. ""The big question is whether they are going to swing the big bat that they have at their disposal.""      (Reporting by Deena Beasley; Editing by Cynthia Osterman and Frances Kerry)",2015-04-30,GILD,"Thu Apr 30, 2015 | 7:05pm EDT",Gilead first-quarter profit doubles on strong hepatitis C drug sales,http://www.reuters.com//article/us-gilead-sciences-results-idUSKBN0NL2KS20150430?type=companyNews
214,"  (Adds analyst comment, company comment)By Deena BeasleyLOS ANGELES, April 30 Gilead Sciences Inc  on Thursday said its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs, as it topped Wall Street estimates.Gilead signaled that, with its hepatitis C franchise established, it is a good time for the company to consider business development opportunities. ""We want to stick very closely to therapeutic areas we are in today,"" Gilead Chief Operating Officer John Milligan said on a conference call.Excluding items, Gilead earned $2.94 per share in the first quarter, beating the average Wall Street estimate of $2.32, according to Thomson Reuters I/B/E/S. The company's shares, which fell 1.8 percent in regular trading, rose 2 percent to $102.52 after hours.Product sales rose 52 percent to $7.41 billion, including $4.55 billion for hepatitis C drugs Sovaldi and Harvoni. Analysts had expected hepatitis C sales of $3.54 billion, according to Deutsche Bank. ""It was an extremely strong quarter,"" said RBC Capital Markets analyst Michael Yee, noting that the sales guidance ""signals confidence in the year.""Gilead said it now expects full-year product sales of $28 billion to $29 billion, up from a previous estimate of $26 billion to $27 billion.In late 2013, Gilead prompted howls of protest about prescription drug prices when it launched Sovaldi at $1,000 a pill, and later Harvoni at an even higher price. But since AbbVie Inc launched a rival treatment late last year, both have fought for market share by offering rebates to group payers. Gilead said earlier this year that its ""gross-to-net"" adjustment for hepatitis C sales would average 46 percent in 2015. The company declined to revisit that estimate on Thursday.Gilead said more than 70,000 U.S. patients and 20,000 European patients were started on its hepatitis C drugs in the first quarter. Because the drugs cure nearly all patients, the market opportunity is limited. Around 3.3 million Americans are believed to be infected with the liver-destroying hepatitis C virus, but only about half of them are aware that they are infected.Gilead posted net income of $4.3 billion, or $2.76 per share, up from $2.2 billion, or $1.33 per share, a year earlier.Cash on hand at the end of the quarter totaled $14.5 billion.""They could pretty much buy anything,"" said Sanford Bernstein analyst Geoffrey Porges. ""The big question is whether they are going to swing the big bat that they have at their disposal.""(Reporting by Deena Beasley; Editing by Cynthia Osterman and Frances Kerry)",2015-04-30,GILD,"Thu Apr 30, 2015 | 7:04pm EDT",UPDATE 2-Gilead first-quarter profit doubles on strong hepatitis C drug sales,http://www.reuters.com//article/gilead-sciences-results-idUSL1N0XR3DD20150430?type=companyNews
215,"  * Apple and Celgene weigh* Jobless claims lowest since 2000* Indexes gain slightly in April* Indexes down: Dow 1.1 pct, S&P 1 pct, Nasdaq 1.6 pct   (Updates close with LinkedIn, solar company shares down after the bell, Gilead up, small caps down, new quote)By Caroline ValetkevitchApril 30 U.S. stocks, led by the Nasdaq, sold off on Thursday as Apple shares declined, and tech and biotech quarterly results disappointed.Upbeat economic reports added to uncertainty about the outlook for interest rates, a day after data showed the U.S. economy had slowed to a crawl in the first quarter and the Federal Reserve pointed to weakness in the labor market and other areas of the U.S. economy.Despite the day's decline, all three major indexes posted slight gains for April. The Nasdaq biotech index dropped 3.1 percent on Thursday, led by a 4.5 percent fall in Celgene, which reported lower-than-expected quarterly revenue.The decline marked a fifth day of losses for the biotech index, which was down 8.1 percent for the week so far.The Nasdaq fell for a fourth straight day, and was off 3 percent from Friday's record closing high. The S&P tech index  slid 1.6 percent, the day's worst-performing sector, while small-cap stocks also underperformed. The Russell 2000 small-cap index was down 2.2 percent. Apple, down 2.7 percent at $125.15, was the biggest drag on the three major indexes. The company limited the availability of the Apple Watch after a key component was found to be defective, according to the Wall Street Journal.""Biotechs and tech were leaders and now they've reversed,"" said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.""Earnings don't really support the valuations at this time, and I think the market needs to correct a bit. As we go into May I would say the best prescription would be to sell in May and go away.""The Dow Jones industrial average fell 195.01 points, or 1.08 percent, to 17,840.52, the S&P 500 lost 21.34 points, or 1.01 percent, to 2,085.51 and the Nasdaq Composite  dropped 82.22 points, or 1.64 percent, to 4,941.42. For the month, the Dow was up 0.4 percent, the S&P 500 gained 0.9 percent and the Nasdaq rose 0.8 percent.The day's data included a report showing the number of Americans filing new claims for unemployment benefits tumbled to a 15-year low last week.After the bell, LinkedIn shares fell 24 percent to $191.70 and Gilead shares gained 3.2 percent to $103.69 following the release of results. First Solar and SunPower both declined after hours following results.During the regular session, Baidu declined 8.5 percent to $200.28 after China's dominant Internet search engine provider reported its slowest quarterly revenue growth rate in almost seven years.S&P 500 earnings for the first quarter now are expected to have risen 1.1 percent, Thomson Reuters data showed, while revenue was expected to be down 3.2 percent.Declining issues outnumbered advancing ones on the NYSE by 2,355 to 693; on the Nasdaq, 2,131 issues fell and 647 advanced. About 8.5 billion shares changed hands on U.S. exchanges, compared with the 6.3 billion daily average for the month to date, according to BATS Global Markets.   (Editing by Savio D'Souza, Meredith Mazzilli and Steve Orlofsky)",2015-04-30,GILD,"Thu Apr 30, 2015 | 5:57pm EDT",US STOCKS-Wall St drops with tech shares; LinkedIn falls late,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XR3W020150430?type=companyNews
216,"  April 30 Gilead Sciences Inc said on Thursday its quarterly net profit nearly doubled, driven by sales of its novel hepatitis C drugs, as it topped Wall Street estimates.Gilead posted first-quarter net income of $4.3 billion, or $2.76 per share, up from $2.2 billion, or $1.33 per share, a year earlier. Product sales for the quarter rose 52 percent to $7.41 billion, including $4.55 billion for hepatitis C drugs Sovaldi and Harvoni. Wall Street analysts, on average, had expected hepatitis C product sales of $3.54 billion, according to Deutsche Bank. Excluding one-time items, Gilead earned $2.94 per share in the quarter, beating the average Wall Street estimate of $2.32, according to Thomson Reuters I/B/E/S. The company also raised its outlook for full-year 2015 product sales to a range of $28 billion to $29 billion from a previous estimate of $26 billion to $27 billion.   (Reporting by Deena Beasley)",2015-04-30,GILD,"Thu Apr 30, 2015 | 4:21pm EDT",Gilead 1st-qtr profit doubles on strong hepatitis C drug sales,http://www.reuters.com//article/gilead-sciences-results-idUSL1N0XQ26120150430?type=companyNews
217,"   By Caroline Valetkevitch  U.S. stocks bounced back sharply on Friday as investors snapped up beaten-down shares in the healthcare and technology sectors, and as data gave further signs of a pickup in the economy.Apple (AAPL.O) provided the biggest boost to the major indexes, jumping 3 percent to $128.95 in its biggest daily percentage gain since January. The stock lost 2.7 percent on Thursday. The Nasdaq snapped a four-day losing streak while the S&P tech sector .SPLRCT gained 1.5 percent, among the day's best-performing sectors.Biotech shares also rebounded, ending a five-day losing streak. The Nasdaq Biotech Index .NBI was up 2.9 percent for the day, but lost 5.5 percent for the week, its worst such decline since March 2014.Shares of Gilead (GILD.O) rose 4.5 percent to $105.01, helping to lift both the Nasdaq and S&P 500, after its quarterly profit nearly doubled. The S&P healthcare index .SPXHC was up 1.3 percent.Investors were also buoyed by an encouraging batch of data for April that suggested the U.S. economy was pulling out of a first-quarter soft patch.""Yesterday people were thinking the market was going to fall off of a cliff, and today we're seeing a lot of institutional buying coming in,"" said Adam Sarhan, chief executive of Sarhan Capital in New York. ""So, the buy-the-dippers show up and defend the market. That leads me to believe there's more upside."" Indexes posted losses for the week, however, with social media shares among the weakest performers following disappointing outlooks and results this week from several key players including Twitter (TWTR.N).The Dow Jones industrial average .DJI rose 183.54 points, or 1.03 percent, to 18,024.06, the S&P 500 .SPX gained 22.78 points, or 1.09 percent, to 2,108.29 and the Nasdaq Composite .IXIC added 63.97 points, or 1.29 percent, to 5,005.39.LinkedIn LNKD.N, Twitter and Yelp (YELP.N) all notched their biggest weekly percentage declines since their debuts. LinkedIn, which reported results late Thursday, dropped 18.6 percent to $205.21.For the week, the Dow was down 0.3 percent, the S&P 500 was down 0.5 percent and the Nasdaq was down 1.7 percent. Consumer sentiment jumped and vehicle sales for GM (GM.N) and Ford (F.N) were stronger-than-expected in April, while manufacturing expansion in the month held steady at near a two-year low.Railcar makers gained after tougher oil-train safety standards, including rules to phase out older tank cars in three years, were announced. Greenbrier (GBX.N) gained 8 percent to $62.33, while Trinity Industries (TRN.N) rose 6.9 percent to $28.96. American Railcar (ARII.O) was up 5.9 percent at $56.18.Advancing issues outnumbered declining ones on the NYSE by 1,850 to 1,201, for a 1.54-to-1 ratio on the upside; on the Nasdaq, 1,664 issues rose and 1,118 fell for a 1.49-to-1 ratio favoring advancers. The benchmark S&P 500 index posted 10 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 69 new lows.  About 6.3 billion shares changed hands on U.S. exchanges, compared with the 7.2 billion daily average for the last five sessions, according to data from BATS Global Markets. (Corrects paragraph 13 to say vehicle sales for Ford and GM stronger than expected.) (Additional reporting by Tanya Agrwal; Editing by Savio D'Souza and Meredith Mazzilli)",2015-05-01,GILD,"Fri May 1, 2015 | 6:47pm EDT",Wall St. ends up sharply as investors buy beaten-down shares,http://www.reuters.com//article/us-markets-stocks-idUSKBN0NM3OT20150501?type=companyNews
218,"  (Corrects paragraph 13 to say vehicle sales for Ford and GM stronger than expected)* Gilead leads as biotechs end 5-day losing streak* Railcar makers gain on new tough oil-train safety rules* Social media stocks underperformers for week* Indexes up: Dow 1 pct, S&P 1.1 pct, Nasdaq 1.3 pctBy Caroline ValetkevitchMay 1 U.S. stocks bounced back sharply on Friday as investors snapped up beaten-down shares in the healthcare and technology sectors, and as data gave further signs of a pickup in the economy.Apple provided the biggest boost to the major indexes, jumping 3 percent to $128.95 in its biggest daily percentage gain since January. The stock lost 2.7 percent on Thursday.The Nasdaq snapped a four-day losing streak while the S&P tech sector gained 1.5 percent, among the day's best-performing sectors. Biotech shares also rebounded, ending a five-day losing streak. The Nasdaq Biotech Index was up 2.9 percent for the day, but lost 5.5 percent for the week, its worst such decline since March 2014.Shares of Gilead rose 4.5 percent to $105.01, helping to lift both the Nasdaq and S&P 500, after its quarterly profit nearly doubled. The S&P healthcare index  was up 1.3 percent.Investors were also buoyed by an encouraging batch of data for April that suggested the U.S. economy was pulling out of a first-quarter soft patch.""Yesterday people were thinking the market was going to fall off of a cliff, and today we're seeing a lot of institutional buying coming in,"" said Adam Sarhan, chief executive of Sarhan Capital in New York. ""So, the buy-the-dippers show up and defend the market. That leads me to believe there's more upside.""Indexes posted losses for the week, however, with social media shares among the weakest performers following disappointing outlooks and results this week from several key players including Twitter.The Dow Jones industrial average rose 183.54 points, or 1.03 percent, to 18,024.06, the S&P 500 gained 22.78 points, or 1.09 percent, to 2,108.29 and the Nasdaq Composite  added 63.97 points, or 1.29 percent, to 5,005.39.LinkedIn, Twitter and Yelp all notched their biggest weekly percentage declines since their debuts. LinkedIn, which reported results late Thursday, dropped 18.6 percent to $205.21. For the week, the Dow was down 0.3 percent, the S&P 500 was down 0.5 percent and the Nasdaq was down 1.7 percent.Consumer sentiment jumped and vehicle sales for GM and Ford were stronger-than-expected in April, while manufacturing expansion in the month held steady at near a two-year low.Railcar makers gained after tougher oil-train safety standards, including rules to phase out older tank cars in three years, were announced.Greenbrier gained 8 percent to $62.33, while Trinity Industries rose 6.9 percent to $28.96. American Railcar  was up 5.9 percent at $56.18.Advancing issues outnumbered declining ones on the NYSE by 1,850 to 1,201, for a 1.54-to-1 ratio on the upside; on the Nasdaq, 1,664 issues rose and 1,118 fell for a 1.49-to-1 ratio favoring advancers.The benchmark S&P 500 index posted 10 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 69 new lows.About 6.3 billion shares changed hands on U.S. exchanges, compared with the 7.2 billion daily average for the last five sessions, according to data from BATS Global Markets.(Additional reporting by Tanya Agrwal; Editing by Savio D'Souza and Meredith Mazzilli)",2015-05-01,GILD,"Fri May 1, 2015 | 6:03pm EDT",CORRECTED-US STOCKS-Wall St ends up sharply as investors buy beaten-down shares,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XS1YC20150501?type=companyNews
219,"  * Gilead leads as biotechs end 5-day losing streak* Railcar makers gain on new tough oil-train safety rules* Social media stocks fall with LinkedIn* Consumer sentiment, auto sales rise* Indexes up: Dow 0.95 pct, S&P 0.98 pct, Nasdaq 1.15 pct   (Updates to late afternoon)By Caroline ValetkevitchMay 1 U.S. stocks bounced back sharply on Friday as investors snapped up some of this week's most beaten-down shares, including in the healthcare and technology sectors, and as data pointed to a pickup in economic activity. Apple gave the three major indexes their biggest boost, with a 2.3 percent increase to $128.01, reversing Thursday's decline. The S&P tech sector was up 1.2 percent, while the Nasdaq was on track to snap a four-day losing streak.Biotech shares also rebounded and were set to snap a five-day losing streak. The Nasdaq Biotech Index was up 2.7 percent.Shares of Gilead rose 5.2 percent to $105.78 after its quarterly profit nearly doubled. The S&P healthcare index was up 1.3 percent and among the day's best-performing sectors.""Today's the first day of a new month, and we're seeing a lot of institutional buying coming in,"" said Adam Sarhan, chief executive of Sarhan Capital in New York. ""The buy-the-dippers have come in"" to bid up stocks, which is a sign of a healthy market. Indexes were still on track to post losses for the week, however. Social media shares were among the weakest performers following disappointing outlooks and results this week from several key players including Twitter.LinkedIn dropped 19 percent to $204.07, a day after reporting results.Investors were also buoyed by an encouraging batch of data for April that suggested the economy was pulling out of a first-quarter soft patch. At 3:20 p.m. the Dow Jones industrial average rose 169.69 points, or 0.95 percent, to 18,010.21, the S&P 500  gained 20.5 points, or 0.98 percent, to 2,106.01 and the Nasdaq Composite added 56.78 points, or 1.15 percent, to 4,998.20.Consumer sentiment jumped and vehicle sales were stronger-than-expected in April, while manufacturing expansion in the month held steady at near a two-year low.Railcar makers gained after tougher oil-train safety standards, including rules to phase out older tank cars in three years, were announced.Greenbrier gained 5.6 percent to $60.97, while Trinity Industries rose 6.3 percent to $28.82. American Railcar was up 5.3 percent at $55.90.Advancing issues outnumbered declining ones on the NYSE by 1,826 to 1,197, for a 1.53-to-1 ratio on the upside; on the Nasdaq, 1,589 issues rose and 1,175 fell for a 1.35-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 10 new 52-week highs and no new lows; the Nasdaq Composite was recording 33 new highs and 64 new lows.     (Additional reporting by Tanya Agrwal; Editing by Savio D'Souza and Meredith Mazzilli)",2015-05-01,GILD,"Fri May 1, 2015 | 3:41pm EDT",US STOCKS-Wall St rebounds as investors buy beaten-down shares,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XS1MT20150501?type=companyNews
220,"  * Gilead leads as biotechs ends 5-day losing streak* Railcar makers gain on new tough oil-train safety rules* Social media stocks fall with LinkedIn* Consumer sentiment, auto sales rise* Indexes up: Dow 0.7 pct, S&P 0.7 pct, Nasdaq 0.8 pct   (Updates to afternoon)By Tanya AgrawalMay 1 Wall Street was higher in afternoon trading on Friday, with the Nasdaq poised to close higher for the first time this week, as healthcare and technology stocks rebounded, and as data pointed to a pick up in economic activity.A majority of the 10 major S&P indexes were higher, with both the health and tech indexes moving up after two days of losses. The Nasdaq biotech index was up 2.6 percent, ending a 5-day losing streak. Apple gave the biggest boost to the Nasdaq and the S&P 500 with a 1.2 percent increase to $126.66. Gilead  rose 5.4 percent to $105.94 after its quarterly profit nearly doubled.Investors were also buoyed by an encouraging batch of data for April that suggested the economy was pulling out of a first-quarter soft patch.Consumer sentiment jumped and vehicle sales were stronger-than-expected in April, while manufacturing expansion in the month held steady at near a two-year low.""We anticipate a little bit of a pick up in the second and third quarter,"" said Paul Nolte, portfolio manager at Kingsview Asset Management in Chicago. ""Its not going to be enough to warrant the Fed to raise rates but its certainly not weak enough to push us into recession.""At 13:39 p.m. EDT (1739 GMT) the Dow Jones industrial average was up 128.08 points, or 0.72 percent, at 17,968.6, the S&P 500 was up 15.29 points, or 0.73 percent, at 2,100.8 and the Nasdaq Composite was up 37.52 points, or 0.76 percent, at 4,978.94.If the gains hold, all three indexes are on track for their best day since April 20. Still, the three are headed to close lower for the week.Social media stock were lower as LinkedIn's results capped a weak quarter for the sector. LinkedIn slumped 20.8 percent to $199.66, Twitter fell 3.8 percent to $37.48 and Facebook was off 0.7 percent at $78.23. Railcar makers gained after tougher oil-train safety standards, including rules to phase out older tank cars in three years, were announced.Greenbrier gained 5.6 percent to $60.97, while Trinity Industries rose 6.3 percent to $28.82. American Railcar was up 5.3 percent at $55.90.Yum Brands jumped 6 percent to hit a record high of $91.14 after Daniel Loeb's Third Point revealed a stake in the company.EnerNOC soared 18.7 percent to $13.12 after the maker of software to regulate power said it partnered with Tesla  in its new battery pack venture.Expedia gained 7.9 percent to $101.75 after posting strong results.Advancing issues outnumbered declining ones on the NYSE by 1,707 to 1,272, for a 1.34-to-1 ratio on the upside; on the Nasdaq, 1,436 issues rose and 1,276 fell for a 1.13-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 10 new 52-week highs and no new lows; the Nasdaq Composite was recording 26 new highs and 57 new lows.   (Editing by Savio D'Souza)",2015-05-01,GILD,"Fri May 1, 2015 | 1:51pm EDT",US STOCKS-Nasdaq snaps four-day losing streak as health stocks rebound,http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XS3WR20150501?type=companyNews
221,"  * Gilead leads as biotechs ends 5-day losing streak* Tech stock snap two-day losing streak* Yum hits record after Loeb reveals stake* Construction spending, manufacturing growth weak* Indexes up: Dow 0.7 pct, S&P 0.6 pct, Nasdaq 0.8 pct   (Updates to open)By Tanya AgrawalMay 1 Wall Street rose at the open on Friday as healthcare and technology stocks, led by Gilead and Apple, rebounded after two weak sessions, and despite data that came in lower-than-expected.A majority of the 10 major S&P indexes were higher, with the health and tech both snapping a 2-day losing streak. Apple shares rose 1.5 percent to $126.94 and was the biggest driver on the Dow, Nasdaq and S&P 500. The Nasdaq biotech index was up 2.6 percent, snapping a 5-day losing streak and on track for its best day since April 8.Gilead led the gains with a 3 percent increase to $103.53 after its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs. The stock was the second-largest boost on the S&P 500 and the Nasdaq.""Its a new month and big institutional investors that allocate on a monthly basis are still moving money into the market,"" said Adam Sarhan, chief executive of Sarhan Capital in New York.The jump in the equity markets comes despite data showing that construction spending fell in March to a six-month low, while manufacturing growth held at its slowest in almost two years in April. At 10:35 a.m. EDT (1435 GMT) the Dow Jones industrial average was up 122.42 points, or 0.69 percent, at 17,962.94, the S&P 500 was up 13 points, or 0.62 percent, at 2,098.51 and the Nasdaq Composite was up 38.01 points, or 0.77 percent, at 4,979.44.Yum Brands jumped 5.5 percent to hit a record high of $90.70 after Daniel Loeb's Third Point revealed a stake in the company and said the KFC-owner had ""turned the page"" on its China troubles and forecast a dramatic profit recovery.CVS climbed 1.6 percent to $100.85 after it reported a better-than-expected quarterly profit. LinkedIn shares slumped 19.5 percent to $202.93, a day after the professional social network operator slashed its full-year profit forecast.EnerNOC soared 22.2 percent to $13.50 after the maker of software to regulate power said it partnered with Tesla  in its new battery pack venture.Expedia gained 6.1 percent to $99.95 after its quarterly profit beat analysts' expectations.S&P 500 earnings for the first quarter now are expected to have risen 1.1 percent, Thomson Reuters data showed, while revenue is expected to have fallen 3.2 percent.Automakers are expected to report that sales moderated in April after rising the previous month. The data is due at 13:30 p.m. (1730 GMT)Advancing issues outnumbered declining ones on the NYSE by 1,786 to 1,015, for a 1.76-to-1 ratio on the upside; on the Nasdaq, 1,549 issues rose and 933 fell for a 1.66-to-1 ratio favoring advancers.The benchmark S&P 500 index was posting 10 new 52-week highs and no new lows; the Nasdaq Composite was recording 20 new highs and 30 new lows.   (Editing by Savio D'Souza)",2015-05-01,GILD,"Fri May 1, 2015 | 10:44am EDT","US STOCKS-Wall St opens higher as tech, health stocks rebound",http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XS3MH20150501?type=companyNews
222,"   By Amrutha Penumudi  Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company's shares down as much as 60 percent to a record low.GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for hepatitis B treatments as hepatitis C drugs flood the market.Hepatitis B is being seen as the next big opportunity in the liver disease market as it is the most common liver infection, affecting about 400 million people worldwide.However, hepatitis B infection is much more difficult to treat than hepatitis C.GlobeImmune, which had a market value of $47 million as of Tuesday's close, is developing three other drugs for infectious diseases and five for different types of cancers. In the trial, the company's hepatitis B drug, GS-4774, was tested in 178 patients who were already on oral antiviral treatment. Gilead's liver drugs portfolio includes its blockbuster hepatitis C drug Sovaldi and Harvoni and the company has another hepatitis B candidate, GS-9620, in its pipeline. With GS-4774 failing the study, Gilead would have to look at other drug developers to find the right hepatitis B drug for its portfolio, analysts said. Other companies developing hepatitis B drugs include Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals Corp, Isis Pharmaceuticals Inc and Assembly Biosciences Inc. ""(Gilead)... is probably watching two leading albeit early players in Hep B: Tekmira and Assembly Biosciences,"" RBC Capital Markets analysts wrote in a note. GlobeImmune's shares were down 51.7 percent at $3.98 in noon trading on the Nasdaq on Wednesday. The stock, which was the top percentage loser on the exchange, hit a record low of $3.33 earlier in the session.     (Editing by Kirti Pandey)",2015-05-27,GILD,"Wed May 27, 2015 | 12:08pm EDT","GlobeImmune Hep B drug fails mid-stage study, shares plunge",http://www.reuters.com//article/us-globeimmune-study-hepatitis-idUSKBN0OC1D720150527?type=companyNews
223,"  * Company developing drug with Gilead Sciences* Hepatitis B affects 400 mln people worldwide* Shares fall as much as 60 pct to record low   (Adds background, analyst comment; updates shares)By Amrutha PenumudiMay 27 Drug developer GlobeImmune Inc  said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company's shares down as much as 60 percent to a record low.GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for hepatitis B treatments as hepatitis C drugs flood the market. Hepatitis B is being seen as the next big opportunity in the liver disease market as it is the most common liver infection, affecting about 400 million people worldwide.However, hepatitis B infection is much more difficult to treat than hepatitis C.GlobeImmune, which had a market value of $47 million as of Tuesday's close, is developing three other drugs for infectious diseases and five for different types of cancers. In the trial, the company's hepatitis B drug, GS-4774, was tested in 178 patients who were already on oral antiviral treatment.Gilead's liver drugs portfolio includes its blockbuster hepatitis C drug Sovaldi and Harvoni and the company has another hepatitis B candidate, GS-9620, in its pipeline. With GS-4774 failing the study, Gilead would have to look at other drug developers to find the right hepatitis B drug for its portfolio, analysts said.Other companies developing hepatitis B drugs include Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals Corp , Isis Pharmaceuticals Inc  and Assembly Biosciences Inc.""(Gilead)... is probably watching two leading albeit early players in Hep B: Tekmira and Assembly Biosciences,"" RBC Capital Markets analysts wrote in a note.GlobeImmune's shares were down 51.7 percent at $3.98 in noon trading on the Nasdaq on Wednesday.The stock, which was the top percentage loser on the exchange, hit a record low of $3.33 earlier in the session.       (Editing by Kirti Pandey)",2015-05-27,GILD,"Wed May 27, 2015 | 12:06pm EDT","UPDATE 2-GlobeImmune Hep B drug fails mid-stage study, shares plunge",http://www.reuters.com//article/globeimmune-study-hepatitis-idUSL3N0YI3W120150527?type=companyNews
224,"  May 27 GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial.However, the drug was found to reduce HBsAg, an antigen that indicates the strength of hepatitis B infection, after 48 weeks, the company said on Wednesday.  GlobeImmune is developing the drug, GS-4774, with Gilead Sciences Inc.    (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey) ",2015-05-27,GILD,"Wed May 27, 2015 | 6:50am EDT","GlobeImmune, Gilead Hep B drug fails in mid-stage study",http://www.reuters.com//article/globeimmune-study-hepatitis-idUSL3N0YI3U820150527?type=companyNews
225,"   By Brendan Pierson  A federal judge has dismissed a whistleblower lawsuit accusing drugmaker Gilead Sciences Inc of distributing HIV/AIDS drugs for about three years after switching manufacturers without government approval. U.S. District Judge Edward Chen in San Francisco said on Friday that while Gilead was required to get approval from the Food and Drug Administration to switch manufacturers, failing to do so did not give rise to a whistleblower claim.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1MXwbaE",2015-06-15,GILD,"Mon Jun 15, 2015 | 6:02pm EDT",Gilead gets whistleblower case over AIDS drug tossed,http://www.reuters.com//article/health-gilead-idUSL1N0Z12EW20150615?type=companyNews
226,"   By Brendan Pierson and Adam Jourdan | NEW YORK/SHANGHAI  NEW YORK/SHANGHAI China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment.Gilead has drawn fire for the cost of its top-selling drug Sovaldi, priced at $1,000 per pill in the United States or $84,000 for a typical 12-week course and its patents have been challenged in the U.S., India and Europe.The application China has rejected was for a so-called prodrug, the inactive form of the drug which then converts into the chemically active compound once in the body, the New York-based Initiative for Medicines, Access & Knowledge (I-MAK) said.Gilead, however, holds the China patent to the base compound in the drug, also known by its generic name sofosbuvir and  China's rejection of the prodrug patent does not open the way for copycat drugs to be made in the world's No. 2 drug market.China-based officials for Gilead were not immediately available for comment. Emails and calls to Gilead's U.S. offices outside office hours went unanswered. Officials at China's State Intellectual Property Office did not confirm the decision when contacted by Reuters, but a notice posted on the body's website said Gilead's application for ""nucleoside phosphramidates"", a kind of prodrug, had recently been rejected.China's move follows a decision by India's patent office in January to reject Gilead's patent application for Sovaldi, finding it was not inventive enough. Gilead is appealing the ruling. Under pressure to cut prices, the California-based firm agreed last year to make the drug available for lower prices in 91 developing countries.I-MAK has brought legal challenges against Gilead's patents or patent applications in five countries not covered by the agreement: China, Argentina, Brazil, Russia and Ukraine.Charities in Europe have also challenged Gilead's patent over its prices. The World Health Organization says as many as 150 million people worldwide live with chronic hepatitis C infection, most of them in low and middle-income countries. It recently added Sovaldi to its essential medicines list and urged lower prices, especially in middle income countries. (Editing by David Gregorio and Edwina Gibbs)",2015-06-19,GILD,"Fri Jun 19, 2015 | 4:26am EDT",China rejects patent linked to Gilead hepatitis C drug,http://www.reuters.com//article/us-gilead-sciences-sovaldi-patents-idUSKBN0OZ0A620150619?type=companyNews
227,"   By Brendan Pierson | June 19  June 19 China has rejected Gilead Sciences Inc's application for a new patent related to its costly hepatitis C drug Sovaldi, removing a potential barrier to generic versions of the drug there, a U.S. legal group announced on Friday.The New York-based group, Initiative for Medicines, Access & Knowledge, or I-MAK, challenged Gilead's patent application this year as part of its campaign to make generic Sovaldi available in several countries. The group said on Friday it had received notice of the patent application rejection from officials in the China State Intellectual Property Office.I-MAK said it challenged the Gilead patent applications in China and other countries so hepatitis C patients could get cheaper generic versions of the drug. Tahir Amin, I-MAK's director of intellectual property, said the latest decision makes it more likely that advocates may challenge another Gilead drug patent in China that currently prevents the introduction of generic treatments for hepatitis C.The application China has rejected was on a so-called prodrug, a chemical used to activate Sovaldi's active chemical once it is in the body, according to I-MAK. Gilead still has a patent in China on sofosbuvir, the main ingredient of Sovaldi, a highly effective treatment for hepatitis C which costs $1,000 per pill in the United States. That adds up to $84,000 for a typical 12-week course.California-based Gilead agreed last year to make the drug available for lower prices in 91 developing countries, although I-MAK has said that more than 59 million low-income hepatitis C patients worldwide are still without access to the drug. In May I-MAK said it had brought legal challenges against Gilead's patents or patent applications in five countries not covered by the agreement: China, Argentina, Brazil, Russia and Ukraine.Amin said he believed the decision by China's patent office to reject the prodrug patent application would encourage challenges to the sofosbuvir patent as well. If that patent were invalidated, he said, it would open the door for Chinese companies to sell generic Sovaldi, as well as to supply raw materials for the drug to manufacturers in other countries.In January, India's patent office refused to grant Gilead a patent on Sovaldi, finding it was not inventive enough. Gilead is appealing the ruling.Last month, the United Nations' World Health Organization added Sovaldi to its essential medicines list and urged lower prices, especially in middle income countries.   (Editing by Ted Botha and David Gregorio)",2015-06-19,GILD,"Fri Jun 19, 2015 | 12:00am EDT",China rejects Gilead hepatitis C drug patent -advocacy group,http://www.reuters.com//article/gilead-sciences-sovaldi-patents-idUSL1N0Z42MT20150619?type=companyNews
228,"   By Deena Beasley  Gilead Sciences Inc (GILD.O) said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers.Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street analysts, according to Thomson Reuters I/B/E/S.Gilead raised its outlook for full-year 2015 product sales by $1 billion to between $29 billion and $30 billion. The company's shares, which rose 2.3 percent to close at $113.07 in regular Nasdaq trading, were up another 3 percent at $116.36 after hours.Gilead faced a backlash from health insurers and other payers when it launched in late 2013 hepatitis C drug Sovaldi at a price of $84,000 for a course of treatment, followed last year by next-generation drug Harvoni at a slightly higher price. The regimens cure most patients of the liver-destroying infection.The company acknowledged earlier this year that it had negotiated price discounts for the two drugs averaging 46 percent with a range of payers in return for multiyear contracts. ""As the market starts to become a bit more predictable in terms of numbers of patients, payers will be more encouraged to open the gates slightly,"" Paul Carter, head of commercial operations at Gilead, said on a conference call, referring to treatment guidelines put in place by payers looking to control their costs. He said Gilead expects 250,000 to 300,000 U.S. hepatitis C patients a year to undergo treatment in coming years, with the main variable being payer restrictions.In Europe, Carter said there has been an early spike in hepatitis C sales volumes as the most ill patients seek treatment. Sanford Bernstein analyst Geoffrey Porges called Gilead's quarterly results ""spectacular,"" adding that the higher 2015 sales forecast ""suggests that there's substantial EPS upside versus current consensus.""    Product sales rose 27 percent to $8.1 billion, including $4.9 billion for hepatitis C drugs Sovaldi and Harvoni. Analysts had expected hepatitis C drug sales of $4.27 billion, according to Deutsche Bank. Gilead, based in Foster City, California, also raised the lower end of its full-year profit margin forecast to 88 percent from 87 percent, while leaving the top end unchanged at 90 percent. It also lowered the range for its 2015 tax rate to between 17 percent and 18 percent from a previous 18 percent to 20 percent.""The company raised revenue and lowered expense guidance. You can't ask for better than that,"" said RBC Capital Markets analyst Michael Yee. Also on the conference call, Gilead Chief Operating Officer John Milligan reiterated that the company, which had cash holdings of $14.7 billion at the end of June, remains open to deal-making in the form of small transactions, or large ""perhaps transformative deals."" (Reporting by Deena Beasley in Los Angeles; Additional reporting by Bill Berkrot in New York; Editing by Tom Brown and Lisa Shumaker)",2015-07-28,GILD,"Tue Jul 28, 2015 | 6:42pm EDT","Gilead hepatitis C sales beat Wall Street, sales outlook raised",http://www.reuters.com//article/us-gilead-results-idUSKCN0Q22EJ20150728?type=companyNews
229,"  * Q2 Hepatitis C drug sales total $4.9 billion* Product sales rise 27 percent to $8.1 billion   (Adds company comment, updates share price)By Deena BeasleyJuly 28 Gilead Sciences Inc said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers.Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street analysts, according to Thomson Reuters I/B/E/S.Gilead raised its outlook for full-year 2015 product sales by $1 billion to between $29 billion and $30 billion. The company's shares, which rose 2.3 percent to close at $113.07 in regular Nasdaq trading, were up another 3 percent at $116.36 after hours. Gilead faced a backlash from health insurers and other payers when it launched in late 2013 hepatitis C drug Sovaldi at a price of $84,000 for a course of treatment, followed last year by next-generation drug Harvoni at a slightly higher price. The regimens cure most patients of the liver-destroying infection.The company acknowledged earlier this year that it had negotiated price discounts for the two drugs averaging 46 percent with a range of payers in return for multiyear contracts.""As the market starts to become a bit more predictable in terms of numbers of patients, payers will be more encouraged to open the gates slightly,"" Paul Carter, head of commercial operations at Gilead, said on a conference call, referring to treatment guidelines put in place by payers looking to control their costs. He said Gilead expects 250,000 to 300,000 U.S. hepatitis C patients a year to undergo treatment in coming years, with the main variable being payer restrictions.In Europe, Carter said there has been an early spike in hepatitis C sales volumes as the most ill patients seek treatment. Sanford Bernstein analyst Geoffrey Porges called Gilead's quarterly results ""spectacular,"" adding that the higher 2015 sales forecast ""suggests that there's substantial EPS upside versus current consensus.""Product sales rose 27 percent to $8.1 billion, including $4.9 billion for hepatitis C drugs Sovaldi and Harvoni. Analysts had expected hepatitis C drug sales of $4.27 billion, according to Deutsche Bank.Gilead, based in Foster City, California, also raised the lower end of its full-year profit margin forecast to 88 percent from 87 percent, while leaving the top end unchanged at 90 percent. It also lowered the range for its 2015 tax rate to between 17 percent and 18 percent from a previous 18 percent to 20 percent.""The company raised revenue and lowered expense guidance. You can't ask for better than that,"" said RBC Capital Markets analyst Michael Yee.Also on the conference call, Gilead Chief Operating Officer John Milligan reiterated that the company, which had cash holdings of $14.7 billion at the end of June, remains open to deal-making in the form of small transactions, or large ""perhaps transformative deals.""   (Reporting by Deena Beasley in Los Angeles; Additional reporting by Bill Berkrot in New York; Editing by Tom Brown and Lisa Shumaker)",2015-07-28,GILD,"Tue Jul 28, 2015 | 6:41pm EDT","UPDATE 2-Gilead hepatitis C sales beat Wall Street, sales outlook raised",http://www.reuters.com//article/gilead-results-idUSL1N1082SI20150728?type=companyNews
230,"  * Some say December rate hike now more likely* Focus on corporate results eclipses China worry* Twitter and Gilead up after the bell; Yelp drops* Indexes close up: Dow 1.09 pct, S&P 1.24 pct, Nasdaq 0.98 pct   (Updates to close)By Noel RandewichJuly 28 U.S. stocks ended sharply higher on Tuesday, breaking a five-day losing streak as attention shifted from trouble in Chinese equities to U.S. corporate earnings and to speculation the first Federal Reserve interest rate hike may not come until December.The Dow Jones industrial average and S&P 500 chalked up gains of more than 1 percent, while the Nasdaq Composite lagged slightly.After the S&P sank over the past week toward the low end of a range it has traded in since February, some investors wagered the market was primed for a technical bounce-back. ""The S&P has had five down days in a row and a lot of people are starting to nibble,"" said Michael Matousek, head trader at U.S. Global Investors Inc in San Antonio, which manages about $1 billion.Market sentiment also reflected expectations the Fed would wait until December, rather than September, to raise interest rates for the first time since 2006, Matousek added.With a two-day Fed policy meeting ending on Wednesday, investors are looking for hints about the timing of that rate increase. No move on rates is expected this week.""September is possible but the probability for a December rate hike is increasing,"" said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management in Minneapolis. The Dow Jones industrial average rose 1.09 percent, to end the session at 17,630.27. The S&P 500 gained 1.24 percent to 2,093.25 and the Nasdaq Composite added 0.98 percent to finish at 5,089.21.All the 10 major S&P 500 sectors rose, with the energy index leaping 2.99 percent as oil prices recovered from near six-month lows.U.S. consumer confidence weakened in July to its lowest level since September, due in part to a less optimistic outlook on the labor market.Ongoing uncertainty related to China's stock market, which closed lower again on Tuesday, took a backseat to U.S. corporate earnings. With second-quarter reports well under way, analysts now expect overall earnings of S&P 500 companies to edge up 0.3 percent and revenue to decline 4.0 percent, according to Thomson Reuters data.""Earnings are growing but very slowly. The market's biggest concern is the lack of top-line growth and where that growth is going to come from,"" said Tim Courtney, chief investment officer of Exencial Wealth Advisors, which oversees $1.3 billion.After the bell, Twitter jumped 5.2 percent and Gilead Sciences rose 3 percent after both companies posted their second-quarter results. Yelp slumped 13 percent after its report.During Tuesday's session, SuperValu jumped 10.60 percent. It said it was exploring a spinoff of its discount grocery chain Save-A-Lot into a publicly-traded company.Advancing issues outnumbered declining ones on the NYSE by 2.7 to 1. On the Nasdaq, 1.67 stocks gained for each that declined.The S&P 500 racked up 15 new 52-week highs and 12 lows. The Nasdaq Composite posted 36 new highs and 163 lows.Some 7.3 billion shares changed hands on U.S. exchanges, above the daily average of 6.7 billion so far this month.   (Additional reporting by Tanya Agrawal; Editing by Don Sebastian and Nick Zieminski)",2015-07-28,GILD,"Tue Jul 28, 2015 | 4:33pm EDT",US STOCKS-Wall Street ends sharply higher as China jitters ebb,http://www.reuters.com//article/markets-stocks-usa-idUSL1N10828Q20150728?type=companyNews
231,"  July 28 Gilead Sciences Inc said on Tuesday its quarterly net  profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates.Looking ahead, Gilead raised its outlook for full-year 2015  product sales by $1 billion to between $29 billion and $30 billion. The company's shares, which rose 2.3 percent to close at $113.07 on Nasdaq, were up another 2.3 percent at $115.82 after hours. Excluding items, Gilead earned $3.15 a share in the second quarter, exceeding the $2.71 average forecast by Wall Street analysts, according to Thomson Reuters I/B/E/S. Net income for the quarter rose to $4.5 billion, or $2.92 per share, from $3.65 billion, or $2.20 per share, a year earlier.  Product sales rose 27 percent to $8.1 billion, including $4.9 billion for hepatitis C drugs Sovaldi and Harvoni. Analysts had expected hepatitis C drug sales of $4.27 billion, according to Deutsche Bank.   (Reporting By Deena Beasley; Editing by Peter Galloway)",2015-07-28,GILD,"Tue Jul 28, 2015 | 4:23pm EDT","Gilead 2nd-quarter profit increases 32 pct, 2015 outlook raised",http://www.reuters.com//article/gilead-results-idUSL1N1081PP20150728?type=companyNews
232,"  * Two-day Fed meeting begins* June consumer confidence falls to lowest level since Sept* Twitter, Gilead to report results after the bell* Indexes up: Dow 1.06 pct, S&P 1.21 pct, Nasdaq 0.99 pct   (Updates to afternoon trade)By Noel RandewichJuly 28 U.S. stocks surged on Tuesday and were on track to break a five-day losing streak as attention shifted from trouble in Chinese equities to U.S. corporate earnings and speculation the first Federal Reserve interest rate hike may not come until December.The Dow Jones industrial average, S&P 500 and Nasdaq Composite all logged intraday gains of 1 percent or more.With the S&P falling over the past week toward the low end of a range it has traded in since February, some investors were betting the market was primed for a technical bounce back. ""The S&P has had five down days in a row and a lot of people are starting to nibble,"" said Michael Matousek, head trader at U.S. Global Investors Inc in San Antonio, which manages about $1 billion.Market sentiment reflected expectations the Fed would wait until December, rather than September, to raise interest rates for the first time since 2006, Matousek said.Investors were looking for any signals from Fed Chair Janet Yellen on the timing of a rate increase when a two-day policy meeting concludes on Wednesday. No move on rates is expected this week.""September is possible but the probability for a December rate hike is increasing,"" said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management in Minneapolis. At 2:37 p.m., the Dow Jones industrial average was up 1.06 percent at 17,624.79. The S&P 500 gained 1.21 percent to 2,092.62 and the Nasdaq Composite added 0.99 percent to 5,089.57. It previously traded as high as 5,098.All the 10 major S&P 500 sectors were higher, with the energy index up 3.1 percent as oil prices recovered from near six-month lows.U.S. consumer confidence weakened in July to its lowest level since September, due in part to a less optimistic outlook on the labor market. Ongoing uncertainty related to China's stock market, which closed lower again on Tuesday, took a backseat to U.S. corporate earnings.With second-quarter reports well under way, analysts now expect overall earnings of S&P 500 companies to edge up 0.3 percent and revenue to decline 4.0 percent, according to Thomson Reuters data.Big names scheduled to report on Tuesday include Twitter , Gilead and Yelp after the close.Pfizer rose 2.66 percent after the drugmaker's quarterly profit beat expectations as vaccine sales rose.SuperValu jumped 13.99 percent. The company said it was exploring a spinoff of its discount grocery chain Save-A-Lot into a publicly traded company.Advancing issues outnumbered declining ones on the NYSE by 2.75 to 1. On the Nasdaq, 1.85 stocks gained for every one that declined.The S&P 500 was posting 13 new 52-week highs and 12 new lows; the Nasdaq was recording 33 new highs and 154 new lows.     (Additional reporting by Tanya Agrawal; Editing by Don Sebastian and Nick Zieminski)",2015-07-28,GILD,"Tue Jul 28, 2015 | 3:17pm EDT",US STOCKS-Wall Street rises after China market steadies,http://www.reuters.com//article/markets-stocks-usa-idUSL1N10824720150728?type=companyNews
233,"   By Ransdell Pierson  Gilead Sciences Inc said on Wednesday its experimental fixed-dose combination treatment for HIV proved as effective in a late-stage study as the company's widely used Truvada combo pill but with significantly less loss of bone mineral density and kidney function.The company has already sought U.S. and European marketing approval for the new combo pill nicknamed F/TAF, which is meant to be a safer replacement for Truvada, a cornerstone of HIV treatment that has been associated with slight declines in bone mineral density and kidney function.""The results of this and other recent trials demonstrate the potential of F/TAF to become a next-generation backbone"" of treatment for HIV, the biotechnology company said in a release.The 48-week study was designed to assess effectiveness and safety of F/TAF among adults switching from Truvada. The combos had similar ability to drive rates of the HIV virus that causes AIDS down to undetectable levels. Overall safety was similar between the two combo pills, Gilead said, with the most common side effects being upper respiratory tract infection, diarrhea and bronchitis.     Gilead said it plans to submit detailed data from the study at a scientific conference next year. Results of the study reinforce the efficacy as well as kidney and bone safety advantages of the new combination pill, Gilead said. Gilead shares were up 0.5 percent to $101.95 in morning trading on the Nasdaq, versus a 0.7 percent gain for the Nasdaq Biotech Index (.NBI). The Foster City, California-based company has become one of the world's biggest and fastest-growing biotech companies thanks to its antiviral drugs, including its top-selling Sovaldi and Harvoni treatments for hepatitis C. Truvada, approved in 2004 for use with other HIV treatments, is a combination of the drugs emtricitabine and tenofovir disoproxil fumarate, chemicals that stop reproduction of the HIV  virus. Both components are from a class of HIV treatments called nucleoside reverse transcriptase inhibitors.F/TAF also contains emtricitabine. But it includes a slightly different form of tenofovir called tenofovir alafenamide meant to reach higher concentrations in HIV-infected cells but lower concentrations in blood plasma and tissues, including bones and kidneys. (Reporting by Ransdell Pierson in New York; Editing by Jeffrey Benkoe)",2015-09-02,GILD,"Wed Sep 2, 2015 | 10:34am EDT",Gilead combo HIV pill matches Truvada efficacy but safer in trial,http://www.reuters.com//article/us-gilead-sciences-hiv-idUSKCN0R21J320150902?type=companyNews
234,"  (Adds chemical differences of combo pills, shared side effects, updates stock price)By Ransdell PiersonSept 2 Gilead Sciences Inc said on Wednesday its experimental fixed-dose combination treatment for HIV proved as effective in a late-stage study as the company's widely used Truvada combo pill but with significantly less loss of bone mineral density and kidney function.The company has already sought U.S. and European marketing approval for the new combo pill nicknamed F/TAF, which is meant to be a safer replacement for Truvada, a cornerstone of HIV treatment that has been associated with slight declines in bone mineral density and kidney function.""The results of this and other recent trials demonstrate the potential of F/TAF to become a next-generation backbone"" of treatment for HIV, the biotechnology company said in a release. The 48-week study was designed to assess effectiveness and safety of F/TAF among adults switching from Truvada.The combos had similar ability to drive rates of the HIV virus that causes AIDS down to undetectable levels. Overall safety was similar between the two combo pills, Gilead said, with the most common side effects being upper respiratory tract infection, diarrhea and bronchitis. Gilead said it plans to submit detailed data from the study at a scientific conference next year.Results of the study reinforce the efficacy as well as kidney and bone safety advantages of the new combination pill, Gilead said. Gilead shares were up 0.5 percent to $101.95 in morning trading on the Nasdaq, versus a 0.7 percent gain for the Nasdaq Biotech Index (.NBI).The Foster City, California-based company has become one of the world's biggest and fastest-growing biotech companies thanks to its antiviral drugs, including its top-selling Sovaldi and Harvoni treatments for hepatitis C.Truvada, approved in 2004 for use with other HIV treatments, is a combination of the drugs emtricitabine and tenofovir disoproxil fumarate, chemicals that stop reproduction of the HIV  virus. Both components are from a class of HIV treatments called nucleoside reverse transcriptase inhibitors.F/TAF also contains emtricitabine. But it includes a slightly different form of tenofovir called tenofovir alafenamide meant to reach higher concentrations in HIV-infected cells but lower concentrations in blood plasma and tissues, including bones and kidneys.   (Reporting by Ransdell Pierson in New York; Editing by Jeffrey Benkoe)",2015-09-02,GILD,"Wed Sep 2, 2015 | 10:31am EDT",UPDATE 1-Gilead combo HIV pill matches Truvada efficacy but safer in trial,http://www.reuters.com//article/gilead-sciences-hiv-idUSL1N1180WO20150902?type=companyNews
235,"  Sept 1 Gilead Sciences Inc said on Wednesday its experimental fixed-dose combination treatment for HIV proved as effective in a late-stage study as the company's widely used Truvada combo pill but with significantly less loss of bone mineral density and kidney function.The company has already sought U.S. and European marketing approval for the new combo pill nicknamed F/TAF, which is meant to be a safer replacement for Truvada, a cornerstone of HIV treatment that has been associated with slight declines in bone mineral density and kidney function.""The results of this and other recent trials demonstrate the potential of F/TAF to become a next-generation backbone"" of treatment for HIV, the biotechnology company said in a release. Gilead said it plans to submit detailed data from the study at a scientific conference next year. Results of the 48-week study reinforce the efficacy as well as kidney and bone safety advantages of the new combination pill, Gilead said. Gilead shares were up 1.6 percent to $102.88 in morning trading on the Nasdaq, outpacing a 1.3 percent gain for the Nasdaq Biotech Index (.NBI).The Foster City, California-based company has become one of the world's biggest and fastest-growing biotech companies thanks to its antiviral drugs, including its top-selling Sovaldi and Harvoni treatments for hepatitis C.   (Reporting by Ransdell Pierson in New York; Editing by Jeffrey Benkoe)",2015-09-02,GILD,"Wed Sep 2, 2015 | 9:39am EDT",Gilead combo HIV pill matches Truvada efficacy but safer in trial,http://www.reuters.com//article/gilead-sciences-hiv-idUSL1N1180UR20150902?type=companyNews
236,"  (Adds details, analyst comments)By Natalie GroverSept 21 Gilead Sciences Inc is edging closer to the approval of the first drug to fight all forms of hepatitis C as the drugmaker's experimental combination showed high rates of effectiveness in four late-stage studies.The trials were evaluating a once-daily, fixed-dose combination of the drugmaker's approved hep C blockbuster, Sovaldi, with experimental NS5A inhibitor velpatasvir.The combination is Gilead's second single-tablet treatment for the viral infection. Harvoni, its approved drug, targets the most common form - genotype 1 infections.The main goal of each trial testing the experimental combination was to achieve a cure 12 weeks after the completion of therapy.Of the 1,053 patients treated with the drug for 12 weeks in three trials, 98 percent were cured. Data from the fourth trial, in more advanced and weaker patients, showed higher cure rates when patients also received ribavirin, an older antiviral.Treatment-related side effects caused the death of nine patients in the trial, the company said.The combination reduces the need for genotyping and potential confusion about which regimen works in which patients, UBS AG's Matthew Roden said. Gilead's twin blockbuster hep C offerings, Sovaldi and Harvoni, brought in combined sales of about $4.9 billion last quarter.Harvoni is expected to remain the treatment of choice in genotype 1, given it is taken for eight weeks, JP Morgan's Cory Casimov said.Gilead's Sovaldi/velpatasvir combination demonstrated significant cure rates after 12 weeks. William Blair's John Sonnier said the combination along with Gilead's GS-9857 could decrease treatment to six weeks while maintaining pan-genotypic potency.In July, the FDA approved two new treatments for less common forms of hep C - AbbVie Inc's Technivie for genotype 4 and Bristol-Myers Squibb Co's Daklinza for genotype 3.""A single, pan-genotypic approach may be particularly attractive in regions outside the United States where genotyping is less routine (or not possible),"" Casimov said.The Sovaldi/velpatasvir combination bodes well for Gilead to penetrate markets outside the United States, where non-genotype 1 hep C is more prevalent, Sonnier added.The Foster City, California-based drugmaker plans to file marketing applications for the combination by the fourth quarter.The company's stock, however, fell 2 percent after Hillary Clinton said she will propose a plan to take on specialty drug price gouging. S&P 500 Healthcare index was down 1 pct.     (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva and Don Sebastian)",2015-09-21,GILD,"Mon Sep 21, 2015 | 12:48pm EDT",UPDATE 2-Gilead experimental drug fights all forms of hep C: data,http://www.reuters.com//article/gilead-sciences-study-idUSL4N11R3SC20150921?type=companyNews
237,"  Gilead Sciences Inc said its experimental combination treatment was effective against all forms of hepatitis C infection, citing data from four late-stage studies.The trials were evaluating a once-daily, fixed-dose combination of the drugmaker's hep C drug, Sovaldi, with velpatasvir, an experimental NS5A inhibitor.The main goal of each study was to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.The combination is Gilead's second single-tablet treatment for hep C. Harvoni, its other treatment, is already approved for genotype 1 infections. Sovaldi and Harvoni brought in combined sales of about $4.9 billion last quarter.The U.S. Food and Drug Administration has granted the experimental combination ""breakthrough therapy"" status, expediting the development and review of the drug. Gilead expects to file marketing applications for the combination - which could eliminate the need for HCV genotype testing altogether - by the fourth quarter, it said on Monday. The Foster City, California-based company's stock was up marginally in early trading on the Nasdaq. (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva)",2015-09-21,GILD,"Mon Sep 21, 2015 | 10:07am EDT",Gilead combo drug fights all forms of hep C infection: data,http://www.reuters.com//article/us-gilead-sciences-study-idUSKCN0RL1I820150921?type=companyNews
238,"   By Sarah N. Lynch | WASHINGTON  WASHINGTON Five Florida residents including two attorneys and an accountant will collectively pay about $489,000 to settle civil charges over insider-trading ahead of Gilead Science's acquisition of Pharmasset, U.S. regulators said Monday.The Securities and Exchange Commission said that attorneys Robert Spallina and Donald Tescher, as well as accountant Steven Rosen, illegally traded after getting information about the pending deal from a mutual friend who served on Pharmasset's board. All defendants have agreed to settle the matter without admitting or denying the charges.   (Reporting by Sarah N. Lynch; Editing by Susan Heavey)",2015-09-28,GILD,"Mon Sep 28, 2015 | 12:57pm EDT",U.S. settles insider trading charges tied to Gilead acquisition,http://www.reuters.com//article/us-sec-insidertrading-idUSKCN0RS23T20150928?type=companyNews
239,"   By Sarah N. Lynch | WASHINGTON, Sept 28  WASHINGTON, Sept 28 Five Florida residents including two attorneys and an accountant will collectively pay about $489,000 to settle civil charges over insider-trading ahead of Gilead Science's acquisition of Pharmasset, U.S. regulators said Monday. The Securities and Exchange Commission said that attorneys Robert Spallina and Donald Tescher, as well as accountant Steven Rosen, illegally traded after getting information about the pending deal from a mutual friend who served on Pharmasset's board.  All defendants have agreed to settle the matter without admitting or denying the charges.   (Reporting by Sarah N. Lynch; Editing by Susan Heavey)",2015-09-28,GILD,"Mon Sep 28, 2015 | 12:56pm EDT",U.S. settles insider trading charges tied to Gilead acquisition,http://www.reuters.com//article/sec-insidertrading-idUSL1N11Y1JG20150928?type=companyNews
240,"   By Sinead Carew | Sept 29  Sept 29 A seven-day selloff of U.S. biotechnology stocks has hit sector investors - especially hedge funds - hard. But some managers say it was overdone and are already eyeing bargains such as Gilead Sciences Inc and Amgen Inc.The Nasdaq Biotechnology index has fallen 18.7 percent over the last seven sessions as investors took flight after Hillary Clinton, front-runner to be the Democratic nominee in next year's U.S. presidential election, vowed on Sept. 21 to take steps to curb high drug prices. Since its July 20 high, the index has fallen around 27 percent.The selloff was exacerbated by general market volatility as investors have been grappling with uncertainty about when policy makers will raise U.S. interest rates and concerns over the global economy.Biotech stocks, which had risen 31 percent this year to their July high after annual increases for the last six years, were also in sellers' sights because they had become richly valued. And the selling was intensified as investment managers did not want to issue third quarter reports showing big holdings in a beaten-down sector.""What you're seeing is that generalist money is getting very worried and thinking that maybe the healthcare trade is over and they're rotating into something else,"" said John Fraunces, co-portfolio manager of the $137 million Turner Medical Sciences Long-Short fund in Berwyn, Pennsylvania.Health-focused hedge funds including Baker Brothers Advisors, Healthcor Management, Palo Alto Investors, and Deerfield Management are each nursing losses of more than 10 percent for September based on their publicly disclosed portfolio at the end of June, data calculated by industry tracking firm Symmetric IO show.Symetric data points to broad holdings of specialty biopharmaceutical company Horizon Pharma, which has tumbled 47.3 percent in the last 7 days and which was listed in six hedge fund portfolios. The stock was a big holding for Deerfield, which manages $7.5 billion, for Healthcor, which oversees $2.6 billion, and for Broadfin Capital, which has held the stock for nearly two years. Horizon Pharma's losses also weighed on Iguana Healthcare Management.At the same time, a sharp drop in pharmaceutical company Valeant  weighed on a number of hedge funds, including prominent activists Pershing Square Capital Management and Jana Partners.A lot of selling took place in healthcare ETFs such as the iShares Nasdaq Biotechnology EFT, which fell almost 19 percent in the last seven days with an average daily trading volume that was 1.6 times higher than its 50 day average. NIBBLES AROUND THE EDGES In the options market, most of the activity was still on the side of expecting further declines, with protective puts outweighing other biotech index trades. But some traders appear to have been snapping up call options in hopes for a sharp rebound, said Jim Smith, options strategist at OTR Global.""People who are in the sector are looking for hedges and people who are not in it are looking for bargains,"" he said. Fraunces has been shorting the ETF, but now he and other investors are already eyeing bargains in the sector. He has been moving money to companies including Horizon Pharmaceuticals, one of the biggest casualties in the biotech sell-off.Some big name stocks, such as Gilead, Amgen, Biogen Inc  and Celgene Corp have sold off sharply enough to make their valuations attractive, according to several investors.Gilead's forward valuation of 8.1 is now less than half its 10-year median of 16.7 and its competitors' average valuations of 14.4. Amgen's forward P/E is 12.5 compared with an average valuation of 16 for its peers. Meanwhile the S&P 500's forward P/E was 15.4 on Tuesday, according to Thomson Reuters data.""That's pretty unusual because the absolute growth rate for those companies is two to three times higher than the S&P,"" said Sven Borho, founding general partner and fund manager at health science investment specialist Orbimed Advisors LLC, in New York.High valuations prompted Seattle-based Smead Capital Management to cut biotech and pharma holdings in its $1.2 billion Smead Value Investor fund in the last 18 months to 16.5 percent from 29 percent, Tony Scherrer, director of research said.But Scherrer, now interested in Amgen and Gilead, described the last week's ETF trading as ""throwing out the baby with the bathwater.""   (Reporting by Sinead Carew; Additional reporting by Svea Herbst, David Randall and Saqib Ahmed; Editing by Frances Kerry)",2015-09-29,GILD,"Tue Sep 29, 2015 | 5:14pm EDT",U.S. biotech bloodbath hits hedge funds but some bargains emerge,http://www.reuters.com//article/usa-biotech-idUSL1N11Z26Q20150929?type=companyNews
241,"  Drugmaker Gilead Sciences Inc said data from a late-stage study showed that its experimental drug, Genvoya, showed reduced side-effects compared with an older version of the drug in treating HIV-infected patients over a longer term.The company said Genvoya was as good as Stribild, which is the older version, after 96 weeks of treatment and had lesser side-effects on patients' kidneys and bones.Genvoya, which is developed from Stribild by replacing one part of the four-drug cocktail, has already received positive opinions from European health regulators. The company's marketing application in Europe was supported by two late-stage studies that showed the same benefit, but over 48 weeks of treatment.Stribild raked in sales of $803 million in the first half of the year, according to a regulatory filing from the company. Gilead shares were up marginally at $102 premarket. Up to Wednesday's close, the stock had gained about 8 percent this year.  (Reporting by Vidya L Nathan in Bengaluru; Editing by Anil D'Silva)",2015-10-22,GILD,"Thu Oct 22, 2015 | 8:14am EDT",Gilead's new HIV drug shows lower side-effects over longer term,http://www.reuters.com//article/gilead-sciences-study-idUSKCN0SG1GH20151022?type=companyNews
242,"  Oct 22 Drugmaker Gilead Sciences Inc  said data from a late-stage study showed that its experimental drug, Genvoya, showed reduced side-effects compared with an older version of the drug in treating HIV-infected patients over a longer term.The company said Genvoya was as good as Stribild, which is the older version, after 96 weeks of treatment and had lesser side-effects on patients' kidneys and bones.Genvoya, which is developed from Stribild by replacing one part of the four-drug cocktail, has already received positive opinions from European health regulators. The company's marketing application in Europe was supported by two late-stage studies that showed the same benefit, but over 48 weeks of treatment. Stribild raked in sales of $803 million in the first half of the year, according to a regulatory filing from the company. Gilead shares were up marginally at $102 premarket. Up to Wednesday's close, the stock had gained about 8 percent this year.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Anil D'Silva)",2015-10-22,GILD,"Thu Oct 22, 2015 | 8:12am EDT",Gilead's new HIV drug shows lower side-effects over longer term,http://www.reuters.com//article/gilead-sciences-study-idUSL3N12M44020151022?type=companyNews
243,"   By Deena Beasley  Gilead Sciences Inc (GILD.O) on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments.Shares of the biotechnology company fell slightly. Gilead's quarterly product sales rose 37 percent to $8.2 billion. Sales of hepatitis C drugs Sovaldi and Harvoni totaled $4.8 billion, which was just ahead of the $4.5 billion average Wall Street estimate, but little changed from second quarter sales. Company officials said hepatitis C sales were likely to stay flat through 2016 as health insurers restrict patient access to Gilead's drugs, which have list prices of more than $1,000 a pill.Gilead's shares, which rose 2 percent in regular trading, were down 2 percent at $108.75 after hours.For hepatitis C sales, ""2016 I think will be a more stable year in the U.S.,"" Gilead Chief Operating Officer John Milligan said on a conference call with analysts and investors. He said the company is ""doing a lot of work to encourage earlier treatment, more screening and so on,"" but U.S. insurers are still being selective in authorizing treatment.U.S. health regulators last week issued a warning of potential risk of serious liver injury for certain patients using hepatitis C treatments made by rival AbbVie Inc (ABBV.N), but more competitors are coming, including from Merck & Co Inc (MRK.N) likely early next year. Gilead officials declined to comment on whether the shifting competitive landscape would affect its pricing strategy.After adjusting for one-time items, Gilead earned $3.22 per share, beating the average Wall Street estimate of $2.87 per share, according to Thomson Reuters I/B/E/S.""The quarter was solid,"" said RBC Capital Markets analyst Michael Yee. ""They had significantly better total sales and they crushed it on EPS. The beat was mostly due to the first generation hepatitis C drug Sovaldi not Harvoni."" Gilead raised its outlook for full-year product sales to between $30 billion and $31 billion, from a previous estimate of $29 billion to $30 billion. But Yee said Wall Street analysts have already estimated higher Gilead sales for the year.Gilead posted quarterly net income of $4.6 billion, or $3.06 per share, compared with $2.7 billion, or $1.67 per share, a year earlier. (Additional reporting by Bill Berkrot; Editing by Alan Crosby and Grant McCool)",2015-10-27,GILD,"Tue Oct 27, 2015 | 6:55pm EDT","Gilead hepatitis C drug sales trend flattens, shares dip",http://www.reuters.com//article/us-gilead-sciences-results-idUSKCN0SL2V820151027?type=companyNews
244,"  (Adds background, updates share price)By Deena BeasleyOct 27 Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments.Shares of the biotechnology company fell slightly. Gilead's quarterly product sales rose 37 percent to $8.2 billion. Sales of hepatitis C drugs Sovaldi and Harvoni totaled $4.8 billion, which was just ahead of the $4.5 billion average Wall Street estimate, but little changed from second quarter sales.Company officials said hepatitis C sales were likely to stay flat through 2016 as health insurers restrict patient access to Gilead's drugs, which have list prices of more than $1,000 a pill. Gilead's shares, which rose 2 percent in regular trading, were down 2 percent at $108.75 after hours.For hepatitis C sales, ""2016 I think will be a more stable year in the U.S.,"" Gilead Chief Operating Officer John Milligan said on a conference call with analysts and investors.He said the company is ""doing a lot of work to encourage earlier treatment, more screening and so on,"" but U.S. insurers are still being selective in authorizing treatment. U.S. health regulators last week issued a warning of potential risk of serious liver injury for certain patients using hepatitis C treatments made by rival AbbVie Inc, but more competitors are coming, including from Merck & Co Inc  likely early next year.Gilead officials declined to comment on whether the shifting competitive landscape would affect its pricing strategy. After adjusting for one-time items, Gilead earned $3.22 per share, beating the average Wall Street estimate of $2.87 per share, according to Thomson Reuters I/B/E/S.""The quarter was solid,"" said RBC Capital Markets analyst Michael Yee. ""They had significantly better total sales and they crushed it on EPS. The beat was mostly due to the first generation hepatitis C drug Sovaldi not Harvoni.""Gilead raised its outlook for full-year product sales to between $30 billion and $31 billion, from a previous estimate of $29 billion to $30 billion. But Yee said Wall Street analysts have already estimated higher Gilead sales for the year.Gilead posted quarterly net income of $4.6 billion, or $3.06 per share, compared with $2.7 billion, or $1.67 per share, a year earlier.   (Additional reporting by Bill Berkrot; Editing by Alan Crosby and Grant McCool)",2015-10-27,GILD,"Tue Oct 27, 2015 | 6:54pm EDT","UPDATE 3-Gilead hepatitis C drug sales trend flattens, shares dip",http://www.reuters.com//article/gilead-sciences-results-idUSL1N12R31C20151027?type=companyNews
245,"  Oct 27 Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales of its key hepatitis C drugs were largely in line with Wall Street estimates, and shares of the biotechnology company were little changed.For the third quarter, Gilead posted net income of $4.6 billion, or $3.06 per share, compared with $2.7 billion, or $1.67 per share a year earlier. The company's shares, which rose 2 percent in regular trading, were up 0.05 percent at $111 after hours. Gilead said third-quarter product sales rose 37 percent to $8.2 billion, including $4.8 billion for hepatitis C drugs Sovaldi and Harvoni. Analysts had expected hepatitis C sales of $4.5 billion, according to Evercore ISI.  Gilead raised its outlook for full-year product sales to between $30 billion and $31 billion, from a previous estimate of $29 billion to $30 billion.   (Reporting by Deena Beasley; Editing by James Dalgleish)",2015-10-27,GILD,"Tue Oct 27, 2015 | 4:21pm EDT","Gilead 3rd quarter profit rises, hepatitis C drug sales in line",http://www.reuters.com//article/gilead-sciences-results-idUSL1N12R1XU20151027?type=companyNews
246,"  Gilead Sciences Inc said the U.S. Food and Drug Administration had approved its HIV drug cocktail, Genvoya, to treat patients aged 12 and above.Genvoya, a combination tablet approved as a complete regimen, is designed to treat previously untreated patients weighing at least 35 kilograms (77 pounds), the FDA said on Thursday. (1.usa.gov/1RYxl7t)The drug also aims to treat adults whose HIV-1 infection is currently suppressed due to antiretroviral therapy.HIV-1 is the most common and pathogenic strain of the virus.Genvoya is not recommended for patients with severe kidney problems, the FDA said.  The treatment carries a boxed warning, which flags potentially fatal risks such as buildup of lactic acid in the blood and severe liver problems. The label also states that Genvoya is not approved to treat patients with chronic hepatitis B virus infection. Genvoya - developed from Stribild, an older version of the four drug cocktail - was also given positive recommendation from European health regulators in September.Stribild raked in about $803 million in the first half of the year, according to a regulatory filing. Shares of Foster City, California-based Gilead were down 1.4 percent at $107.48 in late afternoon trading on Thursday. (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Ted Kerr, Anil D'Silva and Kirti Pandey)",2015-11-05,GILD,"Thu Nov 5, 2015 | 2:32pm EST",FDA approves Gilead Sciences' HIV drug cocktail,http://www.reuters.com//article/us-gilead-sciences-fda-idUSKCN0SU2S320151105?type=companyNews
247,"  (Adds details; updates shares)Nov 5 Gilead Sciences Inc said the U.S. Food and Drug Administration had approved its HIV drug cocktail, Genvoya, to treat patients aged 12 and above.Genvoya, a combination tablet approved as a complete regimen, is designed to treat previously untreated patients weighing at least 35 kilograms (77 pounds), the FDA said on Thursday. (1.usa.gov/1RYxl7t)The drug also aims to treat adults whose HIV-1 infection is currently suppressed due to antiretroviral therapy. HIV-1 is the most common and pathogenic strain of the virus.Genvoya is not recommended for patients with severe kidney problems, the FDA said. The treatment carries a boxed warning, which flags potentially fatal risks such as buildup of lactic acid in the blood and severe liver problems.The label also states that Genvoya is not approved to treat patients with chronic hepatitis B virus infection. Genvoya - developed from Stribild, an older version of the four drug cocktail - was also given positive recommendation from European health regulators in September.Stribild raked in about $803 million in the first half of the year, according to a regulatory filing.Shares of Foster City, California-based Gilead were down 1.4 percent at $107.48 in late afternoon trading on Thursday.   (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Ted Kerr, Anil D'Silva and Kirti Pandey)",2015-11-05,GILD,"Thu Nov 5, 2015 | 2:28pm EST",UPDATE 2-FDA approves Gilead Sciences' HIV drug cocktail,http://www.reuters.com//article/gilead-sciences-fda-idUSL3N1305ZG20151105?type=companyNews
248,"  Drugmaker Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration had approved the expanded use of its blockbuster hepatitis C drug, Harvoni.The drug can now be used to treat patients with subtypes of chronic hepatitis C virus (HCV) and patients who are co-infected with Human Immunodeficiency Virus (HIV), Gilead said in a statement.The once-daily pill, used in combination with antiviral ribavirin, was also approved to be used for 12 weeks as an alternate therapy to Harvoni alone, which is used for 24 weeks to treat patients with cirrhosis.Results from the study showed that about 93 percent of the patients with subtypes of the virus and 96 percent of patients co-infected with HIV showed a sustained response to the virus within 12 weeks of treatment. Sustained viral response is the term for a successful hepatitis C treatment outcome. It means that hepatitis-C virus is undetectable for 12 or more weeks after the end of treatment.Gilead's blockbuster Harvoni was first approved by the FDA in October 2014. The drug had sales of about $3.3 billion in the latest quarter ended Sept 30. Hepatitis C, estimated to infect about 3.2 million Americans, is a viral disease that causes inflammation of the liver that can lead to liver failure.Patients with HCV and HIV co-infection represent about 30 percent of the total HIV-infected population in the United States, Gilead says. Gilead's shares were little changed in the after-market trading. (Reporting by Rosmi Shaji in Bengaluru; Editing by Anil D'Silva and Ken Wills)",2015-11-12,GILD,"Thu Nov 12, 2015 | 6:58pm EST",U.S. FDA approves Gilead's hepatitis C drug for expanded use,http://www.reuters.com//article/us-gilead-sciences-fda-idUSKCN0T12UA20151112?type=companyNews
249,"  A late stage trial of a Gilead Sciences drug in previously treated patients with a particular type of leukemia was unblinded early after independent monitors determined the medicine provided significant benefit in delaying worsening of the disease, the company said on Monday.The study was testing Gilead's Zydelig in combination with the standard treatment, Rituxan and Treanda, compared with the standard treatment alone in patients with chronic lymphocytic leukemia (CLL) whose disease had progressed after prior therapy.Generally, when it becomes clear that a new drug will succeed in a trial, the study is unblinded so that patients receiving other drugs or a placebo can be offered the study drug.A planned interim analysis of data from the 415-patient study by the data monitoring committee found a statistically significant benefit in progression-free survival and overall survival and ordered the trial to be unblinded, Gilead said.Details of the trial and the magnitude of benefit will be presented at a major medical meeting next month. Independent safety monitors oversee blinded trials so that they can be halted or unblinded early in case it is determined that the drug is causing harm or if the benefit becomes clear so that the medicine can be offered to placebo patients. A trial can also be stopped for futility if monitors determine the study is doomed to fail.Gilead said it plans to submit supplemental regulatory filings in the United States and Europe early next year with the hope of expanding the Zydelig approval for use with Rituxan and Treanda in previously treated CLL patients. Zydelig, known chemically as idelalisib, is already approved to treat CLL in combination with Rituxan (rituximab), and for a type of non-Hodgkin lymphoma in patients who have received at least two prior therapies.   (Reporting by Bill Berkrot; Editing by Dan Grebler)",2015-11-16,GILD,"Mon Nov 16, 2015 | 11:53am EST",Gilead leukemia drug trial unblinded early due to success,http://www.reuters.com//article/us-gilead-leukemia-idUSKCN0T520W20151116?type=companyNews
250,"  Nov 16 A late stage trial of a Gilead Sciences  drug in previously treated patients with a particular type of leukemia was unblinded early after independent monitors determined the medicine provided significant benefit in delaying worsening of the disease, the company said on Monday.The study was testing Gilead's Zydelig in combination with the standard treatment, Rituxan and Treanda, compared with the standard treatment alone in patients with chronic lymphocytic leukemia (CLL) whose disease had progressed after prior therapy.Generally, when it becomes clear that a new drug will succeed in a trial, the study is unblinded so that patients receiving other drugs or a placebo can be offered the study drug.A planned interim analysis of data from the 415-patient study by the data monitoring committee found a statistically significant benefit in progression-free survival and overall survival and ordered the trial to be unblinded, Gilead said. Details of the trial and the magnitude of benefit will be presented at a major medical meeting next month. Independent safety monitors oversee blinded trials so that they can be halted or unblinded early in case it is determined that the drug is causing harm or if the benefit becomes clear so that the medicine can be offered to placebo patients. A trial can also be stopped for futility if monitors determine the study is doomed to fail.Gilead said it plans to submit supplemental regulatory filings in the United States and Europe early next year with the hope of expanding the Zydelig approval for use with Rituxan and Treanda in previously treated CLL patients. Zydelig, known chemically as idelalisib, is already approved to treat CLL in combination with Rituxan (rituximab), and for a type of non-Hodgkin lymphoma in patients who have received at least two prior therapies.(Reporting by Bill Berkrot; Editing by Dan Grebler)",2015-11-16,GILD,"Mon Nov 16, 2015 | 11:50am EST",Gilead leukemia drug trial unblinded early due to success,http://www.reuters.com//article/gilead-leukemia-idUSL1N13B1IP20151116?type=companyNews
251,"   By Bill Berkrot  U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences' new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according to a U.S. Senate investigation into pricing of the blockbuster medicines.In the latest salvo against high U.S. prices for important medicines, the 18-month Senate Finance Committee investigation into the cost of Gilead's Sovaldi and follow-on combination treatment Harvoni accused the company of putting maximizing revenue ahead of patient access.The vast majority of the more than 700,000 people on state Medicaid programs for the poor with hepatitis C are still awaiting treatment, the probe found.""It was always Gilead's plan to maximize revenue, and affordability and accessibility was an afterthought,"" Senator Ron Wyden, Democrat from Oregon, said at a news conference to announce the findings along with Iowa Republican Senator Chuck Grassley.The senators said Sovaldi and Harvoni prices did not reflect the cost of research and development or the $11 billion Gilead paid for Pharmasset to acquire the drugs, but purely a desire to maximize profit.Sovaldi was introduced at a list price of $84,000 for a course of treatment, or about $1,000 per pill, creating a furor over its cost. The Gilead drugs represent a vast improvement over prior treatments that had far lower cure rates and many troublesome side effects. While those older treatments were also expensive, they did not cause a similar burden on healthcare budgets as thousands of patients put off treatment while waiting for improved new drugs that promised a cure. ""If Gilead's approach to pricing is the future of how blockbuster drugs are launched, it will cost billions and billions of dollars to treat just a fraction of patients,"" said Wyden, the Finance Committee's ranking member.As an example, the report said Indiana's Medicaid program  spent $40 million to treat 462 people. In 2014 alone, Medicare and Medicaid combined to spend more than $5 billion on Sovaldi and Harvoni before rebates, the probe found.Gilead, in a statement, said it respectfully disagrees with the conclusions of the report.""With the rebates and discounts now in place, the prices today are less than the cost of prior regimens,"" the company said, noting that its treatments reduce the long-term costs associated with managing chronic hepatitis C, such as by preventing liver failure or the need for transplants.  The high price of U.S. prescription medicines has become a major issue in the campaign for the November 2016 presidential election, with Democratic candidates Hillary Clinton, Bernie Sanders and Martin O'Malley calling for changes to limit costs to patients.""If America is to cure Alzheimer's, cancer, diabetes and HIV in the years ahead, these cures must not be unaffordable and beyond the reach of most Americans,"" Wyden said.Some newer cancer treatments cost $150,000 or more a year. (Reporting by Bill Berkrot; Editing by David Gregorio)",2015-12-01,GILD,"Tue Dec 1, 2015 | 1:21pm EST",Gilead put profit ahead of hepatitis C patients: U.S. Senate report,http://www.reuters.com//article/us-usa-healthcare-prices-idUSKBN0TK5HC20151201?type=companyNews
252,"   By Bill Berkrot  Dec 1 U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences' new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according to a U.S. Senate investigation into pricing of the blockbuster medicines.In the latest salvo against high U.S. prices for important medicines, the 18-month Senate Finance Committee investigation into the cost of Gilead's Sovaldi and follow-on combination treatment Harvoni accused the company of putting maximizing revenue ahead of patient access.The vast majority of the more than 700,000 people on state Medicaid programs for the poor with hepatitis C are still awaiting treatment, the probe found.""It was always Gilead's plan to maximize revenue, and affordability and accessibility was an afterthought,"" Senator Ron Wyden, Democrat from Oregon, said at a news conference to announce the findings along with Iowa Republican Senator Chuck Grassley.The senators said Sovaldi and Harvoni prices did not reflect the cost of research and development or the $11 billion Gilead paid for Pharmasset to acquire the drugs, but purely a desire to maximize profit. Sovaldi was introduced at a list price of $84,000 for a course of treatment, or about $1,000 per pill, creating a furor over its cost. The Gilead drugs represent a vast improvement over prior treatments that had far lower cure rates and many troublesome side effects.While those older treatments were also expensive, they did not cause a similar burden on healthcare budgets as thousands of patients put off treatment while waiting for improved new drugs that promised a cure.""If Gilead's approach to pricing is the future of how blockbuster drugs are launched, it will cost billions and billions of dollars to treat just a fraction of patients,"" said Wyden, the Finance Committee's ranking member. As an example, the report said Indiana's Medicaid program  spent $40 million to treat 462 people.In 2014 alone, Medicare and Medicaid combined to spend more than $5 billion on Sovaldi and Harvoni before rebates, the probe found. Gilead, in a statement, said it respectfully disagrees with the conclusions of the report.""With the rebates and discounts now in place, the prices today are less than the cost of prior regimens,"" the company said, noting that its treatments reduce the long-term costs associated with managing chronic hepatitis C, such as by preventing liver failure or the need for transplants.The high price of U.S. prescription medicines has become a major issue in the campaign for the November 2016 presidential election, with Democratic candidates Hillary Clinton, Bernie Sanders and Martin O'Malley calling for changes to limit costs to patients.""If America is to cure Alzheimer's, cancer, diabetes and HIV in the years ahead, these cures must not be unaffordable and beyond the reach of most Americans,"" Wyden said.Some newer cancer treatments cost $150,000 or more a year.   (Reporting by Bill Berkrot; Editing by David Gregorio)",2015-12-01,GILD,"Tue Dec 1, 2015 | 1:17pm EST",Gilead put profit ahead of hepatitis C patients -U.S. Senate report,http://www.reuters.com//article/usa-healthcare-prices-idUSL1N13Q1VC20151201?type=companyNews
253,"  (Adds details, share reaction, analyst comment)BRUSSELS Dec 17 Belgium's Galapagos  has signed a deal potentially worth more than $2 billion with U.S. firm Gilead to develop a drug targeting inflammatory diseases, reviving a project abandoned by former partner AbbVie.Galapagos will receive a $725 million upfront payment for the development of experimental drug filgotinib, made up of a $300 million licence payment and a $425 million equity investment, the Belgian company said.Under the deal, Gilead will buy a 15 percent stake of Galapagos at 58 euros per share, a 20 percent premium to the average closing price over the past 30 days. On top of the upfront payment, Galapagos may receive up to $1.35 billion from Gilead if targets are met, as well as royalties once the drug enters the market.""In the hands of Gilead, filgotinib has found a strong partner,"" said KBC analyst Jan De Kerpel. ""The deal should also remove doubts investors had on the reason why AbbVie didn't lift the option."" Galapagos shares rose as much as 15 percent to a record 60.55 euros early on Thursday.In September, AbbVie scrapped a development deal with Galapagos for filgotinib, a new class of medicine that blocks an inflammation-causing enzyme known as JAK1, in favour of its own project instead. Founded in 1999, Galapagos has several experimental drugs in clinical trials. Filgotinib is its most advanced candidate for the treatment of rheumatoid arthritis and inflammatory bowel disease. Filgotinib may start final clinical trials (Phase III) in 2016 pending regulatory approvals, Galapagos said.Belgium has become an important hub for biotech firms, partly because of its lenient tax treatment for international research staff and patents.Galapagos has other research alliances, with Morphosys  and Servier, as well as a development partnership for cystic fibrosis with AbbVie.   (Reporting by Robert-Jan Bartunek; editing by Biju Dwarakanath and David Clarke)",2015-12-17,GILD,"Thu Dec 17, 2015 | 4:20am EST",UPDATE 1-Belgium's Galapagos signs $2 bln deal with U.S. company Gilead,http://www.reuters.com//article/galapagos-gilead-idUSL8N14611Q20151217?type=companyNews
254,"  BRUSSELS Belgian biotech company Galapagos (GLPG.AS) has signed a development deal for drugs targeting inflammatory diseases potentially worth more than $2 billion with U.S. group Gilead (GILD.O).For the deal, which concerns experimental drug filgotinib, Galapagos will receive a $725 million upfront payment and may receive up $1.35 billion in payments if certain targets are met as well as royalties once the drug enters the market.The $725 million upfront payment is made up of a $300 million license payment and a $425 million equity investment, Galapagos said.  The capital investment will be made through the acquisition of Galapagos shares at 58 euros each, a 20 percent premium to the average closing price over the past 30 days, the group added. After the transaction, Gilead will own a 15 percent stake. Filgotinib may start final clinical trials (Phase III) for rheumatoid arthritis and Crohn's disease in 2016, Galapagos said.   (Reporting by Robert-Jan Bartunek; Editing by Biju Dwarakanath)",2015-12-17,GILD,"Thu Dec 17, 2015 | 1:55am EST",Belgium's Galapagos signs $2 billion deal with U.S. group Gilead,http://www.reuters.com//article/us-galapagos-gilead-idUSKBN0U00MG20151217?type=companyNews
255,"  BRUSSELS Dec 17 Belgian biotech company Galapagos has signed a development deal for drugs targeting inflammatory diseases potentially worth more than $2 billion with U.S. group Gilead.For the deal, which concerns experimental drug filgotinib, Galapagos will receive a $725 million upfront payment and may receive up $1.35 billion in payments if certain targets are met as well as royalties once the drug enters the market. The $725 million upfront payment is made up of a $300 million licence payment and a $425 million equity investment, Galapagos said. The capital investment will be made through the acquisition of Galapagos shares at 58 euros each, a 20 percent premium to the average closing price over the past 30 days, the group added. After the transaction, Gilead will own a 15 percent stake. Filgotinib may start final clinical trials (Phase III) for rheumatoid arthritis and Crohn's disease in 2016, Galapagos said.    (Reporting by Robert-Jan Bartunek; Editing by Biju Dwarakanath)",2015-12-17,GILD,"Thu Dec 17, 2015 | 1:41am EST",Belgium's Galapagos signs $2 bln deal with US group Gilead,http://www.reuters.com//article/galapagos-gilead-idUSL8N1460DZ20151217?type=companyNews
256,"  Dec 17 Galapagos NV :* Galapagos and Gilead announce global partnership to develop filgotinib for the treatment of rheumatoid arthritis and other inflammatory diseases * Galapagos is eligible for payments up to $1.35 billion in milestones, with tiered royalties starting at 20 percent and a profit split in co-promotion territories * Galapagos will receive an upfront payment of $725 million consisting of a license fee of $300 million and a $425 million equity investment in Galapagos * Companies will start phase 3 trials in RA and Crohn's in 2016 pending successful outcome of discussions with regulatory authorities  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",2015-12-17,GILD,"Thu Dec 17, 2015 | 1:11am EST",BRIEF-Galapagos and Gilead announce global partnership,http://www.reuters.com//article/idUSFWN14506O20151217?type=companyNews
257,"  * Gilead up after hep B drug found safe* First Solar up after Goldman upgrades stock to buy* Indexes up: Dow 0.13 pct, S&P 0.22 pct, Nasdaq 0.19 pct   (Updates to open)By Abhiram NandakumarJan 5 U.S. stock indexes were higher on Tuesday morning as investors recovered from a bruising selloff on the first trading day of the year.Stock markets plunged on Monday after weak Chinese economic data rekindled fears of a global slowdown, prompting a near-$20 billion injection by the People's Bank of China to stabilize its markets. U.S. stocks closed sharply lower on Monday, with the Dow making its worst start to a year since 2008. Weak U.S. factory data also added to the worries.Global stocks were down on Tuesday but off the lows they hit in the previous session.""I think everybody's finally getting settled back in and they're trying to assess really how global growth is going to impact their investments for the rest of the year,"" said Kevin Kelly, CIO of Recon Capital Partners. ""You will see market volatility throughout the rest of the month, but you'll start to see the market have a couple of up days because people are putting money to work,"" he said.Crude oil was lower as investors fretted about the state of the Chinese economy, a stronger dollar and rising tensions in the Middle East.At 9:38 a.m. ET (1438 GMT), the Dow Jones industrial average  was up 22.12 points, or 0.13 percent, at 17,171.06, the S&P 500 was up 4.5 points, or 0.22 percent, at 2,017.16 and the Nasdaq Composite index was up 9.26 points, or 0.19 percent, at 4,912.35. Nine of the 10 major S&P sectors were higher, led by a 0.68 percent rise in health stocks.Gilead rose 1.2 percent to $99.21 after its experimental hepatitis B drug was found safer than but as effective as its approved treatment, Viread. The stock provided the biggest boost to the S&P 500 and Nasdaq.First Solar was up 6.5 percent at $71.08 after Goldman Sachs upgraded the stock to ""buy"".Advancing issues outnumbered decliners on the NYSE by 1,703 to 958. On the Nasdaq, 1,185 issues rose and 979 fell.The S&P 500 index showed two new 52-week highs and no new lows, while the Nasdaq recorded six new highs and 11 new lows.   (Reporting by Abhiram Nandakumar in Bengaluru; Editing by Saumyadeb Chakrabarty)",2016-01-05,GILD,"Tue Jan 5, 2016 | 9:55am EST",US STOCKS-Wall St higher as investors recover from selloff,http://www.reuters.com//article/usa-stocks-idUSL3N14P43S20160105?type=companyNews
258,"  Gilead Sciences Inc said its experimental hepatitis B drug was found safer than but as effective as its approved treatment, Viread, in two late-stage studies.The once-daily drug, tenofovir alafenamide (TAF), showed improved renal and bone safety compared with Viread, Gilead said on Tuesday.Gilead's shares rose 1 percent to $99 in premarket trading.The company plans to seek regulatory approval for TAF in the United States and Europe in the first quarter of 2016.      The drugmaker said in September that TAF was found safer than but as effective as its popular HIV drug, Truvada, in a late-stage study.  Patients given TAF experienced significantly lower loss of bone mineral density and kidney function than those on Truvada.Gilead is developing TAF as a safer replacement for Viread and Truvada.  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2016-01-05,GILD,"Tue Jan 5, 2016 | 9:22am EST",Gilead's hep B drug as effective as Viread but safer,http://www.reuters.com//article/us-gilead-sciences-study-idUSKBN0UJ1DQ20160105?type=companyNews
259,"  (Adds details, shares)Jan 5 Gilead Sciences Inc said its experimental hepatitis B drug was found safer than but as effective as its approved treatment, Viread, in two late-stage studies.The once-daily drug, tenofovir alafenamide (TAF), showed improved renal and bone safety compared with Viread, Gilead said on Tuesday. Gilead's shares rose 1 percent to $99 in premarket trading.The company plans to seek regulatory approval for TAF in the United States and Europe in the first quarter of 2016. The drugmaker said in September that TAF was found safer than but as effective as its popular HIV drug, Truvada, in a late-stage study. Patients given TAF experienced significantly lower loss of bone mineral density and kidney function than those on Truvada.Gilead is developing TAF as a safer replacement for Viread and Truvada.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2016-01-05,GILD,"Tue Jan 5, 2016 | 9:20am EST",UPDATE 1-Gilead's hep B drug as effective as Viread but safer,http://www.reuters.com//article/gilead-sciences-study-idUSL3N14P42420160105?type=companyNews
260,"  Jan 5 Gilead Sciences Inc said its once-daily experimental hepatitis B drug was found to be as effective as its approved drug, Viread, in two late-stage studies.The drug, tenofovir alafenamide, or TAF, also showed improved renal and bone safety compared with Viread, Gilead said on Tuesday.  Gilead plans to submit regulatory applications for TAF in the United States and the European Union in the first quarter of 2016.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey) ",2016-01-05,GILD,"Tue Jan 5, 2016 | 8:53am EST",Gilead's hep B drug succeeds in late-stage trials,http://www.reuters.com//article/gilead-sciences-study-idUSL3N14P41I20160105?type=companyNews
261,"  Jan 13 Gilead Sciences Inc and Galapagos NV :* Said Galapagos and Gilead have been cleared by U.S. Federal trade Commission to close global partnership on filgotinib* Deal is expected to close by end of month * Upon closing, Galapagos will receive an upfront license fee of $300 million * Upon closing Gilead will make a $425 million equity investment in Galapagos by subscribing for shares at a price of 58 euros ($62.85) per share * After issuance of shares, Gilead will own approximately 15 percent of outstanding share capital of Galapagos  Source text for Eikon:  Further company coverage:   ($1 = 0.9228 euros)   (Gdynia Newsroom)",2016-01-13,GILD,"Wed Jan 13, 2016 | 1:42am EST",BRIEF-Gilead and Galapagos global partnership cleared by U.S. Federal Trade Commission,http://www.reuters.com//article/idUSFWN14W03G20160113?type=companyNews
262,"  Jan 25 Galapagos NV : * Gilead Sciences through subsidiary Gilead Biopharmaceutics Ireland Unlimited company subscribing capital increase and thus receiving 6,760,701 new Galapagos shares, indirectly holds 14.75 pct of Galapagos shares  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)  ",2016-01-25,GILD,"Mon Jan 25, 2016 | 1:37am EST",BRIEF-Gilead holds 14.75% of Galapagos shares,http://www.reuters.com//article/idUSFWN15505A?type=companyNews
263,"   By Ransdell Pierson and Bill Berkrot  Massachusetts' attorney general is studying whether prices of Gilead Sciences' blockbuster treatments for hepatitis C violate state law, according to a letter the prosecutor sent to the California-based drugmaker.The letter from the state's Attorney General Maura Healey to Gilead Chief Executive Officer John Martin, dated Jan. 22, asked the biotechnology company to reconsider its pricing for Sovaldi and Harvoni, Gilead's treatments with list prices of $84,000 and $94,500, respectively, per course of treatment.""My office is considering whether Gilead's pricing strategy with respect to Sovaldi and Harvoni may constitute an unfair trade practice in violation of Massachusetts law,"" Healey said in the letter, a copy of which was viewed by Reuters.Healey accused Gilead of pricing the drugs ""in a manner that effectively allows hepatitis C to continue spreading through vulnerable populations, as opposed to eradicating the disease altogether,"" the letter said.Gilead spokeswoman Amy Flood said the company received Healey's letter and requested a meeting to discuss the issues. ""We agree with the attorney general about the importance of helping all hepatitis C patients  and that the advent of safe, effective regimens means we can now consider the possibility of eradicating the disease,"" Flood said. Insurers, politicians and patient groups have denounced prices of the two treatments, which can cure well over 90 percent of patients with the liver disease.Gilead contends that the drugs greatly reduce long-term healthcare costs by preventing liver cancer and the need for transplants. More than three million Americans are believed to have the virus. Healey said a U.S. heroin epidemic has fueled rising hepatitis rates in the prison population as the virus can be spread by infected needles, and that state-run prisons are not eligible for discounts available to federal programs.""When you make a deliberate business decision that maximizes profit in a way you know will limit patients' access to that treatment ... it raises questions whether that is a fair practice under our consumer protection laws,"" Healey told Reuters. ""I hope we will have productive conversations. Gilead will make record profits even at a lower price,"" Healey added.RBC Capital Markets analyst Michael Yee said the threatened action amounted to more political rhetoric.""Since when is it a crime to have cured a global epidemic afflicting millions of patients, and the price is the same as the older drugs, which had less cure and bad side effects?,"" Yee asked. (Reporting by Ransdell Pierson and Bill Berkrot in New York; editing by Jonathan Oatis, Matthew Lewis and G Crosse)",2016-01-27,GILD,"Wed Jan 27, 2016 | 4:49pm EST",Massachusetts official challenges Gilead's hepatitis C drug prices,http://www.reuters.com//article/us-gilead-sciences-massachusetts-idUSKCN0V51Y3?type=companyNews
264,"   By Ransdell Pierson and Bill Berkrot  Massachusetts' attorney general is studying whether prices of Gilead Sciences' blockbuster treatments for hepatitis C violate state law, according to a letter the prosecutor sent to the California-based drugmaker.The letter from the state's Attorney General Maura Healey to Gilead Chief Executive Officer John Martin, dated Jan. 22, asked the biotechnology company to reconsider its pricing for Sovaldi and Harvoni, Gilead's treatments with list prices of $84,000 and $94,500, respectively, per course of treatment.""My office is considering whether Gilead's pricing strategy with respect to Sovaldi and Harvoni may constitute an unfair trade practice in violation of Massachusetts law,"" Healey said in the letter, a copy of which was viewed by Reuters.Healey accused Gilead of pricing the drugs ""in a manner that effectively allows hepatitis C to continue spreading through vulnerable populations, as opposed to eradicating the disease altogether,"" the letter said.Gilead spokeswoman Amy Flood said the company received Healey's letter and requested a meeting to discuss the issues. ""We agree with the attorney general about the importance of helping all hepatitis C patients  and that the advent of safe, effective regimens means we can now consider the possibility of eradicating the disease,"" Flood said. Insurers, politicians and patient groups have denounced prices of the two treatments, which can cure well over 90 percent of patients with the liver disease.Gilead contends that the drugs greatly reduce long-term healthcare costs by preventing liver cancer and the need for transplants. More than three million Americans are believed to have the virus. Healey said a U.S. heroin epidemic has fueled rising hepatitis rates in the prison population as the virus can be spread by infected needles, and that state-run prisons are not eligible for discounts available to federal programs.""When you make a deliberate business decision that maximizes profit in a way you know will limit patients' access to that treatment ... it raises questions whether that is a fair practice under our consumer protection laws,"" Healey told Reuters. ""I hope we will have productive conversations. Gilead will make record profits even at a lower price,"" Healey added.RBC Capital Markets analyst Michael Yee said the threatened action amounted to more political rhetoric.""Since when is it a crime to have cured a global epidemic afflicting millions of patients, and the price is the same as the older drugs, which had less cure and bad side effects?,"" Yee asked. (Reporting by Ransdell Pierson and Bill Berkrot in New York; editing by Jonathan Oatis, Matthew Lewis and G Crosse)",2016-01-27,GILD,"Wed Jan 27, 2016 | 4:49pm EST",UPDATE 3-Massachusetts official challenges Gilead's hepatitis C drug prices,http://www.reuters.com//article/gilead-sciences-massachusetts-idUSL2N15B1GS?type=companyNews
265,"   By Ransdell Pierson  Massachusetts' attorney general is studying whether the prices of Gilead Sciences Inc's blockbuster treatments for hepatitis C violate state law, according to a letter the prosecutor sent to the California drugmaker.The letter from Attorney General Maura Healey to Gilead Chief Executive Officer John Martin, dated Jan. 22, asked the biotechnology company to reconsider its pricing for Sovaldi and Harvoni, Gilead's treatments with list prices of $84,000 and $94,500, respectively, per course of treatment.""My office is considering whether Gilead's pricing strategy with respect to Sovaldi and Harvoni may constitute an unfair trade practice in violation of Massachusetts law,"" Healey said in the letter, a copy of which was viewed by Reuters via email.Shares of Gilead were down 2.1 percent at $90.30 on the Nasdaq on Wednesday, outpacing the 0.3 percent decline for the Nasdaq Biotech Index. Gilead has been harshly criticized by insurers, politicians and patient groups for prices of the two treatments, which can cure well over 90 percent of patients with the liver disease. The Foster City, California-based company has defended its prices, saying the drugs greatly reduce long-term costs to the healthcare system by preventing liver cancer and the need for liver transplants.RBC Capital Markets analyst Michael Yee said the targeting of Gilead was more political rhetoric. ""Since when is it a crime to have cured a global epidemic afflicting millions of patients, and the price is the same as the older drugs, which had less cure and bad side effects?"" Yee said.Healey said as many as 3.9 million Americans are infected with the potentially fatal hepatitis C virus, which can steadily damage the liver over decades, and that fewer than 10 percent have been treated. More than 130 million people worldwide are believed to be infected. She accused Gilead of pricing the drugs ""in a manner that effectively allows hepatitis C to continue spreading through vulnerable populations, as opposed to eradicating the disease altogether, (resulting) in massive public harm.""""Patients do not benefit from a drug they cannot afford,"" Healey said, noting that Gilead sells Sovaldi for roughly $10 per pill in Egypt, but $1,000 per pill in the United States.The attorney general's civil enforcement attorneys will continue to examine the potential claim for unfair commercial conduct, Healey said in her letter.Gilead officials could not immediately be reached for comment.",2016-01-27,GILD,"Wed Jan 27, 2016 | 11:19am EST",Massachusetts challenges Gilead's hepatitis C drug prices,http://www.reuters.com//article/gilead-sciences-massachusetts-idUSL2N15B1GT?type=companyNews
266,"  Jan 27 Massachusetts' attorney general is studying whether the prices of Gilead Sciences Inc's  blockbuster treatments for hepatitis C violate state law, according to a letter the prosecutor sent to the California drugmaker.The letter from Attorney General Maura Healey to Gilead Chief Executive Officer John Martin, dated Jan. 22, asked the biotechnology company to reconsider its pricing for Sovaldi and Harvoni, Gilead's treatments with list prices of $84,000 and $94,500, respectively, per course of treatment. ""My office is considering whether Gilead's pricing strategy with respect to Sovaldi and Harvoni may constitute an unfair trade practice in violation of Massachusetts law,"" Healey said in the letter, a copy of which was supplied by email to Reuters. Gilead has been harshly criticized by insurers, politicians and patient groups for prices of the two treatments, which can cure well over 90 percent of patients with the liver disease. The Foster City, California-based company has defended its prices, saying the drugs greatly reduce long-term costs to the healthcare system by preventing liver cancer and the need for liver transplants. Gilead did not immediately respond to an email seeking comment.   (Reporting by Ransdell Pierson; Additional reporting by Bill Berkrot; Editing by Jonathan Oatis)",2016-01-27,GILD,"Wed Jan 27, 2016 | 10:12am EST",Massachusetts challenges Gilead's hepatitis C drug prices,http://www.reuters.com//article/gilead-sciences-massachusetts-idUSL2N15B1CY?type=companyNews
267,"   By Deena Beasley and Caroline Humer  U.S. health insurers and pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.The Food and Drug Administration on Thursday approved Merck's Zepatier for treatment of patients infected with the most common form of the liver-destroying virus, genotype 1, as well as the less common genotype 4.The list price for the new drug is $54,600 for a 12-week regimen - compared with $94,500 for Gilead Sciences Inc's Harvoni. A multi-pill regimen, Viekira Pak, from AbbVie Inc has a list price near $83,000.Express Scripts Holding Co, the largest manager of U.S. prescription drug plans, CVS Health Corp, the No. 2 drug benefit manager, as well as health insurers Aetna Inc and Anthem Inc told Reuters on Friday that they are evaluating the new drug in terms of medical benefit and cost.AbbVie in late 2014 secured an exclusive contract with Express Scripts, resulting in Gilead being forced to discount its own contract prices with a range of other payers. Merck said it priced Zepatier in line with net prices for competing drugs.""We look forward to working with Merck,"" Express Scripts said in an emailed statement. ""Having multiple, clinically effective options allows us to again leverage competition and make medicine more affordable for our clients."" No changes have been made as yet to Express Scripts' preferred formulary, but Harvoni will be added to its Medicare formulary on March 1.CVS, which now gives preferred status to Gilead's hepatitis C drugs, said that it is ""employing a strategic assessment of the therapy landscape and engaging with drugmakers to evaluate options.""Aetna, which also lists Gilead drugs as preferred hepatitis C options, said it plans ""a thorough review of Merck's new hepatitis C drug."" Brian Skorney, an analyst at financial services firm Baird, said Merck will likely discount its price by at least 20 percent, due in part to rebates that are required by law to certain government-sponsored healthcare plans. He expected a negative market reaction ""as it could indicate additional pricing pressures.""Shares of Gilead were down 5 percent at $83.00 in Friday Nasdaq trading - their lowest since June 2014. Merck shares were up 2 percent at $50.35 on the New York Stock Exchange.Analysts estimate that Gilead, with $14 billion in hepatitis C drug sales for the first nine months of 2015, controls about 93 percent of the U.S. market, compared with AbbVie's 7 percent. ""Given Merck's interest in participating in such a large market, we model and fully expect increased price competition and we also view Merck's list price as a rational way to stay out of the drug pricing spotlight,"" Seamus Fernandez, an analyst with healthcare investment bank Leerink, said in a research note.UBS has forecast that Merck will get 8 percent of the U.S.  genotype 1 market this year, rising to 15 percent in 2019.Both Zepatier and Viekira Pak require periodic liver function tests. In addition, Harvoni remains the only eight-week treatment option for genotype 1 patients. (Reporting by Deena Beasley and Caroline Humer. Additional reporting by Bill Berkrot; Editing by Andrew Hay)",2016-01-29,GILD,"Fri Jan 29, 2016 | 4:02pm EST",UPDATE 1-Payers see price leverage with entry of Merck hepatitis C drug,http://www.reuters.com//article/merck-co-gilead-sciences-hepatitis-idUSL2N15D2AM?type=companyNews
268,"   By Deena Beasley and Caroline Humer  Jan 29 U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.The Food and Drug Administration on Thursday approved Merck's Zepatier for treatment of patients infected with the most common form of the liver-destroying virus, genotype 1, as well as the less common genotype 4.The list price for the new drug is $54,600 for a 12-week regimen - compared with $94,500 for Gilead Sciences Inc's  Harvoni. A multi-pill regimen, Viekira Pak, from AbbVie Inc has a list price near $83,000.AbbVie in late 2014 secured an exclusive contract with Express Scripts Holding Co, the largest manager of U.S.  prescription drug plans, which forced Gilead to discount its own contract prices with a range of other payers. Merck said it priced Zepatier in line with net prices for competing drugs. ""We look forward to working with Merck,"" Express Scripts said in an emailed statement on Friday. ""Having multiple, clinically effective options allows us to again leverage competition and make medicine more affordable for our clients while ensuring appropriate patient access.""No changes have been made as yet to Express Scripts' preferred formulary, but Harvoni will be added to its Medicare formulary on March 1. CVS Health Corp, the No. 2 drug benefit manager, which now gives preferred status to Gilead's hepatitis C drugs, said in an email that it is ""employing a strategic assessment of the therapy landscape and engaging with drugmakers to evaluate options.""Shares of Gilead were down 5 percent at $83.00 in Friday Nasdaq trading - their lowest since June 2014. Merck shares were up 2 percent at $50.35 on the New York Stock Exchange. Analysts estimate that Gilead, with $14 billion in hepatitis C drug sales for the first nine months of 2015, controls about 93 percent of the U.S. market, compared with AbbVie's 7 percent.""Given Merck's interest in participating in such a large market, we model and fully expect increased price competition and we also view Merck's list price as a rational way to stay out of the drug pricing spotlight,"" Leerink analyst Seamus Fernandez said in a research note.UBS has forecast that Merck will get 8 percent of the U.S.  genotype 1 market this year, rising to 15 percent in 2019.Both Zepatier and Viekira Pak require periodic liver function tests. In addition, Harvoni remains the only eight-week treatment option for genotype 1 patients.   (Reporting by Deena Beasley; Editing by Andrew Hay)",2016-01-29,GILD,"Fri Jan 29, 2016 | 1:40pm EST",Payers see price leverage with entry of Merck hepatitis C drug,http://www.reuters.com//article/merck-co-gilead-sciences-hepatitis-idUSL2N15D1MX?type=companyNews
269,"   By Deena Beasley  U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.The list price for Zepatier will be $54,600 for a 12-week regimen, which Merck said it expects ""to be in the range of net prices"" for comparable treatments.Gilead Sciences Inc, which secured an early lead in the lucrative market for oral hepatitis C drugs with the $1,000-per-pill Sovaldi, currently sells an enhanced version of that drug as a single-tablet regimen called Harvoni at a list price of $94,500. AbbVie Inc followed in late 2014 with a multi-pill regimen. Nevertheless, AbbVie secured exclusive contracts with payers such as pharmacy benefit manager Express Scripts Holding Co, forcing Gilead to discount its own contract prices. Gilead has continued to dominate the market with hepatitis C drug sales of more than $14 billion in the first nine months of 2015.The Food and Drug Administration approved Zepatier, with or without the older antiviral drug ribavirin, for patients infected with the most common form of hepatitis C, genotype 1, as well as the less common genotype 4. The new drug's FDA label says liver-related blood tests should be performed prior to starting therapy and at certain times during treatment.Clinical trials found that 12 or 16 weeks of treatment with Merck's Zepatier reduced the virus to undetectable levels, which is considered a cure, in more than 94 percent of patients, the FDA said in a statement. Hepatitis C infects an estimated 3.2 million Americans. (Reporting by Deena Beasley; Editing by Leslie Adler, Bernard Orr)",2016-01-29,GILD,"Thu Jan 28, 2016 | 7:50pm EST",FDA approves Merck's new hepatitis C pill,http://www.reuters.com//article/us-merck-co-hepatitis-fda-idUSKCN0V631S?type=companyNews
270,"   By Deena Beasley  U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.The list price for Zepatier will be $54,600 for a 12-week regimen, which Merck said it expects ""to be in the range of net prices"" for comparable treatments.Gilead Sciences Inc, which secured an early lead in the lucrative market for oral hepatitis C drugs with the $1,000-per-pill Sovaldi, currently sells an enhanced version of that drug as a single-tablet regimen called Harvoni at a list price of $94,500. AbbVie Inc followed in late 2014 with a multi-pill regimen. Nevertheless, AbbVie secured exclusive contracts with payers such as pharmacy benefit manager Express Scripts Holding Co, forcing Gilead to discount its own contract prices. Gilead has continued to dominate the market with hepatitis C drug sales of more than $14 billion in the first nine months of 2015.The Food and Drug Administration approved Zepatier, with or without the older antiviral drug ribavirin, for patients infected with the most common form of hepatitis C, genotype 1, as well as the less common genotype 4. The new drug's FDA label says liver-related blood tests should be performed prior to starting therapy and at certain times during treatment.Clinical trials found that 12 or 16 weeks of treatment with Merck's Zepatier reduced the virus to undetectable levels, which is considered a cure, in more than 94 percent of patients, the FDA said in a statement. Hepatitis C infects an estimated 3.2 million Americans. (Reporting by Deena Beasley; Editing by Leslie Adler, Bernard Orr)",2016-01-29,GILD,"Thu Jan 28, 2016 | 7:50pm EST",UPDATE 1-U.S. FDA approves Merck's new hepatitis C pill,http://www.reuters.com//article/merck-co-hepatitis-fda-idUSL2N15C3PV?type=companyNews
271,"   By Deena Beasley | LOS ANGELES  LOS ANGELES Gilead Sciences Inc's (GILD.O) hepatitis C drug sales edged past Wall Street estimates in the fourth quarter, helped by strong sales in Japan, but U.S. results were weaker than expected.The company, which faces growing competition in the lucrative hepatitis C market, projected total 2016 product sales of $30 billion to $31 billion, in line with the average Wall Street estimate of $30.68 billion as compiled by ISI Evercore.For 2015, Gilead's product sales totaled $32.15 billion. ""The most prolific growth story in the large-cap biotech for the last three years just guided sales down,"" RBC Capital Markets analyst Michael Yee said. ""To some extent they are a victim of their own success.""Gilead said it will continue to seek growth through partnerships and acquisitions. The company also increased its dividend by 10 percent, and said it would buy back an additional $12 billion of its stock.""The environment has shifted dramatically in our favor"" in terms of acquisition opportunities, Gilead Chief Operating Officer John Milligan said on a conference call, referring to the recent stock market selloff. Milligan has been named Gilead's next chief executive officer as of March 10, when current CEO John Martin will become executive chairman.Gilead's fourth quarter product sales rose 16 percent to $8.4 billion. Sales of hepatitis C drugs Sovaldi and Harvoni totaled $4.9 billion, ahead of the $4.45 billion average Wall Street estimate.Adjusted earnings totaled $3.32 per share, beating the average Wall Street estimate of $3.00 per share, according to Thomson Reuters I/B/E/S. ""It was a strong overall quarter, driven by strong Japan sales, but U.S. sales were lighter than expected,"" said RBC's Yee. ""Japan is likely taking a price reduction for Gilead's drugs, so there will be questions about that.""Shares of Gilead edged up 60 cents to $83.30 in after hours trading. The stock has been under pressure following recent U.S. regulatory approval of Merck & Co Inc's (MRK.N) new hepatitis C drug.Merck's drug will have a list price of $54,600 for a 12-week regimen. Gilead's Harvoni is listed at $94,500, but is steeply discounted under contracts with health insurers and other payers, including the U.S. Department of Veterans Affairs.  Gilead officials repeatedly said they were confident in the safety profiles and ""real-world"" results from treatment with Harvoni and Sovaldi, and did not expect their prices to be affected by Merck's drug.Gilead drew fire two years ago when it launched Sovaldi, the first in a new class of hepatitis C drugs considered to be a cure for the liver-destroying disease, at a price of $84,000 per course of treatment. An estimated 3.2 million Americans are infected with hepatitis C and insurers have responded by closely monitoring which patients should first be treated with the new drugs.The company estimated on Tuesday that about 3 million Americans are still infected with hepatitis C, including about 1.5 million who remain undiagnosed. (Reporting by Deena Beasley; Editing by Richard Chang)",2016-02-02,GILD,"Tue Feb 2, 2016 | 6:34pm EST","Gilead hepatitis C drug sales beat estimates, but growth stalls",http://www.reuters.com//article/us-gilead-sciences-results-idUSKCN0VB2GY?type=companyNews
272,"   By Deena Beasley | LOS ANGELES  LOS ANGELES Gilead Sciences Inc's (GILD.O) hepatitis C drug sales edged past Wall Street estimates in the fourth quarter, helped by strong sales in Japan, but U.S. results were weaker than expected.The company, which faces growing competition in the lucrative hepatitis C market, projected total 2016 product sales of $30 billion to $31 billion, in line with the average Wall Street estimate of $30.68 billion as compiled by ISI Evercore.For 2015, Gilead's product sales totaled $32.15 billion. ""The most prolific growth story in the large-cap biotech for the last three years just guided sales down,"" RBC Capital Markets analyst Michael Yee said. ""To some extent they are a victim of their own success.""Gilead said it will continue to seek growth through partnerships and acquisitions. The company also increased its dividend by 10 percent, and said it would buy back an additional $12 billion of its stock.""The environment has shifted dramatically in our favor"" in terms of acquisition opportunities, Gilead Chief Operating Officer John Milligan said on a conference call, referring to the recent stock market selloff. Milligan has been named Gilead's next chief executive officer as of March 10, when current CEO John Martin will become executive chairman.Gilead's fourth quarter product sales rose 16 percent to $8.4 billion. Sales of hepatitis C drugs Sovaldi and Harvoni totaled $4.9 billion, ahead of the $4.45 billion average Wall Street estimate.Adjusted earnings totaled $3.32 per share, beating the average Wall Street estimate of $3.00 per share, according to Thomson Reuters I/B/E/S. ""It was a strong overall quarter, driven by strong Japan sales, but U.S. sales were lighter than expected,"" said RBC's Yee. ""Japan is likely taking a price reduction for Gilead's drugs, so there will be questions about that.""Shares of Gilead edged up 60 cents to $83.30 in after hours trading. The stock has been under pressure following recent U.S. regulatory approval of Merck & Co Inc's (MRK.N) new hepatitis C drug.Merck's drug will have a list price of $54,600 for a 12-week regimen. Gilead's Harvoni is listed at $94,500, but is steeply discounted under contracts with health insurers and other payers, including the U.S. Department of Veterans Affairs.  Gilead officials repeatedly said they were confident in the safety profiles and ""real-world"" results from treatment with Harvoni and Sovaldi, and did not expect their prices to be affected by Merck's drug.Gilead drew fire two years ago when it launched Sovaldi, the first in a new class of hepatitis C drugs considered to be a cure for the liver-destroying disease, at a price of $84,000 per course of treatment. An estimated 3.2 million Americans are infected with hepatitis C and insurers have responded by closely monitoring which patients should first be treated with the new drugs.The company estimated on Tuesday that about 3 million Americans are still infected with hepatitis C, including about 1.5 million who remain undiagnosed. (Reporting by Deena Beasley; Editing by Richard Chang)",2016-02-02,GILD,"Tue Feb 2, 2016 | 6:34pm EST","UPDATE 2-Gilead hepatitis C drug sales beat estimates, but growth stalls",http://www.reuters.com//article/gilead-sciences-results-idUSL2N15H2WS?type=companyNews
273,"  Feb 2 Gilead Sciences Inc's sales of hepatitis C drugs beat Wall Street estimates in the fourth quarter, helping to push the biotechnology company's shares 2 percent higher on Tuesday.The company also increased its dividend by 10 percent, and said it would buy back an additional $12 billion in stock.For full-year 2016, Gilead projected total product sales of $30 billion to $31 billion, in line with the average Wall Street estimate of $30.68 billion as compiled by ISI Evercore. Net profit rose more than 30 percent to $4.7 billion, or $3.18 per share, compared with the year-ago quarter. Total fourth quarter product sales rose 16 percent to $8.4 billion. Sales of hepatitis C drugs Sovaldi and Harvoni totaled $4.9 billion, ahead of the $4.45 billion average Wall Street estimate. Shares of Gilead, which have been pressured by new competition from Merck & Co Inc in the hepatitis C market, were up $1.49 at $84.20 after hours.(Reporting by Deena Beasley; Editing by Richard Chang)",2016-02-02,GILD,"Tue Feb 2, 2016 | 4:20pm EST",Gilead hepatitis C drug sales edge past Wall Street estimates,http://www.reuters.com//article/gilead-sciences-results-idUSL2N15H1YX?type=companyNews
274,"  LONDON Drug companies are likely to launch seven ""blockbuster"" drugs in 2016, each with $1 billion-plus annual sales potential, led by new treatments for liver disease and HIV, according to a Thomson Reuters analysis.The assessment means the pharmaceuticals industry is on track for another productive year, although not as good as 2015, which saw the arrival of 11 new blockbusters.The two top hits of 2016 are tipped to be Intercept Pharmaceuticals' (ICPT.O) chronic liver disease drug obeticholic acid, with a consensus sales forecast of $2.6 billion in 2020, and Gilead Sciences' (GILD.O) new fixed dose HIV drug emtricitabine plus tenofovir alafenamide, on $2.0 billion. Other products expected to launch this year with forecast sales above $1 billion in 2020 include a new hepatitis C drug from Merck (MRK.N) and a leukemia medicine from AbbVie (ABBV.N), according to the annual ""Drugs to Watch"" report. Two keenly awaited Roche ROG.VX drugs, each with forecast sales of around $3 billion, are not on list because it is unclear if atezolizumab for cancer and ocrelizumab for multiple sclerosis will be commercially available this year or next.     (Reporting by Ben Hirschler Editing by Jeremy Gaunt)",2016-02-03,GILD,"Wed Feb 3, 2016 | 4:21am EST",Seven $1 billion-plus drugs seen reaching market in 2016,http://www.reuters.com//article/pharmaceuticals-blockbusters-idUSL8N15H2ME?type=companyNews
275,"  NEW YORK The tumble in share prices for biotechnology stocks has created some buying opportunities, with drugmakers Celgene Corp (CELG.O) and Gilead Sciences (GILD.O) poised for a 30 percent rise over the next year, Barron's said. Both companies currently rely on closely related medications for the bulk of their income, creating risk, but the potential for diversification either through developing new treatments or being bought out could provide substantial upside, the publication said. Celgene, which specializes in treatments for a blood plasma cell cancer called myeloma, could see double-digit growth for its Revlimid drug for years to come, with significant growth potential from overseas, Barron's said.  Despite negative publicity related to high prices on its hepatitis-C drugs, Gilead Sciences' products often cure patients within months, the publication said.""That word, cure, isn't used often enough by Big Pharma,"" Barron's said.  The company also expects to generate $85 billion in cumulative free cash through 2020, which the publication said it could use to buy new medicines or repurchase shares.   (Reporting By Luc Cohen; Editing by Sandra Maler)",2016-02-08,GILD,"Sun Feb 7, 2016 | 9:38pm EST","Celgene, Gilead Sciences shares could rise 30 percent: Barron's",http://www.reuters.com//article/us-pharmaceuticals-stocks-idUSKCN0VH053?type=companyNews
276,"  The U.S. Food and Drug Administration has expanded the use of Gilead Sciences Inc's blockbuster drug Harvoni to some hepatitis C patients in the advanced stage of cirrhosis, including those who have undergone liver transplant.Chronic hepatitis C patients often develop scarring and poor liver function also known as cirrhosis, which can lead to complications such as bleeding, jaundice, fluid accumulation in the abdomen and liver cancer.The once-daily pill, used in combination with antiviral ribavirin, was also approved to treat gentotype 1 and 4 liver transplant recipients with compensated cirrhosis, a slightly less severe form of the condition. AbbVie Inc had identified cases of hepatic decompensation and liver failure in patients with liver cirrhosis who were taking its medicines Viekira Pak and Technivie, the FDA said in October. Harvoni had $13.86 billion worldwide sales in 2015.  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)",2016-02-16,GILD,"Tue Feb 16, 2016 | 9:57am EST",FDA expands use of Gilead's liver drug to rare subset of patients,http://www.reuters.com//article/us-gilead-sciences-fda-hepatitis-idUSKCN0VP1UQ?type=companyNews
277,"  The U.S. Food and Drug Administration has expanded the use of Gilead Sciences Inc's blockbuster drug Harvoni to some hepatitis C patients in the advanced stage of cirrhosis, including those who have undergone liver transplant.Chronic hepatitis C patients often develop scarring and poor liver function also known as cirrhosis, which can lead to complications such as bleeding, jaundice, fluid accumulation in the abdomen and liver cancer.The once-daily pill, used in combination with antiviral ribavirin, was also approved to treat gentotype 1 and 4 liver transplant recipients with compensated cirrhosis, a slightly less severe form of the condition. AbbVie Inc had identified cases of hepatic decompensation and liver failure in patients with liver cirrhosis who were taking its medicines Viekira Pak and Technivie, the FDA said in October. Harvoni had $13.86 billion worldwide sales in 2015.  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian)",2016-02-16,GILD,"Tue Feb 16, 2016 | 9:57am EST",FDA expands use of Gilead's liver drug to rare subset of patients,http://www.reuters.com//article/gilead-sciences-fda-hepatitis-idUSL3N15V4L0?type=companyNews
278,"   By Rosmi Shaji  Regulus Therapeutics Inc said interim mid-stage data for its hepatitis C combination drug showed it had the potential to sharply reduce the duration of the treatment to four weeks from 12 weeks.The company's shares recorded their best day in more than 15 months, rising as much as 41 percent to $8.85 in heavy trading on Wednesday.Regulus tested its injectable drug, RG-101, separately with FDA-approved hepatitis C drugs such as Gilead Sciences Inc's Harvoni, Johnson & Johnson's Olysio, and Bristol Myers Squibb's Daklinza.Jefferies analyst Brian Abrahams said Gilead's hepatitis C drug sales may take a hit if Regulus's treatment turns out to be more effective in combination with drugs developed by its rivals. Gilead, with its two blockbuster drugs Harvoni and Sovaldi, has dominated the market for hepatitis C, which affects about 185 million people worldwide. Harvoni's total sales were $13.86 billion in 2015. However, the company has been facing growing competition from rival treatments developed by AbbVie Inc and Merck Inc. Gilead's shares fell 2 percent to $89.22 following Regulus's announcement.Wedbush securities analyst Liana Moussatos said she expected Regulus's drug to be priced either in line or less than the oral pills.Regulus enrolled 79 patients with chronic hepatitis C virus and 38 of these patients were being evaluated through eight weeks of follow up. The data showed 97 percent of these patients had a sustained reduction of the virus at eight weeks of the treatment.Analysts called Regulus's interim data set impressive but cautioned that longer follow-up period would be needed to asses the drug's curative potential.    Regulus said it expected to report 12-week response data in the second quarter. Most adverse events were mild to moderate though it appears there were two serious adverse events that required hospitalization, one possibly occurred after dosing, Abrahams said.Investors will be keen to know whether there will be any other adverse effects related to the treatment during the study, Cowen and Co analyst Eric Schmidt wrote in a note.Regulus shares were up 13 percent at $7.10 on the Nasdaq on Wednesday. (Reporting by Rosmi Shaji in Bengaluru; Editing by Sriraj Kalluvila and Anil d'Silva)",2016-02-17,GILD,"Wed Feb 17, 2016 | 1:16pm EST",UPDATE 2-Regulus hep C combo drug effective in mid-stage study,http://www.reuters.com//article/regulus-study-idUSL3N15W43R?type=companyNews
279,"  Gilead Sciences Inc's experimental cocktail to treat HIV received a green light from European regulators on Friday, boosting the chances of the drug being formally approved by the European Commission. The European Medicines Agency issued a positive opinion on the treatment, Descovy, a combination of emtricitabine and tenofovir alafenamide. Both drugs stop HIV from multiplying.The company is awaiting an approval from the U.S. Food and Drug Administration.One of Gilead's treatments for HIV, Truvada, is an approved drug to be taken in a PrEP regimen, a group of drugs recommended by the U.S. Centers for Disease Control and Prevention to help prevent HIV infection. Gilead's shares rose about 1 percent to $90.89 in light premarket trading on Friday. Europe's drug regulator also recommended approving hemophilia treatments from Biogen Inc and CSL Ltd as well as Eli Lilly & Co's psoriasis treatment. (bit.ly/1LhVgQZ)Eli Lilly's experimental drug, ixekizumab, belongs to a new class of psoriasis treatments called IL-17 receptor antagonists. The drug will compete directly with Novartis AG's newly approved Cosentyx.  (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza and Saumyadeb Chakrabarty)",2016-02-26,GILD,"Fri Feb 26, 2016 | 8:46am EST",Gilead's HIV drug gets closer to getting Europe approval,http://www.reuters.com//article/us-gilead-sciences-ema-idUSKCN0VZ1T7?type=companyNews
280,"  Gilead Sciences Inc's experimental cocktail to treat HIV received a green light from European regulators on Friday, boosting the chances of the drug being formally approved by the European Commission. The European Medicines Agency issued a positive opinion on the treatment, Descovy, a combination of emtricitabine and tenofovir alafenamide. Both drugs stop HIV from multiplying.The company is awaiting an approval from the U.S. Food and Drug Administration.One of Gilead's treatments for HIV, Truvada, is an approved drug to be taken in a PrEP regimen, a group of drugs recommended by the U.S. Centers for Disease Control and Prevention to help prevent HIV infection. Gilead's shares rose about 1 percent to $90.89 in light premarket trading on Friday. Europe's drug regulator also recommended approving hemophilia treatments from Biogen Inc and CSL Ltd as well as Eli Lilly & Co's psoriasis treatment. (bit.ly/1LhVgQZ)Eli Lilly's experimental drug, ixekizumab, belongs to a new class of psoriasis treatments called IL-17 receptor antagonists. The drug will compete directly with Novartis AG's newly approved Cosentyx.  (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza and Saumyadeb Chakrabarty)",2016-02-26,GILD,"Fri Feb 26, 2016 | 8:46am EST",UPDATE 1-Gilead's HIV drug gets closer to getting Europe approval,http://www.reuters.com//article/gilead-sciences-ema-idUSL3N16554Q?type=companyNews
281,"  Feb 26 EU Medicines Agency* Recommends Approval Of CSL Ltd's albutrepenonacog alfa to treat Haemophilia b * Scientific review of known risk of PML with the multiple sclerosis medicine Tysabri is now completed, with CHMP confirming PRAC recommendations * Gilead's Descovy (emtricitabine / tenofovir alafenamide) received a positive opinion for the treatment of HIV infection * Confirmed recommendations from PRAC to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors, a class of type 2 diabetes medicines  Source text (bit.ly/1LhVgQZ) Further company coverage:",2016-02-26,GILD,"Fri Feb 26, 2016 | 7:20am EST",BRIEF-Gilead's experimental cocktail for HIV gets positive EMA opinion,http://www.reuters.com//article/idUSFWN16502U?type=companyNews
282,"  March 1 Gilead Sciences* U.S. Food And Drug Administration Approves Gilead's Second Taf-Based single tablet regimen odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV-1 infection * U.S. Food and drug administration approves Gilead's second taf-based single tablet regimen Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV-1 infection * Odefsey has a boxed warning in its product label regarding risks of lactic acidosis/severe hepatomegaly with steatosis * Odefsey has a boxed warning in its product label regarding risks of post treatment acute exacerbation of Hepatitis B  Source text for Eikon:  Further company coverage:",2016-03-01,GILD,"Tue Mar 1, 2016 | 2:16pm EST",BRIEF-Gilead Sciences says U.S. FDA approves Odefsey,http://www.reuters.com//article/idUSASC08EH3?type=companyNews
283,"   By Jonathan Stempel  A Florida man admitted to conducting insider trading based on a tip he received from a former Morgan Stanley  broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, federal prosecutors said.Jay Fung, 42, of Delray Beach, pleaded guilty on Wednesday to conspiracy to commit securities fraud before U.S. District Judge Anne Thompson in Trenton, New Jersey.He also agreed to repay more than $760,000 of illegal profit and interest to settle related U.S. Securities and Exchange Commission civil charges, that regulator said.The former broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the SEC. Prosecutors said Dowd tipped his friend Fung about the merger of Gilead and Pharmasset on Nov. 18, 2011, three days before it was announced, after learning about it from a Pharmasset director who was the largest customer at Dowd's branch.Fung then illegally bought Pharmasset shares and call options, and sold them after the merger of the two makers of antiviral drugs was announced, prosecutors said. The merger valued Princeton, New Jersey-based Pharmasset at a roughly 89 percent premium over its share price at the time.     Authorities said Fung also gave Dowd kickbacks for the tip.Fung faces a maximum five years in prison at his June 20 sentencing, but is likely to get less under his plea agreement, which notes his cooperation with authorities. ""It has been a long process, and Mr. Fung is happy to put this behind him,"" said James Sallah, a lawyer for Fung.Dowd was sentenced to probation in his criminal case in April 2014, court records show. A lawyer for Dowd declined to comment on Wednesday.Gilead is based in Foster City, California.",2016-03-09,GILD,"Wed Mar 9, 2016 | 4:09pm EST",Florida man pleads guilty in Gilead insider trading case,http://www.reuters.com//article/insidertrading-plea-gileadsciences-idUSL1N16H22T?type=companyNews
284,"   By Jonathan Stempel  A Florida man admitted to conducting insider trading based on a tip he received from a former Morgan Stanley broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, federal prosecutors said.Jay Fung, 42, of Delray Beach, pleaded guilty on Wednesday to conspiracy to commit securities fraud before U.S. District Judge Anne Thompson in Trenton, New Jersey.He also agreed to repay more than $760,000 of illegal profit and interest to settle related U.S. Securities and Exchange Commission civil charges, that regulator said.The former broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the SEC. Prosecutors said Dowd tipped his friend Fung about the merger of Gilead and Pharmasset on Nov. 18, 2011, three days before it was announced, after learning about it from a Pharmasset director who was the largest customer at Dowd's branch.Fung then illegally bought Pharmasset shares and call options, and sold them after the merger of the two makers of antiviral drugs was announced, prosecutors said.The merger valued Princeton, New Jersey-based Pharmasset at a roughly 89 percent premium over its share price at the time.     Authorities said Fung also gave Dowd kickbacks for the tip. Fung faces a maximum five years in prison at his June 20 sentencing, but is likely to get less under his plea agreement, which notes his cooperation with authorities.""It has been a long process, and Mr. Fung is happy to put this behind him,"" said James Sallah, a lawyer for Fung. Dowd was sentenced to probation in his criminal case in April 2014, court records show. A lawyer for Dowd declined to comment on Wednesday.Gilead is based in Foster City, California. (Reporting by Jonathan Stempel in New York; Editing by Lisa Shumaker)",2016-03-09,GILD,"Wed Mar 9, 2016 | 4:04pm EST",Florida man pleads guilty in Gilead insider trading case,http://www.reuters.com//article/us-insidertrading-plea-gileadsciences-idUSKCN0WB2PD?type=companyNews
285,"   By Jonathan Stempel  A Florida man admitted to conducting insider trading based on a tip he received from a former Morgan Stanley broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, federal prosecutors said.Jay Fung, 42, of Delray Beach, pleaded guilty on Wednesday to conspiracy to commit securities fraud before U.S. District Judge Anne Thompson in Trenton, New Jersey.He also agreed to repay more than $760,000 of illegal profit and interest to settle related U.S. Securities and Exchange Commission civil charges, that regulator said.The former broker, Kevin Dowd, pleaded guilty in September 2013 to a criminal conspiracy charge, and has also settled with the SEC. Prosecutors said Dowd tipped his friend Fung about the merger of Gilead and Pharmasset on Nov. 18, 2011, three days before it was announced, after learning about it from a Pharmasset director who was the largest customer at Dowd's branch.Fung then illegally bought Pharmasset shares and call options, and sold them after the merger of the two makers of antiviral drugs was announced, prosecutors said.The merger valued Princeton, New Jersey-based Pharmasset at a roughly 89 percent premium over its share price at the time.     Authorities said Fung also gave Dowd kickbacks for the tip. Fung faces a maximum five years in prison at his June 20 sentencing, but is likely to get less under his plea agreement, which notes his cooperation with authorities.""It has been a long process, and Mr. Fung is happy to put this behind him,"" said James Sallah, a lawyer for Fung. Dowd was sentenced to probation in his criminal case in April 2014, court records show. A lawyer for Dowd declined to comment on Wednesday.Gilead is based in Foster City, California. (Reporting by Jonathan Stempel in New York; Editing by Lisa Shumaker)",2016-03-09,GILD,"Wed Mar 9, 2016 | 4:04pm EST",Florida man pleads guilty in Gilead insider trading case,http://www.reuters.com//article/insidertrading-plea-gileadsciences-idUSL1N16H1SL?type=companyNews
286,"   By Lewis Krauskopf | NEW YORK  NEW YORK Shares of Gilead Sciences Inc (GILD.O) are trading at ultra cheap levels as investors broadly shed biotech holdings and question what the company could do for an encore after several years of torrid growth.While biotech and healthcare stocks have underperformed the broader market all year, Gilead stands out for its low forward price-to-earnings ratio, which is widely used by investors to value stocks.The stock closed at $89.53 on Thursday, having lost more than one-fourth of its value since hitting an all-time high of $123.37 in June.That put the share price at 7.3 times earnings estimates for the next 12 months. No other large U.S. pharmaceutical or biotechnology company trades below a ratio of 10.9, according to Thomson Reuters data.Gilead's valuation in recent weeks has been the lowest since it became a solidly profitable company more than a decade ago. Over the past 10 years, the stock has traded at a forward price-to-earnings ratio of 16.6 times, on average.By other metrics, the stock does not look as appealing. Using a measure of a stock's value called a PEG ratio, which factors in Gilead's lackluster growth outlook and its price-to-earnings ratio, the shares look at least twice as expensive as the average big biotech stock, analysts' estimates show.""People are just skeptical about the long term earnings power of the company,"" said John Fraunces, co-manager for the Turner Investments medical sciences fund in Berwyn, Pennsylvania, which does not own Gilead shares. VICTIM OF OWN SUCCESS To an extent, Gilead is a victim of its own success. The company, the largest biotech by market value at $120 billion, built upon a leading HIV medicine franchise by adding hepatitis C treatments that revolutionized care for the serious liver disease.That medical advance was reflected in its financial performance. From 2013 through last year, Gilead's sales tripled to nearly $33 billion, while earnings shot up more than six times to $12.61 per share. But investors are concerned that Gilead's hepatitis C franchise sales may have peaked.Earnings per share are expected to fall 3 percent this year with no growth expected through 2019, while sales are expected to recede to about $29 billion over the next four years, according to the average estimate of analysts polled by Thomson Reuters.Gilead shares have declined 11 percent in 2016, though that is less than the 19 percent drops for big biotech peers Biogen Inc (BIIB.O) and Celgene Corp (CELG.O), while the Nasdaq Biotechnology Index .NBI has fallen 27 percent. Investors said the company's future could rest in part on what it does with its balance sheet: Gilead amassed $26.2 billion in cash, cash equivalents and marketable securities by the end of 2015.The company's dividend yield sits at 1.9 percent, below the roughly 2.3 percent average for companies in the S&P 500 Health Care index .SPXHC, while it bought back $10 billion worth of its stock last year.A major acquisition of promising companies or new medicines could help propel sales and earnings, but investors are worried about the price of buying such growth. They had also fretted over the $11 billion Gilead paid in 2011 for Pharmasset, but that deal ended up being the foundation for its hepatitis C franchise success.""What investors are worried about is, 'Does management go out and overpay for an acquisition?'"" said John Toohey, head of equities at USAA Investments in San Antonio, which owns Gilead shares.The stock is ""exceptionally cheap,"" Toohey said. ""The (valuation) gap is so big between Gilead and other stocks, we're willing to be patient."" (Reporting by Lewis Krauskopf; editing by Linda Stern and Richard Chang)",2016-03-18,GILD,"Fri Mar 18, 2016 | 7:02am EDT",Gilead shares look cheap but investors fret over growth,http://www.reuters.com//article/us-gilead-sciences-stocks-idUSKCN0WK16I?type=companyNews
287,"   By Lewis Krauskopf | NEW YORK  NEW YORK Shares of Gilead Sciences Inc (GILD.O) are trading at ultra cheap levels as investors broadly shed biotech holdings and question what the company could do for an encore after several years of torrid growth.While biotech and healthcare stocks have underperformed the broader market all year, Gilead stands out for its low forward price-to-earnings ratio, which is widely used by investors to value stocks.The stock closed at $89.53 on Thursday, having lost more than one-fourth of its value since hitting an all-time high of $123.37 in June.That put the share price at 7.3 times earnings estimates for the next 12 months. No other large U.S. pharmaceutical or biotechnology company trades below a ratio of 10.9, according to Thomson Reuters data.Gilead's valuation in recent weeks has been the lowest since it became a solidly profitable company more than a decade ago. Over the past 10 years, the stock has traded at a forward price-to-earnings ratio of 16.6 times, on average.By other metrics, the stock does not look as appealing. Using a measure of a stock's value called a PEG ratio, which factors in Gilead's lackluster growth outlook and its price-to-earnings ratio, the shares look at least twice as expensive as the average big biotech stock, analysts' estimates show.""People are just skeptical about the long term earnings power of the company,"" said John Fraunces, co-manager for the Turner Investments medical sciences fund in Berwyn, Pennsylvania, which does not own Gilead shares. VICTIM OF OWN SUCCESS To an extent, Gilead is a victim of its own success. The company, the largest biotech by market value at $120 billion, built upon a leading HIV medicine franchise by adding hepatitis C treatments that revolutionized care for the serious liver disease.That medical advance was reflected in its financial performance. From 2013 through last year, Gilead's sales tripled to nearly $33 billion, while earnings shot up more than six times to $12.61 per share. But investors are concerned that Gilead's hepatitis C franchise sales may have peaked.Earnings per share are expected to fall 3 percent this year with no growth expected through 2019, while sales are expected to recede to about $29 billion over the next four years, according to the average estimate of analysts polled by Thomson Reuters.Gilead shares have declined 11 percent in 2016, though that is less than the 19 percent drops for big biotech peers Biogen Inc (BIIB.O) and Celgene Corp (CELG.O), while the Nasdaq Biotechnology Index .NBI has fallen 27 percent. Investors said the company's future could rest in part on what it does with its balance sheet: Gilead amassed $26.2 billion in cash, cash equivalents and marketable securities by the end of 2015.The company's dividend yield sits at 1.9 percent, below the roughly 2.3 percent average for companies in the S&P 500 Health Care index .SPXHC, while it bought back $10 billion worth of its stock last year.A major acquisition of promising companies or new medicines could help propel sales and earnings, but investors are worried about the price of buying such growth. They had also fretted over the $11 billion Gilead paid in 2011 for Pharmasset, but that deal ended up being the foundation for its hepatitis C franchise success.""What investors are worried about is, 'Does management go out and overpay for an acquisition?'"" said John Toohey, head of equities at USAA Investments in San Antonio, which owns Gilead shares.The stock is ""exceptionally cheap,"" Toohey said. ""The (valuation) gap is so big between Gilead and other stocks, we're willing to be patient."" (Reporting by Lewis Krauskopf; editing by Linda Stern and Richard Chang)",2016-03-18,GILD,"Fri Mar 18, 2016 | 7:02am EDT",Gilead shares look cheap but investors fret over growth,http://www.reuters.com//article/gilead-sciences-stocks-idUSL2N16P1BX?type=companyNews
288,"   By Rory Carroll and Andrew Chung | SAN JOSE  SAN JOSE A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.The verdict in federal court in San Jose, California, is a major setback for Gilead, whose drugs Sovaldi and Harvoni brought in $19.2 billion in worldwide sales last year. Merck has demanded more than $2 billion in damages and a royalty of 10 percent of Gilead's sales going forward. The jury must now decide exactly how much Gilead owes. In a statement, Gilead spokeswoman Michele Rest said, ""Although we are disappointed by the jury's verdict today, there are a number of remaining issues to be decided by the jury and the judge.""Merck spokeswoman Lainie Keller said the verdict ""accurately reflects the evidence in this case,"" adding that strong patent protection is essential to innovation. The trial, which began on March 7, came as pharmaceutical companies race to capture a slice of the lucrative market for the newest hepatitis C treatments, which can cure well over 90 percent of patients with the liver disease. Insurers, politicians and patient groups have denounced the list prices of the drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen. In January, the U.S. Food and Drug Administration approved Merck's Zepatier drug.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.",2016-03-22,GILD,"Tue Mar 22, 2016 | 5:46pm EDT",Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com//article/gilead-sciences-merck-co-verdict-idUSL2N16U2A5?type=companyNews
289,"   By Andrew Chung | NEW YORK, March 22  NEW YORK, March 22 A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.  The verdict in federal court in San Jose, California, is a major setback for Gilead, whose drugs Sovaldi and Harvoni brought in $19.2 billion in worldwide sales last year. Merck has demanded more than $2 billion in damages and a royalty of 10 percent of Gilead's sales going forward. The jury must now decide exactly how much Gilead owes.   (Reporting by Andrew Chung; Editing by Jonathan Oatis) ",2016-03-22,GILD,"Tue Mar 22, 2016 | 5:27pm EDT",Merck patents on Hepatitis C treatment found valid in dispute with Gilead,http://www.reuters.com//article/gilead-sciences-merck-co-verdict-idUSL2N16U26U?type=companyNews
290,"   By Rory Carroll and Andrew Chung | SAN JOSE  SAN JOSE Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.After returning its verdict in favor of Merck on Tuesday, the jury in San Jose, California immediately began hearing evidence on how much Gilead owes Merck for infringing the patents.Bruce Genderson, an attorney for Merck, said the company is seeking a 10 percent royalty on Gilead's U.S. sales of nearly $21 billion for 2014 and 2015. Merck has also asked for a royalty of 10 percent going forward on Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni, which generated $19.2 billion in worldwide sales last year.  Following the verdict, Gilead shares fell $1.92 to $91.80 in after-hours trading. Merck rose 57 cents to $53.60.In a statement, Gilead spokeswoman Michele Rest said, ""Although we are disappointed by the jurys verdict today, there are a number of remaining issues to be decided by the jury and the judge."" She declined to comment on any potential appeal. A spokeswoman for Merck said the verdict ""accurately reflects the evidence in this case."" The trial, which began on March 7, came as pharmaceutical companies race to capture a slice of the lucrative market for the newest hepatitis C treatments, which can cure well over 90 percent of patients with the liver disease. Insurers, politicians and patient groups have denounced the list prices of the drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen. In January, the U.S. Food and Drug Administration approved Merck's Zepatier drug.In 2013 Merck contacted Gilead saying the active ingredient in Gilead's drugs, sofosbuvir, infringed Merck's patents, according to court papers.  Foster City, California-based Gilead then asked the U.S. District Court for the Northern District of California in San Jose to declare the patents invalid, saying they do not clearly describe any disease fighting effects. Merck, based in Kenilworth, New Jersey, countersued for infringement. Gilead said in court filings that Merck played no role in sofosbuvir's discovery, but that when its breakthrough potential became clear, ""Merck came knocking on Gileads door with its two patents in hand."" Last month, U.S. District Judge Beth Labson Freeman ruled that the sale and use of Gilead's drugs infringe Merck's patents.   Michael Yee, biotech analyst for RBC Capital Markets, said ""while it does not sound good that Gilead could theoretically owe billions of dollars in financial damages...it is a small amount relative to Gilead's $127 billion market cap."" He said he expected Gilead to appeal. The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung in New York and Rory Carroll in San Jose; additional reporting by Bill Berkrot; Editing by Alexia Garamfalvi, Chris Reese and Diane Craft)",2016-03-23,GILD,"Wed Mar 23, 2016 | 4:41am EDT",Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com//article/us-gilead-sciences-merck-co-verdict-idUSKCN0WO353?type=companyNews
291,"  * Crude falls more than 3 pct* Nike down after revenue misses estimates* Yum Brands up on talks to sell stake in China business* Indexes down: Dow 0.51 pct, S&P 0.63 pct, Nasdaq 1 pct   (Updates to afternoon)By Laila KearneyMarch 23 Falling oil and materials prices dragged the benchmark S&P 500 index lower for the year on Wednesday, while investors remained cautious a day after deadly bombing attacks in Belgium.Wall Street's fading five-week rally was further diminished  by comments over the past two days by U.S. Federal reserve officials, who indicated the possibility of more interest rate hikes than investors had anticipated.The possibility of more than the expected two rate hikes for 2016 has sent the dollar higher, pushing down commodity prices. ""That has caused somewhat of a headwind for stocks,"" said Bucky Hellwig, senior vice president at BB&T Wealth Management in Birmingham, Alabama.Gold and metals prices also fell as the dollar strengthened.U.S. Oil prices also fell more than 3 percent after data showing a rise in U.S. stockpiles last week rekindled worries about a global glut. Adding to the downturn, investors were deterred by the shortened trading week and uncertainty tied to Tuesday's bombings in Brussels, said Brad McMillan, chief investment officer at Commonwealth Financial in Waltham, Massachusetts.The Dow Jones industrial average fell 89.5 points, or 0.51 percent, to 17,493.07, the S&P 500 lost 12.84 points, or 0.63 percent, to 2,036.96 and the Nasdaq Composite  dropped 49.13 points, or 1.02 percent, to 4,772.53.Eight of the 10 major S&P sectors were lower, led by the 1.8-percent fall in the energy sector. Chevron  and ConocoPhillips were among the biggest decliners.Nike shares were down 3.5 percent at $62.71 after the world's largest footwear maker reported quarterly revenue below estimates. Gilead Sciences was down 3.5 percent at $90.43 and Merck was up 0.4 percent. A federal jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.Gilead was the biggest drag on the S&P 500 and the Nasdaq.Vertex Pharmaceuticals fell 6.1 percent to $81.45 after Goldman Sachs cuts its price target on the stock.Yum Brands was up 2 percent at $80.49 after the Wall Street Journal reported that the fast-food chain's owner was in  talks with KKR about a possible sale of a 19.9-percent stake in its China business.Declining issues outnumbered advancing ones on the NYSE by 2,137 to 818, for a 2.61-to-1 ratio on the downside; on the Nasdaq, 2,086 issues fell and 662 advanced for a 3.15-to-1 ratio favoring decliners.The S&P 500 posted 17 new 52-week highs and no new lows; the Nasdaq recorded 19 new highs and 34 new lows.     (Reporting by Abhiram Nandakumar in Bengaluru; Editing by Nick Zieminski)",2016-03-23,GILD,"Wed Mar 23, 2016 | 2:55pm EDT",US STOCKS-Dropping commodities prices drag down Wall Street,http://www.reuters.com//article/usa-stocks-idUSL2N16V1N2?type=companyNews
292,"  * Crude falls more 2 pct* Nike down after revenue misses estimates* Yum Brands up on talks to sell stake in China business* Indexes down: Dow 0.16 pct, S&P 0.35 pct, Nasdaq 0.73 pct   (Updates to early afternoon)By Abhiram NandakumarMarch 23 A decline in energy stocks weighed on Wall Street on a quiet Wednesday as investors shied away from big bets after the Brussels attacks and ahead of the long Easter weekend.Oil prices fell more than 2 percent after data showing a rise in U.S. stockpiles last week rekindled worries about a global glut. Gold and metals prices also fell as the dollar strengthened on hawkish comments from U.S. Federal Reserve policymakers.The Dow Jones industrial average held on to meager gains for the year after a five-week rally helped the market recover from a steep selloff at the start of 2016. The S&P 500 flip-flopped between gains and losses for the year.""We don't like to have big positions over long weekends, and we'll probably work on cleaning those up over the next few days so we can watch basketball in peace,"" said Doug Burtnick, senior investment manager at Aberdeen Asset Management.Commodity prices, strength in the dollar and uncertainty about interest rates were having a bigger impact on the market on a day with relatively few news events, he added. At 12:27 p.m. ET (1627 GMT), the Dow Jones industrial average was down 28.93 points, or 0.16 percent, at 17,553.64, the S&P 500 was down 7.13 points, or 0.35 percent, at 2,042.67 and the Nasdaq Composite was down 35.22 points, or 0.73 percent, at 4,786.44.Eight of the 10 major S&P sectors were lower, led by the 1.5 percent fall in the energy sector. Chevron's 2 percent fall weighed the most on the sector.Nike shares were down 3.5 percent at $62.66 after the world's largest footwear maker reported quarterly revenue below estimates. The stock was the biggest drag on the Dow. Gilead Sciences was down 3.3 percent at $90.71 after a federal jury upheld the validity of two Merck  patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C. Merck was up 0.2 percent.Gilead was the biggest drag on the S&P 500 and the Nasdaq.Vertex Pharmaceuticals was down 6.4 percent at $81.23 after Goldman Sachs cuts its price target on the stock.Yum Brands was up 2 percent at $80.53 after the Wall Street Journal reported that the fast-food chains owner was in  talks with KKR about a possible sale of a 19.9 percent stake in its China business.Declining issues outnumbered advancing ones on the NYSE by 2,006 to 875. On the Nasdaq, 2,006 issues fell and 670 rose.The S&P 500 index showed 14 new 52-week highs and no new lows, while the Nasdaq recorded 16 new highs and 29 new lows.   (Reporting by Abhiram Nandakumar in Bengaluru; Editing by Ted Kerr and Don Sebastian)",2016-03-23,GILD,"Wed Mar 23, 2016 | 12:59pm EDT",US STOCKS-Energy slide drags down indexes,http://www.reuters.com//article/usa-stocks-idUSL3N16V4GC?type=companyNews
293,"  * Crude falls more 2 pct* Nike down after revenue misses estimates* Indexes down: Dow 0.13 pct, S&P 0.22 pct, Nasdaq 0.56 pct   (Adds details, changes comment, updates prices)By Abhiram NandakumarMarch 23 A decline in energy stocks weighed on Wall Street on Wednesday as investors backed away from risk in a week marred by the Brussels attacks and shortened by the Good Friday holiday.Oil prices fell more than 2 percent after data showing a rise in U.S. stockpiles last week rekindled worries about a global glut.Gold and metals prices also fell as the dollar strengthened on hawkish comments from U.S. Federal Reserve policymakers. The Dow Jones industrial average held on to meager gains for the year after a five-week rally helped the market recover from a steep selloff at the start of 2016. The S&P 500 flip-flopped between gains and losses for the year.""We don't like to have big positions over long weekends, and we'll probably work on cleaning those up over the next few days so we can watch basketball in peace,"" said Doug Burtnick, senior investment manager at Aberdeen Asset Management.Commodity prices, strength in the dollar and uncertainty about interest rates were having a bigger impact on the market on a day with relatively few news events, he added. At 10:50 a.m. ET (1450 GMT), the Dow Jones industrial average was down 22.42 points, or 0.13 percent, at 17,560.15, the S&P 500 was down 4.49 points, or 0.22 percent, at 2,045.31 and the Nasdaq Composite was down 26.87 points, or 0.56 percent, at 4,794.79.Eight of the 10 major S&P sectors were lower, led by the 1.5 percent fall in the energy sector. Chevron's 2.2 percent fall weighed the most on the sector.Nike shares were down 4.1 percent at $61.23 after the world's largest footwear maker reported quarterly revenue below estimates. The stock was the biggest drag on the Dow. Gilead Sciences was down 3 percent at $90.94 after a federal jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C. Merck was up 0.8 percent.Gilead was the biggest drag on the S&P 500 and the Nasdaq.Vertex Pharmaceuticals was down 5 percent at $82.45 after Goldman Sachs cuts its price target on the stock.Declining issues outnumbered advancing ones on the NYSE by 2,020 to 780. On the Nasdaq, 1,927 issues fell and 600 advanced.The S&P 500 index showed eight new 52-week highs and no new lows, while the Nasdaq recorded 12 new highs and 23 new lows.   (Reporting by Abhiram Nandakumar in Bengaluru; Editing by Ted Kerr and Don Sebastian)",2016-03-23,GILD,"Wed Mar 23, 2016 | 11:23am EDT",US STOCKS-Decline in energy stocks weighs on Wall St,http://www.reuters.com//article/usa-stocks-idUSL3N16V475?type=companyNews
294,"   By Rory Carroll and Andrew Chung | SAN JOSE  SAN JOSE Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.After returning its verdict in favor of Merck on Tuesday, the jury in San Jose, California immediately began hearing evidence on how much Gilead owes Merck for infringing the patents.Bruce Genderson, an attorney for Merck, said the company is seeking a 10 percent royalty on Gilead's U.S. sales of nearly $21 billion for 2014 and 2015. Merck has also asked for a royalty of 10 percent going forward on Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni, which generated $19.2 billion in worldwide sales last year.  Following the verdict, Gilead shares fell $1.92 to $91.80 in after-hours trading. Merck rose 57 cents to $53.60.In a statement, Gilead spokeswoman Michele Rest said, ""Although we are disappointed by the jurys verdict today, there are a number of remaining issues to be decided by the jury and the judge."" She declined to comment on any potential appeal. A spokeswoman for Merck said the verdict ""accurately reflects the evidence in this case."" The trial, which began on March 7, came as pharmaceutical companies race to capture a slice of the lucrative market for the newest hepatitis C treatments, which can cure well over 90 percent of patients with the liver disease. Insurers, politicians and patient groups have denounced the list prices of the drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen. In January, the U.S. Food and Drug Administration approved Merck's Zepatier drug.In 2013 Merck contacted Gilead saying the active ingredient in Gilead's drugs, sofosbuvir, infringed Merck's patents, according to court papers.  Foster City, California-based Gilead then asked the U.S. District Court for the Northern District of California in San Jose to declare the patents invalid, saying they do not clearly describe any disease fighting effects. Merck, based in Kenilworth, New Jersey, countersued for infringement. Gilead said in court filings that Merck played no role in sofosbuvir's discovery, but that when its breakthrough potential became clear, ""Merck came knocking on Gileads door with its two patents in hand."" Last month, U.S. District Judge Beth Labson Freeman ruled that the sale and use of Gilead's drugs infringe Merck's patents.   Michael Yee, biotech analyst for RBC Capital Markets, said ""while it does not sound good that Gilead could theoretically owe billions of dollars in financial damages...it is a small amount relative to Gilead's $127 billion market cap."" He said he expected Gilead to appeal. The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung in New York and Rory Carroll in San Jose; additional reporting by Bill Berkrot; Editing by Alexia Garamfalvi, Chris Reese and Diane Craft)",2016-03-23,GILD,"Wed Mar 23, 2016 | 4:41am EDT",UPDATE 3-Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com//article/gilead-sciences-merck-co-verdict-idUSL2N16U28H?type=companyNews
295,"  SAN JOSE, Calif., March 24 A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C. The damages amount was far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs, Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015.    (Reporting by Andrew Chung; Editing by Sandra Maler)  ",2016-03-24,GILD,"Thu Mar 24, 2016 | 7:59pm EDT",Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com//article/gilead-sciences-merck-co-damages-idUSL2N16W1AM?type=companyNews
296,"   By Laila Kearney  Wall Street closed lower on Wednesday as oil and materials share prices dropped while investors remained cautious a day after deadly bombing attacks in Belgium. The benchmark S&P 500 index fell back into negative territory for the year after closing positive on Friday for the first time in 2016.U.S. stocks' fading five-week rally was further diminished by comments over the past two days by Federal Reserve officials, who expressed views that suggested an appetite for more U.S. interest rate hikes than investors had anticipated.The possibility of more than the two expected rate hikes through December has sent the dollar higher .DXY, pushing down commodity prices .TRJCRB.""That's basically what's leaning on the market today,"" said Peter Cardillo, Chief Market Economist at First Standard Financial in New York. ""It's all about commodities.""Gold XAU= and metals CMCU3 prices fell as the dollar strengthened.U.S. oil prices CLc1 LCOc1 also were also damaged after data showing a rise in U.S. stockpiles last week rekindled worries about a global glut. Eight of the 10 major S&P sectors were lower, led by a 2.1-percent fall in the energy sector .SPNY. Chevron (CVX.N) and ConocoPhillips (COP.N) were among the biggest decliners.     Utilities .SPLRCU rose 0.7 percent and was the best performing sector.The Dow Jones industrial average .DJI closed down 79.98 points, or 0.45 percent, to 17,502.59, the S&P 500 .SPX lost 13.09 points, or 0.64 percent, to 2,036.71 and the Nasdaq Composite .IXIC fell 52.80 points, or 1.1 percent, to 4,768.86.Adding to the downturn, investors were deterred by the shortened trading week ahead of the Good Friday holiday and uncertainty tied to Tuesday's bombings in Brussels, Cardillo said.Earnings weakness has been another concern for investors, with first-quarter S&P 500 earnings forecast to fall 6.9 percent from a year ago, according to Thomson Reuters data.  Nike (NKE.N) shares were down 3.8 percent at $62.44 after the world's largest footwear maker reported quarterly revenue below estimates.Gilead Sciences (GILD.O) was down 3.9 percent at $90.08 while Merck (MRK.N) was up 0.09 percent. A federal jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C.Gilead was the biggest drag on the S&P 500 and the Nasdaq. Vertex Pharmaceuticals (VRTX.O) fell 7.6 percent to $80.15 after Goldman Sachs cuts its price target on the stock.Yum Brands (YUM.N) was up 2 percent at $80.55 after the Wall Street Journal reported that the fast-food chain's owner was in  talks with KKR (KKR.N) about a possible sale of a 19.9-percent stake in its China business.Volume was lighter than in recent sessions. About 6.8 billion shares changed hands on U.S. exchanges, compared with the 8.1 billion daily average for the past 20 trading days.Declining issues outnumbered advancing ones on the NYSE by 2,257 to 771, for a 2.93-to-1 ratio on the downside; on the Nasdaq, 2,221 issues fell and 579 advanced for a 3.84-to-1 ratio favoring decliners.The S&P 500 posted 17 new 52-week highs and no new lows; the Nasdaq recorded 21 new highs and 40 new lows.   (Additional reporting by Abhiram Nandakumar in Bengaluru; Editing by Nick Zieminski and James Dalgleish)",2016-03-24,GILD,"Wed Mar 23, 2016 | 8:23pm EDT","Wall Street rally fizzles out as oil, materials fall",http://www.reuters.com//article/us-usa-stocks-idUSKCN0WP1AI?type=companyNews
297,"   By Rory Carroll and Andrew Chung | SAN JOSE, Calif.,/NEW YORK  SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co  $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015.Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.Merck, which in January won approval on its own hepatitis C drug, Zepatier, is also asking for a 10 percent royalty on Gilead's sales going forward. That issue will be argued in a separate non-jury trial before U.S. District Judge Beth Labson Freeman starting next week. Gilead spokeswoman Michele Rest said the company does not believe Merck is entitled to any damages. ""In the event the judge maintains the jury's verdict, we will appeal,"" she said.In a statement, Merck said, ""We are pleased that the jury recognized that patent protections are essential to the development of new medical treatments.""In after-hours trading, Merck shares were down 50 cents to $52.57. Gilead shares gained slightly. Insurers, politicians and patient groups have denounced the list prices of the new drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen.Gilead obtained the active ingredient in its drugs,   sofosbuvir, by acquiring Pharmasset, Inc in 2011. Merck said Pharmasset developed the chemical from a Merck patent that was filed in 2002. Gilead, meanwhile, said Merck's patents were derived from Pharmasset's work. After Merck, based in Kenilworth, New Jersey, demanded royalties in 2013, Gilead and Merck sued each other in the U.S. District Court for the Northern District of California. Last month, Freeman ruled that Gilead's drugs infringe Merck's patents.In calculating damages, jurors said they sought a middle ground. ""We worked to get to something we could all agree so we weren't hurting one side or the other,"" juror Cody Shump, a 20-year-old San Jose resident, told Reuters.Merck's partner and co-owner of the patents, Ionis Pharmaceuticals Inc, will get 20 percent of the damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.",2016-03-25,GILD,"Thu Mar 24, 2016 | 10:51pm EDT",Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com//article/gilead-sciences-merck-co-damages-idUSL2N16X011?type=companyNews
298,"   By Rory Carroll and Andrew Chung | SAN JOSE, Calif.,/NEW YORK  SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015. Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease. Merck, which in January won approval on its own hepatitis C drug, Zepatier, is also asking for a 10 percent royalty on Gilead's sales going forward. That issue will be argued in a separate non-jury trial before U.S. District Judge Beth Labson Freeman starting next week. Gilead spokeswoman Michele Rest said the company does not believe Merck is entitled to any damages. ""In the event the judge maintains the jury's verdict, we will appeal,"" she said. In a statement, Merck said, ""We are pleased that the jury recognized that patent protections are essential to the development of new medical treatments.""In after-hours trading, Merck shares were down 50 cents to $52.57. Gilead shares gained slightly.Insurers, politicians and patient groups have denounced the list prices of the new drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen.  Gilead obtained the active ingredient in its drugs,   sofosbuvir, by acquiring Pharmasset, Inc in 2011. Merck said Pharmasset developed the chemical from a Merck patent that was filed in 2002. Gilead, meanwhile, said Merck's patents were derived from Pharmasset's work. After Merck, based in Kenilworth, New Jersey, demanded royalties in 2013, Gilead and Merck sued each other in the U.S. District Court for the Northern District of California. Last month, Freeman ruled that Gilead's drugs infringe Merck's patents. In calculating damages, jurors said they sought a middle ground. ""We worked to get to something we could all agree so we werent hurting one side or the other,"" juror Cody Shump, a 20-year-old San Jose resident, told Reuters.  Merck's partner and co-owner of the patents, Ionis Pharmaceuticals Inc (IONS.O), will get 20 percent of the damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung in New York and Rory Carroll in San Jose; Editing by Alexia Garamfalvi, Diane Craft and Leslie Adler)",2016-03-25,GILD,"Thu Mar 24, 2016 | 9:58pm EDT",Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute,http://www.reuters.com//article/us-gilead-sciences-merck-co-damages-idUSKCN0WR00V?type=companyNews
299,"   By Rory Carroll and Andrew Chung | SAN JOSE, Calif.,/NEW YORK  SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015. Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease. Merck, which in January won approval on its own hepatitis C drug, Zepatier, is also asking for a 10 percent royalty on Gilead's sales going forward. That issue will be argued in a separate non-jury trial before U.S. District Judge Beth Labson Freeman starting next week. Gilead spokeswoman Michele Rest said the company does not believe Merck is entitled to any damages. ""In the event the judge maintains the jury's verdict, we will appeal,"" she said. In a statement, Merck said, ""We are pleased that the jury recognized that patent protections are essential to the development of new medical treatments.""In after-hours trading, Merck shares were down 50 cents to $52.57. Gilead shares gained slightly.Insurers, politicians and patient groups have denounced the list prices of the new drugs. Harvoni, at $1,125 per pill before discounts, costs $94,000 for a 12-week regimen.  Gilead obtained the active ingredient in its drugs,   sofosbuvir, by acquiring Pharmasset, Inc in 2011. Merck said Pharmasset developed the chemical from a Merck patent that was filed in 2002. Gilead, meanwhile, said Merck's patents were derived from Pharmasset's work. After Merck, based in Kenilworth, New Jersey, demanded royalties in 2013, Gilead and Merck sued each other in the U.S. District Court for the Northern District of California. Last month, Freeman ruled that Gilead's drugs infringe Merck's patents. In calculating damages, jurors said they sought a middle ground. ""We worked to get to something we could all agree so we werent hurting one side or the other,"" juror Cody Shump, a 20-year-old San Jose resident, told Reuters.  Merck's partner and co-owner of the patents, Ionis Pharmaceuticals Inc (IONS.O), will get 20 percent of the damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung in New York and Rory Carroll in San Jose; Editing by Alexia Garamfalvi, Diane Craft and Leslie Adler)",2016-03-25,GILD,"Thu Mar 24, 2016 | 9:58pm EDT",UPDATE 3-Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com//article/gilead-sciences-merck-co-damages-idUSL2N16X009?type=companyNews
300,"   By Andrew Chung  By Andrew Chung Gilead Sciences Inc on Wednesday will attempt to wipe out $200 million in damages for infringing two Merck & Co patents with its blockbuster hepatitis C treatments by claiming that Merck was dishonest in obtaining the patents, an argument that attorneys say could be difficult to prove. A bench trial on Wednesday will pit Gilead's Fish & Richardson attorneys against Merck's lawyers from Williams & Connolly, on Gilead's claim that Merck has ""unclean hands"" because it used Gilead's technology in its own patent applications and so should be precluded from enforcing its patents. Merck says the jury has already found that its patents are valid, foreclosing any unclean hands defense. To read the full story on Westlaw Practitioner Insights, click here: bit.ly/1RN28ZM",2016-03-29,GILD,"Tue Mar 29, 2016 | 7:06am EDT",Gilead says Merck 'deceitful' in hepatitis C drug patent fight,http://www.reuters.com//article/ip-gilead-hearing-idUSL2N1710BZ?type=companyNews
301,"   By Ritsuko  Shimizu | TOKYO  TOKYO Global drugmakers said they could cut research spending in Japan due to new rules requiring them to slash prices on some blockbuster drugs, including Gilead Sciences Inc's highly effective but expensive hepatitis C drug, Sovaldi.Drugmakers such as the Japanese arms of Pfizer Inc and Eli Lilly and Co said the change, which could as much as half the price of popular medication, risks penalizing companies for developing revolutionary drugs like Sovaldi. ""Without stability and predictability in drug prices, investments will go elsewhere,"" Patrick Johnson, chief executive of Eli Lilly in Japan, recently told reporters.The comments come as the government works to attract research and development investment from pharmaceutical firms as a key part of a broader economic growth agenda.But the government also needs to curb soaring medical and nursing costs in a rapidly aging society, to help balance its primary budget by the fiscal year through March 2021.Policies focusing on medical costs rather than advanced development ""raise the risk of less investment in Japan,"" Pfizer's Japan head Ichiro Umeda told Reuters. ""A market that appreciates innovation allows for more investment and enables continuous development of revolutionary new drugs,"" he said.Beginning April 1, the government will lower the prices drugmakers can charge for popular drugs. For instance, prices will be cut by as much as 50 percent for drugs with annual Japan sales exceeding 150 billion yen ($1.34 billion) and that are 30 percent over estimates manufacturers file with the government.For Gilead's Sovaldi, the price will fall about 30 percent. Sovaldi has been shown to cure more than 90 percent of patients with the liver-destroying hepatitis C, without the side effects of older medicines. However, a price of $84,000 for a course of treatment in the United States drew criticism from insurers, politicians and patient groups.Gilead has since agreed to lower the price in over 90 mostly developing countries. But not in Japan, where about 1.5 million people are diagnosed with hepatitis C, and where Gilead said sales had helped push up global sales in the three months through December.When asked about Japan's rule change, the drugmaker told Reuters it was committed to ""delivering new treatments to as many patients as possible amid a changing market environment."" Others were more critical. Akira Kawahara, senior managing director of the Japan Pharmaceutical Manufacturers Association, told Reuters the rules were ""suddenly proposed and suddenly implemented.""Drugmakers had advised the government against the move when it came up for debate late last year. The Pharmaceutical Research and Manufacturers of America, which represents U.S. biopharmaceutical firms and researchers, had said the change would penalize firms for successful drug development.($1 = 112.2900 yen) (Reporting by Ritsuko Shimizu; Writing by Ritsuko Ando; Editing by Christopher Cushing)",2016-04-01,GILD,"Fri Apr 1, 2016 | 5:54am EDT",Drugmakers say Japan R&D spending at risk after government forces price cuts,http://www.reuters.com//article/us-japan-drug-idUSKCN0WY46I?type=companyNews
302,"   By Bill Berkrot  An experimental once-daily combination hepatitis C treatment being developed by AbbVie Inc demonstrated very high cure rates across a wide range of disease genotypes, according to data presented on Saturday, likely giving the company a more competitive product if approved. Cure rates of 97 percent to 100 percent over either eight or 12 weeks of treatment were achieved in the clinical trials with the one pill, once-a-day combination of ABT-493 and ABT-530, which use different methods to block virus replication.The combination would provide greater convenience for a wider variety of patients than AbbVie's Viekira Pak, improving  chances of making inroads into the market domination currently enjoyed by Gilead Sciences Inc.Viekira Pak, which is approved for genotype 1, the most common form of the serious liver disease in the United States, consists of four drugs and involves taking three pills in the morning and one in the evening. It currently has only about 5 percent of the market, with Gilead owning about 90 percent.Another AbbVie product treats genotype 4, which is most common in Egypt and other parts of Africa. The new one pill combination proved effective across the spectrum of genotypes 1-6 in the midstage studies presented at a European liver disease meeting in Barcelona.In patients without cirrhosis who were not helped by an older regimen, 97 percent of those with genotype 1 and 98 percent of those with genotype 2 had no detectable hepatitis C virus in the blood 12 weeks after completing eight weeks of therapy, which is considered cured. Patients with genotype 3 and no cirrhosis receiving treatment for the first time had a 97 percent cure rate with eight weeks of therapy.Cure rates of 100 percent were achieved with 12 weeks of treatment in genotype 3 patients with cirrhosis, and in non-cirrhotic patients with genotypes 4, 5 and 6.""These new data show us the potential of ABT-493 and ABT-530 in genotype 3 patients new to therapy even with the added complication of compensated cirrhosis,"" Dr. Paul Kwo, one of the lead investigators and professor of medicine at the Indiana University School of Medicine, said in a statement.  Cirrhosis, a form or severe scarring, is an indication of advanced disease that can lead to diminished liver function or liver failure.The most common side effects were fatigue, headache, nausea and diarrhea, the company reported. (Reporting by Bill Berkrot; Editing by Bernard Orr)",2016-04-16,GILD,"Sat Apr 16, 2016 | 1:02am EDT",New AbbVie hepatitis C regimen shows high cure rates -studies,http://www.reuters.com//article/abbvie-hepatitis-idUSL2N17I1LK?type=companyNews
303,"  April 25 Gilead Sciences Inc * European commission grants marketing authorization for Gilead's fixed-dose combination descovy (emtricitabine, tenofovir alafenamide) for treatment of HIV  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ",2016-04-25,GILD,"Mon Apr 25, 2016 | 7:26am EDT",BRIEF-Gilead's treatment for HIV receives marketing authorization from european commission,http://www.reuters.com//article/idUSFWN17S0EF?type=companyNews
304,"   By Deena Beasley  Gilead Sciences Inc's first quarter net profit fell 18 percent as pricing pressure resulted in lower U.S. sales of hepatitis C drug Harvoni.The biotechnology company's shares, which fell 3.7 percent in regular trading, were down another 5.4 percent at $91.75 after hours.Gilead's total product sales rose 4 percent to $7.7 billion. Sales of hepatitis C drugs Sovaldi and Harvoni, the company's second generation hepatitis treatment, totaled $4.29 billion, which was short of the $4.63 billion average Wall Street estimate, as compiled by ISI Evercore. ""The hep C numbers are a little light in the USA and that could be due to higher rebating and more competition,"" said RBC Capital Markets analyst Michael Yee.Gilead Chief Financial Officer Robin Washington said on a conference call that U.S. Harvoni sales declined due to an ""increase in discounts required to open up access to patients with lower (liver) fibrosis scores,"" as well as a modest shift in sales to deeply-discounted government payers, including the  Department of Veterans Affairs. Gilead drew fire more than two years ago when it launched Sovaldi, the first in a new class of hepatitis C drugs considered to be a cure for the liver-destroying disease, at a price of $84,000 per course of treatment. An estimated 3.2 million Americans are infected with hepatitis C and insurers have responded by closely monitoring which patients should be treated with the new drugs.The Foster City, California-based company has since faced competition from new hepatitis C treatments sold by other drugmakers - first AbbVie followed more recently by Merck & Co Inc.Gilead said it continues to assess business development opportunities.  ""M&A (mergers and acquisition) is always a process,"" said Chief Executive Officer John Milligan, noting that Gilead has never said it would be unwilling to pursue a hostile deal, although ""we do prefer a friendly process.""Adjusting for one-time items, Gilead earned $3.03 per share in the quarter, compared with the average Wall Street estimate of $3.15 per share, according to Thomson Reuters I/B/E/S. The biotechnology company's first quarter net profit fell to $3.57 billion from $4.33 billion a year earlier.RBC's Yee said results were also hurt by a $200 million charge for litigation with Merck. For full-year 2016, Gilead said it still expects total product sales of $30 billion to $31 billion, in line with the average Wall Street estimate of $30.16 billion. (Reporting By Deena Beasley; Editing by Andrew Hay, Chris Reese and Bernard Orr)",2016-04-28,GILD,"Thu Apr 28, 2016 | 6:37pm EDT",Price pressure hits Gilead first quarter U.S. hepatitis C drug sales,http://www.reuters.com//article/us-gilead-results-idUSKCN0XP2YX?type=companyNews
305,"  April 29 Gilead Sciences Inc * European chmp adopts positive opinion for gilead's taf-based single tablet regimen odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for treatment of hiv  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ",2016-04-29,GILD,"Fri Apr 29, 2016 | 8:28am EDT",BRIEF-Gilead Sciences says European CHMP adopts positive opinion for its drug,http://www.reuters.com//article/idUSFWN17W0OS?type=companyNews
306,"  April 29 EU Medicines Agency:* EU Medicines Agency recommendations for April 2016 * EU Medicines Agency recommends approval of Biogen Inc  and AbbVie Inc's daclizumab to treat multiple sclerosis * EU Medicines Agency recommends approval of Allergan Plc's  zavicefta to treat severe infection * EU Medicines Agency gave positive recommendation for Gilead Sciences Inc's odefsey to treat HIV infection  For full text, click on: (bit.ly/1pO1nm0) Further company coverage:    (Bengaluru Newsroom: +91 806 749 1136)",2016-04-29,GILD,"Fri Apr 29, 2016 | 7:32am EDT",BRIEF-European regulators recommends approval of Gilead's new HIV treatment,http://www.reuters.com//article/idUSFWN17W0XM?type=companyNews
307,"   By Deena Beasley  India has reversed course and granted approval to Gilead Sciences Inc's patent for its hepatitis C drug Sovaldi, marking a setback for patient groups who said the move could stop affordable copies of the drug.The drug, which has a list price of $1,000 a pill in the United States, was rejected for a patent by the Indian patent authority in January 2015 on the basis it represented only minor changes to a previous formulation, and the company already had licensing deals with manufacturers in India.After an appeal by Gilead, the Indian Patent Office of New Delhi on Monday approved its application for the drug saying it found its compounds to be ""novel"" and ""inventive."" Gilead, in a statement, welcomed the move, but said it will have no impact on availability of the compound, which is already licensed to 11 generic manufacturers in India for distribution in 101 developing countries. Patents guarantee drugmakers exclusive sales for a decade or more, before generic competition is allowed, so the companies can recoup their investment and use profits to then develop new medicines. Gilead said the goal of its voluntary licensing program, and ""partnership"" with Indian manufacturers, is to enable access to medicines for as many people as possible, as quickly as possible.But patient groups said Gilead's licensing deals do not serve patients and the patent approval could prevent exports of raw materials to other countries seeking to make the drug, hailed by some as a breakthrough in the global fight against hepatitis. ""Like unmerited patents, these schemes manipulate the market, violate patients' rights and block millions of people from getting the medicines they need,"" the Initiative for Medicines, Access & Knowledge said in a statement. Gilead said eight of its licensees have launched sales in India and other licensed territories under the company's program for supplying its hepatitis C, hepatitis B and HIV drugs to ""resource-challenged countries."" Licenses have also been granted to two manufacturers in Egypt and one in Pakistan.Sovaldi was first launched in the United States in 2013 at a  list price of $28,000 for a 28-tablet bottle, or $1,000 a pill. The list price in India as of April 26, according to the Asia Pacific Network of People Living with HIV, was $384 per bottle, or about $14 per pill.The liver-destroying hepatitis C virus infects as many as 150 million people globally, according to the World Health Organization. (Reporting By Deena Beasley; Editing by Andrew Hay)",2016-05-10,GILD,"Wed May 11, 2016 | 6:52am EDT",India Patent Office approves Gilead's hepatitis C drug patent,http://www.reuters.com//article/gilead-india-patent-idUSL2N1871CW?type=companyNews
308,"   By Deena Beasley  India has reversed course and granted approval to Gilead Sciences Inc's patent for its hepatitis C drug Sovaldi, marking a setback for patient groups who said the move could stop affordable copies of the drug.The drug, which has a list price of $1,000 a pill in the United States, was rejected for a patent by the Indian patent authority in January 2015 on the basis it represented only minor changes to a previous formulation, and the company already had licensing deals with manufacturers in India.After an appeal by Gilead, the Indian Patent Office of New Delhi on Monday approved its application for the drug saying it found its compounds to be ""novel"" and ""inventive."" Gilead, in a statement, welcomed the move, but said it will have no impact on availability of the compound, which is already licensed to 11 generic manufacturers in India for distribution in 101 developing countries. Patents guarantee drugmakers exclusive sales for a decade or more, before generic competition is allowed, so the companies can recoup their investment and use profits to then develop new medicines. Gilead said the goal of its voluntary licensing program, and ""partnership"" with Indian manufacturers, is to enable access to medicines for as many people as possible, as quickly as possible.But patient groups said Gilead's licensing deals do not serve patients and the patent approval could prevent exports of raw materials to other countries seeking to make the drug, hailed by some as a breakthrough in the global fight against hepatitis. ""Like unmerited patents, these schemes manipulate the market, violate patients' rights and block millions of people from getting the medicines they need,"" the Initiative for Medicines, Access & Knowledge said in a statement. Gilead said eight of its licensees have launched sales in India and other licensed territories under the company's program for supplying its hepatitis C, hepatitis B and HIV drugs to ""resource-challenged countries."" Licenses have also been granted to two manufacturers in Egypt and one in Pakistan.Sovaldi was first launched in the United States in 2013 at a  list price of $28,000 for a 28-tablet bottle, or $1,000 a pill. The list price in India as of April 26, according to the Asia Pacific Network of People Living with HIV, was $384 per bottle, or about $14 per pill.The liver-destroying hepatitis C virus infects as many as 150 million people globally, according to the World Health Organization. (Reporting By Deena Beasley; Editing by Andrew Hay)",2016-05-11,GILD,"Wed May 11, 2016 | 6:52am EDT",India Patent Office approves Gilead's hepatitis C drug patent,http://www.reuters.com//article/us-gilead-india-patent-idUSKCN0Y12NA?type=companyNews
309,"  May 16 (Reuters) -* Temasek Holdings raises share stake in Gilead Sciences Inc by 8.1 percent to 13.83 million shares  Source text for quarter ended March 31, 2016: (1.usa.gov/1TguNln) Source text for quarted ended Dec. 31, 2015: (1.usa.gov/1TguI11)  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-05-16,GILD,"Mon May 16, 2016 | 6:27am EDT",BRIEF-Temasek Holdings raises share stake in Gilead by 8.1 pct,http://www.reuters.com//article/idUSFWN18D0EL?type=companyNews
310,"  May 24 Gilead Sciences Inc* Paul R. Carter, executive vice president, commercial operations, has decided to depart Gilead  * Gilead Sciences announces appointment of Kevin Young CBE as chief operating officer and Martin Silverstein, MD as executive vice president, strategy    Source text for Eikon:    Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780) ",2016-05-24,GILD,"Tue May 24, 2016 | 4:52pm EDT",BRIEF-Gilead Sciences appoints Kevin Young as COO,http://www.reuters.com//article/idUSASC08R4O?type=companyNews
311,"  (Adds details, share price movement)May 27 An advisory panel to the European drug regulator recommended an approval for Gilead Sciences Inc's  new drug combination to treat hepatitis C.The European Medicines Agency (EMA) said on Friday that the Committee for Medicinal Products for Human Use backed Gilead's combination of velpatasvir and sofosbuvir. (bit.ly/20JOyWA)Sofosbuvir is at the centre of a patent battle between Gilead and Merck & Co Inc. Gilead's combination treatment shares an active ingredient with Sovaldi, the company's blockbuster drug for hepatitis C. The panel on Friday also recommended granting marketing approval for Merck's combination of elbasvir and grazoprevir to treat viral infection of the liver.Merck is trying to catch up with Gilead, which dominates the market with a new generation of hepatitis C drugs that can cure over 90 percent of patients with the liver disease. The EMA said Gilead's new combination therapy targeted all six genotypes of the virus, while Merck's combination drug targets only two kinds.Gilead shares were little changed in pre-market trading on the Nasdaq.   (Reporting by Rahul B in Bengaluru; Editing by Don Sebastian)",2016-05-27,GILD,"Fri May 27, 2016 | 8:07am EDT",UPDATE 1-EU regulators back approval of Gilead's new hep C drug,http://www.reuters.com//article/gilead-sciences-hepatitis-idUSL3N18O3UT?type=companyNews
312,"  Gilead Sciences Inc's new hepatitis C drug combination, which shares an active ingredient with blockbuster Sovaldi, was recommended for marketing approval by the European Medicines Agency.The EMA's Committee for Medicinal Products for Human Use said it recommended approval of the combination of sofosbuvir and velpatasvir. Sofosbuvir is at the center of a patent battle between Gilead and Merck & Co Inc. (bit.ly/20JOyWA) Sovaldi generated $1.28 bln of sales in the first quarter for Gilead.   (Reporting by Rahul B in Bengaluru; Editing by Don Sebastian)",2016-05-27,GILD,"Fri May 27, 2016 | 8:06am EDT",EU regulators recommend approving Gilead's new hepatitis C drug,http://www.reuters.com//article/us-gilead-sciences-hepatitis-idUSKCN0YI1HR?type=companyNews
313,"  Gilead Sciences Inc's new hepatitis C drug combination, which shares an active ingredient with blockbuster Sovaldi, was recommended for marketing approval by the European Medicines Agency.The EMA's Committee for Medicinal Products for Human Use said it recommended approval of the combination of sofosbuvir and velpatasvir. Sofosbuvir is at the center of a patent battle between Gilead and Merck & Co Inc. (bit.ly/20JOyWA) Sovaldi generated $1.28 bln of sales in the first quarter for Gilead.   (Reporting by Rahul B in Bengaluru; Editing by Don Sebastian)",2016-05-27,GILD,"Fri May 27, 2016 | 8:06am EDT",EU regulators recommend approving Gilead's new hepatitis C drug,http://www.reuters.com//article/gilead-sciences-hepatitis-idUSL3N18O3SJ?type=companyNews
314,"   By Andrew Chung | NEW YORK  NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc  from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni.The dramatic ruling comes after a federal jury in San Jose, California, on March 24 ordered Gilead to pay $200 million in damages, based on findings that Merck's patents were valid.U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck deceptively used confidential information from Pharmasset, Inc, a company Gilead bought in 2011.Freeman also said Merck cannot enforce the patents because Merck's own lawyer gave inconsistent and untruthful testimony during the trial. ""Merck's acts are even more egregious because the main perpetrator of its misconduct was its attorney,"" she said.In a statement, Merck spokeswoman Lainie Keller said Gilead's allegations against the patents are without merit and the company would appeal. ""The judge's ruling does not reflect the facts of this case."" Gilead feels ""vindicated"" by the decision, spokeswoman Michele Rest said.Gilead had also been facing a demand from Merck for an ongoing royalty of at least 12 percent of all future sales of the drugs, according to court papers. Gilead made $23 billion on the two pills in the U.S. alone over the last two years. Pharmaceutical firms such as Merck, which recently launched its own hepatitis C drug, Zepatier, are trying to chip away at Gilead's dominant position in the market for a new generation of drugs, which cure the liver disease in well over 90 percent of patients.Some policy makers and insurers have criticized their costs. Harvoni, for instance, lists at $1,125 per pill before discounts and $94,000 for a 12-week regimen.The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs. After the jury verdict, Freeman separately dealt with Foster City, California-based Gilead's accusations of Merck's unethical conduct in obtaining the patents.Merck, based in Kenilworth, New Jersey, countered that it had already known of the technology Gilead claimed was Pharmasset's.Merck's partner in the suit and co-owner of the patents, Ionis Pharmaceuticals Inc, stood to receive 20 percent of any damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.",2016-06-07,GILD,"Tue Jun 7, 2016 | 6:57am EDT",Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL1N18Z01W?type=companyNews
315,"   By Andrew Chung | NEW YORK  NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni. The dramatic ruling comes after a federal jury in San Jose, California, on March 24 ordered Gilead to pay $200 million in damages, based on findings that Merck's patents were valid. U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck deceptively used confidential information from Pharmasset, Inc, a company Gilead bought in 2011.Freeman also said Merck cannot enforce the patents because Merck's own lawyer gave inconsistent and untruthful testimony during the trial. ""Merck's acts are even more egregious because the main perpetrator of its misconduct was its attorney,"" she said.In a statement, Merck spokeswoman Lainie Keller said Gilead's allegations against the patents are without merit and the company would appeal. ""The judge's ruling does not reflect the facts of this case."" Gilead feels ""vindicated"" by the decision, spokeswoman Michele Rest said.Gilead had also been facing a demand from Merck for an ongoing royalty of at least 12 percent of all future sales of the drugs, according to court papers. Gilead made $23 billion on the two pills in the U.S. alone over the last two years.Pharmaceutical firms such as Merck, which recently launched its own hepatitis C drug, Zepatier, are trying to chip away at Gilead's dominant position in the market for a new generation of drugs, which cure the liver disease in well over 90 percent of patients. Some policy makers and insurers have criticized their costs. Harvoni, for instance, lists at $1,125 per pill before discounts and $94,000 for a 12-week regimen. The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs.After the jury verdict, Freeman separately dealt with Foster City, California-based Gilead's accusations of Merck's unethical conduct in obtaining the patents.  Merck, based in Kenilworth, New Jersey, countered that it had already known of the technology Gilead claimed was Pharmasset's. Merck's partner in the suit and co-owner of the patents, Ionis Pharmaceuticals Inc, stood to receive 20 percent of any damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung; Editing by Bernard Orr and Andrew Hay)",2016-06-07,GILD,"Tue Jun 7, 2016 | 6:06am EDT",Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com//article/us-gilead-sciences-merck-co-ruling-idUSKCN0YT01A?type=companyNews
316,"   By Andrew Chung | NEW YORK  NEW YORK A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni. The dramatic ruling comes after a federal jury in San Jose, California, on March 24 ordered Gilead to pay $200 million in damages, based on findings that Merck's patents were valid. U.S. District Judge Beth Labson Freeman said Gilead proved that in the process of applying for its patents, Merck deceptively used confidential information from Pharmasset, Inc, a company Gilead bought in 2011.Freeman also said Merck cannot enforce the patents because Merck's own lawyer gave inconsistent and untruthful testimony during the trial. ""Merck's acts are even more egregious because the main perpetrator of its misconduct was its attorney,"" she said.In a statement, Merck spokeswoman Lainie Keller said Gilead's allegations against the patents are without merit and the company would appeal. ""The judge's ruling does not reflect the facts of this case."" Gilead feels ""vindicated"" by the decision, spokeswoman Michele Rest said.Gilead had also been facing a demand from Merck for an ongoing royalty of at least 12 percent of all future sales of the drugs, according to court papers. Gilead made $23 billion on the two pills in the U.S. alone over the last two years.Pharmaceutical firms such as Merck, which recently launched its own hepatitis C drug, Zepatier, are trying to chip away at Gilead's dominant position in the market for a new generation of drugs, which cure the liver disease in well over 90 percent of patients. Some policy makers and insurers have criticized their costs. Harvoni, for instance, lists at $1,125 per pill before discounts and $94,000 for a 12-week regimen. The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs.After the jury verdict, Freeman separately dealt with Foster City, California-based Gilead's accusations of Merck's unethical conduct in obtaining the patents.  Merck, based in Kenilworth, New Jersey, countered that it had already known of the technology Gilead claimed was Pharmasset's. Merck's partner in the suit and co-owner of the patents, Ionis Pharmaceuticals Inc, stood to receive 20 percent of any damages awarded Merck.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057. (Reporting by Andrew Chung; Editing by Bernard Orr and Andrew Hay)",2016-06-07,GILD,"Tue Jun 7, 2016 | 6:06am EDT",UPDATE 2-Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL1N18Z00Z?type=companyNews
317,"  June 23 Gilead Sciences Inc* European Commission grants marketing authorization for Gilead's single tablet regimen Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV * Gilead sciences says under agreement, co is responsible for manufacturing, registration, distribution, commercialization of Odefsey in most countries * Odefsey approval is part of ongoing development and commercialization agreement between Gilead And Janssen, first established in 2009 * Says Janssen will distribute it in approximately 18 markets and have co-detailing rights in several key markets  Source text for Eikon:  Further company coverage:",2016-06-23,GILD,"Thu Jun 23, 2016 | 9:18am EDT",BRIEF-Gilead says European Commission grants marketing authorization for Odefsey,http://www.reuters.com//article/idUSFWN19F020?type=companyNews
318,"  U.S. health regulators on Tuesday approved a combination drug by Gilead Sciences Inc that is the first available treatment for all six major forms of hepatitis C, advancing the company's leadership in the field and sending its shares up more than 4 percent.Gilead said in a separate statement that it priced the drug at $74,760 for a 12-week regimen.Gilead has dominated the hepatitis C market over rivals AbbVie and Merck & Co with its high-priced and highly effective treatments Sovaldi and the combination drug Harvoni. The new treatment, to be sold under the brand name Epclusa, combines Sovaldi (sofosbuvir), which was approved in 2013, with a new anti-viral drug velpatasvir.Epclusa costs less than the $84,000 that Sovaldi sold for when it launched in late 2013. Gilead now offers discounts and rebates on that older drug, which was at the center of a national uproar over soaring drug costs. Epclusa is approved for patients with and without cirrhosis, a form of scarring seen in patients with advanced disease that can lead to liver failure and need for a transplant. For those with moderate to severe cirrhosis, Epclusa must be taken with the older drug ribavirin, the Food and Drug Administration said.""This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,"" Edward Cox, director of the FDA's Office of Antimicrobial Products, said in a statement. While the majority of U.S. patients have the genotype 1 form of hepatitis C, about 20 percent to 25 percent have genotypes 2 or 3, with small numbers infected with genotypes 4, 5 or 6. In other parts of the world, other genotypes are far more prevalent, such as in Egypt, where genotype 4 is widespread.In pivotal clinical trials, Epclusa led to cure rates of 95 percent to 99 percent in patients without or with mild cirrhosis after 12 weeks of treatment. In a separate trial of patients with moderate to severe cirrhosis, cure rates of 94 percent were seen. In afternoon trading, Gilead shares were up $3.35, or 4.28 percent at $81.60 on Nasdaq. (Reporting by Bill Berkrot in New York and Shailesh Kuber in Bengaluru; Editing by Bill Trott and Diane Craft)",2016-06-28,GILD,"Tue Jun 28, 2016 | 2:42pm EDT",Gilead wins U.S. nod for drug for all types of hepatitis C,http://www.reuters.com//article/us-gilead-sciences-fda-idUSKCN0ZE1U6?type=companyNews
319,"  U.S. health regulators on Tuesday approved a combination drug by Gilead Sciences Inc that is the first available treatment for all six major forms of hepatitis C, advancing the company's leadership in the field and sending its shares up more than 4 percent.Gilead said in a separate statement that it priced the drug at $74,760 for a 12-week regimen.Gilead has dominated the hepatitis C market over rivals AbbVie and Merck & Co with its high-priced and highly effective treatments Sovaldi and the combination drug Harvoni. The new treatment, to be sold under the brand name Epclusa, combines Sovaldi (sofosbuvir), which was approved in 2013, with a new anti-viral drug velpatasvir.Epclusa costs less than the $84,000 that Sovaldi sold for when it launched in late 2013. Gilead now offers discounts and rebates on that older drug, which was at the center of a national uproar over soaring drug costs. Epclusa is approved for patients with and without cirrhosis, a form of scarring seen in patients with advanced disease that can lead to liver failure and need for a transplant. For those with moderate to severe cirrhosis, Epclusa must be taken with the older drug ribavirin, the Food and Drug Administration said.""This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,"" Edward Cox, director of the FDA's Office of Antimicrobial Products, said in a statement. While the majority of U.S. patients have the genotype 1 form of hepatitis C, about 20 percent to 25 percent have genotypes 2 or 3, with small numbers infected with genotypes 4, 5 or 6. In other parts of the world, other genotypes are far more prevalent, such as in Egypt, where genotype 4 is widespread.In pivotal clinical trials, Epclusa led to cure rates of 95 percent to 99 percent in patients without or with mild cirrhosis after 12 weeks of treatment. In a separate trial of patients with moderate to severe cirrhosis, cure rates of 94 percent were seen. In afternoon trading, Gilead shares were up $3.35, or 4.28 percent at $81.60 on Nasdaq. (Reporting by Bill Berkrot in New York and Shailesh Kuber in Bengaluru; Editing by Bill Trott and Diane Craft)",2016-06-28,GILD,"Tue Jun 28, 2016 | 2:42pm EDT",UPDATE 2-Gilead wins U.S. nod for drug for all types of hepatitis C,http://www.reuters.com//article/gilead-sciences-fda-idUSL4N19K47B?type=companyNews
320,"  June 28 The U.S. Food and Drug Administration approved Gilead Sciences Inc's drug for treating chronic hepatitis C virus infection.The drug, Epclusa, is approved for use in combination with ribavirin. Epclusa is the first drug to treat all six major types of hepatitis C virus infection.  Gilead shares were up 4 pct at $81.03 in morning trading on the Nasdaq.   (Reporting by Shailesh Kuber in Bengaluru; Editing by Don Sebastian)",2016-06-28,GILD,"Tue Jun 28, 2016 | 10:46am EDT",U.S. FDA approves Gilead's hep C drug Epclusa,http://www.reuters.com//article/gilead-sciences-fda-idUSL4N19K45M?type=companyNews
321,"   By Andrew Chung  Gilead Sciences Inc may have scored a dramatic and unexpected win over Merck & Co earlier this month in a patent dispute over the world's best-selling hepatitis C cure, but the war over this highly lucrative class of treatments has only just begun. Gilead, the world's biggest biotechnology company, faces separate intellectual property attacks against its drugs for the liver disease, Sovaldi and Harvoni, on several other fronts, both in the United States and around the world.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/29390ho",2016-06-29,GILD,"Wed Jun 29, 2016 | 7:17am EDT","After hepatitis C patent win over Merck, Gilead faces other foes",http://www.reuters.com//article/ip-gilead-lawsuits-idUSL1N19L0B3?type=companyNews
322,"   By Brendan Pierson  Merck & Co has appealed a California federal judge's order that overturned a $200 million verdict it won in a patent case against Gilead Sciences over Gilead's lucrative hepatitis C drugs on the grounds that Merck engaged in extensive misconduct. On Tuesday, the same day Merck filed its notice of appeal, Gilead asked U.S. District Judge Beth Labson Freeman in San Jose to rule that Merck's patents were invalid as a matter of law, renewing a motion it filed before the verdict in the case.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/29jZ42d",2016-07-07,GILD,"Thu Jul 7, 2016 | 7:06am EDT",Merck appeals order reversing its $200 mln verdict against Gilead,http://www.reuters.com//article/health-merck-idUSL1N19T0BF?type=companyNews
323,"  July 8 Ligand Pharmaceuticals Inc* Ligand enters into Omniab platform license agreement with Gilead Sciences * Gilead will be responsible for all costs related to programs  * Ligand is eligible to receive annual platform access payments, milestone payments and royalties  Source text for Eikon:  Further company coverage:    )",2016-07-08,GILD,"Fri Jul 8, 2016 | 9:10am EDT",BRIEF-Ligand enters into Omniab platform license agreement with Gilead Sciences,http://www.reuters.com//article/idUSASC08WFP?type=companyNews
324,"   By Brendan Pierson  A California federal judge has dismissed a lawsuit filed by the non-profit AIDS Healthcare Foundation challenging Gilead Sciences' patents on AIDS drugs and accusing it of suppressing competition. U.S. District Judge William Alsup in San Francisco said in an opinion Wednesday that, while he was bound to dismiss the case by appellate precedent, he would not have dismissed the patent challenge if he were ""writing on a clean slate.""  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/29sCGFS",2016-07-08,GILD,"Fri Jul 8, 2016 | 7:21am EDT",AIDS Healthcare Foundation lawsuit over Gilead AIDS drugs dismissed,http://www.reuters.com//article/health-gilead-idUSL1N19U0EI?type=companyNews
325,"  July 14 Gilead Sciences Inc * Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic Hepatitis C  Source text for Eikon:  Further company coverage:  ",2016-07-14,GILD,"Thu Jul 14, 2016 | 7:53am EDT",BRIEF-Gilead Sciences gets Canada approval for Hepatitis C treatment Epclusa,http://www.reuters.com//article/idUSFWN1A00GO?type=companyNews
326,"  July 21 Gilead Sciences Inc :* Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week objective in two phase 3B studies  * Plans to submit data for presentation at scientific conferences in 2016.  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-07-21,GILD,"Thu Jul 21, 2016 | 4:45pm EDT",BRIEF-Gilead's Odefsey meets primary objective in phase 3B studies,http://www.reuters.com//article/idUSFWN1A70UI?type=companyNews
327,"  July 22 Gilead Sciences Inc* European CHMP adopts positive opinion on Gilead's type II variation application for Truvada for reducing the risk of sexually acquired HIV. * CHMP's recommendation to be reviewed by european commission * Within EU, Truvada is currently available for prep in france under a temporary recommendation for use by French regulatory agency. * Gilead Sciences Inc says use of Truvada for prep is investigational in EU and its safety and efficacy have not been established.  Source text for Eikon:  Further company coverage:",2016-07-22,GILD,"Fri Jul 22, 2016 | 7:33am EDT","BRIEF-EMA adopts positive opinion on expanded approval of Gilead's HIV drug, Truvada",http://www.reuters.com//article/idUSFWN1A80G7?type=companyNews
328,"   By Deena Beasley  Gilead Sciences Inc (GILD.O) on Monday lowered its full-year sales outlook, citing slower-than-expected demand for its key hepatitis C drugs, and said second-quarter profits fell 22 percent.The biotechnology company's shares, which had closed 2.3 percent higher, fell 4 percent to $85 after hours.Product sales fell to $7.65 billion from $8.13 billion in the year-ago quarter, Gilead said in a statement. Sales of hepatitis C drugs Sovaldi and Harvoni dropped to $4 billion from $4.9 billion. Wall Street analysts, on average, had forecast hepatitis C sales of $4.09 billion, according to a poll by ISI Evercore.Gilead lowered its 2016 product sales outlook to between $29.5 billion and $30.5 billion, from a previous range of $30 billion to $31 billion. The company said non-government U.S. health insurance plans were still limiting the number of patients who get the treatments, which many critics have said are far too expensive. Other factors behind the lower sales forecast include weaker hepatitis C drug pricing in some European markets, a trend toward shorter treatments and the loss of market share to competition, Chief Financial Officer Robin Washington told analysts on conference call after the results were released.    Gilead drew fire more than two years ago when it charged $84,000 per course of treatment for Sovaldi, the first in a new class of hepatitis C drugs considered to be a cure for the liver-destroying disease.While the list price has not changed, Gilead has offered discounts to certain insurers. Competing therapies have been launched by AbbVie Inc ABBV.O and Merck & Co Inc (MRK.N) over the past year. The number of U.S. patients who started undergoing treatment with hepatitis C drugs was little changed from the first quarter, suggesting that the market has stabilized, ISI Group analyst Mark Schoenebaum said in a research note on Monday.Gilead's quarterly net profit fell to $3.5 billion from $4.5 billion a year earlier. Adjusting for one-time items, Gilead earned $3.08 per share, which beat analysts' average estimate of $3.02, according to Thomson Reuters I/B/E/S. An estimated 3.2 million Americans are infected with hepatitis C and insurers have responded by closely monitoring which patients should be treated with the new drugs.The virus is spread by contact with contaminated blood of an infected person, by sharing needles or other equipment to inject drugs. Most patients have no symptoms, but some have fatigue, nausea, loss of appetite, and yellowing of the eyes and skin. (Reporting by Deena Beasley; Editing by Richard Chang)",2016-07-25,GILD,"Mon Jul 25, 2016 | 6:44pm EDT","Gilead cuts 2016 sales forecast, cites hepatitis C drugs",http://www.reuters.com//article/us-gilead-earns-idUSKCN10529S?type=companyNews
329,"  July 25 Gilead Sciences Inc said on Monday its second-quarter net profit fell 22 percent, due mostly to lower sales of its hepatitis C drug Harvoni.The biotechnology company's shares, which rose 2.3 percent to close at $88.55, fell 3.2 percent after hours. Quarterly net profit fell to $3.5 billion from $4.5 billion a year earlier. Adjusting for one-time items, Gilead said it earned $3.08 per share. Total product sales fell to $7.65 billion from $8.13 billion a year earlier. Sales of hepatitis C drugs Sovaldi and Harvoni dropped to $4 billion from $4.9 billion. Wall Street analysts, on average, had forecast hepatitis C sales of $4.09 billion, according to a poll by ISI Evercore. (Reporting by Deena Beasley; Editing by Richard Chang)",2016-07-25,GILD,"Mon Jul 25, 2016 | 4:28pm EDT",Gilead second-quarter net profit falls 22 percent,http://www.reuters.com//article/gilead-earns-idUSL1N1AB1JR?type=companyNews
330,  July 25 Gilead Sciences Inc :* Sets quarterly cash dividend of $0.47per share  * Sets quarterly cash dividend of $0.47per share  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-07-25,GILD,"Mon Jul 25, 2016 | 4:26pm EDT",BRIEF-Gilead Sciences sets qtrly dividend of $0.47 per share,http://www.reuters.com//article/idUSFWN1AB0OW?type=companyNews
331,"  July 25 Gilead Sciences Inc :* Q2 Harvoni sales $ 2.56 billion versus $3.61 billion last year* Revised full year 2016 guidance* Q2 Sovaldi sales $ 1.36 billion versus $1.29 billion last year* Sees Fy Diluted EPS Impact Of Acquisition-Related, restructuring, stock-based compensation expenses and other $1.47 - $1.53 * Fy2016 revenue view $31.02 billion -- Thomson Reuters I/B/E/S* Gilead Sciences announces second quarter 2016 financial results* Q2 non-GAAP earnings per share $3.08 * Q2 earnings per share $2.58* Q2 earnings per share view $3.02 -- Thomson Reuters I/B/E/S * Q2 total revenue $7.78 billion versus $8.24 billion last year* Q2 revenue view $7.77 billion -- Thomson Reuters I/B/E/S* Revised full year 2016 guidance* Sees NON-GAAP FY net product sales $29.5 - $30.5 billion  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-25,GILD,"Mon Jul 25, 2016 | 4:25pm EDT",BRIEF-Gilead Sciences Q2 non-GAAP earnings per share $3.08,http://www.reuters.com//article/idUSASC08Y47?type=companyNews
332,"   By Andrew Chung  Gilead Sciences Inc urged a California federal judge on Tuesday to not put off a decision on whether it is owed $15.5 million in legal fees in a patent fight over a lucrative cure for hepatitis C with drugmaker Merck & Co. Gilead, represented by Fish & Richardson, said U.S. District Judge Beth Labson Freeman in San Jose would be following 9th U.S. Circuit Court of Appeals precedent by ruling on attorneys' fees immediately and not waiting for Merck's appeal of its loss in the case.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2aj0UVi",2016-07-28,GILD,"Thu Jul 28, 2016 | 6:53am EDT","Gilead, Merck lock horns on legal fees in hepatitis C patent fight",http://www.reuters.com//article/ip-gilead-fees-idUSL1N1AE0CY?type=companyNews
333,"  (Recasts headline)Aug 5 Gilead Sciences * In July 2016, Massachusetts attorney general's office notified co of their decision to suspend co's obligations under CID until further notice  * Civil investigative demand related to attorney general's office requesting that co produce documents related to its HCV products  Source text for Eikon: (bit.ly/2aXd5sE) Further company coverage:",2016-08-05,GILD,"Fri Aug 5, 2016 | 5:05pm EDT",REFILE-BRIEF-Massachusetts attorney general's office notifies Gilead of decision to suspend co's obligations under CID until further notice,http://www.reuters.com//article/idUSFWN1AM1HF?type=companyNews
334,"  Aug 10 Genmab A/S :* Genmab enters commercial license agreement with Gilead for DuoBody(R) Technology* Genmab is entitled to potential development, regulatory and sales milestones of up to USD 277 million * Agreement is not expected to have a material impact on Genmab's 2016 financial guidance* Genmab will receive an upfront payment of USD 5 million from Gilead Sciences * Genmab will be entitled to single-digit royalties on Gilead's sales of any commercialized products * Deal also includes further milestones for subsequent products* Commercial license agreement follows a research collaboration between Genmab and Gilead Sciences for DuoBody Technology signed in 2014  Source text for Eikon:  Further company coverage:",2016-08-10,GILD,"Wed Aug 10, 2016 | 1:39pm EDT",BRIEF-Genmab enters commercial license agreement with Gilead for DuoBody(R)Technology,http://www.reuters.com//article/idUSASC09292?type=companyNews
335,"   By Anya George Tharakan  Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled.In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead's blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices. In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case. Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease. The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs.The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.",2016-08-12,GILD,"Thu Aug 11, 2016 | 8:46pm EDT",Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL1N1AT01I?type=companyNews
336,"  Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled.In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead's blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices.In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case.  Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs. The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.  (Reporting by Anya George Tharakan in Bengaluru; Editing by Leslie Adler)",2016-08-12,GILD,"Thu Aug 11, 2016 | 8:43pm EDT",Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com//article/us-gilead-sciences-merck-co-ruling-idUSKCN10N02Y?type=companyNews
337,"  Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled.In June, Gilead was freed from paying up $200 million in damages for infringing two Merck patents related to Gilead's blockbuster drugs Sovaldi and Harvoni, after a U.S. judge found a pattern of misconduct by Merck including lying under oath and other unethical practices.In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case.  Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.The case dates back to 2013 when Gilead and Merck sued each other, claiming ownership of laboratory work underlying sofosbuvir, the active ingredient in Gilead's drugs. The case is Gilead Sciences, Inc v Merck & Co, Inc, in the U.S. District Court for the Northern District of California, No. 13-cv-4057.  (Reporting by Anya George Tharakan in Bengaluru; Editing by Leslie Adler)",2016-08-12,GILD,"Thu Aug 11, 2016 | 8:43pm EDT",Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com//article/gilead-sciences-merck-co-ruling-idUSL3N1AT05H?type=companyNews
338,"  Aug 22 Gilead Sciences Inc* European Commission grants marketing authorization for Gilead's once-daily Truvada for reducing the risk of sexually acquired HIV-1  * Truvada is also authorized for prep in Australia, Canada, Kenya, Peru, South Africa and United States  Source text for Eikon:  Further company coverage: ",2016-08-22,GILD,"Mon Aug 22, 2016 | 11:59am EDT",BRIEF-Gilead Sciences - European Commission grants marketing authorization for Truvada,http://www.reuters.com//article/idUSFWN1B30GW?type=companyNews
339,"  Aug 23 Gilead Sciences Inc* Kelly A. Kramer joins Gilead Sciences' board of directors  * Says Kramer is currently Executive Vice President and Chief Financial Officer of Cisco Systems, Inc  Source text for Eikon:  Further company coverage: ",2016-08-23,GILD,"Tue Aug 23, 2016 | 9:00am EDT",BRIEF-Kelly Kramer joins Gilead Sciences' Board of Directors,http://www.reuters.com//article/idUSASC093ZL?type=companyNews
340,  Sept 15 Gilead Sciences Inc :* Gilead prices $5 billion of senior unsecured notes* Priced $1.25 billion of 2.950% senior notes maturing in 2027 * Priced $750 million of 2.500% senior notes maturing in 2023 * Has priced $500 million of 1.950% senior notes maturing in 2022 * Says priced $750 million of 4.000% senior notes maturing in 2036* Says priced $1.75 billion of 4.150% senior notes maturing in 2047  Source text for Eikon:  Further company coverage:,2016-09-16,GILD,"Thu Sep 15, 2016 | 10:40pm EDT",BRIEF-Gilead Sciences prices $5 bln of senior unsecured notes,http://www.reuters.com//article/idUSASC096KD?type=companyNews
341,"   By Ransdell Pierson and Natalie Grover  Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.Just hours later on Tuesday, Allergan announced it would also pay $50 million upfront and make future milestone payments for Akarna Therapeutics Ltd, a privately held company that is planning early-stage studies of a treatment for NASH.There are no approved treatments for the disease affecting more than 15 million Americans, which involves accumulation of fat in the liver not caused by alcohol, and can lead to cirrhosis, liver transplants or liver cancer.""Allergan is making an excellent move into the NASH space, which is under appreciated by Wall Street and one of the major categories of untreated diseases,"" said Len Yaffe, portfolio manager of StocDoc Partners who holds shares of Tobira.Allergan's offer on Tuesday of $28.35 upfront per Tobira share is a whopping 500 percent premium to the stock's close on Monday, which had given Tobira a market capitalization of about $89 million. Tobira shareholders could receive up to $49.84 per share, contingent on the company achieving certain milestones.Tobira's stock surged 720 percent to $38.91 on Tuesday. But Allergan's fell 2.7 percent to $238.67 as some industry analysts said the deal came at a steep price. Tobira shares have been on a roller coaster ride since July 25, when they tumbled 60 percent to $4.50 after the company's lead product, cenicriviroc, failed its main goal in a mid-stage trial of showing a 2-point reduction on a scale that measures features of NASH (nonalcoholic steatohepatitis).    But cenicriviroc achieved a secondary goal by reducing by at least one stage the extent of fibrosis, a scarring of the liver that can lead to cirrhosis, without worsening of NASH. Tobira said the drug has potential to be approved if that favorable secondary finding can be duplicated in a larger late-stage study.Yaffe said cenicriviroc and related therapies being developed by the company have potential to reap annual sales of $5 billion.He said experimental NASH drugs being developed by Gilead Sciences Inc have similar sales potential and that treatments being studied by Intercept Pharmaceuticals Inc and others also have blockbuster sales potential. Allergan research chief David Nicholson, in an interview, said liver biopsies are now required to confirm NASH, but less-invasive diagnostic tests should be available by the time the first NASH treatments reach the market, or soon after.""The science in NASH is breaking now and this could become one of Allergan's largest categories"" of medicines, Nicholson said.  The proposed acquisition is the latest in a string of deals orchestrated by Brent Saunders, Allergan's chief executive, since the company's planned $160 billion merger with Pfizer Inc collapsed in April because of unfavorable new U.S. tax regulations.Allergan, best known for its Botox anti-wrinkle treatment,  last week said it would pay $639 million for Vitae Pharmaceuticals, which is developing drugs for psoriasis, eczema and autoimmune disorders. It agreed on Sept. 6 to pay $60 million for RetroSense, a privately held company developing an ophthalmology gene therapy. Other major contenders in the race to develop a drug to treat NASH include Conatus Pharmaceuticals Inc, whose shares rose 19.4 percent, and Galectin Therapeutics Inc, whose stock gained 14.8 percent.Covington & Burling are Allergan's lead legal counsel.  Centerview Partners and Citi are Tobira's financial advisers, while Skadden, Arps, Slate, Meagher & Flom LLP and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP are its legal counsel. (Reporting by Ransdell Pierson in New York and Natalie Grover in Bengaluru; Editing by Savio D'Souza and Matthew Lewis)",2016-09-20,GILD,"Tue Sep 20, 2016 | 6:50pm EDT",UPDATE 3-Allergan to buy Tobira in push for fatty liver disease drugs,http://www.reuters.com//article/tobira-ma-allergan-idUSL3N1BW3GA?type=companyNews
342,"  Sept 21 Gilead Sciences Inc :* 5745 in patients with ulcerative colitis* A phase 3 study of GS-5745 is ongoing in patients with Gastric Cancer * DMC recommended that study be terminated early due to meeting pre-specified futility and efficacy criteria* Decision follows a planned interim analysis of unblinded efficacy and safety data by data monitoring committee * No safety concerns were noted in this interim analysis. * Determined there is insufficient evidence of a treatment benefit in group of patients randomized to receive either one of two doses of GS-5745* Additional phase 2 studies in moderately to severely active crohn's disease, Rheumatoid Arthritis and Cystic Fibrosis is ongoing  Source text for Eikon:  Further company coverage:",2016-09-21,GILD,"Wed Sep 21, 2016 | 5:09pm EDT",BRIEF-Gilead terminates phase 2/3 study of GS-5745 in patients with Ulcerative Colitis,http://www.reuters.com//article/idUSFWN1BX0P2?type=companyNews
343,  Sept 27 Gilead Sciences* Gilead Sciences and the World Health Organization announce five-year visceral leishmaniasis collaboration * Partnership with World Health Organization to expand access to diagnostic services and treatment for visceral leishmaniasis  * Gilead donates $20 million to enhance access to treatment for often fatal neglected tropical disease  Source text for Eikon:  Further company coverage:,2016-09-27,GILD,"Tue Sep 27, 2016 | 4:14pm EDT","BRIEF-Gilead sciences, WHO announce 5-year visceral leishmaniasis collaboration",http://www.reuters.com//article/idUSFWN1C30LV?type=companyNews
344,"  Oct 20 Gilead Sciences Inc :* Gilead announces top-line phase 2 results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD)* Gilead Sciences Inc - GS-4997 demonstrates anti-fibrotic activity in open-label phase 2 NASH study * Gilead Sciences Inc - Data support plans to advance GS-4997 into phase 3 clinical trials* Gilead Sciences Inc - Due to insufficient evidence of efficacy, Gilead has decided not to pursue phase 3 studies of GS-4997 in PAH or DKD at this time * Gilead Sciences - GS-4997 was well tolerated with no dose-related increase in incidence of treatment-emergent adverse events or serious adverse events * Gilead Sciences Inc says phase 2 study of GS-4997 in PAH did not achieve its primary endpoint* Gilead Sciences Inc says phase 2 study in DKD did not achieve its primary endpoint based on a preliminary analysis  Source text for Eikon:  Further company coverage:",2016-10-20,GILD,"Thu Oct 20, 2016 | 10:17am EDT",BRIEF-Gilead Sciences says phase 2 study of GS-4997 in PAH did not achieve primary endpoint,http://www.reuters.com//article/idUSFWN1CQ0RQ?type=companyNews
345,"  Oct 20 Gilead Sciences Inc* Gilead announces SVR12 rates from four phase 3 studies of a once-daily, fixed-dose combination of Sofosbuvir, Velpatasvir and Voxilaprevir in treatment-nave and treatment-experienced genotype 1-6 chronic HCV-infected patients * Gilead Sciences Inc - U.S. Nda planned for Q4 2016  * GILEAD SCIENCES-patients with sof/vel/vox for 12 or 8 weeks had similar overall incidence of adverse events compared to placebo-treated or SOF/VEL-treated patients  Source text for Eikon:  Further company coverage:",2016-10-20,GILD,"Thu Oct 20, 2016 | 10:12am EDT","BRIEF-Gilead announces SVR12 rates from four phase 3 studies of combination of Sofosbuvir, Velpatasvir And Voxilaprevir",http://www.reuters.com//article/idUSFWN1CQ0RS?type=companyNews
346,"   By Deena Beasley  Gilead Sciences Inc (GILD.O) on Tuesday posted a 28 percent drop in quarterly net profit due to lower sales of its hepatitis C drugs Harvoni and Sovaldi, but its HIV drug sales beat Wall Street's expectations and the biotech company made no changes to its full-year outlook.Shares of Gilead, which closed at $74.07 on the Nasdaq exchange, were slightly lower at $73.69 in after-hours trading.Quarterly net profits dropped to $3.3 billion from $4.6 billion a year earlier. Adjusting for one-time items, Gilead said it earned $2.75 per share, compared with an average analyst estimate of $2.86, according to Thomson Reuters I/B/E/S.Total product sales fell to $7.4 billion from $8.2 billion in the same 2015 period.Sales of hepatitis C drugs Sovaldi, Harvoni and recently launched Epclusa totaled $3.3 billion, compared with $4.8 billion a year earlier for Sovaldi and Harvoni. Wall Street analysts, on average, had forecast hepatitis C drug sales of $3.74 billion, according to a poll by Evercore ISI. Sales of HIV and other antiviral drugs rose 21 percent from the year-ago period to $3.5 billion, due to robust sales of a new generation of Gilead medications, growing use of Gilead's older drug Truvada to prevent HIV infection and a one-time $332 million adjustment to the company's rebate reserve.HIV sales were mixed, especially once one-time rebates are excluded, Jefferies analyst Brian Abrahams said in a research note. But he noted that the results ""should bode well for HIV franchise sustainability."" Gilead drew fire after its 2014 launch of Sovaldi, the first in a new class of hepatitis C drugs considered to be a cure for the liver-destroying disease, at a price of $1,000 per pill. An estimated 3.2 million Americans are infected with hepatitis C and insurers have responded by closely monitoring which patients should be treated.Health insurers and other payers have also been able to command steep discounts from Gilead now that competing hepatitis C drugs have been launched by AbbVie Inc (ABBV.N) and Merck & Co Inc (MRK.N).For the full year, Gilead said it expects net product sales of between $29.5 billion and $30.5 billion. Chief Executive Officer John Martin said the company is ""still very actively evaluating"" potential acquisitions and other investments, including ""a series of different partnerships.""But he emphasized that ""the bar remains high"" and said opportunities considered so far have either been ""too early for us or too expensive."" (Reporting by Deena Beasley; editing by Dan Grebler and David Gregorio)",2016-11-01,GILD,"Tue Nov 1, 2016 | 6:08pm EDT","Gilead 3rd-quarter profit falls, HIV sales rise",http://www.reuters.com//article/us-gilead-sciences-results-idUSKBN12W4ZA?type=companyNews
347,"   By Deena Beasley  Gilead Sciences Inc (GILD.O) on Tuesday posted a 28 percent drop in quarterly net profit due to lower sales of its hepatitis C drugs Harvoni and Sovaldi, but its HIV drug sales beat Wall Street's expectations and the biotech company made no changes to its full-year outlook.Shares of Gilead, which closed at $74.07 on the Nasdaq exchange, were slightly lower at $73.69 in after-hours trading.Quarterly net profits dropped to $3.3 billion from $4.6 billion a year earlier. Adjusting for one-time items, Gilead said it earned $2.75 per share, compared with an average analyst estimate of $2.86, according to Thomson Reuters I/B/E/S.Total product sales fell to $7.4 billion from $8.2 billion in the same 2015 period.Sales of hepatitis C drugs Sovaldi, Harvoni and recently launched Epclusa totaled $3.3 billion, compared with $4.8 billion a year earlier for Sovaldi and Harvoni. Wall Street analysts, on average, had forecast hepatitis C drug sales of $3.74 billion, according to a poll by Evercore ISI. Sales of HIV and other antiviral drugs rose 21 percent from the year-ago period to $3.5 billion, due to robust sales of a new generation of Gilead medications, growing use of Gilead's older drug Truvada to prevent HIV infection and a one-time $332 million adjustment to the company's rebate reserve.HIV sales were mixed, especially once one-time rebates are excluded, Jefferies analyst Brian Abrahams said in a research note. But he noted that the results ""should bode well for HIV franchise sustainability."" Gilead drew fire after its 2014 launch of Sovaldi, the first in a new class of hepatitis C drugs considered to be a cure for the liver-destroying disease, at a price of $1,000 per pill. An estimated 3.2 million Americans are infected with hepatitis C and insurers have responded by closely monitoring which patients should be treated.Health insurers and other payers have also been able to command steep discounts from Gilead now that competing hepatitis C drugs have been launched by AbbVie Inc (ABBV.N) and Merck & Co Inc (MRK.N).For the full year, Gilead said it expects net product sales of between $29.5 billion and $30.5 billion. Chief Executive Officer John Martin said the company is ""still very actively evaluating"" potential acquisitions and other investments, including ""a series of different partnerships.""But he emphasized that ""the bar remains high"" and said opportunities considered so far have either been ""too early for us or too expensive."" (Reporting by Deena Beasley; editing by Dan Grebler and David Gregorio)",2016-11-01,GILD,"Tue Nov 1, 2016 | 6:08pm EDT","UPDATE 2-Gilead 3rd-quarter profit falls, HIV sales rise",http://www.reuters.com//article/gilead-sciences-results-idUSL1N1D221E?type=companyNews
348,"  Nov 1 Gilead Sciences Inc said on Tuesday its third-quarter net profit fell 28 percent, due to lower sales of its flagship hepatitis C drugs Harvoni and Sovaldi.Quarterly net profit dropped to $3.3 billion from $4.6 billion a year earlier. Adjusting for one-time items, Gilead said it earned $2.75 per share, compared with $3.22 per share a year earlier. The biotechnology company's shares, which closed at $74.07, were down slightly at $73.52 in after-hours trading.  (Reporting By Deena Beasley; Editing by Dan Grebler) ",2016-11-01,GILD,"Tue Nov 1, 2016 | 4:18pm EDT",Gilead third quarter net profit falls 28 percent,http://www.reuters.com//article/gilead-sciences-results-idUSL1N1D216B?type=companyNews
349,"  Nov 1 Gilead Sciences Inc -* Q3 sovaldi sales $825 million versus $1,466 million last year* Q3 total tevenues $7,500 million versus $8,295 million last year* Qtrly harvoni sales $1,860 million versus $3,332 million * Gilead reiterates its full year 2016 guidance* FY2016 earnings per share view $11.75, revenue view $30.34 billion -- Thomson Reuters I/B/E/S * Gilead sciences announces third quarter 2016 financial results * Q3 non-GAAP earnings per share $2.75* Q3 earnings per share $2.49* Q3 earnings per share view $2.86 -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:",2016-11-01,GILD,"Tue Nov 1, 2016 | 4:14pm EDT",BRIEF-Gilead Q3 earnings per share $2.49,http://www.reuters.com//article/idUSASC09EUE?type=companyNews
350,"   By Julie Steenhuysen | CHICAGO  CHICAGO An experimental HIV vaccine from Johnson & Johnson combined with an immune system booster from Gilead Sciences Inc showed promise at keeping the virus at bay in monkeys even after treatments had stopped, marking yet another step toward the development of a so-called functional cure for HIV.Both companies are currently testing the products separately in early-stage trials in people with HIV.The study, published on Wednesday in the journal Nature, evaluated monkeys infected with simian immunodeficiency virus, the monkey version of HIV, and showed the treatments were much more effective when used together than separately.All nine monkeys that got both treatments showed significantly reduced viral loads. In three of them, the combination therapy has kept the virus at bay for six months after antiretroviral therapy or ART drugs were stopped.The study is part of ongoing efforts to develop a so-called functional cure for HIV that would allow people infected with the virus to stop taking daily antiretroviral therapy. [L1N1CJ134] ""Current antiretroviral drugs, although they're lifesaving, do not cure HIV. They merely hold it in check. We are trying to develop strategies to achieve ART-free, long-term viral suppression,"" said study author Dr. Dan Barouch, a vaccine researcher at Harvard-affiliated Beth Israel Deaconess Medical Center in Boston.For the study, the team used what is known as a ""kick and kill"" approach. The two-punch strategy is designed to lure dormant HIV-infected immune cells out of hiding places in the body and then attempt to eradicate them.The trial evaluated a therapeutic vaccine called Ad26/MVA, which J&J and partners are testing in early-stage human trials. The vaccine works by provoking a broad immune response from the adaptive immune system, the part that recognizes specific pathogens and produces lasting immunity. They combined this with Gilead's experimental drug called GS-986, a so-called TLR-7 agonist that kickstarts the innate immune system, a more generalized line of defense that mounts the body's initial response to infection. Gilead is also testing this in trials of HIV-infected patients.In the study, they evaluated 36 monkeys infected with SIV that had been treated with ART for six months to get the virus under control. They then divided the group into four arms, with one getting the Ad26/MVA vaccine alone, another getting the TLR-7 agonist alone, a third getting the combination of the two, and a fourth getting a placebo.Then, they discontinued ART in all of the animals and monitored levels of the virus in their blood and lymph nodes. Animals that got Gilead's TLR-7 agonist saw no benefit and the virus quickly rebounded. Those that got the vaccine alone showed some reduction of viral load and a modest delay in viral rebound. The biggest effect was in the combination group, which saw a 2.5 times longer delay in viral rebound compared to the control group. In this group, levels of virus in the blood were 50 times lower than in the controls, and the virus fell to undetectable levels in three of the animals, which have been off ART for six months with no viral rebound.If all the animals' viral loads had been undetectable, that would have been a home run, said Barouch. But the fact that all animals showed a reduction in viral load and three out of nine were undetectable, thats a solid base hit. Its definitely something that we can work from.Barouch said his team has been in talks with both companies to test the combination therapy in patients with HIV. (Reporting by Julie Steenhuysen; Editing by David Gregorio)",2016-11-09,GILD,"Wed Nov 9, 2016 | 3:06pm EST",J&J vaccine plus Gilead immune booster shows promise as HIV fighter,http://www.reuters.com//article/us-hiv-vaccine-cure-idUSKBN134364?type=companyNews
351,"   By Julie Steenhuysen | CHICAGO  CHICAGO An experimental HIV vaccine from Johnson & Johnson combined with an immune system booster from Gilead Sciences Inc showed promise at keeping the virus at bay in monkeys even after treatments had stopped, marking yet another step toward the development of a so-called functional cure for HIV.Both companies are currently testing the products separately in early-stage trials in people with HIV.The study, published on Wednesday in the journal Nature, evaluated monkeys infected with simian immunodeficiency virus, the monkey version of HIV, and showed the treatments were much more effective when used together than separately.All nine monkeys that got both treatments showed significantly reduced viral loads. In three of them, the combination therapy has kept the virus at bay for six months after antiretroviral therapy or ART drugs were stopped.The study is part of ongoing efforts to develop a so-called functional cure for HIV that would allow people infected with the virus to stop taking daily antiretroviral therapy. [L1N1CJ134] ""Current antiretroviral drugs, although they're lifesaving, do not cure HIV. They merely hold it in check. We are trying to develop strategies to achieve ART-free, long-term viral suppression,"" said study author Dr. Dan Barouch, a vaccine researcher at Harvard-affiliated Beth Israel Deaconess Medical Center in Boston.For the study, the team used what is known as a ""kick and kill"" approach. The two-punch strategy is designed to lure dormant HIV-infected immune cells out of hiding places in the body and then attempt to eradicate them.The trial evaluated a therapeutic vaccine called Ad26/MVA, which J&J and partners are testing in early-stage human trials. The vaccine works by provoking a broad immune response from the adaptive immune system, the part that recognizes specific pathogens and produces lasting immunity. They combined this with Gilead's experimental drug called GS-986, a so-called TLR-7 agonist that kickstarts the innate immune system, a more generalized line of defense that mounts the body's initial response to infection. Gilead is also testing this in trials of HIV-infected patients.In the study, they evaluated 36 monkeys infected with SIV that had been treated with ART for six months to get the virus under control. They then divided the group into four arms, with one getting the Ad26/MVA vaccine alone, another getting the TLR-7 agonist alone, a third getting the combination of the two, and a fourth getting a placebo.Then, they discontinued ART in all of the animals and monitored levels of the virus in their blood and lymph nodes. Animals that got Gilead's TLR-7 agonist saw no benefit and the virus quickly rebounded. Those that got the vaccine alone showed some reduction of viral load and a modest delay in viral rebound. The biggest effect was in the combination group, which saw a 2.5 times longer delay in viral rebound compared to the control group. In this group, levels of virus in the blood were 50 times lower than in the controls, and the virus fell to undetectable levels in three of the animals, which have been off ART for six months with no viral rebound.If all the animals' viral loads had been undetectable, that would have been a home run, said Barouch. But the fact that all animals showed a reduction in viral load and three out of nine were undetectable, thats a solid base hit. Its definitely something that we can work from.Barouch said his team has been in talks with both companies to test the combination therapy in patients with HIV. (Reporting by Julie Steenhuysen; Editing by David Gregorio)",2016-11-09,GILD,"Wed Nov 9, 2016 | 3:06pm EST",J&J vaccine plus Gilead immune booster shows promise as HIV fighter,http://www.reuters.com//article/hiv-vaccine-cure-idUSL1N1DA29Z?type=companyNews
352,"  (Adds details)Nov 10 Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved its drug to treat chronic hepatitis B infection in patients with scarred liver.The drug, Vemlidy, comes with a boxed warning, the strongest warning issued by the FDA that highlights serious risks such as lactic acid buildup, accumulation of fat on the liver or aggravation of the infection. The drug has been approved as a once-daily treatment for the condition, which the World Health Organization estimates is responsible for more than 686,000 deaths every year worldwide. Data from a late-stage study showed in January that the drug was not only effective, but also safer than the company's approved treatment, Viread. Gilead's shares were down 0.7 pct at $77.90 in afternoon trading.   (Reporting by Dipika Jain in Bengaluru; Editing by Anil D'Silva)",2016-11-10,GILD,"Thu Nov 10, 2016 | 2:27pm EST",UPDATE 1-Gilead's hepatitis B drug gets U.S. approval,http://www.reuters.com//article/gilead-sciences-fda-idUSL4N1DB5Q2?type=companyNews
353,"  Nov 10 Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration approved its drug for patients with chronic hepatitis B virus infection.The drug, Vemlidy, comes with a boxed warning, the strongest warning issued by the FDA.  The company's shares were down 1.1 pct in afternoon trading.   (Reporting by Dipika Jain in Bengaluru; Editing by Anil D'Silva) ",2016-11-10,GILD,"Thu Nov 10, 2016 | 1:34pm EST",Gilead's hepatitis B drug wins U.S. approval,http://www.reuters.com//article/gilead-sciences-fda-idUSL4N1DB5PJ?type=companyNews
354,"  Nov 14 Gilead Sciences Inc :* Gilead Sciences Inc - results demonstrate improvement in fibrosis stage among nash patients with moderate to severe fibrosis* Gilead Sciences Inc - results demonstrate improvement in fibrosis stage among nash patients with moderate to severe fibrosis * Gilead Sciences Inc - selonsertib demonstrated no dose-related increases in treatment-emergent adverse events or serious adverse events * Gilead - data for combination of selonsertib, gs-9674 in rodent model of advanced fibrosis resulted in greater anti-fibrotic activity than either agent alone * Press release - phase 2 data for selonsertib in nonalcoholic steatohepatitis (nash) presented at the liver meeting 2016  Source text for Eikon:  Further company coverage:",2016-11-14,GILD,"Mon Nov 14, 2016 | 4:46pm EST","BRIEF-Gilead - data for combination of selonsertib, gs-9674 in rodent model of advanced fibrosis resulted in greater anti-fibrotic activity than either agent alone",http://www.reuters.com//article/idUSASC09ISW?type=companyNews
355,  Nov 16 Gilead Sciences Inc :* Gilead Sciences Inc - non-inferiority was not achieved for key secondary endpoint of response rate in total symptom score (TSS)* Gilead announces top-line results from two phase 3 studies evaluating momelotinib for patients with myelofibrosis * Simplify-1 study achieved its pre-specified primary endpoint * Simplify-2 did not achieve its primary endpoint  Source text for Eikon:  Further company coverage: ,2016-11-16,GILD,"Wed Nov 16, 2016 | 4:36pm EST",BRIEF-Gilead announces top-line results from two phase 3 studies,http://www.reuters.com//article/idUSFWN1DH0SZ?type=companyNews
356,"   By Brendan Pierson  Gilead Sciences Inc has lost a bid to invalidate two Merck & Co patents on hepatitis C treatments, which Merck claims are infringed by Gilead's blockbuster Harvoni and Sovaldi. U.S. District Judge Leonard Stark in Delaware ruled on Wednesday that Gilead will have to make its argument against the patents' validity at a trial set to start next month, rejecting its argument that they are too indefinite to be put into practice.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2f59B44",2016-11-17,GILD,"Thu Nov 17, 2016 | 5:06pm EST",Gilead loses bid to invalidate two Merck hepatitis C patents ahead of trial,http://www.reuters.com//article/health-gilead-idUSL1N1DI2FM?type=companyNews
357,"   By Brendan Pierson  Early next month, Gilead Sciences Inc will try to convince a federal jury in Delaware that a Merck & Co patent on hepatitis C drugs is invalid. The trial, set to begin on Dec. 5, is the latest development in a long-running dispute between the two companies over patents related to the drugs. Merck claims Gilead's blockbuster hepatitis C drugs Harvoni and Sovaldi infringe its patent.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2gntGnZ",2016-11-28,GILD,"Mon Nov 28, 2016 | 7:19am EST","Gilead, Merck to face off before jury over hepatitis C drug patents",http://www.reuters.com//article/health-idenix-idUSL1N1DT0DD?type=companyNews
358,"   By Jilian Mincer | NEW YORK  NEW YORK Gilead Sciences Inc has begun marketing its HIV treatment Truvada in a way thousands of consumers already use it  to prevent infection with the virus that causes AIDS.The company introduced Truvada to the U.S. market in 2004 for HIV treatment. In 2012, Gilead won approval to market it for prevention after two large, peer-reviewed studies showed it also was effective at preventing infections in healthy people. But the company decided against promoting the drug as a preventative treatment, deferring to patient advocates who feared it could encourage promiscuity and unsafe practices, such as having sex without condoms.Even without Gilead's help, many consumers learned Truvada was more than 90 percent effective in tests at preventing HIV infection. In 2014, the U.S. Centers for Disease Control and Prevention recommended it as an option for people at high risk for HIV infection.As many as 90,000 people in the United States used the drug for prevention, or pre-exposure prophylaxis (PrEP), last quarter. That's up from 60,000 to 70,000 earlier this year, the company said. Usage also is growing in France, where about 2,000 people have been prescribed Truvada for prevention since January.In July, the drugmaker began marketing Truvada for PrEP to doctors through professional publications, digital advertising and other channels, including the website PreventHIV.com.And this fall, the drugmaker began marketing directly to consumers with print advertisements in publications geared toward the lesbian, gay, bisexual and transgender community, including OUT, Advocate and SWERV. It plans soon to expand to social media and digital.Gilead said it wants to reach people whose doctors are either unaware or reluctant to prescribe Truvada for prevention. The marketing ""is primarily driven by demand by patients,"" said David Piontkowsky, Gilead's vice president of HIV Medical Affairs, in an interview. Attitudes toward Truvada started to change a couple years ago as doctors, AIDS activists and potential users saw its effectiveness, he said. The ""criticism now is we're not saying enough.""Truvada is helping bolster Gilead's profits as sales of its biggest moneymakers  treatments for hepatitis C  decline. U.S. net product sales of Truvada for the first nine months of 2016 were $1.8 billion compared with $1.5 billion for the same period in 2015. The company said in its earnings report that the gain was driven by price increases as well as ""increased usage of Truvada for PrEP.""""We expect PrEP to continue to be a significant part of Gilead's growth in HIV going forward, particularly in the U.S.,"" Gilead Chief Operating Officer Kevin Young recently told investors.The new Truvada campaign has been well received, even by those who once opposed promoting the drug for prevention. They include David Duran, a writer and HIV advocate, who helped popularize the term ""Truvada Whore"" in a 2012 article describing his fear that it would encourage people to have sex without condoms. Duran began rethinking that concern about a year later in light of newer research showing that PrEP helped prevent more cases of HIV, without a rise in other sexually transmitted disease, which suggested people were using condoms.""I'm thrilled they are starting to pump some money into marketing and awareness,"" Duran said. ""There is a solid base of folks who know about PrEP, but it's still not a topic the country as a whole knows about."" GROWTH POTENTIAL As a preventive measure,the blue Truvada pill is taken once daily. Some people experience nausea, vomiting or headaches during the first few weeks on the drug. Users must be tested every three months to ensure they don't have HIV or other sexually transmitted diseases and to monitor kidney function and bone density.Some Medicaid programs and most private insurance cover the treatment, which lists for $1,500 a month before any negotiated discounts. With greater awareness and favorable coverage for preventative treatments, the number of Americans using Truvada could rise, said the company and healthcare providers. An estimated 50,000 new U.S. HIV infections are diagnosed each year. The CDC estimated in 2015 that about 1.2 million Americans were at substantial risk of HIV infection and could benefit from PrEP. That includes men who have sex with men, transgender women who have sex with men, partners of people who are HIV-positive and intravenous drug users who share needles.The number of high risk groups ""is much broader than one might think,"" said Dr. Jennifer Childs-Roshak, president and CEO of Planned Parenthood League of Massachusetts.""It is not just men with multiple partners. There are a whole host of folks who could benefit.""At least 15 patients have gone on Truvada for prevention since Planned Parenthood's six Massachusetts clinics began offering it this fall. Planned Parenthood of New York City plans to offer the treatment to all of its 50,000 patients, said Julia Sullivan, associate director of quality management. Wider use also could buffer Gilead when Truvada, the only drug currently approved in the United States for PrEP, loses patent protection in 2021. Gilead has a successor treatment in the works. The once-daily F/TAF (emtricitabine/tenofovir alafenamide) has been approved for HIV treatment and is under study as a preventative.""PrEP is indeed a significant part of Truvada,"" said Leerink Partners analyst Geoffrey Porges. ""It can certainly keep Truvada relatively flat but the key question is, when will they show that TAF works for PrEP?""In the meantime, the concept of taking an HIV drug to prevent infection is making inroads in popular U.S. culture. It came up in an episode of ""Transparent,"" the Emmy award-winning Amazon series about a family with a transgender parent, when a character was contemplating sex with an HIV-positive partner.""We were trying to make the conversation reflect what happens in real life,"" said a writer on the show who works under the name Our Lady J. ""PrEP is a big part of that conversation. As an HIV positive person, I'm struck with the level of ignorance around PrEP."" (Reporting By Jilian Mincer; Editing by Michele Gershberg and Lisa Girion)",2016-11-30,GILD,"Wed Nov 30, 2016 | 1:05am EST","Switching course, Gilead markets HIV drug for prevention",http://www.reuters.com//article/us-aids-day-truvada-idUSKBN13P0EG?type=companyNews
